No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 4fkwA, 1.0000, 0.00, 1.000, 280, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2, 4fkuA, 0.9974, 0.31, 1.000, 293, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3, 5ievA, 0.9969, 0.34, 0.996, 284, 280, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
4, 4fkvA, 0.9964, 0.38, 1.000, 282, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
5, 2xnbA, 0.9959, 0.40, 0.996, 296, 280, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
6, 5ieyA, 0.9954, 0.43, 0.996, 286, 280, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
7, 3uliA, 0.9942, 0.56, 0.993, 286, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
8, 3lfnA, 0.9938, 0.52, 0.993, 285, 280, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
9, 2b52A, 0.9935, 0.53, 0.996, 283, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
10, 3pj8A, 0.9927, 0.57, 0.996, 288, 280, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
11, 2c6iA, 0.9924, 0.40, 0.996, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
12, 2a0cX, 0.9923, 0.57, 0.993, 294, 280, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
13, 1ykrA, 0.9923, 0.56, 0.996, 298, 280, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
14, 2xmyA, 0.9914, 0.62, 0.996, 295, 280, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
15, 4lynA, 0.9912, 0.46, 0.996, 287, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
16, 1pxjA, 0.9912, 0.61, 0.993, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
17, 3wblA, 0.9911, 0.46, 0.996, 283, 279, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
18, 2clxA, 0.9909, 0.62, 0.996, 293, 280, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
19, 1pxoA, 0.9909, 0.70, 0.993, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
20, 1di8A, 0.9909, 0.47, 1.000, 283, 279, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
21, 5iexA, 0.9907, 0.48, 1.000, 285, 279, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
22, 1pxpA, 0.9907, 0.63, 0.996, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
23, 2vv9A, 0.9906, 0.52, 1.000, 279, 279, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
24, 3qxoA, 0.9902, 0.64, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
25, 1hckA, 0.9902, 0.66, 0.993, 294, 280, HUMAN CYCLIN-DEPENDENT KINASE 2
26, 2exmA, 0.9901, 0.63, 0.993, 298, 280, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
27, 2c6kA, 0.9899, 0.51, 0.996, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
28, 3r1sA, 0.9895, 0.66, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
29, 2w1hA, 0.9895, 0.54, 0.996, 283, 279, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
30, 1hclA, 0.9894, 0.67, 0.993, 294, 280, HUMAN CYCLIN-DEPENDENT KINASE 2
31, 3raiA, 0.9893, 0.67, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
32, 3qtwA, 0.9893, 0.68, 0.986, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
33, 2b54A, 0.9893, 0.66, 0.993, 298, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
34, 3r8uA, 0.9892, 0.67, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
35, 3r73A, 0.9892, 0.67, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
36, 2v0dA, 0.9891, 0.54, 0.996, 292, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
37, 3r6xA, 0.9890, 0.68, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
38, 2c69A, 0.9890, 0.55, 0.996, 292, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
39, 1pw2A, 0.9890, 0.68, 0.993, 294, 280, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
40, 3rkbA, 0.9888, 0.70, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
41, 3r71A, 0.9888, 0.68, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
42, 4fkrA, 0.9886, 0.42, 1.000, 282, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
43, 3r1yA, 0.9886, 0.69, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
44, 3rk9A, 0.9885, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
45, 3qtqA, 0.9884, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
46, 3rpoA, 0.9883, 0.70, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
47, 1pxiA, 0.9883, 0.69, 0.993, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
48, 3royA, 0.9882, 0.71, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
49, 3rm7A, 0.9882, 0.71, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
50, 5aneA, 0.9880, 0.72, 0.993, 294, 280, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
51, 1ke9A, 0.9880, 0.44, 1.000, 281, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
52, 3qzhA, 0.9879, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
53, 1y8yA, 0.9879, 0.59, 0.996, 292, 279, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
54, 1ke5A, 0.9879, 0.45, 0.996, 281, 278, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
55, 3qqfA, 0.9878, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L1
56, 2w06A, 0.9878, 0.45, 1.000, 282, 278, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
57, 1ke8A, 0.9878, 0.45, 0.996, 282, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
58, 1ke7A, 0.9878, 0.45, 0.996, 281, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
59, 3r9dA, 0.9877, 0.74, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
60, 3qzfA, 0.9877, 0.72, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
61, 3s0oA, 0.9876, 0.75, 0.989, 293, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
62, 3r7vA, 0.9876, 0.71, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
63, 3r28A, 0.9876, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
64, 1wccA, 0.9876, 0.61, 0.993, 283, 279, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
65, 1fvtA, 0.9875, 0.46, 0.996, 282, 278, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
66, 3qu0A, 0.9874, 0.76, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
67, 3rk7A, 0.9873, 0.77, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
68, 3r7eA, 0.9873, 0.73, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
69, 3s00A, 0.9872, 0.72, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L4-14
70, 3rk5A, 0.9871, 0.78, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
71, 3r7yA, 0.9871, 0.73, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
72, 2vtoA, 0.9868, 0.49, 0.996, 283, 278, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
73, 3tiyA, 0.9866, 0.66, 0.996, 293, 279, CDK2 IN COMPLEX WITH NSC 35676
74, 3r8zA, 0.9866, 0.77, 0.996, 290, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
75, 2c6lA, 0.9866, 0.50, 0.996, 291, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
76, 4fkqA, 0.9863, 0.52, 1.000, 283, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
77, 5k4jA, 0.9862, 0.54, 0.996, 282, 278, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
78, 3r1qA, 0.9861, 0.78, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
79, 3rjcA, 0.9860, 0.78, 0.986, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L4-12
80, 3fz1A, 0.9858, 0.54, 0.996, 284, 278, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
81, 3ti1A, 0.9857, 0.80, 0.996, 294, 280, CDK2 IN COMPLEX WITH SUNITINIB
82, 3r8vA, 0.9856, 0.79, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
83, 3qx2A, 0.9856, 0.78, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
84, 3qtxA, 0.9856, 0.80, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
85, 3qqjA, 0.9854, 0.78, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L2
86, 2w17A, 0.9853, 0.64, 0.993, 278, 278, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
87, 4kd1A, 0.9852, 0.78, 0.996, 298, 280, CDK2 IN COMPLEX WITH DINACICLIB
88, 3rpvA, 0.9852, 0.81, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
89, 1y91A, 0.9849, 0.57, 0.996, 286, 278, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
90, 3sqqA, 0.9848, 0.82, 0.996, 288, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
91, 3ql8A, 0.9848, 0.82, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
92, 1ke6A, 0.9848, 0.43, 1.000, 280, 277, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
93, 3rniA, 0.9846, 0.83, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
94, 3qxpA, 0.9846, 0.83, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
95, 5anjA, 0.9845, 0.58, 0.996, 291, 278, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
96, 3qtzA, 0.9845, 0.85, 0.986, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
97, 3qwjA, 0.9844, 0.82, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
98, 3qqkA, 0.9842, 0.84, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L4
99, 3pxrA, 0.9842, 0.83, 0.996, 294, 280, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
100, 4bzdA, 0.9841, 0.47, 0.996, 277, 277, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
101, 1w0xC, 0.9841, 0.45, 1.000, 280, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
102, 3r9hA, 0.9840, 0.85, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
103, 2b53A, 0.9840, 0.81, 0.993, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
104, 3rm6A, 0.9839, 0.73, 0.986, 293, 279, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
105, 3qx4A, 0.9839, 0.83, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
106, 2vtiA, 0.9838, 0.47, 0.996, 280, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
107, 2uzoA, 0.9838, 0.47, 1.000, 290, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
108, 3tizA, 0.9833, 0.74, 0.996, 293, 279, CDK2 IN COMPLEX WITH NSC 111848
109, 3qziA, 0.9833, 0.85, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
110, 2vtpA, 0.9831, 0.50, 0.996, 281, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
111, 2c6mA, 0.9830, 0.51, 0.996, 290, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
112, 1pf8A, 0.9830, 0.97, 0.989, 298, 280, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
113, 1h08A, 0.9830, 0.51, 0.996, 283, 277, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
114, 2c6oA, 0.9829, 0.51, 0.996, 290, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
115, 4ez3A, 0.9828, 0.89, 0.996, 294, 280, CDK2 IN COMPLEX WITH NSC 134199
116, 3qwkA, 0.9828, 0.88, 0.986, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
117, 3qqgA, 0.9828, 0.85, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L2-5
118, 2vtmA, 0.9825, 0.52, 0.996, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
119, 4erwA, 0.9824, 0.79, 1.000, 292, 279, CDK2 IN COMPLEX WITH STAUROSPORINE
120, 3r8lA, 0.9823, 0.87, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L3-4
121, 3qzgA, 0.9823, 0.89, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
122, 1h0vA, 0.9823, 0.65, 0.996, 288, 278, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
123, 3r8pA, 0.9821, 0.88, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
124, 1pxnA, 0.9821, 0.86, 0.996, 294, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
125, 3r7uA, 0.9819, 0.55, 0.996, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
126, 2vtsA, 0.9819, 0.54, 0.996, 282, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
127, 3iggA, 0.9818, 0.55, 0.996, 290, 277, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
128, 3ezvA, 0.9817, 0.59, 0.996, 277, 277, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
129, 1gihA, 0.9816, 0.41, 1.000, 276, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
130, 2vtrA, 0.9815, 0.56, 0.996, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
131, 3rmfA, 0.9814, 0.71, 1.000, 278, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
132, 3r83A, 0.9814, 0.88, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
133, 3qruA, 0.9814, 0.91, 0.996, 295, 280, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
134, 3sw7A, 0.9813, 0.72, 1.000, 278, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
135, 3qtuA, 0.9813, 0.98, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
136, 3unkA, 0.9810, 0.91, 0.996, 295, 280, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
137, 3rpyA, 0.9810, 0.60, 1.000, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
138, 1w8cA, 0.9810, 0.58, 0.996, 290, 277, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
139, 1b39A, 0.9809, 0.58, 0.996, 290, 277, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
140, 3rzbA, 0.9808, 0.61, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
141, 2r3rA, 0.9808, 0.59, 0.996, 290, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
142, 3r9oA, 0.9807, 0.62, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
143, 2r3jA, 0.9807, 0.45, 0.996, 278, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
144, 2b55A, 0.9807, 0.47, 1.000, 276, 276, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
145, 1giiA, 0.9807, 0.45, 0.986, 279, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
146, 4acmA, 0.9806, 0.45, 1.000, 277, 276, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
147, 1pxmA, 0.9806, 0.60, 1.000, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
148, 1pxlA, 0.9806, 0.59, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
149, 2vtlA, 0.9805, 0.60, 0.996, 290, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
150, 2r3kA, 0.9805, 0.46, 0.996, 277, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
151, 2ds1A, 0.9804, 0.60, 0.986, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
152, 2c68A, 0.9804, 0.60, 0.996, 290, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
153, 4fkiA, 0.9803, 0.61, 0.996, 287, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
154, 3py0A, 0.9803, 0.91, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR SU9516
155, 2r3fA, 0.9803, 0.60, 0.996, 290, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
156, 1h07A, 0.9802, 0.47, 0.996, 285, 276, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
157, 4fkoA, 0.9797, 0.76, 1.000, 291, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
158, 1h0wA, 0.9797, 0.79, 0.996, 283, 277, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
159, 3r7iA, 0.9796, 0.63, 0.996, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
160, 2r3mA, 0.9795, 0.50, 0.996, 278, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
161, 3qqhA, 0.9794, 0.94, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L2-2
162, 3pxyA, 0.9793, 0.94, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR JWS648
163, 3qqlA, 0.9791, 0.98, 0.989, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR L3
164, 1b38A, 0.9790, 0.65, 0.996, 290, 277, HUMAN CYCLIN-DEPENDENT KINASE 2
165, 3qrtA, 0.9789, 1.00, 0.993, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
166, 1h00A, 0.9786, 0.38, 0.996, 278, 275, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
167, 1pxkA, 0.9785, 0.67, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
168, 1v1kA, 0.9784, 0.54, 0.996, 277, 276, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
169, 3qtsA, 0.9783, 0.69, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
170, 2r3hA, 0.9783, 0.55, 0.996, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
171, 4ek8A, 0.9782, 0.56, 0.996, 280, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
172, 3rahA, 0.9782, 0.69, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
173, 2r3pA, 0.9782, 0.56, 0.996, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
174, 2r3lA, 0.9781, 0.41, 1.000, 275, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
175, 4fklA, 0.9780, 0.68, 0.996, 290, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
176, 4fkpA, 0.9779, 0.57, 0.996, 279, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
177, 2uznA, 0.9778, 0.57, 1.000, 279, 276, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
178, 1gz8A, 0.9777, 0.69, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
179, 1e1vA, 0.9777, 0.69, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
180, 4fkjA, 0.9776, 0.58, 0.996, 278, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
181, 5anoA, 0.9775, 0.43, 0.996, 277, 275, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
182, 3qtrA, 0.9775, 0.72, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
183, 3rprA, 0.9774, 0.71, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
184, 2vtaA, 0.9774, 0.44, 0.996, 278, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
185, 3s1hA, 0.9773, 0.72, 1.000, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
186, 2vthA, 0.9771, 0.45, 0.996, 278, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
187, 1e1xA, 0.9771, 0.71, 0.996, 290, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
188, 3sw4A, 0.9770, 0.46, 1.000, 279, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
189, 3r9nA, 0.9769, 0.73, 1.000, 282, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
190, 2vtjA, 0.9769, 0.46, 1.000, 276, 275, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
191, 4fkgA, 0.9765, 0.61, 0.996, 286, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
192, 2r64A, 0.9764, 0.63, 0.996, 279, 276, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
193, 2r3oA, 0.9762, 0.62, 0.996, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
194, 2c5yA, 0.9759, 0.75, 0.996, 290, 277, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
195, 3ralA, 0.9758, 0.77, 1.000, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
196, 3rakA, 0.9758, 0.78, 1.000, 277, 277, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
197, 2r3iA, 0.9758, 0.63, 0.996, 289, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
198, 3ns9A, 0.9757, 0.64, 0.996, 289, 276, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
199, 3lfsA, 0.9757, 0.75, 0.996, 290, 277, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
200, 4bghA, 0.9754, 0.53, 1.000, 275, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
201, 4ek5A, 0.9753, 0.66, 0.996, 289, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
202, 3ig7A, 0.9749, 0.55, 0.996, 278, 275, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
203, 2w05A, 0.9748, 0.56, 1.000, 276, 275, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
204, 5jq8A, 0.9746, 0.40, 0.996, 278, 274, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
205, 3s2pA, 0.9746, 0.68, 0.996, 279, 276, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
206, 5osjA, 0.9744, 0.79, 0.996, 292, 277, CDK2(WT) WITH COVALENT ADDUCT AT C177
207, 1ckpA, 0.9743, 0.70, 0.996, 279, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
208, 1aq1A, 0.9742, 0.68, 1.000, 277, 276, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
209, 1g5sA, 0.9739, 0.59, 0.996, 275, 275, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
210, 3r8mA, 0.9738, 1.09, 0.982, 286, 279, CDK2 IN COMPLEX WITH INHIBITOR L3-3
211, 2vtnA, 0.9734, 0.48, 1.000, 274, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
212, 4ek6A, 0.9732, 0.61, 0.996, 278, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
213, 5aniA, 0.9731, 0.61, 0.996, 280, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
214, 4fksA, 0.9731, 0.48, 1.000, 275, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
215, 4gcjA, 0.9727, 1.10, 0.989, 304, 280, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
216, 2vtqA, 0.9721, 0.53, 1.000, 274, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
217, 3unjA, 0.9719, 1.11, 0.996, 294, 280, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
218, 4nj3A, 0.9718, 0.83, 1.000, 277, 276, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
219, 1vyzA, 0.9713, 0.55, 1.000, 279, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
220, 4fktA, 0.9711, 0.55, 0.996, 278, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
221, 3lfqA, 0.9707, 0.80, 0.996, 289, 276, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
222, 1r78A, 0.9707, 0.42, 1.000, 273, 273, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
223, 2r3nA, 0.9705, 0.70, 0.996, 275, 275, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
224, 2j9mA, 0.9702, 0.72, 0.996, 275, 275, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
225, 2btrA, 0.9701, 0.60, 1.000, 275, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
226, 2bheA, 0.9699, 0.61, 0.996, 274, 274, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
227, 1gijA, 0.9696, 0.46, 0.989, 273, 273, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
228, 1dm2A, 0.9693, 0.64, 0.996, 274, 274, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
229, 3ezrA, 0.9690, 0.49, 1.000, 273, 273, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
230, 2vu3A, 0.9690, 1.11, 0.986, 285, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
231, 2r3gA, 0.9688, 0.64, 0.996, 287, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
232, 1jsvA, 0.9683, 0.65, 0.996, 287, 274, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
233, 5mhqA, 0.9678, 0.78, 0.993, 291, 275, CCT068127 IN COMPLEX WITH CDK2
234, 5oo0A, 0.9676, 0.78, 0.996, 288, 275, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
235, 5osmA, 0.9668, 0.80, 0.985, 292, 275, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
236, 4ek4A, 0.9666, 0.71, 0.996, 287, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
237, 1urwA, 0.9660, 0.47, 0.996, 274, 272, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
238, 2r3qA, 0.9659, 0.61, 0.996, 286, 273, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
239, 5jq5A, 0.9656, 0.74, 0.993, 287, 274, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
240, 4ek3A, 0.9652, 0.75, 0.996, 287, 274, CRYSTAL STRUCTURE OF APO CDK2
241, 4rj3A, 0.9651, 0.75, 0.996, 287, 274, CDK2 WITH EGFR INHIBITOR COMPOUND 8
242, 2bhhA, 0.9642, 0.79, 0.996, 274, 274, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
243, 2btsA, 0.9635, 0.80, 0.996, 274, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
244, 2a4lA, 0.9635, 0.69, 0.996, 286, 273, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
245, 1oitA, 0.9623, 0.48, 0.993, 273, 271, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
246, 2vttA, 0.9622, 0.70, 0.996, 272, 272, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
247, 5fp6A, 0.9599, 0.85, 0.985, 278, 273, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
248, 2fvdA, 0.9592, 0.87, 0.993, 284, 273, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
249, 1oirA, 0.9585, 0.84, 0.996, 286, 273, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
250, 4ez7A, 0.9584, 1.40, 0.975, 302, 280, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
251, 1h01A, 0.9581, 0.85, 0.996, 286, 273, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
252, 2duvA, 0.9578, 0.66, 1.000, 272, 271, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
253, 1p2aA, 0.9577, 0.68, 0.993, 271, 271, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
254, 4d1xA, 0.9572, 0.54, 1.000, 274, 270, CDK2 IN COMPLEX WITH LUCIFERIN
255, 5andA, 0.9571, 0.54, 0.996, 273, 270, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
256, 3pxqA, 0.9548, 1.47, 0.968, 298, 280, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
257, 3le6A, 0.9539, 0.66, 0.996, 283, 270, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
258, 5ankA, 0.9532, 0.68, 0.996, 273, 270, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
259, 3py1A, 0.9531, 1.47, 0.971, 302, 280, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
260, 5angA, 0.9526, 0.46, 0.996, 268, 268, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
261, 3pxfA, 0.9526, 1.49, 0.968, 302, 280, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
262, 1jvpP, 0.9501, 0.63, 0.985, 268, 268, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
263, 3pxzA, 0.9493, 1.55, 0.968, 302, 280, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
264, 1pyeA, 0.9449, 0.46, 1.000, 266, 266, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
265, 5d1jA, 0.9440, 0.31, 1.000, 265, 265, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
266, 1oiqA, 0.9394, 0.38, 1.000, 264, 264, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
267, 1buhA, 0.9391, 1.39, 0.989, 287, 274, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
268, 5fp5A, 0.9338, 0.65, 1.000, 264, 264, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
269, 1fvvA, 0.9334, 2.01, 0.996, 298, 280, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
270, 4fx3A, 0.9331, 1.88, 0.996, 298, 279, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
271, 4fx3C, 0.9321, 1.89, 0.996, 298, 279, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
272, 3qhwC, 0.9298, 1.83, 0.996, 297, 277, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
273, 3qhwA, 0.9291, 1.84, 0.996, 297, 277, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
274, 3qhrC, 0.9283, 1.84, 0.996, 297, 277, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
275, 4eokA, 0.9281, 1.92, 0.978, 293, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
276, 1h1pA, 0.9280, 1.83, 0.957, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
277, 3qhrA, 0.9279, 1.85, 0.996, 297, 277, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
278, 2uzdA, 0.9274, 1.86, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
279, 1ob3A, 0.9263, 1.22, 0.627, 277, 268, STRUCTURE OF P. FALCIPARUM PFPK5
280, 1v0pA, 0.9257, 1.23, 0.627, 277, 268, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
281, 2c6tA, 0.9255, 1.90, 1.000, 295, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
282, 3eocA, 0.9253, 2.12, 0.996, 295, 280, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
283, 1h1sC, 0.9253, 1.91, 0.986, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
284, 1h1pC, 0.9253, 1.87, 0.957, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
285, 4yc6E, 0.9252, 1.37, 0.652, 285, 270, CDK1/CKS1
286, 4cfxC, 0.9247, 2.02, 0.989, 298, 279, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
287, 2cchC, 0.9240, 1.91, 0.953, 296, 277, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
288, 5if1A, 0.9239, 2.02, 0.996, 298, 279, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
289, 2iw8A, 0.9238, 1.98, 0.978, 297, 278, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
290, 4ii5A, 0.9231, 1.94, 0.996, 295, 277, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
291, 4eolA, 0.9231, 1.94, 0.975, 294, 277, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
292, 5cyiA, 0.9230, 2.05, 0.986, 298, 279, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
293, 4ii5C, 0.9229, 1.94, 0.996, 295, 277, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
294, 2wxvA, 0.9226, 2.04, 0.986, 302, 279, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
295, 1v0bA, 0.9224, 1.29, 0.616, 286, 268, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
296, 1h1rC, 0.9224, 1.94, 0.982, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
297, 4yc6A, 0.9221, 1.43, 0.652, 285, 270, CDK1/CKS1
298, 4i3zA, 0.9221, 1.97, 0.996, 295, 277, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
299, 4eoiC, 0.9221, 1.97, 0.982, 296, 277, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
300, 3ej1A, 0.9221, 2.14, 0.996, 295, 280, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
301, 5cyiC, 0.9220, 1.97, 0.986, 296, 277, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
302, 4yc6C, 0.9216, 1.44, 0.652, 285, 270, CDK1/CKS1
303, 2i40A, 0.9216, 2.13, 1.000, 291, 279, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
304, 1oiyC, 0.9216, 1.98, 0.986, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
305, 4i3zC, 0.9215, 1.97, 0.996, 295, 277, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
306, 4eonC, 0.9215, 2.01, 0.978, 298, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
307, 1h1qC, 0.9207, 1.99, 0.989, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
308, 4eopC, 0.9206, 1.98, 0.986, 296, 277, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
309, 3ddpC, 0.9206, 2.06, 0.986, 298, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
310, 3eidA, 0.9202, 2.16, 1.000, 292, 279, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
311, 1finA, 0.9200, 2.08, 0.996, 298, 279, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
312, 1oi9C, 0.9199, 1.99, 0.986, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
313, 1h1sA, 0.9195, 2.00, 0.989, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
314, 2wihA, 0.9194, 2.08, 0.986, 302, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
315, 2iw6C, 0.9190, 1.96, 0.982, 295, 276, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
316, 1jstC, 0.9190, 2.10, 1.000, 297, 279, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
317, 1qmzC, 0.9188, 2.00, 0.989, 296, 277, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
318, 1qmzA, 0.9183, 2.01, 0.989, 296, 277, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
319, 2g9xA, 0.9180, 2.12, 0.986, 298, 279, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
320, 4bcoA, 0.9179, 2.11, 0.986, 298, 279, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
321, 3ddpA, 0.9178, 2.08, 0.986, 297, 278, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
322, 2uzeC, 0.9178, 1.99, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
323, 4eolC, 0.9177, 2.05, 0.986, 299, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
324, 1vywA, 0.9176, 2.12, 0.986, 302, 279, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
325, 2uzlC, 0.9175, 2.01, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
326, 1h1rA, 0.9175, 2.03, 0.982, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
327, 3dogA, 0.9174, 2.12, 0.989, 297, 279, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
328, 2uzlA, 0.9173, 2.01, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
329, 1oiuA, 0.9172, 2.10, 0.989, 296, 278, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
330, 3bhuA, 0.9171, 2.13, 0.989, 297, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
331, 1oiyA, 0.9171, 2.05, 0.989, 293, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
332, 4yc6G, 0.9169, 1.55, 0.652, 285, 270, CDK1/CKS1
333, 2uzeA, 0.9168, 2.00, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
334, 4eosC, 0.9167, 2.03, 0.989, 296, 277, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
335, 2iw9A, 0.9167, 2.09, 0.986, 293, 278, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
336, 4bcnA, 0.9166, 2.15, 0.989, 296, 279, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
337, 1h1qA, 0.9166, 2.06, 0.986, 296, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
338, 5hq0A, 0.9165, 1.53, 0.659, 292, 270, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
339, 4y72A, 0.9165, 1.53, 0.659, 292, 270, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
340, 4bcpA, 0.9165, 2.13, 0.986, 298, 279, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
341, 4eonA, 0.9164, 2.18, 0.975, 299, 279, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
342, 1oi9A, 0.9164, 2.05, 0.989, 295, 277, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
343, 2cchA, 0.9163, 2.06, 0.986, 296, 277, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
344, 1oguA, 0.9162, 2.11, 0.989, 296, 278, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
345, 5nevA, 0.9159, 2.01, 0.982, 295, 276, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
346, 1gy3C, 0.9159, 2.03, 1.000, 295, 277, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
347, 1gy3A, 0.9158, 2.03, 1.000, 295, 277, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
348, 5lmkA, 0.9157, 2.16, 0.986, 296, 279, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
349, 4eoiA, 0.9151, 2.16, 0.982, 294, 279, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
350, 4cfwC, 0.9150, 2.06, 0.986, 297, 277, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
351, 5lqeA, 0.9148, 2.05, 0.982, 295, 276, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
352, 3bhtA, 0.9146, 2.16, 0.989, 297, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
353, 3ddqA, 0.9145, 2.17, 0.986, 296, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
354, 2bpmA, 0.9144, 2.15, 0.986, 302, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
355, 4eokC, 0.9143, 2.09, 0.975, 299, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
356, 4cfxA, 0.9139, 2.17, 0.982, 298, 279, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
357, 3gc0A, 0.9135, 1.77, 0.554, 278, 271, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
358, 5lqfA, 0.9132, 1.52, 0.658, 287, 269, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
359, 4eopA, 0.9131, 2.13, 0.982, 297, 278, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
360, 4eorA, 0.9130, 2.14, 0.989, 293, 278, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
361, 4d1zA, 0.9129, 0.63, 1.000, 258, 258, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
362, 2iw6A, 0.9126, 2.06, 0.986, 292, 276, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
363, 2c4gC, 0.9126, 2.21, 0.986, 300, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
364, 2bkzA, 0.9124, 2.32, 0.986, 302, 280, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
365, 4eooC, 0.9121, 2.12, 0.986, 297, 277, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
366, 4cfmA, 0.9120, 2.11, 0.989, 296, 277, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
367, 1h28A, 0.9119, 2.10, 0.989, 296, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
368, 4bcnC, 0.9118, 2.02, 0.989, 295, 275, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
369, 2cciC, 0.9118, 2.11, 0.989, 296, 277, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
370, 4eojA, 0.9117, 2.22, 0.975, 295, 279, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
371, 3f5xC, 0.9116, 2.30, 0.996, 298, 280, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
372, 1h28C, 0.9115, 2.11, 0.989, 296, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
373, 2wpaA, 0.9114, 2.21, 0.986, 302, 279, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
374, 2uzbA, 0.9110, 2.09, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
375, 1fvvC, 0.9110, 2.29, 0.993, 298, 280, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
376, 2c5nC, 0.9107, 2.19, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
377, 2c5nA, 0.9106, 2.20, 1.000, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
378, 5lqfD, 0.9104, 1.51, 0.657, 285, 268, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
379, 2c5vC, 0.9104, 2.19, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
380, 2c4gA, 0.9103, 2.15, 0.953, 301, 278, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
381, 4eosA, 0.9100, 2.18, 0.989, 296, 278, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
382, 3f5xA, 0.9100, 2.29, 0.996, 297, 279, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
383, 3bhvA, 0.9100, 2.24, 0.986, 297, 279, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
384, 1ol2C, 0.9100, 2.19, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
385, 1fq1B, 0.9100, 2.12, 0.996, 295, 278, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
386, 2wmbA, 0.9097, 2.15, 0.989, 296, 277, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
387, 1urcC, 0.9096, 2.23, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
388, 2wxvC, 0.9095, 2.23, 0.986, 299, 279, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
389, 2wevC, 0.9094, 2.21, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
390, 2uzbC, 0.9092, 2.12, 1.000, 292, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
391, 1ol1C, 0.9091, 2.22, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
392, 5nevC, 0.9089, 2.13, 0.986, 296, 277, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
393, 4bcmA, 0.9089, 2.16, 0.989, 295, 277, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
394, 3my5A, 0.9089, 2.26, 0.989, 296, 279, CDK2/CYCLINA IN COMPLEX WITH DRB
395, 4cfnA, 0.9085, 2.23, 0.986, 296, 278, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
396, 4cfwA, 0.9082, 2.27, 0.986, 299, 279, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
397, 4cfnC, 0.9082, 2.06, 0.985, 296, 275, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
398, 2v22C, 0.9082, 2.24, 0.996, 296, 278, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
399, 2c5oC, 0.9082, 2.24, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
400, 4eooA, 0.9080, 2.21, 0.986, 294, 278, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
401, 3tnwA, 0.9080, 2.27, 0.989, 295, 279, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
402, 2c5oA, 0.9079, 2.24, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
403, 1h26A, 0.9078, 2.18, 0.989, 296, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
404, 4cfuA, 0.9077, 2.28, 0.989, 299, 279, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
405, 2bkzC, 0.9077, 2.35, 0.986, 298, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
406, 4cfvA, 0.9076, 2.27, 0.986, 300, 279, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
407, 4eomA, 0.9075, 2.23, 0.975, 296, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
408, 1pkdA, 0.9072, 2.19, 0.989, 296, 277, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
409, 2cciA, 0.9071, 2.18, 0.989, 296, 277, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
410, 4bcmC, 0.9070, 2.10, 0.985, 294, 275, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
411, 5lqeC, 0.9069, 2.19, 0.986, 296, 277, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
412, 5hbhA, 0.9069, 2.18, 0.386, 336, 280, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
413, 2c5vA, 0.9068, 2.25, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
414, 4crlA, 0.9063, 2.12, 0.384, 339, 279, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
415, 2wevA, 0.9062, 2.25, 1.000, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
416, 2uueC, 0.9062, 2.28, 0.996, 296, 278, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
417, 2x1nC, 0.9060, 2.28, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
418, 2c6tC, 0.9060, 2.15, 1.000, 295, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
419, 2c5xA, 0.9058, 2.27, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
420, 1urcA, 0.9057, 2.28, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
421, 2c5xC, 0.9054, 2.26, 0.996, 296, 278, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
422, 1vywC, 0.9054, 2.41, 0.986, 299, 280, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
423, 2x1nA, 0.9052, 2.30, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
424, 2wmaA, 0.9051, 2.23, 0.986, 296, 277, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
425, 4eoqA, 0.9050, 2.26, 0.989, 295, 278, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
426, 2wipA, 0.9048, 2.06, 0.985, 297, 274, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
427, 1e9hC, 0.9048, 2.19, 0.989, 296, 277, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
428, 1ua2A, 0.9045, 1.74, 0.430, 286, 270, CRYSTAL STRUCTURE OF HUMAN CDK7
429, 2wihC, 0.9044, 2.30, 0.986, 299, 279, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
430, 1okvC, 0.9042, 2.26, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
431, 2wfyC, 0.9039, 2.28, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
432, 5a14A, 0.9038, 2.25, 0.953, 284, 277, HUMAN CDK2 WITH TYPE II INHIBITOR
433, 1okwC, 0.9038, 2.28, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
434, 5uq2A, 0.9036, 2.27, 0.996, 296, 277, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
435, 2uzdC, 0.9034, 2.20, 1.000, 295, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
436, 3gbzA, 0.9033, 1.78, 0.556, 274, 268, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
437, 3eocC, 0.9033, 2.31, 0.996, 293, 278, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
438, 2whbA, 0.9033, 2.33, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
439, 5if1C, 0.9032, 2.30, 0.993, 296, 278, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
440, 1ua2D, 0.9031, 1.76, 0.433, 286, 270, CRYSTAL STRUCTURE OF HUMAN CDK7
441, 4ec8A, 0.9026, 2.22, 0.396, 325, 278, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
442, 1pkdC, 0.9023, 2.24, 0.989, 296, 277, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
443, 1ua2B, 0.9022, 1.78, 0.433, 286, 270, CRYSTAL STRUCTURE OF HUMAN CDK7
444, 1p5eA, 0.9021, 2.25, 0.989, 296, 277, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
445, 2whbC, 0.9020, 2.32, 0.996, 296, 278, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
446, 2v22A, 0.9020, 2.32, 0.996, 296, 278, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
447, 3tnwC, 0.9017, 2.06, 0.996, 291, 273, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
448, 1ol2A, 0.9016, 2.33, 1.000, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
449, 2uueA, 0.9014, 2.34, 0.996, 296, 278, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
450, 2bpmC, 0.9010, 2.48, 0.982, 299, 280, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
451, 2wpaC, 0.9009, 2.36, 0.986, 299, 279, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
452, 2i40C, 0.9006, 2.36, 0.996, 296, 278, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
453, 1h27A, 0.9006, 2.27, 0.989, 296, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
454, 1p5eC, 0.9004, 2.25, 0.989, 296, 277, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
455, 1f5qA, 0.9001, 2.32, 0.939, 296, 277, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
456, 1e9hA, 0.9001, 2.28, 1.000, 295, 277, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
457, 1ua2C, 0.8994, 1.83, 0.433, 286, 270, CRYSTAL STRUCTURE OF HUMAN CDK7
458, 1jstA, 0.8994, 2.40, 0.993, 297, 279, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
459, 5ceiA, 0.8989, 2.18, 0.381, 345, 278, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
460, 5xs2A, 0.8988, 2.32, 0.386, 366, 280, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
461, 1ol1A, 0.8986, 2.36, 1.000, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
462, 3ej1C, 0.8981, 2.40, 0.996, 294, 279, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
463, 1okwA, 0.8975, 2.38, 0.996, 296, 278, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
464, 5hbjA, 0.8974, 2.17, 0.378, 342, 278, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
465, 1finC, 0.8973, 2.39, 0.993, 298, 279, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
466, 5icpA, 0.8966, 2.33, 0.386, 343, 280, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
467, 2wipC, 0.8962, 2.10, 0.985, 292, 272, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
468, 2wfyA, 0.8962, 2.35, 0.996, 295, 277, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
469, 6b3eC, 0.8961, 2.35, 0.428, 307, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
470, 5idpA, 0.8956, 2.20, 0.378, 342, 278, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
471, 4f7sA, 0.8956, 2.25, 0.381, 339, 278, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
472, 5l2wA, 0.8953, 2.10, 0.985, 297, 271, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
473, 4f6uA, 0.8936, 2.25, 0.371, 334, 278, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
474, 4ogrI, 0.8933, 2.43, 0.399, 318, 278, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
475, 5hnbA, 0.8932, 2.23, 0.383, 342, 277, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
476, 1h25A, 0.8932, 2.25, 0.982, 293, 274, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
477, 4or5A, 0.8928, 2.42, 0.401, 319, 277, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
478, 5idnA, 0.8927, 2.40, 0.384, 336, 279, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
479, 4yc3A, 0.8927, 1.96, 0.644, 295, 270, CDK1/CYCLINB1/CKS2 APO
480, 1blxA, 0.8927, 2.11, 0.498, 305, 271, P19INK4D/CDK6 COMPLEX
481, 6b3eA, 0.8926, 2.40, 0.424, 309, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
482, 5xqxA, 0.8926, 2.32, 0.385, 340, 278, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
483, 4ogrA, 0.8926, 2.45, 0.399, 314, 278, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
484, 5hbeA, 0.8924, 2.28, 0.384, 344, 279, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
485, 1okvA, 0.8923, 2.37, 0.924, 295, 275, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
486, 3my1A, 0.8919, 2.32, 0.399, 314, 276, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
487, 5uq1A, 0.8918, 2.06, 0.963, 288, 270, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
488, 2cjmC, 0.8915, 2.32, 0.993, 294, 276, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
489, 4j71A, 0.8914, 2.30, 0.332, 347, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
490, 4g6lA, 0.8912, 2.21, 0.380, 336, 276, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
491, 1unlB, 0.8911, 2.09, 0.585, 292, 270, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
492, 4bckA, 0.8910, 2.43, 0.986, 298, 278, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
493, 4f7nA, 0.8907, 2.31, 0.381, 334, 278, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
494, 4j1rC, 0.8906, 2.32, 0.336, 344, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
495, 4bcgA, 0.8905, 2.31, 0.402, 312, 276, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
496, 4or5F, 0.8904, 2.47, 0.404, 324, 277, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
497, 4j1rA, 0.8904, 2.32, 0.336, 343, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
498, 5i5zA, 0.8903, 2.31, 0.381, 345, 278, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
499, 4j1rD, 0.8903, 2.32, 0.336, 345, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
500, 5uq1C, 0.8899, 2.07, 0.996, 289, 270, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
501, 5oy4B, 0.8893, 2.35, 0.332, 353, 274, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
502, 1h24A, 0.8890, 2.32, 0.985, 293, 274, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
503, 4bchA, 0.8889, 2.33, 0.402, 308, 276, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
504, 1v0bB, 0.8883, 1.22, 0.591, 261, 257, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
505, 5fgkA, 0.8875, 2.35, 0.384, 331, 279, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
506, 4ogrE, 0.8873, 2.34, 0.398, 310, 274, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
507, 1gngB, 0.8872, 2.38, 0.332, 355, 274, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
508, 4bcfA, 0.8869, 2.34, 0.407, 307, 275, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
509, 5l1zA, 0.8863, 2.35, 0.398, 310, 274, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
510, 1w98A, 0.8863, 2.28, 0.985, 297, 271, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
511, 3eidC, 0.8862, 2.44, 0.996, 290, 277, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
512, 5bnjA, 0.8861, 2.32, 0.381, 343, 278, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
513, 4j71B, 0.8860, 2.37, 0.332, 347, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
514, 4au8B, 0.8860, 2.00, 0.598, 277, 266, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
515, 4bcjA, 0.8856, 2.40, 0.404, 309, 275, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
516, 5kpmA, 0.8852, 2.37, 0.336, 344, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
517, 4f6wA, 0.8849, 2.37, 0.381, 330, 278, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
518, 3mi9A, 0.8845, 2.53, 0.401, 328, 277, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
519, 4bcqC, 0.8843, 2.26, 0.989, 292, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
520, 3lq5A, 0.8843, 2.31, 0.398, 307, 274, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
521, 4pteB, 0.8840, 2.39, 0.336, 347, 274, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
522, 2jgzA, 0.8840, 2.12, 0.985, 288, 269, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
523, 4j1rB, 0.8839, 2.32, 0.338, 346, 272, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
524, 3g33A, 0.8835, 1.70, 0.479, 291, 263, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
525, 1f5qC, 0.8835, 2.22, 0.930, 288, 270, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
526, 3miaA, 0.8834, 2.54, 0.401, 324, 277, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
527, 5f94B, 0.8832, 2.41, 0.336, 349, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
528, 4f7lA, 0.8830, 2.33, 0.377, 328, 276, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 2 (TERT- BUTYL [3-({[3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5- YL]CARBAMOYL}AMINO)PROPYL]CARBAMATE)
529, 1h24C, 0.8830, 2.36, 0.985, 293, 274, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
530, 3zdiA, 0.8829, 2.45, 0.332, 348, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
531, 1h27C, 0.8829, 2.26, 0.989, 291, 272, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
532, 5oy4A, 0.8828, 2.44, 0.328, 349, 274, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
533, 4f6sA, 0.8828, 2.43, 0.379, 328, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
534, 3i4bA, 0.8828, 2.34, 0.339, 359, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
535, 3rgfA, 0.8827, 2.28, 0.376, 321, 274, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC
536, 3g33C, 0.8827, 1.71, 0.479, 291, 263, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
537, 3i4bB, 0.8826, 2.37, 0.332, 347, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
538, 5f94A, 0.8825, 2.42, 0.336, 346, 274, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
539, 4ptcB, 0.8823, 2.41, 0.339, 347, 274, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
540, 4bckC, 0.8821, 2.30, 0.989, 293, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
541, 4cxaA, 0.8819, 2.57, 0.424, 329, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
542, 5hvyA, 0.8818, 2.43, 0.377, 335, 276, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
543, 4ptcA, 0.8817, 2.37, 0.339, 342, 274, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
544, 5l2sA, 0.8813, 1.43, 0.512, 263, 258, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
545, 4f7jA, 0.8810, 2.36, 0.380, 326, 276, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
546, 4bciA, 0.8810, 2.41, 0.405, 308, 274, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
547, 2w99B, 0.8810, 1.78, 0.473, 291, 264, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
548, 5hlnB, 0.8809, 2.43, 0.336, 346, 274, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
549, 4imyE, 0.8809, 2.48, 0.408, 313, 277, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
550, 5kpmB, 0.8808, 2.44, 0.336, 345, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
551, 1ob3B, 0.8807, 1.23, 0.620, 258, 255, STRUCTURE OF P. FALCIPARUM PFPK5
552, 3gb2A, 0.8803, 2.30, 0.339, 340, 271, GSK3BETA INHIBITOR COMPLEX
553, 4f70A, 0.8802, 2.33, 0.382, 327, 275, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 4 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[2-(MORPHOLIN-4-YL) ETHYL]UREA)
554, 1j1bB, 0.8799, 2.36, 0.339, 364, 274, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
555, 1v0oA, 0.8798, 1.81, 0.612, 276, 263, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
556, 5kpkB, 0.8796, 2.45, 0.336, 344, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
557, 2w9zB, 0.8796, 1.64, 0.479, 287, 261, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
558, 1uv5A, 0.8793, 2.37, 0.336, 348, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
559, 4pteA, 0.8791, 2.35, 0.342, 341, 272, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
560, 3sayB, 0.8791, 2.47, 0.332, 347, 274, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
561, 1gngA, 0.8788, 2.41, 0.330, 348, 273, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
562, 3zrmB, 0.8784, 2.50, 0.332, 347, 274, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
563, 1v0pB, 0.8784, 1.28, 0.616, 258, 255, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
564, 3zrmA, 0.8782, 2.45, 0.333, 344, 273, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
565, 3zrlB, 0.8781, 2.50, 0.332, 347, 274, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
566, 3eb0A, 0.8781, 2.20, 0.361, 311, 269, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
567, 2o5kA, 0.8781, 2.42, 0.332, 350, 274, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
568, 3zrkA, 0.8778, 2.45, 0.333, 345, 273, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
569, 3zrkB, 0.8777, 2.50, 0.332, 348, 274, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
570, 3sd0B, 0.8775, 2.48, 0.336, 349, 274, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
571, 2cjmA, 0.8775, 2.37, 0.993, 285, 272, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
572, 4bbmA, 0.8772, 2.21, 0.399, 314, 268, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
573, 3sayA, 0.8772, 2.39, 0.338, 347, 272, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
574, 5kpkA, 0.8771, 2.49, 0.332, 346, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
575, 1j1cB, 0.8769, 2.40, 0.339, 364, 274, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
576, 1j1bA, 0.8768, 2.43, 0.336, 354, 274, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
577, 4e7wA, 0.8766, 2.48, 0.363, 359, 273, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
578, 3m1sB, 0.8766, 2.41, 0.337, 349, 273, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
579, 3nuxA, 0.8765, 1.44, 0.506, 261, 257, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
580, 3f88B, 0.8765, 2.35, 0.338, 340, 272, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
581, 3tn8A, 0.8764, 2.37, 0.407, 304, 273, CDK9/CYCLIN T IN COMPLEX WITH CAN508
582, 5hlnA, 0.8763, 2.52, 0.336, 346, 274, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
583, 3zrlA, 0.8762, 2.48, 0.333, 345, 273, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
584, 3nizA, 0.8761, 2.37, 0.568, 288, 271, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
585, 3f88A, 0.8761, 2.34, 0.338, 340, 272, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
586, 4imyA, 0.8759, 2.62, 0.408, 314, 277, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
587, 1h8fB, 0.8759, 2.49, 0.339, 350, 274, GLYCOGEN SYNTHASE KINASE 3 BETA.
588, 1h8fA, 0.8758, 2.49, 0.339, 352, 274, GLYCOGEN SYNTHASE KINASE 3 BETA.
589, 1q41B, 0.8757, 2.44, 0.336, 343, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
590, 4nm0A, 0.8750, 2.51, 0.336, 356, 274, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
591, 6b8jA, 0.8746, 2.56, 0.333, 344, 273, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
592, 4aaaA, 0.8745, 2.15, 0.412, 295, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
593, 4nu1A, 0.8744, 2.57, 0.339, 356, 274, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
594, 4acgA, 0.8744, 2.50, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
595, 3eb0C, 0.8739, 2.22, 0.358, 310, 268, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
596, 5acbC, 0.8738, 2.66, 0.432, 324, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
597, 4au8A, 0.8738, 1.80, 0.586, 276, 261, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
598, 1j1cA, 0.8736, 2.44, 0.332, 354, 274, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
599, 4krcA, 0.8735, 2.41, 0.565, 297, 271, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
600, 3f7zB, 0.8735, 2.36, 0.337, 339, 270, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
601, 4nstC, 0.8734, 2.67, 0.424, 317, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
602, 2jldB, 0.8734, 2.45, 0.337, 349, 273, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
603, 2jldA, 0.8732, 2.47, 0.337, 349, 273, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
604, 4acdA, 0.8730, 2.51, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
605, 3sd0A, 0.8730, 2.55, 0.332, 350, 274, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
606, 3m1sA, 0.8730, 2.45, 0.338, 348, 272, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
607, 1q5kA, 0.8730, 2.38, 0.336, 345, 271, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
608, 4achA, 0.8728, 2.51, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
609, 2ow3A, 0.8728, 2.57, 0.336, 346, 274, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
610, 5l2iA, 0.8727, 1.46, 0.512, 260, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
611, 4nstA, 0.8727, 2.67, 0.424, 322, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
612, 4imyC, 0.8726, 2.49, 0.405, 310, 274, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
613, 4achB, 0.8726, 2.48, 0.332, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
614, 1v0oB, 0.8725, 1.78, 0.613, 274, 261, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
615, 1o9uA, 0.8725, 2.60, 0.336, 349, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
616, 5hlpA, 0.8723, 2.39, 0.344, 337, 270, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
617, 5l2tA, 0.8721, 1.47, 0.512, 261, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
618, 2ow3B, 0.8721, 2.59, 0.332, 351, 274, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
619, 4afjA, 0.8718, 2.40, 0.341, 342, 270, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
620, 4acgB, 0.8716, 2.49, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
621, 4acdB, 0.8716, 2.53, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
622, 6gn1A, 0.8714, 2.41, 0.336, 339, 271, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
623, 6gn1B, 0.8713, 2.41, 0.336, 339, 271, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
624, 4accA, 0.8711, 2.49, 0.332, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
625, 3pupB, 0.8708, 2.51, 0.341, 347, 273, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
626, 3pupA, 0.8707, 2.51, 0.341, 346, 273, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
627, 3mtlA, 0.8704, 2.38, 0.485, 294, 272, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INDIRUBIN E804
628, 1r0eB, 0.8703, 2.57, 0.332, 344, 274, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
629, 1pyxA, 0.8703, 2.36, 0.341, 343, 270, GSK-3 BETA COMPLEXED WITH AMP-PNP
630, 5f95A, 0.8702, 2.37, 0.339, 345, 271, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
631, 4accB, 0.8702, 2.55, 0.336, 350, 274, GSK3B IN COMPLEX WITH INHIBITOR
632, 1r0eA, 0.8700, 2.57, 0.332, 344, 274, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
633, 5airB, 0.8699, 2.46, 0.342, 361, 272, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
634, 4gubA, 0.8699, 2.32, 0.313, 329, 268, CASEIN KINASE II BOUND TO INHIBITOR
635, 4nm3A, 0.8694, 2.67, 0.339, 357, 274, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
636, 4b7tA, 0.8693, 2.62, 0.332, 350, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
637, 4bcqA, 0.8687, 2.42, 0.985, 292, 271, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
638, 4afjB, 0.8687, 2.46, 0.337, 346, 270, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
639, 4krdA, 0.8685, 2.39, 0.569, 294, 269, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
640, 5t31B, 0.8683, 2.32, 0.341, 333, 267, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
641, 5acbD, 0.8683, 2.74, 0.432, 319, 278, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
642, 5airA, 0.8680, 2.47, 0.342, 353, 272, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
643, 3ofmA, 0.8680, 2.40, 0.320, 325, 269, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
644, 3od6X, 0.8679, 1.96, 0.374, 344, 262, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
645, 3gc8A, 0.8679, 2.32, 0.368, 347, 269, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
646, 5efqC, 0.8678, 2.76, 0.439, 325, 278, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
647, 4i5hA, 0.8675, 2.39, 0.379, 335, 269, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
648, 4ec9A, 0.8675, 2.44, 0.401, 306, 272, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
649, 4ib5A, 0.8674, 2.37, 0.317, 331, 268, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
650, 1g3nE, 0.8673, 2.10, 0.492, 293, 264, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
651, 4kiqA, 0.8672, 2.28, 0.381, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
652, 2pk9A, 0.8672, 2.27, 0.560, 287, 266, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
653, 4nm7A, 0.8671, 2.69, 0.326, 355, 273, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
654, 5m56A, 0.8670, 2.43, 0.320, 331, 269, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
655, 5efqA, 0.8670, 2.78, 0.435, 321, 278, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
656, 4ez5A, 0.8669, 1.44, 0.512, 258, 254, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
657, 4nm5A, 0.8668, 2.70, 0.326, 361, 273, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
658, 4kipB, 0.8666, 2.37, 0.379, 338, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
659, 3wowA, 0.8664, 2.41, 0.309, 334, 269, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
660, 5lxdB, 0.8663, 2.26, 0.323, 385, 266, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
661, 4un0C, 0.8663, 2.75, 0.430, 308, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
662, 3be9A, 0.8663, 2.44, 0.312, 327, 269, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
663, 1g3nA, 0.8662, 2.12, 0.492, 293, 264, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
664, 5lxdA, 0.8661, 2.26, 0.323, 385, 266, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
665, 4nh1B, 0.8655, 2.46, 0.312, 332, 269, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
666, 4nh1A, 0.8655, 2.46, 0.312, 330, 269, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
667, 5n9lA, 0.8654, 2.48, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
668, 3at3A, 0.8654, 2.47, 0.312, 332, 269, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
669, 1q3wA, 0.8654, 2.45, 0.341, 344, 270, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
670, 4ubaA, 0.8652, 2.44, 0.309, 333, 269, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
671, 5kplB, 0.8651, 2.43, 0.342, 339, 269, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
672, 5kwhB, 0.8650, 2.48, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
673, 1pyxB, 0.8650, 2.35, 0.347, 338, 268, GSK-3 BETA COMPLEXED WITH AMP-PNP
674, 5ztnB, 0.8649, 2.16, 0.326, 395, 264, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
675, 1xo2B, 0.8649, 2.18, 0.506, 289, 265, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
676, 5ztnA, 0.8648, 2.16, 0.326, 395, 264, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
677, 4md7H, 0.8646, 2.41, 0.317, 330, 268, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
678, 3o17B, 0.8646, 2.28, 0.372, 357, 266, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
679, 3q3bA, 0.8645, 2.45, 0.341, 344, 270, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
680, 3ngaA, 0.8645, 2.47, 0.312, 331, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
681, 3at4A, 0.8645, 2.49, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
682, 2h96B, 0.8645, 2.36, 0.367, 357, 267, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
683, 5t31A, 0.8644, 2.28, 0.340, 334, 265, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
684, 5v62A, 0.8643, 2.38, 0.377, 349, 268, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
685, 5h8bA, 0.8643, 2.45, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
686, 4md7F, 0.8643, 2.40, 0.317, 332, 268, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
687, 3q9wA, 0.8643, 2.45, 0.317, 328, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
688, 5v61A, 0.8642, 2.35, 0.377, 348, 268, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
689, 5h8bB, 0.8642, 2.49, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
690, 4kiqC, 0.8642, 2.28, 0.381, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
691, 5ooiA, 0.8641, 2.44, 0.320, 329, 269, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
692, 4kwpA, 0.8641, 2.47, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
693, 4mq2A, 0.8640, 2.26, 0.347, 343, 265, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
694, 5k5nA, 0.8638, 2.28, 0.350, 331, 266, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
695, 5h8eB, 0.8638, 2.49, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
696, 5n9nA, 0.8637, 2.52, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
697, 5buiA, 0.8637, 2.21, 0.372, 338, 266, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
698, 4qp8B, 0.8637, 2.28, 0.375, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
699, 4md7E, 0.8637, 2.41, 0.317, 332, 268, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
700, 3warA, 0.8637, 2.47, 0.309, 334, 269, CRYSTAL STRUCTURE OF HUMAN CK2A
701, 3u9cA, 0.8637, 2.42, 0.317, 331, 268, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
702, 3gc9A, 0.8637, 2.32, 0.362, 335, 268, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
703, 3tniA, 0.8635, 2.31, 0.403, 297, 268, STRUCTURE OF CDK9/CYCLIN T F241L
704, 3q9zA, 0.8635, 2.49, 0.312, 332, 269, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
705, 1q3wB, 0.8635, 2.41, 0.342, 341, 269, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
706, 5nhjA, 0.8634, 2.49, 0.383, 345, 269, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
707, 1lpuA, 0.8634, 2.47, 0.316, 327, 269, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
708, 5cqwA, 0.8633, 2.47, 0.312, 331, 269, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
709, 4md7G, 0.8633, 2.43, 0.317, 332, 268, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
710, 4kipA, 0.8633, 2.32, 0.377, 337, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
711, 3c13A, 0.8632, 2.47, 0.317, 328, 268, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
712, 5hlpB, 0.8631, 2.39, 0.341, 335, 267, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
713, 4rlkA, 0.8631, 2.47, 0.316, 327, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
714, 4azfA, 0.8631, 2.18, 0.326, 404, 264, HUMAN DYRK2 IN COMPLEX WITH LEUCETTINE L41
715, 3q04A, 0.8631, 2.49, 0.312, 328, 269, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
716, 5ku8B, 0.8630, 2.51, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
717, 4md8F, 0.8630, 2.46, 0.309, 332, 269, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
718, 3wikA, 0.8630, 2.45, 0.309, 334, 269, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
719, 3ngaB, 0.8629, 2.49, 0.312, 331, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
720, 5h8eA, 0.8628, 2.47, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
721, 3wilA, 0.8628, 2.39, 0.313, 331, 268, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
722, 2pvhA, 0.8627, 2.49, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
723, 5u6iA, 0.8626, 2.47, 0.381, 339, 268, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
724, 3kvwA, 0.8626, 2.18, 0.326, 403, 264, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
725, 3f7zA, 0.8626, 2.36, 0.333, 339, 267, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
726, 2pvnA, 0.8626, 2.49, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
727, 6g97A, 0.8625, 2.44, 0.381, 344, 268, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
728, 5n9kA, 0.8625, 2.53, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
729, 1ds5A, 0.8624, 2.48, 0.316, 328, 269, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
730, 4kiqB, 0.8623, 2.32, 0.381, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
731, 3o2mB, 0.8623, 2.28, 0.361, 358, 266, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
732, 1dayA, 0.8623, 2.48, 0.316, 327, 269, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
733, 1dawA, 0.8623, 2.50, 0.316, 327, 269, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
734, 5cu2A, 0.8622, 2.41, 0.313, 328, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
735, 4kinB, 0.8622, 2.37, 0.383, 341, 269, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
736, 3fl5A, 0.8622, 2.49, 0.316, 324, 269, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
737, 2g01B, 0.8622, 2.31, 0.357, 356, 266, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
738, 1ds5B, 0.8622, 2.49, 0.316, 328, 269, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
739, 3k2lA, 0.8621, 2.36, 0.325, 402, 265, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
740, 2zoqB, 0.8621, 2.39, 0.392, 351, 268, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
741, 1jamA, 0.8621, 2.50, 0.316, 327, 269, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
742, 5ooiB, 0.8620, 2.45, 0.320, 325, 269, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
743, 4yljA, 0.8620, 2.27, 0.347, 346, 265, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
744, 3pvgA, 0.8620, 2.48, 0.316, 326, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
745, 5cx9A, 0.8619, 2.43, 0.313, 328, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
746, 5b0xA, 0.8619, 2.49, 0.312, 329, 269, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
747, 3bqcA, 0.8619, 2.49, 0.317, 328, 268, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
748, 3at2A, 0.8619, 2.47, 0.309, 334, 269, CRYSTAL STRUCTURE OF CK2ALPHA
749, 1ds5C, 0.8619, 2.49, 0.316, 328, 269, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
750, 3u9cB, 0.8618, 2.43, 0.317, 331, 268, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
751, 3u87A, 0.8618, 2.49, 0.312, 329, 269, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
752, 1lp4A, 0.8618, 2.50, 0.316, 327, 269, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
753, 4md8E, 0.8617, 2.48, 0.312, 332, 269, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
754, 3pzhA, 0.8617, 2.50, 0.316, 327, 269, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
755, 5ct0A, 0.8616, 2.36, 0.311, 326, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
756, 4yu2A, 0.8615, 2.34, 0.346, 348, 266, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
757, 4md9H, 0.8615, 2.50, 0.309, 328, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
758, 2pvkA, 0.8615, 2.49, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
759, 5mmrA, 0.8614, 2.36, 0.311, 326, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
760, 5kwhA, 0.8614, 2.51, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
761, 5cu0A, 0.8614, 2.34, 0.315, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
762, 4dgmA, 0.8614, 2.50, 0.316, 326, 269, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
763, 3e3bX, 0.8614, 2.50, 0.320, 334, 269, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
764, 3q9xB, 0.8613, 2.44, 0.317, 330, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
765, 5motA, 0.8612, 2.40, 0.318, 328, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
766, 5modA, 0.8612, 2.36, 0.311, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
767, 4qp9A, 0.8612, 2.29, 0.375, 335, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
768, 3pe1A, 0.8612, 2.45, 0.313, 327, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
769, 3blrA, 0.8612, 2.41, 0.400, 300, 270, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
770, 2fysA, 0.8612, 2.30, 0.375, 348, 267, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
771, 1ds5D, 0.8612, 2.50, 0.316, 328, 269, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
772, 5mohA, 0.8610, 2.34, 0.316, 326, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
773, 5kplA, 0.8610, 2.40, 0.337, 339, 267, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
774, 4md8H, 0.8610, 2.50, 0.312, 331, 269, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
775, 4aguB, 0.8610, 2.21, 0.398, 276, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
776, 3q9zB, 0.8610, 2.46, 0.317, 332, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
777, 3owkA, 0.8610, 2.55, 0.312, 330, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
778, 3mb7A, 0.8610, 2.56, 0.312, 330, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
779, 3du8A, 0.8610, 2.39, 0.340, 336, 268, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
780, 1jwhB, 0.8610, 2.54, 0.312, 335, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
781, 5oueA, 0.8609, 2.46, 0.313, 328, 268, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
782, 5oniA, 0.8609, 2.46, 0.310, 334, 268, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
783, 4md8G, 0.8609, 2.50, 0.309, 332, 269, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
784, 3o2mA, 0.8609, 2.29, 0.361, 358, 266, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
785, 3kxgA, 0.8609, 2.49, 0.316, 326, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
786, 5oniB, 0.8608, 2.38, 0.310, 334, 268, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
787, 3mb6A, 0.8608, 2.54, 0.317, 329, 268, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
788, 5t1hB, 0.8607, 2.53, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
789, 5cquA, 0.8607, 2.42, 0.313, 328, 268, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
790, 4mygB, 0.8607, 2.38, 0.386, 335, 267, MAPK13 ACTIVE FORM
791, 3axwA, 0.8607, 2.51, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
792, 4dgnA, 0.8606, 2.51, 0.316, 325, 269, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
793, 3pe2A, 0.8606, 2.45, 0.313, 327, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
794, 6gmdB, 0.8605, 2.38, 0.311, 326, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
795, 5oumA, 0.8605, 2.37, 0.311, 326, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
796, 1unlA, 0.8605, 2.41, 0.572, 292, 269, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
797, 1i09B, 0.8605, 2.47, 0.338, 341, 269, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
798, 5os7A, 0.8604, 2.38, 0.311, 326, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
799, 5nhhA, 0.8604, 2.54, 0.383, 348, 269, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
800, 4rllA, 0.8604, 2.55, 0.312, 329, 269, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
801, 4dgoA, 0.8604, 2.52, 0.316, 325, 269, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
802, 3r0tA, 0.8604, 2.46, 0.313, 327, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
803, 2pvmA, 0.8604, 2.50, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
804, 5othA, 0.8603, 2.40, 0.311, 326, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
805, 5ctpB, 0.8603, 2.46, 0.313, 327, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
806, 5cqwB, 0.8603, 2.51, 0.312, 331, 269, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
807, 4yljD, 0.8603, 2.27, 0.347, 347, 265, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
808, 4ib5C, 0.8603, 2.55, 0.312, 332, 269, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
809, 3q9xA, 0.8603, 2.53, 0.312, 330, 269, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
810, 5ot5A, 0.8602, 2.40, 0.311, 326, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
811, 5mmfA, 0.8602, 2.38, 0.311, 326, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
812, 3q3bB, 0.8602, 2.45, 0.342, 341, 269, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
813, 1q5kB, 0.8601, 2.43, 0.336, 344, 268, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
814, 5h8gA, 0.8600, 2.25, 0.313, 324, 265, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
815, 3owlA, 0.8600, 2.55, 0.312, 330, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
816, 3owjA, 0.8600, 2.55, 0.312, 328, 269, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
817, 4yljC, 0.8599, 2.30, 0.347, 346, 265, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
818, 3fwqB, 0.8599, 2.49, 0.289, 334, 270, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
819, 2pvlA, 0.8599, 2.52, 0.312, 327, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
820, 1j91B, 0.8599, 2.60, 0.315, 327, 270, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
821, 5otlB, 0.8598, 2.40, 0.311, 326, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
822, 5orhB, 0.8598, 2.35, 0.312, 325, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
823, 5n1vB, 0.8598, 2.51, 0.312, 331, 269, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
824, 1q41A, 0.8598, 2.39, 0.348, 339, 267, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
825, 4anmA, 0.8597, 2.50, 0.316, 328, 269, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
826, 3du8B, 0.8597, 2.42, 0.343, 339, 268, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
827, 5csvA, 0.8596, 2.41, 0.318, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
828, 4qp7A, 0.8596, 2.33, 0.375, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
829, 4ptgA, 0.8596, 2.33, 0.353, 333, 266, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
830, 4md9G, 0.8596, 2.52, 0.312, 329, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
831, 4lfiB, 0.8596, 2.54, 0.290, 371, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
832, 4lfiA, 0.8596, 2.54, 0.290, 370, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
833, 4auaA, 0.8596, 1.39, 0.510, 256, 251, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
834, 4aguA, 0.8596, 2.26, 0.398, 277, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
835, 3u87B, 0.8596, 2.52, 0.312, 329, 269, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
836, 2pvjA, 0.8596, 2.51, 0.312, 326, 269, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
837, 1zogA, 0.8596, 2.51, 0.316, 325, 269, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
838, 1lr4A, 0.8596, 2.52, 0.316, 327, 269, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
839, 5mo8A, 0.8595, 2.40, 0.311, 325, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
840, 5v60A, 0.8594, 2.43, 0.384, 347, 268, PHOSPHO-ERK2 BOUND TO AMP-PCP
841, 4aguC, 0.8594, 2.22, 0.398, 278, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
842, 3ocgA, 0.8594, 2.28, 0.372, 336, 266, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
843, 4yu2B, 0.8592, 2.31, 0.347, 347, 265, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
844, 4md9P, 0.8592, 2.52, 0.309, 328, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
845, 2pvrA, 0.8592, 2.48, 0.313, 328, 268, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
846, 1m2qA, 0.8592, 2.59, 0.316, 327, 269, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
847, 1jsuA, 0.8592, 2.56, 0.924, 285, 264, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
848, 3u4uA, 0.8591, 2.38, 0.311, 327, 267, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
849, 5nhoA, 0.8590, 2.53, 0.390, 343, 269, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
850, 5cspA, 0.8590, 2.41, 0.318, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
851, 4md9E, 0.8590, 2.52, 0.309, 329, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
852, 4dglD, 0.8590, 2.55, 0.312, 328, 269, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
853, 5nqcA, 0.8589, 2.60, 0.310, 331, 271, CK2ALPHA IN COMPLEX WITH NMR154
854, 5mo5A, 0.8589, 2.36, 0.312, 326, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
855, 1zohA, 0.8589, 2.52, 0.316, 326, 269, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
856, 5moeA, 0.8588, 2.35, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
857, 5mo7A, 0.8588, 2.41, 0.311, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
858, 3vuiA, 0.8588, 2.48, 0.360, 355, 267, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
859, 3o17A, 0.8588, 2.37, 0.361, 357, 266, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
860, 2qc6A, 0.8588, 2.54, 0.316, 326, 269, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
861, 5t1hA, 0.8587, 2.51, 0.312, 331, 269, CRYSTAL STRUCTURE OF CK2
862, 5ot6A, 0.8587, 2.41, 0.311, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
863, 4mq2D, 0.8587, 2.27, 0.348, 329, 264, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
864, 1na7A, 0.8587, 2.45, 0.313, 326, 268, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
865, 5k5nB, 0.8586, 2.21, 0.350, 334, 263, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
866, 3kxmA, 0.8586, 2.53, 0.316, 326, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
867, 5m4cA, 0.8585, 2.49, 0.312, 329, 269, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
868, 4qteA, 0.8585, 2.53, 0.387, 348, 269, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
869, 3qa0A, 0.8585, 2.55, 0.312, 330, 269, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
870, 1om1A, 0.8585, 2.53, 0.316, 325, 269, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
871, 5cvhA, 0.8584, 2.43, 0.311, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA
872, 4kiqD, 0.8584, 2.41, 0.377, 338, 268, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
873, 5cu0B, 0.8583, 2.40, 0.311, 325, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
874, 4yu2D, 0.8583, 2.31, 0.347, 346, 265, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
875, 4qp4A, 0.8583, 2.34, 0.375, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
876, 2gmxB, 0.8583, 2.45, 0.356, 357, 267, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
877, 4fv6A, 0.8582, 2.23, 0.371, 332, 264, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
878, 3vugA, 0.8582, 2.49, 0.360, 356, 267, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
879, 3q9yA, 0.8582, 2.49, 0.313, 327, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
880, 2vx3A, 0.8582, 2.31, 0.347, 346, 265, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
881, 4md9F, 0.8581, 2.44, 0.310, 327, 268, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
882, 5otiA, 0.8580, 2.45, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
883, 3qa0B, 0.8580, 2.49, 0.317, 330, 268, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
884, 2oxxA, 0.8580, 2.54, 0.316, 325, 269, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
885, 2oxdA, 0.8580, 2.53, 0.316, 325, 269, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
886, 5cu6A, 0.8579, 2.44, 0.315, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA
887, 4fv7A, 0.8579, 2.43, 0.382, 342, 267, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
888, 2h96A, 0.8579, 2.38, 0.361, 358, 266, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
889, 1j91A, 0.8579, 2.58, 0.316, 327, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
890, 5ts8A, 0.8578, 2.56, 0.320, 332, 269, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
891, 5otyA, 0.8578, 2.44, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
892, 3w55A, 0.8578, 2.49, 0.381, 335, 268, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
893, 3vuhA, 0.8578, 2.49, 0.360, 355, 267, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
894, 5otzA, 0.8577, 2.47, 0.313, 327, 268, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
895, 5clpB, 0.8577, 2.47, 0.313, 327, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
896, 3mvlB, 0.8576, 2.37, 0.378, 339, 267, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
897, 1m2pA, 0.8576, 2.54, 0.316, 325, 269, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
898, 3kxnA, 0.8575, 2.52, 0.316, 327, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
899, 2zoqA, 0.8575, 2.52, 0.394, 351, 269, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
900, 2oxyA, 0.8575, 2.54, 0.316, 327, 269, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
901, 3gc9B, 0.8573, 2.40, 0.351, 339, 268, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
902, 5orjA, 0.8572, 2.39, 0.312, 325, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
903, 5oquA, 0.8571, 2.41, 0.312, 324, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
904, 5mpjA, 0.8570, 2.43, 0.311, 326, 267, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
905, 4md9M, 0.8570, 2.56, 0.309, 331, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
906, 1zoeA, 0.8570, 2.54, 0.316, 325, 269, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
907, 5owlB, 0.8569, 2.54, 0.312, 332, 269, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
908, 5movA, 0.8569, 2.39, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
909, 5m4uA, 0.8569, 2.51, 0.321, 332, 268, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
910, 3zduA, 0.8569, 2.45, 0.348, 297, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
911, 5mo6A, 0.8568, 2.39, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
912, 3gc8B, 0.8568, 2.42, 0.351, 346, 268, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
913, 5mowA, 0.8567, 2.39, 0.312, 328, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
914, 5mo7B, 0.8567, 2.40, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
915, 5ku8A, 0.8567, 2.54, 0.313, 328, 268, CRYSTAL STRUCTURE OF CK2
916, 3kxhA, 0.8567, 2.54, 0.316, 326, 269, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
917, 5othB, 0.8566, 2.41, 0.312, 324, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
918, 4mq1A, 0.8566, 2.29, 0.348, 345, 264, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
919, 4md9K, 0.8566, 2.55, 0.312, 328, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
920, 3vukA, 0.8566, 2.50, 0.360, 355, 267, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
921, 3juhA, 0.8566, 2.59, 0.317, 334, 271, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
922, 6gihA, 0.8565, 2.35, 0.318, 324, 264, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
923, 6ehkA, 0.8565, 2.45, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
924, 5os8A, 0.8565, 2.50, 0.313, 327, 268, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
925, 4yljB, 0.8565, 2.33, 0.347, 347, 265, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
926, 4kinD, 0.8565, 2.42, 0.376, 339, 266, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
927, 5ot5B, 0.8564, 2.41, 0.312, 325, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
928, 2zjwA, 0.8564, 2.45, 0.313, 332, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
929, 5n1vA, 0.8563, 2.54, 0.312, 331, 269, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
930, 5mp8A, 0.8563, 2.38, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
931, 5k4iA, 0.8563, 2.31, 0.372, 336, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
932, 4grbA, 0.8563, 2.41, 0.311, 327, 267, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
933, 5bvdA, 0.8562, 2.14, 0.370, 330, 262, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
934, 3mvlA, 0.8562, 2.37, 0.378, 339, 267, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
935, 1pjkA, 0.8562, 2.48, 0.313, 331, 268, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
936, 5ot6B, 0.8561, 2.39, 0.312, 326, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
937, 5omyA, 0.8561, 2.41, 0.315, 332, 267, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
938, 5m56B, 0.8561, 2.58, 0.320, 328, 269, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
939, 3h30B, 0.8561, 2.62, 0.310, 333, 271, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
940, 4yu2C, 0.8560, 2.36, 0.347, 346, 265, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
941, 4nifE, 0.8560, 2.47, 0.387, 348, 269, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
942, 6gmdA, 0.8559, 2.39, 0.308, 325, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
943, 5orkA, 0.8559, 2.42, 0.312, 324, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
944, 1zz2A, 0.8559, 2.43, 0.381, 337, 268, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
945, 5owlA, 0.8558, 2.69, 0.312, 331, 269, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
946, 5cu2B, 0.8558, 2.40, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
947, 5os7B, 0.8557, 2.40, 0.308, 325, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
948, 5mo8B, 0.8557, 2.42, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
949, 4nifB, 0.8557, 2.48, 0.387, 349, 269, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
950, 4md9L, 0.8557, 2.58, 0.309, 328, 269, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
951, 4azeA, 0.8557, 2.36, 0.347, 348, 265, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
952, 1q4lA, 0.8557, 2.43, 0.345, 342, 267, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
953, 5oulA, 0.8556, 2.46, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
954, 4mq2C, 0.8556, 2.24, 0.350, 339, 263, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
955, 4fbxA, 0.8556, 2.41, 0.315, 333, 267, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
956, 4azeC, 0.8556, 2.37, 0.347, 348, 265, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
957, 4mq1B, 0.8555, 2.31, 0.348, 340, 264, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
958, 4kinA, 0.8555, 2.38, 0.386, 338, 267, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
959, 4azeB, 0.8555, 2.36, 0.347, 345, 265, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
960, 3rpsA, 0.8555, 2.40, 0.315, 334, 267, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
961, 2qkrA, 0.8555, 2.06, 0.564, 273, 259, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
962, 2gmxA, 0.8555, 2.39, 0.372, 357, 266, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
963, 5otdA, 0.8554, 2.45, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
964, 5m4fA, 0.8554, 2.57, 0.312, 330, 269, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
965, 2g01A, 0.8554, 2.49, 0.367, 355, 267, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
966, 5cu3A, 0.8553, 2.42, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
967, 4mq2B, 0.8553, 2.33, 0.348, 338, 264, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
968, 5ouuB, 0.8552, 2.42, 0.312, 325, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
969, 1f0qA, 0.8552, 2.60, 0.316, 329, 269, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
970, 5bveA, 0.8551, 2.15, 0.370, 330, 262, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
971, 4fmqA, 0.8551, 2.47, 0.381, 350, 268, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
972, 5oumB, 0.8550, 2.41, 0.312, 326, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
973, 5otoA, 0.8550, 2.45, 0.311, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
974, 5ke0A, 0.8550, 2.62, 0.383, 340, 269, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
975, 3vudA, 0.8550, 2.42, 0.368, 355, 266, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
976, 2y9qA, 0.8550, 2.43, 0.378, 349, 267, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
977, 5cx9B, 0.8548, 2.41, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
978, 5cvfA, 0.8547, 2.41, 0.320, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
979, 2oxyB, 0.8547, 2.57, 0.316, 327, 269, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
980, 2no3A, 0.8547, 2.43, 0.361, 357, 266, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
981, 2gphA, 0.8547, 2.47, 0.377, 345, 268, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
982, 5orjB, 0.8546, 2.41, 0.312, 324, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
983, 4ib5B, 0.8546, 2.64, 0.312, 329, 269, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
984, 5orhA, 0.8545, 2.41, 0.312, 324, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
985, 5cu3B, 0.8544, 2.44, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
986, 4ubaB, 0.8544, 2.57, 0.309, 333, 269, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
987, 5oslA, 0.8543, 2.50, 0.313, 328, 268, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
988, 6eiiB, 0.8542, 2.43, 0.312, 326, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
989, 5owhA, 0.8542, 2.42, 0.315, 334, 267, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
990, 5y86A, 0.8541, 2.43, 0.321, 391, 265, CRYSTAL STRUCTURE OF KINASE 
991, 4cxaC, 0.8541, 2.86, 0.431, 330, 274, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
992, 3h30A, 0.8541, 2.66, 0.310, 333, 271, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
993, 5lxcB, 0.8540, 2.48, 0.323, 385, 266, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
994, 4iq6B, 0.8540, 2.42, 0.350, 332, 266, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
995, 3zu7A, 0.8538, 2.45, 0.352, 344, 267, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
996, 5oueB, 0.8537, 2.44, 0.312, 326, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
997, 5mmrB, 0.8537, 2.41, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
998, 4iz5D, 0.8536, 2.47, 0.366, 347, 268, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
999, 4iz5A, 0.8536, 2.47, 0.366, 347, 268, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
1000, 3gp0A, 0.8536, 2.28, 0.354, 333, 263, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
1001, 5cu4A, 0.8535, 2.52, 0.313, 327, 268, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1002, 4iz5B, 0.8535, 2.47, 0.366, 347, 268, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
1003, 5mo6B, 0.8534, 2.44, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1004, 5mmfB, 0.8534, 2.42, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1005, 4iz5C, 0.8534, 2.47, 0.366, 347, 268, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
1006, 6ehuB, 0.8533, 2.42, 0.316, 327, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1007, 5cvhB, 0.8533, 2.44, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA
1008, 3oxiA, 0.8533, 2.29, 0.360, 322, 264, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
1009, 5ct0B, 0.8532, 2.42, 0.312, 326, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1010, 4qnyA, 0.8532, 2.45, 0.331, 333, 269, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
1011, 2vx3B, 0.8532, 2.32, 0.348, 340, 264, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
1012, 1h4lA, 0.8532, 2.18, 0.590, 278, 261, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1013, 6eiiA, 0.8531, 2.44, 0.312, 326, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
1014, 4mygA, 0.8531, 2.55, 0.390, 335, 267, MAPK13 ACTIVE FORM
1015, 1di9A, 0.8531, 2.42, 0.378, 348, 267, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
1016, 5otrA, 0.8530, 2.50, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
1017, 5oquB, 0.8530, 2.44, 0.312, 324, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
1018, 5mpjB, 0.8530, 2.42, 0.312, 324, 266, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1019, 1q3dB, 0.8530, 2.47, 0.343, 339, 268, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
1020, 1q3dA, 0.8530, 2.51, 0.343, 339, 268, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
1021, 3zuvC, 0.8529, 2.51, 0.388, 357, 268, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
1022, 3o0gA, 0.8529, 2.43, 0.577, 289, 267, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1023, 4mwhA, 0.8528, 2.62, 0.290, 371, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1024, 2no3B, 0.8528, 2.47, 0.372, 357, 266, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
1025, 5moeB, 0.8527, 2.38, 0.309, 323, 265, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1026, 5etaB, 0.8527, 2.33, 0.371, 335, 264, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1027, 5cshA, 0.8527, 2.44, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1028, 3juhB, 0.8527, 2.80, 0.312, 334, 272, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1029, 4fi1A, 0.8526, 2.62, 0.290, 371, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1030, 3i60A, 0.8526, 2.31, 0.379, 335, 264, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
1031, 2b9iA, 0.8526, 2.52, 0.392, 338, 268, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
1032, 5mo5B, 0.8525, 2.43, 0.312, 325, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1033, 5cs6A, 0.8524, 2.53, 0.311, 327, 267, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1034, 3nszA, 0.8524, 2.46, 0.311, 327, 267, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
1035, 3mvmA, 0.8523, 2.37, 0.376, 335, 263, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1036, 1m2rA, 0.8523, 2.64, 0.316, 327, 269, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1037, 5g6vA, 0.8522, 2.96, 0.529, 308, 276, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
1038, 2vx3D, 0.8522, 2.33, 0.348, 342, 264, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
1039, 4h3qA, 0.8521, 2.53, 0.387, 352, 269, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1040, 3pwdA, 0.8521, 2.62, 0.316, 327, 269, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
1041, 3o8uA, 0.8521, 2.31, 0.365, 332, 263, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1042, 3blqA, 0.8521, 2.47, 0.403, 295, 268, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
1043, 1w82A, 0.8521, 2.55, 0.377, 351, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1044, 3zuvA, 0.8520, 2.52, 0.381, 357, 268, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
1045, 3rpsB, 0.8520, 2.43, 0.293, 334, 266, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1046, 4f9cA, 0.8519, 2.22, 0.281, 306, 263, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND XL413
1047, 3fklA, 0.8519, 2.50, 0.379, 344, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
1048, 5ctpA, 0.8518, 2.45, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1049, 5otdB, 0.8516, 2.46, 0.312, 324, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
1050, 5ouuA, 0.8515, 2.39, 0.314, 324, 264, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1051, 4jqeA, 0.8514, 2.65, 0.290, 369, 269, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
1052, 3v3vA, 0.8514, 2.50, 0.361, 351, 266, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
1053, 5bujA, 0.8513, 2.18, 0.370, 331, 262, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
1054, 4kinC, 0.8513, 2.42, 0.376, 338, 266, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1055, 3fmhA, 0.8513, 2.45, 0.378, 347, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1056, 5modB, 0.8512, 2.46, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1057, 2wo6B, 0.8512, 2.36, 0.348, 339, 264, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
1058, 4ux9D, 0.8511, 2.28, 0.368, 344, 261, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1059, 4f99A, 0.8509, 2.36, 0.280, 312, 264, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1060, 5mowB, 0.8508, 2.46, 0.312, 324, 266, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1061, 5cvgA, 0.8508, 2.40, 0.313, 326, 265, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1062, 3c9wA, 0.8508, 2.46, 0.390, 336, 267, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
1063, 2vx3C, 0.8508, 2.28, 0.350, 338, 263, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
1064, 3hv4B, 0.8507, 2.63, 0.381, 338, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1065, 2pmiC, 0.8507, 2.39, 0.567, 285, 263, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
1066, 5nhlA, 0.8506, 2.62, 0.384, 345, 268, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1067, 3fwqA, 0.8506, 2.65, 0.289, 334, 270, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1068, 5cshB, 0.8505, 2.35, 0.316, 323, 263, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1069, 3w8lB, 0.8505, 2.54, 0.313, 326, 268, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1070, 3blhA, 0.8505, 2.45, 0.410, 291, 266, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
1071, 1q99A, 0.8505, 2.52, 0.302, 354, 268, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
1072, 5y9mA, 0.8504, 2.36, 0.314, 320, 264, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1073, 4f9bC, 0.8503, 2.36, 0.280, 316, 264, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1074, 3anqA, 0.8503, 2.42, 0.347, 342, 265, HUMAN DYRK1A/INHIBITOR COMPLEX
1075, 2b9hA, 0.8503, 2.58, 0.390, 337, 269, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
1076, 3nupA, 0.8502, 1.36, 0.500, 252, 248, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1077, 1wbwA, 0.8502, 2.60, 0.372, 351, 269, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1078, 2rg6A, 0.8501, 2.35, 0.379, 335, 264, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
1079, 2erkA, 0.8500, 2.53, 0.381, 351, 268, PHOSPHORYLATED MAP KINASE ERK2
1080, 1q8zA, 0.8500, 2.53, 0.310, 354, 268, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
1081, 1q4lB, 0.8499, 2.37, 0.343, 337, 265, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
1082, 1h4lB, 0.8499, 2.22, 0.590, 278, 261, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1083, 5bueA, 0.8498, 2.22, 0.370, 329, 262, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
1084, 2b9jA, 0.8498, 2.58, 0.390, 337, 269, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
1085, 5otoB, 0.8496, 2.49, 0.312, 324, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
1086, 3c9wB, 0.8496, 2.49, 0.390, 336, 267, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
1087, 5nhvA, 0.8495, 2.63, 0.384, 345, 268, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1088, 4qnyB, 0.8495, 2.49, 0.327, 339, 269, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
1089, 4f9bA, 0.8495, 2.37, 0.280, 318, 264, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1090, 2rg5A, 0.8495, 2.30, 0.380, 333, 263, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
1091, 1lewA, 0.8495, 2.49, 0.386, 341, 267, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
1092, 5nhpA, 0.8494, 2.63, 0.384, 338, 268, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1093, 5lxcA, 0.8494, 2.41, 0.326, 383, 264, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
1094, 1unhA, 0.8494, 2.15, 0.587, 276, 259, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1095, 3ctqA, 0.8493, 2.49, 0.365, 336, 266, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
1096, 4mq1D, 0.8492, 2.33, 0.350, 336, 263, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1097, 3gcuB, 0.8492, 2.66, 0.381, 337, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1098, 5oyfA, 0.8491, 2.45, 0.316, 327, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
1099, 2b9fA, 0.8491, 2.52, 0.392, 337, 268, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
1100, 2jd5A, 0.8490, 2.48, 0.318, 353, 267, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
1101, 5orkB, 0.8489, 2.46, 0.309, 323, 265, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
1102, 3nnxA, 0.8489, 2.51, 0.385, 336, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
1103, 3hllA, 0.8489, 2.50, 0.384, 337, 268, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
1104, 1wbsA, 0.8489, 2.63, 0.377, 351, 268, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1105, 6ehuA, 0.8487, 2.58, 0.315, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1106, 3nieA, 0.8487, 2.69, 0.402, 369, 271, CRYSTAL STRUCTURE OF PF11_0147
1107, 2r7iB, 0.8487, 2.42, 0.316, 322, 263, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1108, 4f9aC, 0.8486, 2.39, 0.280, 317, 264, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1109, 2g9xC, 0.8486, 1.97, 0.988, 274, 255, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
1110, 3mvmB, 0.8484, 2.34, 0.373, 332, 263, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1111, 3anrA, 0.8483, 2.45, 0.347, 342, 265, HUMAN DYRK1A/HARMINE COMPLEX
1112, 2r7iD, 0.8483, 2.43, 0.316, 322, 263, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1113, 4fv8A, 0.8482, 2.31, 0.373, 333, 263, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
1114, 3d7zA, 0.8480, 2.58, 0.369, 348, 268, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1115, 1zyjA, 0.8479, 2.41, 0.373, 331, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
1116, 1jwhA, 0.8478, 2.61, 0.309, 336, 269, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1117, 5y9mX, 0.8477, 2.37, 0.316, 319, 263, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1118, 3hv5B, 0.8477, 2.68, 0.381, 339, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1119, 3bv2A, 0.8477, 2.40, 0.374, 337, 265, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
1120, 5mz3A, 0.8476, 2.62, 0.375, 350, 267, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
1121, 4ewqA, 0.8476, 2.50, 0.363, 346, 267, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
1122, 3nnwA, 0.8476, 2.63, 0.373, 349, 268, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
1123, 3nieB, 0.8476, 2.71, 0.402, 367, 271, CRYSTAL STRUCTURE OF PF11_0147
1124, 6g9aA, 0.8475, 2.65, 0.381, 341, 268, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1125, 4mq1C, 0.8475, 2.29, 0.351, 328, 262, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1126, 4f9aA, 0.8475, 2.40, 0.284, 315, 264, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1127, 4qtbA, 0.8474, 2.65, 0.388, 351, 268, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1128, 3anqB, 0.8474, 2.46, 0.347, 343, 265, HUMAN DYRK1A/INHIBITOR COMPLEX
1129, 2f9gA, 0.8474, 2.49, 0.393, 332, 267, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
1130, 6g93A, 0.8473, 2.65, 0.381, 343, 268, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1131, 5bvfA, 0.8473, 2.12, 0.367, 327, 259, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1132, 3py3A, 0.8473, 2.47, 0.383, 355, 266, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
1133, 4izaA, 0.8472, 2.55, 0.367, 346, 267, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1134, 1q99B, 0.8471, 2.75, 0.299, 364, 271, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
1135, 3hl7A, 0.8469, 2.47, 0.386, 336, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
1136, 2zb0A, 0.8469, 2.65, 0.379, 349, 269, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1137, 2r7iA, 0.8469, 2.45, 0.312, 322, 263, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1138, 2onlB, 0.8469, 2.51, 0.391, 339, 266, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1139, 1q8zB, 0.8469, 2.76, 0.299, 364, 271, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
1140, 4qtbB, 0.8468, 2.66, 0.388, 348, 268, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1141, 3p7cA, 0.8468, 2.43, 0.365, 332, 263, P38 INHIBITOR-BOUND
1142, 3flyA, 0.8468, 2.52, 0.375, 347, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1143, 3rocA, 0.8467, 2.54, 0.388, 337, 268, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1144, 4l7fA, 0.8466, 2.57, 0.352, 354, 267, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1145, 4fv9A, 0.8466, 2.30, 0.382, 331, 262, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1146, 1unhB, 0.8465, 2.18, 0.583, 276, 259, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1147, 5mp8B, 0.8464, 2.43, 0.311, 323, 264, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1148, 1ouyA, 0.8464, 2.51, 0.382, 350, 267, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
1149, 1lezA, 0.8464, 2.51, 0.386, 343, 267, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1150, 2okrA, 0.8463, 2.53, 0.391, 339, 266, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1151, 5m4iA, 0.8462, 2.60, 0.288, 331, 267, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1152, 3flzA, 0.8462, 2.52, 0.375, 347, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1153, 3anrB, 0.8462, 2.47, 0.347, 342, 265, HUMAN DYRK1A/HARMINE COMPLEX
1154, 1howA, 0.8462, 2.58, 0.317, 346, 268, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
1155, 3p5kA, 0.8460, 2.49, 0.367, 332, 264, P38 INHIBITOR-BOUND
1156, 4ub7A, 0.8459, 2.47, 0.298, 334, 265, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1157, 3ptgA, 0.8459, 2.48, 0.380, 340, 266, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1158, 3nnvA, 0.8459, 2.62, 0.377, 348, 268, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
1159, 3e3pA, 0.8459, 2.58, 0.362, 337, 265, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1160, 5yf9B, 0.8458, 2.35, 0.313, 319, 262, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1161, 3nwwA, 0.8458, 2.54, 0.393, 339, 267, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
1162, 4ptgB, 0.8457, 2.32, 0.345, 332, 261, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
1163, 3vulA, 0.8457, 2.42, 0.360, 344, 264, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1164, 1wboA, 0.8457, 2.58, 0.373, 351, 268, FRAGMENT BASED P38 INHIBITORS
1165, 5yf9X, 0.8456, 2.35, 0.317, 319, 262, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1166, 5f95B, 0.8456, 2.37, 0.344, 338, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1167, 4nctD, 0.8456, 2.43, 0.345, 331, 264, HUMAN DYRK1A IN COMPLEX WITH PKC412
1168, 2wo6A, 0.8456, 2.53, 0.347, 344, 265, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
1169, 4jr7A, 0.8455, 2.54, 0.284, 367, 264, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1170, 1wbtA, 0.8455, 2.64, 0.371, 351, 267, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1171, 5xyyA, 0.8454, 2.67, 0.375, 350, 269, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1172, 3iphA, 0.8454, 2.62, 0.377, 345, 268, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1173, 1oukA, 0.8454, 2.45, 0.357, 348, 266, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
1174, 5etaA, 0.8453, 2.37, 0.369, 336, 263, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1175, 2y8oA, 0.8453, 2.46, 0.385, 339, 265, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A MAPK DOCKING PEPTIDE
1176, 2balA, 0.8453, 2.53, 0.393, 337, 267, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1177, 3odzX, 0.8451, 2.35, 0.385, 335, 262, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1178, 3kf7A, 0.8451, 2.51, 0.386, 337, 267, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1179, 5otlA, 0.8450, 2.39, 0.321, 320, 262, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
1180, 4ka3A, 0.8449, 2.50, 0.383, 340, 266, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1181, 3dt1A, 0.8449, 2.60, 0.381, 356, 268, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
1182, 3mptA, 0.8448, 2.60, 0.381, 347, 268, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
1183, 1q97B, 0.8448, 2.78, 0.299, 361, 271, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
1184, 5otqA, 0.8447, 2.63, 0.311, 327, 267, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 33
1185, 3nnuA, 0.8446, 2.69, 0.377, 348, 268, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1186, 3bv3A, 0.8446, 2.52, 0.380, 338, 266, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1187, 5xvuB, 0.8445, 2.54, 0.311, 321, 267, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1188, 5g6vB, 0.8445, 3.01, 0.524, 302, 275, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
1189, 3bx5A, 0.8445, 2.51, 0.383, 338, 266, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1190, 2onlA, 0.8445, 2.50, 0.396, 338, 265, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1191, 2jd5B, 0.8445, 2.77, 0.299, 360, 271, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
1192, 3anqC, 0.8444, 2.49, 0.347, 340, 265, HUMAN DYRK1A/INHIBITOR COMPLEX
1193, 5x8iA, 0.8443, 2.70, 0.296, 328, 267, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1194, 5oszA, 0.8443, 2.52, 0.316, 327, 266, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
1195, 2ozaB, 0.8443, 2.53, 0.365, 340, 266, STRUCTURE OF P38ALPHA COMPLEX
1196, 2eu9A, 0.8442, 2.74, 0.290, 345, 269, CRYSTAL STRUCTURE OF CLK3
1197, 5x8iB, 0.8441, 2.71, 0.296, 327, 267, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1198, 3mh0A, 0.8441, 2.47, 0.369, 332, 263, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1199, 5a3xB, 0.8440, 2.49, 0.347, 340, 265, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1200, 6fyrA, 0.8439, 2.67, 0.291, 355, 268, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
1201, 3w8lA, 0.8438, 2.59, 0.310, 326, 268, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1202, 2r7iC, 0.8438, 2.45, 0.313, 321, 262, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1203, 3p78A, 0.8437, 2.52, 0.367, 332, 264, P38 INHIBITOR-BOUND
1204, 5a4eA, 0.8436, 2.38, 0.346, 341, 263, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1205, 5a3xD, 0.8436, 2.46, 0.348, 331, 264, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1206, 5a4qB, 0.8435, 2.45, 0.348, 335, 264, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1207, 3p7bA, 0.8435, 2.52, 0.367, 332, 264, P38 INHIBITOR-BOUND
1208, 5hd7A, 0.8434, 2.77, 0.379, 347, 269, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1209, 3uvpA, 0.8434, 2.61, 0.374, 334, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1210, 3p79A, 0.8434, 2.52, 0.367, 332, 264, P38 INHIBITOR-BOUND
1211, 3gcvA, 0.8433, 2.50, 0.373, 338, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1212, 4eojC, 0.8432, 2.35, 0.962, 282, 260, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
1213, 2zb1A, 0.8432, 2.68, 0.373, 345, 268, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1214, 3e92A, 0.8430, 2.66, 0.369, 348, 268, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1215, 1w83A, 0.8430, 2.68, 0.371, 351, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1216, 3tnhA, 0.8429, 2.38, 0.412, 288, 262, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1217, 1r3cA, 0.8429, 2.63, 0.377, 349, 268, THE STRUCTURE OF P38ALPHA C162S MUTANT
1218, 1h25C, 0.8428, 2.26, 0.981, 278, 259, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1219, 5tbeA, 0.8427, 2.30, 0.368, 332, 261, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1220, 5a4lB, 0.8427, 2.47, 0.348, 339, 264, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1221, 3lffA, 0.8427, 2.57, 0.370, 335, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1222, 6g33B, 0.8426, 2.86, 0.299, 337, 268, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1223, 3kq7A, 0.8426, 2.69, 0.375, 348, 267, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1224, 4f9yA, 0.8425, 2.58, 0.382, 339, 267, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1225, 4ehvA, 0.8425, 2.53, 0.377, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1226, 4eh2A, 0.8425, 2.46, 0.383, 337, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1227, 4looA, 0.8423, 2.57, 0.384, 349, 268, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
1228, 3flwA, 0.8423, 2.61, 0.371, 345, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1229, 2ghmA, 0.8423, 2.51, 0.380, 336, 266, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1230, 4fa2A, 0.8422, 2.61, 0.386, 339, 267, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1231, 6gdqA, 0.8421, 2.61, 0.378, 339, 267, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1232, 4ic7A, 0.8421, 2.68, 0.401, 355, 269, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1233, 3flsA, 0.8421, 2.44, 0.375, 343, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1234, 1w84A, 0.8420, 2.53, 0.357, 351, 266, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1235, 3vumA, 0.8419, 2.46, 0.348, 347, 264, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1236, 3hv4A, 0.8419, 2.92, 0.387, 339, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1237, 3e3pB, 0.8419, 2.66, 0.362, 337, 265, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1238, 1q97A, 0.8417, 2.52, 0.316, 351, 266, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
1239, 3uvrA, 0.8416, 2.65, 0.370, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1240, 3p4kA, 0.8415, 2.49, 0.374, 338, 265, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1241, 5a54B, 0.8414, 2.49, 0.348, 339, 264, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1242, 4nctB, 0.8414, 2.51, 0.348, 333, 264, HUMAN DYRK1A IN COMPLEX WITH PKC412
1243, 4h3pA, 0.8413, 2.73, 0.379, 342, 269, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1244, 3mgyA, 0.8413, 2.25, 0.375, 329, 259, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1245, 5xvuA, 0.8412, 2.59, 0.311, 321, 267, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1246, 3e93A, 0.8412, 2.72, 0.371, 346, 267, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1247, 5xvuC, 0.8411, 2.59, 0.311, 321, 267, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1248, 5clpA, 0.8411, 2.49, 0.316, 322, 263, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1249, 4ux9A, 0.8411, 2.58, 0.374, 343, 265, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1250, 5lw1H, 0.8408, 2.66, 0.351, 355, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1251, 2okrD, 0.8408, 2.51, 0.383, 339, 264, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1252, 5lw1B, 0.8407, 2.65, 0.362, 355, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1253, 1bl6A, 0.8406, 2.60, 0.360, 351, 267, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1254, 5nzzE, 0.8405, 2.43, 0.376, 343, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1255, 4f9wA, 0.8405, 2.49, 0.377, 336, 265, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1256, 3o8tA, 0.8405, 2.56, 0.364, 332, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1257, 4nctA, 0.8404, 2.51, 0.348, 341, 264, HUMAN DYRK1A IN COMPLEX WITH PKC412
1258, 1ungA, 0.8404, 2.50, 0.570, 288, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1259, 5lw1E, 0.8403, 2.67, 0.362, 355, 268, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1260, 5a3xA, 0.8402, 2.55, 0.347, 342, 265, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1261, 3s3iA, 0.8401, 2.65, 0.381, 349, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1262, 5larA, 0.8400, 2.71, 0.348, 350, 267, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
1263, 4yr8C, 0.8399, 2.21, 0.345, 318, 258, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1264, 3e7oA, 0.8399, 2.57, 0.356, 342, 267, CRYSTAL STRUCTURE OF JNK2
1265, 5nzzF, 0.8398, 2.39, 0.378, 341, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1266, 5a4lA, 0.8398, 2.52, 0.348, 341, 264, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1267, 5a54A, 0.8397, 2.52, 0.348, 341, 264, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1268, 3anrC, 0.8397, 2.56, 0.347, 337, 265, HUMAN DYRK1A/HARMINE COMPLEX
1269, 1q8yA, 0.8397, 2.54, 0.316, 351, 266, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
1270, 4ux9C, 0.8396, 2.74, 0.371, 333, 267, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1271, 3n9xB, 0.8395, 2.78, 0.413, 374, 271, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1272, 6fyvA, 0.8393, 2.68, 0.286, 329, 266, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
1273, 1ywrA, 0.8393, 2.58, 0.380, 338, 266, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1274, 6fypA, 0.8392, 2.94, 0.289, 348, 270, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
1275, 5hd4A, 0.8392, 2.75, 0.384, 347, 268, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1276, 5a4tB, 0.8392, 2.52, 0.345, 339, 264, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1277, 5a3xC, 0.8391, 2.56, 0.347, 333, 265, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1278, 1wbnA, 0.8391, 2.73, 0.375, 351, 267, FRAGMENT BASED P38 INHIBITORS
1279, 6fyoA, 0.8390, 2.86, 0.296, 331, 267, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
1280, 2gtnA, 0.8390, 2.63, 0.380, 337, 266, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1281, 6fykB, 0.8389, 2.83, 0.287, 349, 268, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1282, 4aa4A, 0.8389, 2.51, 0.394, 347, 264, P38ALPHA MAP KINASE BOUND TO CMPD 22
1283, 1m7qA, 0.8389, 2.60, 0.371, 348, 267, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1284, 4qyyA, 0.8388, 2.71, 0.353, 337, 266, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
1285, 5a4eB, 0.8387, 2.66, 0.352, 322, 264, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1286, 4zthA, 0.8387, 2.65, 0.380, 339, 266, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1287, 2zazA, 0.8387, 2.52, 0.375, 345, 264, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1288, 6ft9C, 0.8386, 2.95, 0.299, 337, 268, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1289, 5j1vA, 0.8386, 2.83, 0.296, 338, 267, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1290, 5a4qA, 0.8385, 2.53, 0.348, 341, 264, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1291, 3hp2A, 0.8385, 2.63, 0.383, 341, 266, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1292, 3i5zA, 0.8384, 2.40, 0.378, 331, 262, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1293, 1bl7A, 0.8384, 2.61, 0.371, 351, 267, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1294, 3lhjA, 0.8383, 2.63, 0.368, 341, 266, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1295, 3ds6D, 0.8383, 2.64, 0.381, 349, 268, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1296, 2lgcA, 0.8383, 2.57, 0.372, 359, 266, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1297, 1wbvA, 0.8383, 2.73, 0.375, 351, 267, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1298, 5a4tA, 0.8381, 2.53, 0.348, 341, 264, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1299, 4fv4A, 0.8381, 2.29, 0.378, 329, 259, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1300, 3gcuA, 0.8378, 2.81, 0.376, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1301, 6g33A, 0.8377, 2.77, 0.294, 335, 265, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1302, 4iz7C, 0.8377, 2.67, 0.352, 340, 267, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1303, 2zduA, 0.8377, 2.70, 0.378, 330, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1304, 5m44A, 0.8376, 2.62, 0.291, 329, 265, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1305, 5etfA, 0.8375, 2.57, 0.370, 338, 265, STRUCTURE OF DEAD KINASE MAPK14 WITH BOUND THE KIM DOMAIN OF MKK6
1306, 5a4tD, 0.8375, 2.50, 0.350, 332, 263, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1307, 4aa5A, 0.8375, 2.48, 0.395, 340, 263, P38ALPHA MAP KINASE BOUND TO CMPD 33
1308, 3newA, 0.8375, 2.47, 0.373, 334, 263, P38-ALPHA COMPLEXED WITH COMPOUND 10
1309, 3fmkA, 0.8375, 2.57, 0.383, 346, 266, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1310, 3fmjA, 0.8375, 2.54, 0.371, 344, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1311, 3kvxA, 0.8374, 2.46, 0.373, 327, 263, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1312, 1bmkA, 0.8374, 2.59, 0.357, 351, 266, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1313, 4ux9B, 0.8373, 2.64, 0.369, 327, 263, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1314, 4qp8A, 0.8373, 2.57, 0.375, 335, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
1315, 4ic7D, 0.8373, 2.76, 0.398, 353, 269, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
1316, 3n9xA, 0.8373, 2.83, 0.410, 374, 271, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1317, 6ekdA, 0.8372, 2.45, 0.364, 325, 264, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1318, 5aikB, 0.8371, 2.59, 0.347, 342, 265, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1319, 4e73A, 0.8371, 2.53, 0.364, 318, 264, CRYSTAL STRUCTURE OF JNK1BETA-JIP IN COMPLEX WITH AN AZAQUINOLONE INHBITOR
1320, 4nctC, 0.8370, 2.51, 0.346, 339, 263, HUMAN DYRK1A IN COMPLEX WITH PKC412
1321, 4fv5A, 0.8370, 2.42, 0.378, 330, 262, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1322, 4bgqA, 0.8370, 2.43, 0.388, 276, 263, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1323, 4aacA, 0.8369, 2.50, 0.395, 350, 263, P38ALPHA MAP KINASE BOUND TO CMPD 29
1324, 3anqD, 0.8369, 2.51, 0.350, 334, 263, HUMAN DYRK1A/INHIBITOR COMPLEX
1325, 2pmiA, 0.8369, 2.32, 0.568, 284, 257, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
1326, 6ft9A, 0.8368, 2.85, 0.296, 336, 267, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1327, 6fykA, 0.8367, 2.85, 0.284, 349, 268, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1328, 4eh7A, 0.8367, 2.62, 0.385, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1329, 1q8yB, 0.8367, 2.78, 0.295, 357, 268, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
1330, 5j1wA, 0.8366, 2.85, 0.296, 338, 267, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1331, 3hv5A, 0.8365, 2.82, 0.376, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1332, 3c5uA, 0.8365, 2.58, 0.376, 338, 266, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1333, 3gfeA, 0.8364, 2.63, 0.368, 352, 266, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1334, 5a4eD, 0.8363, 2.58, 0.348, 331, 264, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1335, 4eh8A, 0.8363, 2.50, 0.380, 336, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1336, 3fv8A, 0.8362, 2.52, 0.367, 331, 264, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1337, 5a4qD, 0.8361, 2.52, 0.350, 334, 263, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1338, 6fykC, 0.8360, 2.82, 0.288, 349, 267, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1339, 4o2zA, 0.8359, 2.62, 0.347, 363, 265, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1340, 5nguA, 0.8358, 2.74, 0.386, 339, 267, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1341, 5aikC, 0.8358, 2.61, 0.347, 342, 265, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1342, 2yixA, 0.8357, 2.65, 0.356, 351, 267, TRIAZOLOPYRIDINE INHIBITORS OF P38
1343, 1wzyA, 0.8357, 2.79, 0.379, 350, 269, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
1344, 1cm8B, 0.8357, 2.47, 0.377, 327, 260, PHOSPHORYLATED MAP KINASE P38-GAMMA
1345, 4dglC, 0.8356, 2.81, 0.309, 334, 269, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1346, 3qudA, 0.8356, 2.70, 0.387, 345, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1347, 2xrwA, 0.8356, 2.48, 0.347, 348, 262, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1348, 2eufB, 0.8356, 2.18, 0.525, 282, 255, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1349, 1cm8A, 0.8356, 2.47, 0.377, 327, 260, PHOSPHORYLATED MAP KINASE P38-GAMMA
1350, 5aikA, 0.8355, 2.55, 0.348, 344, 264, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1351, 4o6eA, 0.8354, 2.65, 0.387, 328, 266, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
1352, 3flnC, 0.8354, 2.44, 0.388, 343, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1353, 1zzlA, 0.8354, 2.66, 0.360, 351, 267, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1354, 3fmmA, 0.8353, 2.57, 0.358, 346, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1355, 3ds6A, 0.8353, 2.70, 0.367, 343, 267, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1356, 3flqA, 0.8352, 2.48, 0.376, 345, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1357, 5a4lD, 0.8351, 2.54, 0.350, 334, 263, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1358, 4iz7A, 0.8351, 2.63, 0.351, 344, 265, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1359, 3fknA, 0.8351, 2.73, 0.367, 346, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1360, 5a4qC, 0.8350, 2.53, 0.350, 332, 263, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1361, 3o0gB, 0.8350, 1.78, 0.593, 264, 248, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1362, 2f49A, 0.8350, 2.80, 0.356, 335, 267, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
1363, 1p38A, 0.8350, 2.65, 0.358, 351, 265, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1364, 4l8mA, 0.8349, 2.71, 0.376, 339, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1365, 3l1sA, 0.8349, 2.33, 0.351, 336, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1366, 1w7hA, 0.8349, 2.62, 0.370, 351, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1367, 5mtxA, 0.8348, 2.54, 0.376, 331, 263, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1368, 4eh6A, 0.8347, 2.47, 0.378, 335, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1369, 4g1wA, 0.8344, 2.55, 0.360, 322, 264, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 7-FLUORO-3- [4-(2-HYDROXY-ETHANESULFONYL)-BENZYL]-4-OXO-1-PHENYL-14-DIHYDRO- QUINOLINE-2-CARBOXYLIC ACID METHYL ESTER
1370, 3hecA, 0.8344, 2.53, 0.364, 329, 261, P38 IN COMPLEX WITH IMATINIB
1371, 4awiA, 0.8343, 2.65, 0.371, 352, 267, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1372, 5uojA, 0.8342, 2.65, 0.358, 343, 265, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1373, 5a54C, 0.8340, 2.54, 0.354, 332, 263, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1374, 6g33C, 0.8339, 2.98, 0.299, 336, 268, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1375, 5aikD, 0.8339, 2.59, 0.348, 342, 264, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1376, 3rinA, 0.8339, 2.83, 0.379, 349, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1377, 1yw2A, 0.8338, 2.75, 0.378, 341, 267, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1378, 4eh3A, 0.8337, 2.64, 0.383, 339, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1379, 6dcgA, 0.8336, 2.70, 0.337, 326, 264, DISCOVERY OF MK-8353: AN ORALLY BIOAVAILABLE DUAL MECHANISM ERK INHIBITOR FOR ONCOLOGY 
1380, 3queA, 0.8336, 2.71, 0.387, 343, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1381, 2zdtA, 0.8336, 2.67, 0.382, 342, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1382, 4lopD, 0.8335, 2.57, 0.376, 351, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1383, 3zyaA, 0.8335, 2.55, 0.364, 346, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1384, 4qp1B, 0.8334, 2.64, 0.381, 343, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1385, 3p7aA, 0.8334, 2.55, 0.369, 332, 263, P38 INHIBITOR-BOUND
1386, 2ojjA, 0.8334, 2.81, 0.346, 344, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1387, 5j1vB, 0.8333, 2.91, 0.296, 337, 267, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1388, 1oguC, 0.8333, 2.02, 0.980, 272, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1389, 3rawA, 0.8332, 2.90, 0.291, 351, 268, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1390, 3u8wA, 0.8330, 2.65, 0.368, 349, 266, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1391, 6g9hA, 0.8328, 2.78, 0.368, 343, 266, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1392, 4r3cA, 0.8328, 2.57, 0.354, 335, 263, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1393, 4bbmB, 0.8328, 2.22, 0.416, 292, 255, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1394, 3hp5A, 0.8328, 2.45, 0.375, 330, 261, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1395, 2ojgA, 0.8328, 2.83, 0.352, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1396, 5etcA, 0.8326, 2.69, 0.361, 355, 266, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1397, 1z57A, 0.8326, 3.00, 0.299, 333, 268, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
1398, 4qp7B, 0.8325, 2.62, 0.375, 335, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
1399, 3nr9A, 0.8325, 2.93, 0.287, 341, 268, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1400, 5byyA, 0.8324, 2.64, 0.402, 338, 266, ERK5 IN COMPLEX WITH SMALL MOLECULE
1401, 5a4lC, 0.8324, 2.57, 0.350, 332, 263, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1402, 5cs6B, 0.8323, 2.35, 0.318, 316, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1403, 4qtaA, 0.8322, 2.66, 0.340, 335, 265, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1404, 3uvqA, 0.8321, 2.52, 0.392, 333, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1405, 3anrD, 0.8321, 2.57, 0.350, 340, 263, HUMAN DYRK1A/HARMINE COMPLEX
1406, 3nr9C, 0.8320, 2.87, 0.288, 347, 267, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1407, 5n66A, 0.8319, 2.52, 0.382, 332, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1408, 4fv3A, 0.8319, 2.84, 0.382, 346, 267, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
1409, 6g8xA, 0.8318, 2.75, 0.378, 338, 267, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1410, 4xj0A, 0.8317, 2.69, 0.381, 345, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1411, 3oefX, 0.8317, 2.81, 0.389, 334, 265, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1412, 3fkoA, 0.8317, 2.52, 0.361, 343, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1413, 2fysB, 0.8317, 2.69, 0.377, 338, 268, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
1414, 3o8pA, 0.8316, 2.67, 0.348, 336, 264, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1415, 3l1sB, 0.8316, 2.39, 0.347, 330, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1416, 4iq6A, 0.8315, 2.37, 0.349, 324, 258, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1417, 3gi3A, 0.8315, 2.51, 0.368, 330, 261, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1418, 6ft8A, 0.8314, 3.03, 0.299, 338, 268, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
1419, 4hyuA, 0.8313, 2.57, 0.348, 322, 264, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(3- METHANESULFONYL-PROPOXY)-INDAZOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
1420, 5a54D, 0.8312, 2.59, 0.354, 334, 263, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1421, 3d83A, 0.8312, 2.75, 0.377, 347, 265, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1422, 4xrlA, 0.8311, 2.76, 0.361, 337, 266, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1423, 3erkA, 0.8311, 2.86, 0.377, 350, 268, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
1424, 6cpwA, 0.8310, 2.68, 0.338, 328, 263, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
1425, 2wu6A, 0.8310, 2.97, 0.283, 350, 269, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI
1426, 4qp4B, 0.8309, 2.68, 0.373, 335, 268, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1427, 4fuxA, 0.8309, 2.79, 0.382, 342, 267, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
1428, 2ojiA, 0.8309, 2.83, 0.352, 344, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1429, 3teiA, 0.8308, 2.70, 0.387, 339, 266, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1430, 5nzzG, 0.8307, 2.55, 0.388, 342, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1431, 4qtdA, 0.8307, 2.70, 0.371, 355, 267, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1432, 4eorC, 0.8307, 2.04, 0.944, 270, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1433, 3bhuC, 0.8307, 2.05, 0.988, 271, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
1434, 3mpaA, 0.8306, 2.47, 0.375, 331, 261, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1435, 1a9uA, 0.8306, 2.70, 0.343, 351, 265, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1436, 4izyA, 0.8305, 2.58, 0.348, 322, 264, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(4- METHANESULFONYL-PIPERIDIN-1-YL)-INDOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
1437, 4dljA, 0.8305, 2.56, 0.363, 336, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1438, 3fskA, 0.8305, 2.63, 0.370, 342, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1439, 3cgfA, 0.8305, 2.78, 0.381, 346, 268, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1440, 6g91A, 0.8304, 2.75, 0.371, 344, 267, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1441, 4ylkA, 0.8304, 2.67, 0.323, 341, 263, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-CHLORO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5S
1442, 4yllA, 0.8303, 2.68, 0.323, 340, 263, CRYSTAL STRUCTURE OF DYRK1AA IN COMPLEX WITH 10-BROMO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5T
1443, 4h3pD, 0.8302, 2.75, 0.386, 338, 267, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
1444, 6ft7B, 0.8301, 2.90, 0.286, 356, 269, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
1445, 3obgA, 0.8301, 2.58, 0.380, 332, 263, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1446, 4y46A, 0.8298, 2.70, 0.382, 340, 267, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1447, 4qpaB, 0.8298, 2.65, 0.352, 345, 264, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1448, 3itzA, 0.8298, 2.86, 0.366, 357, 268, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1449, 5j1wB, 0.8297, 2.94, 0.292, 337, 267, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1450, 5ci6B, 0.8297, 2.60, 0.352, 350, 264, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1451, 4eomC, 0.8297, 2.18, 0.972, 275, 253, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
1452, 3rawB, 0.8297, 2.93, 0.295, 349, 268, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1453, 2gfsA, 0.8296, 2.58, 0.357, 344, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1454, 4zzoA, 0.8295, 2.73, 0.361, 339, 266, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1455, 4ditA, 0.8295, 2.24, 0.344, 328, 256, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1456, 2ghlA, 0.8294, 2.53, 0.385, 334, 262, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1457, 4eh4A, 0.8293, 2.60, 0.378, 337, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1458, 1oveA, 0.8293, 2.72, 0.368, 349, 266, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1459, 3eljA, 0.8292, 2.74, 0.367, 347, 267, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1460, 3nr9B, 0.8291, 2.86, 0.289, 347, 266, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1461, 2wu7A, 0.8291, 3.06, 0.285, 348, 270, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25
1462, 6g9nA, 0.8290, 2.71, 0.352, 344, 264, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1463, 6eq9A, 0.8290, 2.68, 0.380, 350, 266, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
1464, 4ianA, 0.8290, 2.64, 0.309, 321, 265, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
1465, 1oz1A, 0.8290, 2.65, 0.371, 344, 264, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1466, 6g9dA, 0.8289, 2.80, 0.368, 345, 266, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1467, 5etiA, 0.8289, 2.69, 0.355, 355, 265, STRUCTURE OF DEAD KINASE MAPK14
1468, 5a4tC, 0.8289, 2.61, 0.354, 332, 263, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1469, 4erkA, 0.8288, 2.85, 0.360, 350, 267, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
1470, 4yr8A, 0.8287, 2.57, 0.370, 320, 262, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1471, 3hv3A, 0.8286, 2.59, 0.370, 335, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1472, 6g9mA, 0.8285, 2.85, 0.368, 341, 266, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1473, 3bhtC, 0.8285, 2.05, 0.964, 270, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
1474, 3amyA, 0.8285, 2.46, 0.308, 318, 260, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
1475, 2vagA, 0.8285, 2.87, 0.294, 330, 265, CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR
1476, 1ungB, 0.8285, 2.15, 0.586, 268, 251, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1477, 1i09A, 0.8285, 2.38, 0.357, 338, 258, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1478, 4qp1A, 0.8284, 2.73, 0.366, 342, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1479, 3fmnA, 0.8284, 2.48, 0.375, 341, 261, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1480, 4fv1A, 0.8283, 2.89, 0.342, 342, 266, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
1481, 3pzeA, 0.8283, 2.78, 0.352, 347, 267, JNK1 IN COMPLEX WITH INHIBITOR
1482, 4fv2A, 0.8282, 2.93, 0.381, 344, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
1483, 2gtmA, 0.8282, 2.64, 0.384, 341, 263, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1484, 1wfcA, 0.8281, 2.62, 0.350, 340, 263, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1485, 4bcoC, 0.8280, 2.04, 0.988, 269, 250, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1486, 1r39A, 0.8280, 2.70, 0.364, 345, 264, THE STRUCTURE OF P38ALPHA
1487, 4un0D, 0.8279, 2.64, 0.452, 276, 263, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
1488, 3gcqA, 0.8279, 2.62, 0.366, 337, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1489, 1jnkA, 0.8279, 2.73, 0.382, 346, 267, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1490, 3pg1A, 0.8278, 2.81, 0.331, 341, 266, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1491, 3hegA, 0.8278, 2.56, 0.356, 333, 261, P38 IN COMPLEX WITH SORAFENIB
1492, 1ukiA, 0.8278, 2.64, 0.352, 328, 264, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1493, 3s4qA, 0.8276, 2.24, 0.383, 326, 256, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1494, 2fa2A, 0.8276, 2.88, 0.356, 333, 267, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
1495, 1golA, 0.8276, 2.88, 0.356, 357, 267, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
1496, 6ge0A, 0.8275, 2.84, 0.368, 343, 266, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1497, 5lcjA, 0.8274, 2.73, 0.357, 345, 266, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1498, 2iw9C, 0.8274, 1.99, 0.984, 268, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
1499, 4xp3A, 0.8273, 2.78, 0.361, 339, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1500, 3mh1A, 0.8272, 2.66, 0.342, 337, 263, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1501, 5unpA, 0.8270, 2.94, 0.288, 347, 267, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
1502, 4tyhB, 0.8270, 2.53, 0.368, 335, 261, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1503, 4hysA, 0.8270, 2.63, 0.348, 321, 264, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-(4- INDAZOL-1-YL-PYRIMIDIN-2-YLAMINO)-CYCLOHEXAN
1504, 2r9sA, 0.8270, 2.54, 0.368, 325, 261, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1505, 1erkA, 0.8270, 2.94, 0.348, 357, 267, STRUCTURE OF SIGNAL-REGULATED KINASE
1506, 5unpB, 0.8269, 2.94, 0.288, 347, 267, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
1507, 5nhfA, 0.8269, 2.87, 0.386, 339, 267, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1508, 4zzmA, 0.8269, 2.82, 0.382, 344, 267, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
1509, 3cgoA, 0.8269, 2.74, 0.382, 332, 267, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1510, 5umoA, 0.8268, 2.89, 0.352, 347, 267, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
1511, 4x21B, 0.8268, 2.61, 0.370, 336, 265, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1512, 2r9sB, 0.8267, 2.53, 0.368, 325, 261, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1513, 1tvoA, 0.8267, 2.92, 0.381, 350, 268, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1514, 4y5hA, 0.8266, 2.75, 0.382, 349, 267, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1515, 3tg1A, 0.8266, 2.61, 0.363, 334, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1516, 3ds6B, 0.8266, 2.77, 0.382, 343, 267, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1517, 4xp2A, 0.8264, 2.89, 0.363, 337, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1518, 4s34A, 0.8263, 2.87, 0.342, 343, 266, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
1519, 1yqjA, 0.8263, 2.75, 0.355, 356, 265, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1520, 4s2zA, 0.8262, 2.92, 0.348, 346, 267, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
1521, 2p33A, 0.8262, 2.74, 0.382, 332, 267, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1522, 3lfbA, 0.8261, 2.61, 0.379, 333, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1523, 6ft7A, 0.8260, 3.02, 0.285, 356, 270, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
1524, 4s33A, 0.8259, 2.93, 0.341, 347, 267, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
1525, 4lopA, 0.8259, 2.68, 0.383, 351, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1526, 3g90X, 0.8259, 2.70, 0.381, 345, 265, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1527, 3fmlA, 0.8258, 2.54, 0.364, 342, 261, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1528, 4x21A, 0.8257, 2.75, 0.361, 336, 266, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1529, 4lopB, 0.8257, 2.69, 0.383, 350, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1530, 4kkhA, 0.8257, 2.86, 0.381, 351, 268, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1531, 5nzzH, 0.8255, 2.51, 0.378, 335, 259, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1532, 4eoqC, 0.8254, 2.24, 0.988, 275, 253, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
1533, 5uq3A, 0.8253, 2.53, 0.941, 270, 253, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1-P27 TERNARY COMPLEX
1534, 4kkeA, 0.8253, 2.76, 0.382, 354, 267, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1535, 3objA, 0.8253, 2.78, 0.357, 332, 263, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1536, 4izaC, 0.8252, 2.70, 0.341, 335, 264, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
1537, 4s31A, 0.8251, 2.91, 0.342, 347, 266, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
1538, 3qywA, 0.8251, 2.79, 0.361, 340, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1539, 3bhvC, 0.8251, 2.13, 0.988, 271, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
1540, 2i6lA, 0.8251, 2.63, 0.330, 292, 261, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1541, 1kv1A, 0.8251, 2.57, 0.387, 331, 261, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1542, 4w4wA, 0.8250, 2.86, 0.381, 349, 268, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1543, 4b99A, 0.8250, 2.68, 0.409, 335, 264, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
1544, 4zznA, 0.8249, 2.78, 0.368, 338, 266, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
1545, 4ifcB, 0.8248, 2.68, 0.311, 329, 264, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
1546, 3fl4A, 0.8248, 2.57, 0.383, 339, 261, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1547, 2fa2B, 0.8248, 2.97, 0.356, 332, 267, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
1548, 6g9kA, 0.8245, 2.84, 0.347, 343, 265, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1549, 2puuA, 0.8245, 2.49, 0.375, 330, 259, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1550, 6ft9B, 0.8244, 2.99, 0.281, 337, 267, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1551, 3fi4A, 0.8243, 2.43, 0.390, 339, 259, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1552, 2z7lA, 0.8243, 2.85, 0.387, 329, 266, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
1553, 2f49B, 0.8243, 2.94, 0.356, 337, 267, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
1554, 4n4sA, 0.8242, 2.84, 0.348, 342, 267, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1555, 3v6sB, 0.8242, 2.61, 0.367, 340, 264, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1556, 4ifcA, 0.8240, 2.73, 0.313, 327, 265, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
1557, 6eq9B, 0.8239, 2.66, 0.351, 332, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
1558, 4cfuC, 0.8238, 2.16, 0.988, 272, 251, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1559, 3ttiA, 0.8238, 2.79, 0.382, 341, 267, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1560, 3r63A, 0.8238, 2.98, 0.341, 347, 267, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
1561, 3k3iA, 0.8238, 2.62, 0.379, 332, 261, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1562, 4s32A, 0.8237, 2.96, 0.341, 346, 267, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
1563, 4qp3B, 0.8236, 2.50, 0.390, 331, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1564, 3g9nA, 0.8236, 2.75, 0.383, 346, 266, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1565, 3ds6C, 0.8236, 2.74, 0.368, 349, 266, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1566, 2qd9A, 0.8236, 2.57, 0.391, 330, 261, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1567, 2o0uA, 0.8236, 2.76, 0.382, 331, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1568, 4eh9A, 0.8234, 2.56, 0.385, 334, 260, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1569, 3v6sA, 0.8234, 2.75, 0.368, 349, 266, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1570, 4qp3A, 0.8233, 2.67, 0.366, 339, 262, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
1571, 4kkgA, 0.8233, 2.77, 0.382, 353, 267, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1572, 4g6oA, 0.8233, 2.92, 0.380, 339, 266, CRYSTAL STRUCTURE OF THE ERK2
1573, 4g6nA, 0.8233, 2.91, 0.350, 341, 266, CRYSTAL STRUCTURE OF THE ERK2
1574, 3l8xA, 0.8233, 2.24, 0.373, 326, 255, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1575, 6g9jA, 0.8230, 2.78, 0.357, 347, 263, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1576, 5mtyA, 0.8230, 2.51, 0.372, 328, 258, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1577, 5tcoA, 0.8228, 2.63, 0.367, 327, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1578, 5lckA, 0.8228, 2.77, 0.366, 345, 265, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
1579, 4h36A, 0.8226, 2.88, 0.382, 353, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1580, 3oc1A, 0.8226, 2.49, 0.371, 330, 259, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1581, 4xneA, 0.8225, 2.88, 0.351, 344, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1582, 4h3bC, 0.8225, 2.89, 0.382, 351, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1583, 4h3bA, 0.8225, 2.89, 0.382, 351, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1584, 5byzA, 0.8224, 2.96, 0.398, 348, 269, ERK5 IN COMPLEX WITH SMALL MOLECULE
1585, 4bcpC, 0.8224, 2.02, 0.988, 267, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1586, 3e7oB, 0.8224, 2.61, 0.333, 326, 261, CRYSTAL STRUCTURE OF JNK2
1587, 2pk9C, 0.8224, 2.00, 0.565, 266, 248, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1588, 4yr8E, 0.8223, 2.66, 0.366, 317, 262, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1589, 3ttjA, 0.8222, 2.97, 0.377, 333, 268, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1590, 2iw8C, 0.8222, 1.91, 0.984, 265, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
1591, 1pmuA, 0.8222, 2.77, 0.383, 342, 266, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1592, 4zsjA, 0.8221, 2.74, 0.356, 344, 264, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1593, 3gc7A, 0.8220, 2.83, 0.365, 349, 266, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1594, 6fylA, 0.8219, 2.87, 0.259, 340, 266, X-RAY STRUCTURE OF CLK2-KD(136-496)/CX-4945 AT 1.95A 
1595, 4gt3A, 0.8219, 2.97, 0.346, 347, 266, ATP-BOUND FORM OF THE ERK2 KINASE
1596, 3mh2A, 0.8219, 2.52, 0.375, 330, 259, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1597, 5j1wC, 0.8218, 2.70, 0.308, 316, 260, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1598, 4dliA, 0.8218, 2.59, 0.358, 334, 260, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1599, 6g92A, 0.8217, 2.87, 0.378, 343, 267, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1600, 5o90A, 0.8217, 2.53, 0.398, 330, 261, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1601, 3mh3A, 0.8216, 2.58, 0.358, 334, 260, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1602, 4iirB, 0.8215, 2.56, 0.314, 327, 261, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
1603, 4ianB, 0.8215, 2.75, 0.291, 319, 265, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
1604, 3npcA, 0.8215, 3.02, 0.371, 357, 267, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1605, 3o71A, 0.8214, 2.94, 0.360, 340, 267, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
1606, 1ukhA, 0.8214, 2.58, 0.341, 321, 261, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1607, 4xozA, 0.8213, 2.93, 0.350, 341, 266, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1608, 4ijpB, 0.8213, 2.75, 0.291, 333, 265, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
1609, 1h26C, 0.8213, 2.05, 0.988, 267, 248, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
1610, 4ijpA, 0.8212, 2.65, 0.304, 330, 263, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
1611, 3hvcA, 0.8212, 2.45, 0.388, 327, 258, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1612, 3hv6A, 0.8212, 2.57, 0.378, 331, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1613, 5j1vC, 0.8211, 2.70, 0.305, 314, 259, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1614, 4yr8F, 0.8211, 2.11, 0.364, 300, 250, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1615, 2f2cB, 0.8211, 2.27, 0.514, 280, 253, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
1616, 4a9yA, 0.8210, 2.77, 0.378, 334, 262, P38ALPHA MAP KINASE BOUND TO CMPD 8
1617, 2bakA, 0.8210, 2.77, 0.378, 334, 262, P38ALPHA MAP KINASE BOUND TO MPAQ
1618, 1ianA, 0.8210, 2.56, 0.382, 328, 259, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1619, 4s30A, 0.8209, 2.94, 0.350, 342, 266, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
1620, 5o8uA, 0.8208, 2.61, 0.373, 331, 260, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1621, 5o7iA, 0.8208, 2.77, 0.373, 340, 263, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
1622, 1pmnA, 0.8207, 2.78, 0.383, 344, 266, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1623, 2wajA, 0.8205, 2.75, 0.385, 348, 265, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1624, 2xs0A, 0.8204, 2.80, 0.361, 346, 266, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1625, 4qp6A, 0.8203, 2.66, 0.352, 339, 261, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1626, 1pmeA, 0.8203, 2.76, 0.379, 333, 264, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
1627, 4loqD, 0.8202, 2.76, 0.383, 351, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1628, 4zsgA, 0.8201, 2.75, 0.356, 347, 264, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1629, 3v6rA, 0.8201, 2.90, 0.363, 349, 267, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1630, 4iirA, 0.8200, 2.64, 0.317, 325, 262, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
1631, 6gdmA, 0.8198, 2.88, 0.358, 341, 265, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1632, 4whzA, 0.8197, 2.92, 0.381, 342, 268, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1633, 2i0hA, 0.8197, 2.89, 0.347, 349, 265, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1634, 3pg3A, 0.8196, 2.82, 0.357, 337, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1635, 3fc1X, 0.8196, 2.65, 0.365, 330, 260, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1636, 3mw1A, 0.8195, 2.76, 0.373, 342, 263, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1637, 5myvB, 0.8194, 2.79, 0.284, 349, 264, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1638, 3dogC, 0.8193, 2.08, 0.984, 267, 248, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
1639, 4w4yA, 0.8192, 2.82, 0.376, 350, 266, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1640, 4ynoA, 0.8191, 2.93, 0.368, 342, 266, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1641, 3v6rB, 0.8191, 2.67, 0.367, 346, 264, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1642, 5awmA, 0.8190, 2.67, 0.361, 345, 263, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1643, 2wmbC, 0.8189, 2.02, 1.000, 266, 247, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1644, 3uibA, 0.8187, 2.36, 0.332, 309, 256, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1645, 6fyiA, 0.8185, 2.95, 0.281, 336, 267, X-RAY STRUCTURE OF CLK2-KD(130-496)/TG003 AT 2.6A 
1646, 5lmkC, 0.8184, 2.00, 0.988, 265, 246, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
1647, 3qyzA, 0.8183, 2.95, 0.382, 339, 267, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1648, 4xrjA, 0.8182, 2.94, 0.351, 344, 265, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1649, 4qp2A, 0.8182, 2.70, 0.352, 336, 261, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1650, 5n65A, 0.8181, 2.75, 0.378, 333, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1651, 4xj0B, 0.8181, 2.68, 0.387, 338, 261, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
1652, 3ha8A, 0.8181, 2.92, 0.347, 342, 265, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1653, 4xp0A, 0.8180, 2.81, 0.371, 336, 264, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1654, 4qpaA, 0.8180, 2.59, 0.390, 331, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
1655, 4w4xA, 0.8179, 2.84, 0.376, 342, 266, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1656, 5myvC, 0.8178, 2.71, 0.297, 348, 263, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1657, 2excX, 0.8177, 2.72, 0.380, 335, 263, INHIBITOR COMPLEX OF JNK3
1658, 4qp2B, 0.8176, 2.53, 0.384, 329, 258, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
1659, 3hrbA, 0.8176, 2.82, 0.371, 344, 264, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1660, 3begA, 0.8176, 2.76, 0.281, 348, 263, CRYSTAL STRUCTURE OF SR PROTEIN KINASE 1 COMPLEXED TO ITS SUBSTRATE ASF/SF2
1661, 5ax3A, 0.8175, 2.49, 0.385, 329, 257, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1662, 4loqB, 0.8175, 2.80, 0.383, 351, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1663, 3fsfA, 0.8175, 2.67, 0.369, 340, 260, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1664, 4ic8B, 0.8174, 2.99, 0.348, 336, 267, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1665, 3iw6A, 0.8174, 2.95, 0.377, 337, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1666, 2w96B, 0.8174, 1.62, 0.496, 267, 242, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1667, 3hv7A, 0.8173, 2.62, 0.386, 330, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1668, 5n68A, 0.8172, 2.56, 0.384, 328, 258, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1669, 4qp6B, 0.8172, 2.58, 0.390, 334, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
1670, 1oiuC, 0.8172, 2.01, 0.980, 265, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
1671, 5xyxA, 0.8171, 2.62, 0.364, 337, 258, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1672, 1pmvA, 0.8171, 2.86, 0.382, 347, 267, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1673, 5mxxA, 0.8170, 2.74, 0.270, 361, 263, CRYSTAL STRUCTURE OF HUMAN SR PROTEIN KINASE 1 (SRPK1) IN COMPLEX WITH COMPOUND 1
1674, 2o2uA, 0.8170, 2.75, 0.386, 319, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1675, 4z9lA, 0.8168, 2.97, 0.375, 333, 267, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1676, 5ci6A, 0.8167, 2.76, 0.376, 335, 263, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1677, 4gvaA, 0.8167, 3.01, 0.350, 345, 266, ADP-BOUND FORM OF THE ERK2 KINASE
1678, 4zslA, 0.8166, 2.89, 0.360, 341, 264, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
1679, 3lltA, 0.8164, 2.87, 0.273, 341, 264, CRYSTAL STRUCTURE OF PF14_0431 KINASE DOMAIN.
1680, 5w5qA, 0.8163, 2.23, 0.274, 291, 252, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
1681, 4w4vA, 0.8163, 2.86, 0.372, 342, 266, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1682, 3da6A, 0.8162, 2.88, 0.383, 328, 266, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1683, 3iw7A, 0.8161, 2.92, 0.375, 335, 264, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1684, 5o8vA, 0.8160, 2.47, 0.375, 328, 256, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1685, 4loqA, 0.8160, 2.81, 0.383, 352, 266, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1686, 4fuyA, 0.8160, 2.82, 0.390, 329, 264, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
1687, 4cfmC, 0.8159, 2.09, 0.988, 266, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1688, 3k3jA, 0.8159, 2.62, 0.382, 329, 259, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1689, 2ok1A, 0.8159, 2.88, 0.377, 333, 265, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1690, 3ddqC, 0.8156, 2.08, 0.984, 266, 247, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
1691, 3zsiA, 0.8154, 2.74, 0.388, 326, 260, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1692, 3zshA, 0.8148, 2.84, 0.365, 331, 263, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1693, 4lopC, 0.8145, 2.63, 0.371, 341, 259, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1694, 3npcB, 0.8142, 3.12, 0.371, 356, 267, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1695, 3hucA, 0.8142, 2.89, 0.361, 337, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1696, 6cnhA, 0.8139, 2.67, 0.279, 321, 262, HUMAN PRPF4B IN COMPLEX WITH REBASTINIB
1697, 4fv0A, 0.8139, 3.03, 0.332, 341, 265, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
1698, 3hubA, 0.8139, 2.75, 0.366, 335, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1699, 3odyX, 0.8138, 2.37, 0.401, 321, 252, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
1700, 5n63A, 0.8135, 2.41, 0.386, 325, 254, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1701, 3rtpA, 0.8135, 2.68, 0.372, 331, 261, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1702, 4xoyA, 0.8134, 2.76, 0.364, 326, 261, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
1703, 3l8sA, 0.8132, 2.79, 0.379, 334, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1704, 3lfaA, 0.8131, 2.73, 0.373, 333, 260, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1705, 4eh5A, 0.8130, 2.50, 0.383, 329, 256, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1706, 5n67A, 0.8128, 2.54, 0.383, 327, 256, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1707, 1kv2A, 0.8126, 2.48, 0.395, 325, 256, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1708, 3lfeA, 0.8125, 2.84, 0.378, 334, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1709, 4n0sA, 0.8119, 3.04, 0.355, 348, 265, COMPLEX OF ERK2 WITH CAFFEIC ACID
1710, 4h39A, 0.8118, 2.95, 0.377, 340, 265, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1711, 4gsbA, 0.8116, 2.92, 0.379, 343, 264, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
1712, 3sa0A, 0.8116, 3.05, 0.351, 354, 265, COMPLEX OF ERK2 WITH NORATHYRIOL
1713, 2x7gA, 0.8116, 3.08, 0.263, 344, 266, STRUCTURE OF HUMAN SERINE-ARGININE-RICH PROTEIN-SPECIFIC KINASE 2 (SRPK2) BOUND TO PURVALANOL B
1714, 6emhA, 0.8115, 2.73, 0.368, 344, 261, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1715, 5d7aB, 0.8113, 2.36, 0.262, 286, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1716, 4e5aX, 0.8113, 2.64, 0.368, 332, 258, THE W197A MUTANT OF P38A MAP KINASE
1717, 4n4sB, 0.8112, 2.97, 0.346, 337, 266, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1718, 5d7aA, 0.8110, 2.37, 0.266, 289, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1719, 3oy1A, 0.8110, 2.69, 0.364, 329, 261, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1720, 2w9fB, 0.8110, 1.76, 0.481, 261, 241, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1721, 2fslX, 0.8109, 2.70, 0.384, 332, 258, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1722, 3my5C, 0.8107, 2.17, 0.984, 266, 247, CDK2/CYCLINA IN COMPLEX WITH DRB
1723, 4e6cA, 0.8106, 2.80, 0.381, 330, 260, P38A-PERIFOSINE COMPLEX
1724, 3oz6B, 0.8102, 2.97, 0.387, 341, 266, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1725, 2baqA, 0.8102, 2.78, 0.398, 329, 259, P38ALPHA BOUND TO RO3201195
1726, 5ekoA, 0.8101, 3.04, 0.366, 341, 265, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1727, 2ewaA, 0.8100, 2.64, 0.381, 330, 257, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1728, 4zxtA, 0.8098, 3.10, 0.351, 348, 265, COMPLEX OF ERK2 WITH CATECHOL
1729, 3g9lX, 0.8097, 2.84, 0.374, 336, 262, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1730, 2yiwA, 0.8096, 2.49, 0.388, 325, 255, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1731, 6emhB, 0.8094, 2.75, 0.368, 344, 261, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1732, 3lfcA, 0.8094, 2.74, 0.367, 334, 259, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1733, 1jowB, 0.8093, 2.26, 0.516, 277, 250, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1734, 6anlA, 0.8092, 2.91, 0.359, 338, 262, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
1735, 4u79A, 0.8092, 2.84, 0.383, 337, 264, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1736, 5n64A, 0.8091, 2.59, 0.383, 329, 256, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1737, 4eymA, 0.8090, 3.05, 0.366, 340, 265, MAPK13 COMPLEX WITH INHIBITOR
1738, 5d7aC, 0.8087, 2.25, 0.272, 286, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1739, 5cwzB, 0.8085, 2.30, 0.256, 284, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1740, 4eyjA, 0.8085, 3.02, 0.356, 338, 264, MAPK13 COMPLEX WITH INHIBITOR
1741, 4aa0A, 0.8085, 2.74, 0.388, 328, 258, P38ALPHA MAP KINASE BOUND TO CMPD 2
1742, 6f5eB, 0.8084, 2.86, 0.347, 346, 262, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1743, 5lenB, 0.8084, 2.86, 0.347, 346, 262, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1744, 3iw5A, 0.8084, 3.10, 0.377, 336, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1745, 1bi7A, 0.8081, 2.21, 0.468, 269, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
1746, 4u43A, 0.8078, 2.38, 0.274, 287, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
1747, 4geoA, 0.8077, 2.52, 0.378, 326, 254, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1748, 5wjjA, 0.8076, 2.86, 0.352, 338, 261, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
1749, 5cwzA, 0.8076, 2.32, 0.260, 284, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1750, 1s9iA, 0.8074, 2.18, 0.297, 303, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1751, 2b1pA, 0.8068, 2.89, 0.361, 331, 263, INHIBITOR COMPLEX OF JNK3
1752, 1bi8C, 0.8067, 2.20, 0.484, 264, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
1753, 1bi8A, 0.8067, 2.20, 0.484, 264, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
1754, 3iw8A, 0.8066, 2.89, 0.364, 334, 261, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1755, 3rp9A, 0.8064, 2.90, 0.387, 350, 261, CRYSTAL STRUCTURE OF THE APO MAPK FROM TOXOPLASMA GONDII 25.M01780 OR TGME49_007820
1756, 4lmnA, 0.8062, 2.35, 0.288, 292, 250, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
1757, 3gcsA, 0.8062, 2.87, 0.379, 331, 261, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1758, 1wakA, 0.8062, 2.90, 0.263, 353, 262, X-RAY STRUCTURE OF SRPK1
1759, 4zp5A, 0.8060, 2.42, 0.267, 284, 251, MAP4K4 IN COMPLEX WITH INHIBITOR
1760, 5ax9C, 0.8056, 2.32, 0.267, 282, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1761, 6emhD, 0.8053, 2.71, 0.373, 331, 260, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1762, 5wp1A, 0.8051, 3.10, 0.345, 340, 264, COMPLEX OF ERK2 WITH 5;7-DIHYDROXYCHROMONE 
1763, 5ax9A, 0.8051, 2.33, 0.263, 282, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1764, 4u40A, 0.8049, 2.40, 0.274, 295, 252, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1765, 3zsgA, 0.8049, 3.00, 0.347, 337, 262, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1766, 4cfvC, 0.8046, 2.15, 0.984, 264, 245, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1767, 3zs5A, 0.8045, 2.98, 0.347, 340, 262, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1768, 3mblA, 0.8042, 2.28, 0.285, 290, 249, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
1769, 5eknA, 0.8040, 2.99, 0.359, 336, 262, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1770, 5di1A, 0.8039, 2.46, 0.267, 285, 251, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1771, 4u81A, 0.8036, 2.36, 0.296, 289, 250, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
1772, 2yisA, 0.8036, 2.54, 0.390, 325, 254, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1773, 2p55A, 0.8034, 2.26, 0.293, 289, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1774, 5j95A, 0.8032, 2.47, 0.267, 284, 251, MAP4K4 IN COMPLEX WITH INHIBITOR
1775, 4wuaA, 0.8031, 3.04, 0.258, 344, 264, CRYSTAL STRUCTURE OF HUMAN SRPK1 COMPLEXED TO AN INHIBITOR SRPIN340
1776, 1wbpA, 0.8030, 3.03, 0.255, 350, 263, SRPK1 BOUND TO 9MER DOCKING MOTIF PEPTIDE
1777, 3v04A, 0.8029, 2.37, 0.296, 289, 250, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1778, 4u7zA, 0.8026, 2.36, 0.296, 291, 250, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
1779, 4u44A, 0.8026, 2.48, 0.278, 286, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
1780, 4arkA, 0.8026, 2.38, 0.288, 291, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
1781, 3dv3A, 0.8026, 2.44, 0.288, 288, 250, MEK1 WITH PF-04622664 BOUND
1782, 2wmaC, 0.8025, 2.21, 0.959, 265, 246, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
1783, 6emhC, 0.8022, 2.80, 0.372, 334, 261, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1784, 3e8nA, 0.8022, 2.37, 0.292, 291, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
1785, 5xv7A, 0.8019, 3.09, 0.250, 350, 264, SRPK1 IN COMPLEX WITH ALECTINIB
1786, 3pp1A, 0.8019, 2.40, 0.288, 291, 250, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
1787, 3v01A, 0.8018, 2.40, 0.296, 289, 250, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1788, 3oz6A, 0.8018, 2.88, 0.383, 343, 261, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1789, 4u80A, 0.8017, 2.39, 0.292, 286, 250, MEK 1 KINASE BOUND TO G799
1790, 3fi2A, 0.8017, 2.69, 0.367, 326, 259, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1791, 4zk5A, 0.8016, 2.42, 0.263, 286, 251, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1792, 4u45A, 0.8014, 2.50, 0.274, 289, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
1793, 3is5F, 0.8012, 2.00, 0.292, 266, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1794, 3eqbA, 0.8011, 2.39, 0.292, 289, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1795, 4loqC, 0.8010, 2.69, 0.375, 337, 256, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1796, 3eqgA, 0.8010, 2.31, 0.285, 314, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
1797, 3eqfA, 0.8010, 2.31, 0.285, 314, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
1798, 5myvA, 0.8008, 3.14, 0.275, 352, 265, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1799, 3fi3A, 0.8006, 2.63, 0.366, 328, 257, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1800, 1s9jA, 0.8006, 2.40, 0.292, 289, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1801, 5ml5A, 0.8004, 2.88, 0.384, 326, 258, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1802, 3gcpA, 0.8002, 3.12, 0.354, 337, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1803, 3eqhA, 0.8001, 2.32, 0.281, 314, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
1804, 4e6aA, 0.8000, 2.71, 0.380, 324, 255, P38A-PIA23 COMPLEX
1805, 4u42A, 0.7999, 2.33, 0.265, 282, 249, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
1806, 4e8aA, 0.7999, 2.85, 0.381, 327, 257, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1807, 2fsmX, 0.7994, 2.72, 0.380, 326, 255, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1808, 2npqA, 0.7993, 2.69, 0.380, 326, 255, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1809, 5my8A, 0.7991, 3.12, 0.254, 355, 264, CRYSTAL STRUCTURE OF SRPK1 IN COMPLEX WITH SPHINX31
1810, 4e5bA, 0.7991, 2.73, 0.380, 324, 255, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1811, 2fstX, 0.7990, 2.70, 0.378, 324, 254, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
1812, 4obpA, 0.7988, 2.55, 0.274, 285, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1813, 2fsoX, 0.7983, 2.61, 0.383, 325, 253, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
1814, 4rvtA, 0.7981, 2.46, 0.280, 281, 250, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1815, 4u41A, 0.7977, 2.40, 0.266, 275, 248, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
1816, 3lfdA, 0.7977, 2.90, 0.364, 331, 258, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
1817, 4dc2A, 0.7976, 2.31, 0.300, 328, 247, STRUCTURE OF PKC IN COMPLEX WITH A SUBSTRATE PEPTIDE FROM PAR-3
1818, 3eqcA, 0.7975, 2.37, 0.285, 312, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
1819, 4oboA, 0.7973, 2.42, 0.266, 275, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
1820, 3vn9A, 0.7969, 2.58, 0.250, 291, 252, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
1821, 4an2A, 0.7966, 2.39, 0.281, 282, 249, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1822, 3zlsA, 0.7965, 2.38, 0.281, 315, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
1823, 4ualA, 0.7958, 2.83, 0.264, 403, 254, MRCK BETA IN COMPLEX WITH BDP00005290
1824, 5otfA, 0.7955, 2.84, 0.264, 411, 254, MRCK BETA IN COMPLEX WITH BDP-00009066
1825, 4aw2A, 0.7955, 2.75, 0.265, 398, 253, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
1826, 4anbA, 0.7954, 2.42, 0.285, 282, 249, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1827, 5myvD, 0.7950, 3.32, 0.256, 351, 266, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1828, 3eqiA, 0.7950, 2.41, 0.285, 315, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
1829, 5bx0A, 0.7949, 2.41, 0.281, 315, 249, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
1830, 3os3A, 0.7949, 2.31, 0.291, 272, 247, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4858061 AND MGATP
1831, 2x7fB, 0.7949, 2.49, 0.267, 288, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1832, 3eqdA, 0.7946, 2.40, 0.285, 315, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
1833, 3zh8A, 0.7943, 2.35, 0.304, 318, 247, A NOVEL SMALL MOLECULE APKC INHIBITOR
1834, 4fzaB, 0.7942, 2.32, 0.271, 281, 247, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1835, 3zh8B, 0.7939, 2.35, 0.304, 317, 247, A NOVEL SMALL MOLECULE APKC INHIBITOR
1836, 3slsA, 0.7938, 2.37, 0.282, 292, 248, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1837, 2gfcA, 0.7935, 2.43, 0.283, 335, 247, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1838, 2i6lB, 0.7934, 2.82, 0.304, 269, 253, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1839, 4an3A, 0.7932, 2.49, 0.285, 280, 249, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1840, 3zlwA, 0.7932, 2.43, 0.281, 312, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
1841, 4zjiA, 0.7930, 2.41, 0.304, 278, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1842, 2q0nA, 0.7930, 2.57, 0.274, 293, 248, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1843, 3coiA, 0.7928, 3.28, 0.365, 344, 266, CRYSTAL STRUCTURE OF P38DELTA KINASE
1844, 5oteA, 0.7927, 2.77, 0.261, 407, 253, MRCK BETA IN COMPLEX WITH BDP-00008900
1845, 4mneE, 0.7927, 2.46, 0.285, 286, 249, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1846, 3zlyA, 0.7927, 2.39, 0.286, 310, 248, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
1847, 3zh8C, 0.7927, 2.32, 0.305, 312, 246, A NOVEL SMALL MOLECULE APKC INHIBITOR
1848, 3vvhA, 0.7926, 2.44, 0.282, 287, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1849, 2gniA, 0.7926, 2.43, 0.300, 338, 247, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1850, 1s9iB, 0.7926, 2.34, 0.287, 291, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1851, 4fzfB, 0.7925, 2.27, 0.269, 279, 245, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
1852, 2gnjA, 0.7924, 2.45, 0.296, 335, 247, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1853, 3zlxA, 0.7922, 2.43, 0.285, 312, 249, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
1854, 2i0eB, 0.7921, 2.31, 0.255, 300, 247, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1855, 1o6kA, 0.7920, 2.41, 0.296, 317, 247, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1856, 4zjjA, 0.7919, 2.48, 0.306, 280, 248, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
1857, 4uakA, 0.7919, 2.80, 0.261, 404, 253, MRCK BETA IN COMPLEX WITH ADP
1858, 4ij9A, 0.7919, 2.47, 0.283, 335, 247, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
1859, 3aglB, 0.7919, 2.48, 0.287, 335, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1860, 4ic8A, 0.7918, 2.97, 0.353, 325, 258, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1861, 3tkuA, 0.7918, 2.83, 0.261, 395, 253, MRCK BETA IN COMPLEX WITH FASUDIL
1862, 2f7eE, 0.7917, 2.46, 0.283, 336, 247, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1863, 3qamE, 0.7916, 2.47, 0.279, 348, 247, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1864, 1jbpE, 0.7916, 2.45, 0.283, 339, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1865, 3zm4A, 0.7915, 2.34, 0.283, 309, 247, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
1866, 3tkuB, 0.7915, 2.83, 0.261, 395, 253, MRCK BETA IN COMPLEX WITH FASUDIL
1867, 1rejA, 0.7915, 2.47, 0.283, 333, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1868, 2bajA, 0.7914, 2.78, 0.386, 337, 254, P38ALPHA BOUND TO PYRAZOLOUREA
1869, 1fmoE, 0.7914, 2.46, 0.283, 336, 247, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1870, 4zjiD, 0.7913, 2.41, 0.298, 280, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1871, 1re8A, 0.7913, 2.46, 0.283, 337, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1872, 1rekA, 0.7912, 2.47, 0.283, 336, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1873, 5n3lA, 0.7911, 2.45, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
1874, 5m0lA, 0.7911, 2.46, 0.287, 338, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
1875, 2ojfE, 0.7911, 2.47, 0.283, 336, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1876, 2f7xE, 0.7911, 2.46, 0.283, 336, 247, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1877, 1q24A, 0.7911, 2.48, 0.279, 335, 247, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1878, 3qfvA, 0.7910, 2.71, 0.262, 395, 252, MRCK BETA IN COMPLEX WITH TPCA-1
1879, 4zjiB, 0.7909, 2.45, 0.308, 276, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1880, 3slsB, 0.7909, 2.44, 0.282, 294, 248, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1881, 3fhiA, 0.7909, 2.49, 0.283, 336, 247, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1882, 2oh0E, 0.7909, 2.45, 0.283, 336, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1883, 1o6lA, 0.7909, 2.43, 0.296, 316, 247, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1884, 5m0cA, 0.7908, 2.48, 0.287, 336, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
1885, 4l44A, 0.7908, 2.44, 0.310, 321, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
1886, 2uzuE, 0.7908, 2.46, 0.283, 336, 247, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1887, 2uvxA, 0.7908, 2.47, 0.279, 335, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1888, 2gnfA, 0.7907, 2.46, 0.300, 339, 247, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1889, 2uzvA, 0.7905, 2.49, 0.283, 336, 247, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1890, 4fzdB, 0.7904, 2.37, 0.264, 275, 246, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
1891, 3qfvB, 0.7904, 2.73, 0.262, 396, 252, MRCK BETA IN COMPLEX WITH TPCA-1
1892, 3fjqE, 0.7903, 2.48, 0.283, 334, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1893, 4an9A, 0.7902, 2.48, 0.289, 281, 249, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1894, 2gcdB, 0.7902, 2.55, 0.288, 308, 250, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1895, 4hptE, 0.7901, 2.48, 0.283, 335, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
1896, 1apmE, 0.7901, 2.47, 0.283, 338, 247, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1897, 1q61A, 0.7900, 2.48, 0.283, 335, 247, PKA TRIPLE MUTANT MODEL OF PKB
1898, 4uj9A, 0.7899, 2.50, 0.287, 339, 247, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1899, 3d0eB, 0.7899, 2.46, 0.296, 322, 247, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1900, 3d0eA, 0.7899, 2.45, 0.296, 322, 247, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1901, 5bx6A, 0.7898, 2.48, 0.287, 343, 247, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
1902, 3vvhC, 0.7898, 2.46, 0.285, 283, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1903, 4yxrA, 0.7897, 2.50, 0.283, 334, 247, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1904, 3mvjA, 0.7897, 2.49, 0.287, 334, 247, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1905, 4ujaA, 0.7896, 2.50, 0.287, 336, 247, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1906, 4zjjB, 0.7895, 2.46, 0.308, 277, 247, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
1907, 4mneA, 0.7895, 2.49, 0.285, 286, 249, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1908, 3vvhB, 0.7895, 2.45, 0.285, 290, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1909, 1q62A, 0.7895, 2.50, 0.279, 336, 247, PKA DOUBLE MUTANT MODEL OF PKB
1910, 1bkxA, 0.7895, 2.45, 0.283, 337, 247, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1911, 5n1gA, 0.7894, 2.45, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
1912, 4mneH, 0.7894, 2.43, 0.286, 275, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1913, 2uw7A, 0.7894, 2.49, 0.279, 335, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1914, 2jdrA, 0.7894, 2.46, 0.296, 316, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1915, 2c1bA, 0.7894, 2.50, 0.283, 335, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1916, 3nx8A, 0.7893, 2.47, 0.287, 333, 247, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1917, 3aglA, 0.7893, 2.48, 0.287, 338, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1918, 2x7fC, 0.7893, 2.52, 0.276, 285, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1919, 2jdtA, 0.7893, 2.50, 0.279, 334, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1920, 2c1aA, 0.7893, 2.49, 0.283, 335, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1921, 1atpE, 0.7893, 2.48, 0.283, 334, 247, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1922, 5bx7A, 0.7892, 2.50, 0.287, 343, 247, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
1923, 4uj2A, 0.7892, 2.50, 0.287, 335, 247, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1924, 2uw4A, 0.7892, 2.44, 0.285, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1925, 2gngA, 0.7892, 2.47, 0.300, 338, 247, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1926, 1jluE, 0.7892, 2.49, 0.283, 337, 247, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1927, 4l46A, 0.7891, 2.47, 0.315, 317, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
1928, 4ujbA, 0.7890, 2.50, 0.287, 344, 247, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1929, 2vo7A, 0.7890, 2.50, 0.283, 335, 247, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1930, 3e8eP, 0.7889, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1931, 4yxsA, 0.7888, 2.50, 0.283, 335, 247, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1932, 3vqhA, 0.7888, 2.51, 0.287, 344, 247, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
1933, 3dneA, 0.7888, 2.51, 0.283, 336, 247, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1934, 5n3pA, 0.7887, 2.47, 0.289, 336, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
1935, 5n3tA, 0.7886, 2.47, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
1936, 5n1hA, 0.7886, 2.47, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
1937, 4o0xA, 0.7886, 2.68, 0.274, 290, 248, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1938, 3ma6B, 0.7886, 2.19, 0.322, 266, 242, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
1939, 3e8eB, 0.7886, 2.52, 0.283, 337, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1940, 3e8eA, 0.7886, 2.53, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1941, 1cdkB, 0.7886, 2.50, 0.287, 342, 247, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1942, 5ng3A, 0.7885, 2.63, 0.226, 283, 248, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1943, 5n3nA, 0.7885, 2.46, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
1944, 5n3jA, 0.7885, 2.47, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
1945, 5n3gA, 0.7885, 2.46, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
1946, 4nw6A, 0.7885, 2.40, 0.301, 302, 246, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1947, 3ornA, 0.7885, 2.46, 0.277, 280, 249, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4987655 AND MGAMP-PNP
1948, 5n3rA, 0.7884, 2.46, 0.289, 336, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
1949, 4o22A, 0.7884, 2.45, 0.285, 336, 246, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1950, 4nw5A, 0.7884, 2.41, 0.301, 302, 246, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1951, 3oogA, 0.7884, 2.50, 0.287, 333, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1952, 3idbA, 0.7884, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1953, 2f7zE, 0.7884, 2.51, 0.283, 336, 247, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1954, 1ydsE, 0.7884, 2.50, 0.283, 334, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1955, 1svgA, 0.7884, 2.51, 0.283, 338, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1956, 5n3qA, 0.7883, 2.47, 0.289, 336, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
1957, 5m57A, 0.7883, 2.20, 0.300, 261, 243, NEK2 BOUND TO ARYLAMINOPURINE 6
1958, 4mneD, 0.7883, 2.44, 0.286, 285, 248, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1959, 3twjC, 0.7883, 2.78, 0.279, 396, 251, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
1960, 5n3oA, 0.7882, 2.50, 0.289, 335, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
1961, 4uj1A, 0.7882, 2.50, 0.287, 335, 247, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1962, 3x2vA, 0.7882, 2.46, 0.285, 331, 246, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1963, 1ydrE, 0.7882, 2.50, 0.283, 334, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1964, 1l3rE, 0.7882, 2.48, 0.285, 338, 246, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1965, 4wb7B, 0.7881, 2.47, 0.289, 402, 246, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
1966, 2y4iC, 0.7881, 2.35, 0.280, 313, 246, KSR2-MEK1 HETERODIMER
1967, 5n1fA, 0.7880, 2.47, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
1968, 3e88B, 0.7880, 2.49, 0.296, 319, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1969, 3e88A, 0.7880, 2.49, 0.296, 319, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1970, 2uw8A, 0.7880, 2.47, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1971, 4c38A, 0.7879, 2.46, 0.293, 334, 246, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
1972, 4axaA, 0.7879, 2.52, 0.279, 335, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
1973, 2uw3A, 0.7879, 2.47, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1974, 4o21A, 0.7878, 2.47, 0.285, 333, 246, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1975, 3x2wA, 0.7878, 2.45, 0.285, 336, 246, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1976, 4zjiC, 0.7877, 2.37, 0.301, 281, 246, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
1977, 4l3lA, 0.7877, 2.48, 0.319, 291, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
1978, 3amaA, 0.7877, 2.51, 0.291, 342, 247, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1979, 5cwzC, 0.7876, 2.26, 0.266, 271, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1980, 3qalE, 0.7876, 2.52, 0.279, 339, 247, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1981, 1cdkA, 0.7876, 2.51, 0.287, 342, 247, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1982, 4ie9A, 0.7875, 2.52, 0.283, 335, 247, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
1983, 3e8eE, 0.7875, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1984, 2gnhA, 0.7875, 2.51, 0.300, 338, 247, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1985, 2erzE, 0.7875, 2.52, 0.283, 334, 247, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1986, 5uzkA, 0.7874, 2.53, 0.287, 335, 247, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
1987, 5n3iA, 0.7874, 2.48, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
1988, 5n3hA, 0.7874, 2.49, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
1989, 4wb7A, 0.7874, 2.48, 0.289, 402, 246, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
1990, 4ib3A, 0.7874, 2.47, 0.285, 336, 246, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
1991, 3is5A, 0.7874, 2.08, 0.308, 260, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
1992, 3e8eL, 0.7874, 2.54, 0.283, 336, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1993, 2x39A, 0.7874, 2.50, 0.296, 316, 247, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1994, 2uvyA, 0.7874, 2.47, 0.280, 333, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1995, 5n3sA, 0.7873, 2.49, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
1996, 4u40B, 0.7873, 2.48, 0.229, 299, 249, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1997, 4iacA, 0.7873, 2.45, 0.285, 333, 246, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
1998, 3wf7A, 0.7873, 2.53, 0.315, 288, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
1999, 3mvjE, 0.7873, 2.48, 0.287, 334, 247, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2000, 1rdqE, 0.7873, 2.54, 0.279, 340, 247, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2001, 6c0uA, 0.7872, 2.47, 0.287, 338, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
2002, 5ajqA, 0.7872, 2.67, 0.315, 280, 251, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
2003, 3owpA, 0.7872, 2.53, 0.287, 334, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2004, 3is5B, 0.7872, 2.02, 0.301, 260, 239, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2005, 2jdvA, 0.7872, 2.51, 0.279, 334, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
2006, 5n3mA, 0.7871, 2.49, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
2007, 3iw4B, 0.7871, 2.47, 0.275, 325, 247, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2008, 3idcA, 0.7871, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2009, 3e8eI, 0.7871, 2.53, 0.283, 345, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2010, 2jdsA, 0.7871, 2.48, 0.285, 334, 246, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
2011, 2i0eA, 0.7871, 2.40, 0.263, 326, 247, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2012, 2cpkE, 0.7871, 2.48, 0.285, 333, 246, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2013, 1xh9A, 0.7871, 2.54, 0.287, 336, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2014, 4xbuA, 0.7870, 2.62, 0.279, 292, 247, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
2015, 4wb8A, 0.7870, 2.50, 0.289, 334, 246, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
2016, 1sveA, 0.7870, 2.52, 0.283, 341, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
2017, 5n3kA, 0.7869, 2.49, 0.289, 337, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
2018, 5li1A, 0.7869, 2.36, 0.306, 331, 245, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
2019, 5lcqA, 0.7869, 2.50, 0.287, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
2020, 4c37A, 0.7869, 2.48, 0.293, 335, 246, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
2021, 4o0yA, 0.7868, 2.70, 0.274, 290, 248, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2022, 3zo4A, 0.7868, 2.54, 0.283, 335, 247, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2023, 3e8cF, 0.7868, 2.54, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2024, 3e8cC, 0.7868, 2.54, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2025, 3e8cA, 0.7868, 2.54, 0.283, 341, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2026, 2vnyA, 0.7868, 2.49, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
2027, 2uw5A, 0.7868, 2.50, 0.280, 333, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2028, 4z84A, 0.7867, 2.54, 0.283, 335, 247, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
2029, 4c36A, 0.7867, 2.47, 0.293, 335, 246, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
2030, 3oxtA, 0.7867, 2.58, 0.287, 335, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2031, 3iw4C, 0.7867, 2.46, 0.275, 332, 247, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2032, 3e8cD, 0.7867, 2.54, 0.283, 344, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2033, 4dh8A, 0.7866, 2.49, 0.285, 333, 246, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
2034, 3e8cE, 0.7866, 2.54, 0.283, 336, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2035, 3e8cB, 0.7866, 2.54, 0.283, 344, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2036, 2uzwE, 0.7866, 2.53, 0.283, 336, 247, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2037, 1ydtE, 0.7866, 2.53, 0.283, 334, 247, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
2038, 5ar8B, 0.7865, 2.64, 0.225, 274, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
2039, 4wb5A, 0.7865, 2.50, 0.289, 335, 246, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2040, 3pooA, 0.7865, 2.54, 0.287, 331, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2041, 1xh6A, 0.7865, 2.56, 0.283, 331, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2042, 4o0vA, 0.7864, 2.69, 0.278, 290, 248, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2043, 4c33A, 0.7864, 2.48, 0.293, 335, 246, PKA-S6K1 CHIMERA APO
2044, 3x2uA, 0.7864, 2.48, 0.285, 336, 246, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
2045, 3agmA, 0.7864, 2.54, 0.287, 337, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
2046, 1xh8A, 0.7864, 2.50, 0.283, 337, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2047, 1xh5A, 0.7864, 2.53, 0.283, 335, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2048, 4wb6B, 0.7863, 2.57, 0.291, 340, 247, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2049, 3ovvA, 0.7863, 2.54, 0.287, 335, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2050, 1vebA, 0.7863, 2.53, 0.283, 338, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
2051, 1svhA, 0.7863, 2.53, 0.283, 335, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
2052, 2vo6A, 0.7862, 2.51, 0.285, 335, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
2053, 4x6rA, 0.7861, 2.49, 0.285, 347, 246, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2054, 4ekkA, 0.7861, 2.51, 0.296, 318, 247, AKT1 WITH AMP-PNP
2055, 3kkvA, 0.7861, 2.48, 0.285, 335, 246, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
2056, 3dndA, 0.7861, 2.52, 0.283, 334, 247, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2057, 2uvzA, 0.7860, 2.50, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
2058, 5m0bA, 0.7859, 2.51, 0.287, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
2059, 4xw6A, 0.7859, 2.49, 0.285, 334, 246, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
2060, 4l43A, 0.7859, 2.52, 0.310, 316, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
2061, 5m51A, 0.7858, 2.18, 0.298, 260, 242, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
2062, 2f2uB, 0.7858, 2.75, 0.279, 383, 251, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2063, 1u5qB, 0.7858, 2.60, 0.288, 308, 250, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2064, 5i0bA, 0.7856, 2.71, 0.274, 288, 248, STRUCTURE OF PAK4
2065, 5ax9B, 0.7856, 2.43, 0.268, 274, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2066, 4dh7A, 0.7856, 2.51, 0.285, 333, 246, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
2067, 5wnoA, 0.7855, 2.68, 0.201, 302, 249, CRYSTAL STRUCTURE OF C. ELEGANS LET-23 KINASE DOMAIN COMPLEXED WITH AMP-PNP
2068, 3thbA, 0.7855, 2.50, 0.276, 287, 246, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
2069, 3iw4A, 0.7855, 2.49, 0.275, 330, 247, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
2070, 2z7rA, 0.7855, 2.09, 0.321, 265, 240, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
2071, 2vnwA, 0.7855, 2.50, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
2072, 2gu8A, 0.7855, 2.55, 0.283, 335, 247, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
2073, 1smhA, 0.7855, 2.53, 0.283, 348, 247, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
2074, 1q8tA, 0.7855, 2.53, 0.283, 338, 247, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
2075, 4tthB, 0.7854, 2.12, 0.544, 256, 239, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
2076, 4l3jA, 0.7854, 2.54, 0.315, 291, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
2077, 4dg2E, 0.7854, 2.50, 0.285, 347, 246, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2078, 2uztA, 0.7854, 2.55, 0.283, 336, 247, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
2079, 1xhaA, 0.7854, 2.52, 0.283, 348, 247, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2080, 4dh5A, 0.7853, 2.49, 0.285, 333, 246, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
2081, 4dfxE, 0.7853, 2.50, 0.285, 347, 246, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2082, 2vo3A, 0.7853, 2.50, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2083, 2qcsA, 0.7853, 2.52, 0.285, 335, 246, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2084, 4iafA, 0.7852, 2.50, 0.285, 333, 246, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2085, 3zo2A, 0.7852, 2.49, 0.285, 340, 246, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2086, 3p0mA, 0.7852, 2.54, 0.287, 335, 247, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2087, 2vo0A, 0.7852, 2.54, 0.279, 340, 247, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2088, 4wihA, 0.7851, 2.57, 0.287, 350, 247, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
2089, 4ib0A, 0.7851, 2.51, 0.285, 334, 246, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2090, 4ekkB, 0.7851, 2.53, 0.296, 318, 247, AKT1 WITH AMP-PNP
2091, 3zo3A, 0.7851, 2.49, 0.285, 337, 246, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2092, 3ow3A, 0.7851, 2.56, 0.283, 334, 247, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2093, 3e8dB, 0.7851, 2.53, 0.296, 317, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2094, 2x7fA, 0.7851, 2.44, 0.279, 276, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2095, 1stcE, 0.7851, 2.50, 0.279, 334, 247, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
2096, 6fd3A, 0.7850, 2.69, 0.323, 296, 248, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
2097, 4dfzE, 0.7850, 2.50, 0.285, 347, 246, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2098, 3e8dA, 0.7850, 2.53, 0.296, 315, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2099, 2gnlA, 0.7850, 2.56, 0.296, 338, 247, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
2100, 5xvaA, 0.7849, 2.71, 0.275, 292, 247, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH216
2101, 4iakA, 0.7849, 2.49, 0.285, 334, 246, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2102, 5xvfA, 0.7848, 2.71, 0.274, 289, 248, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
2103, 4xw4A, 0.7848, 2.48, 0.285, 334, 246, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
2104, 4iadA, 0.7848, 2.52, 0.285, 334, 246, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2105, 4ib1A, 0.7847, 2.51, 0.285, 335, 246, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2106, 4dh3A, 0.7847, 2.51, 0.285, 333, 246, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
2107, 3e87B, 0.7847, 2.52, 0.296, 321, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2108, 3e87A, 0.7847, 2.52, 0.296, 321, 247, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2109, 3twjA, 0.7846, 2.85, 0.275, 396, 251, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2110, 3cquA, 0.7846, 2.53, 0.296, 318, 247, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2111, 2cdzA, 0.7846, 2.64, 0.280, 289, 246, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
2112, 4njdA, 0.7845, 2.65, 0.275, 290, 247, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
2113, 4l45A, 0.7845, 2.53, 0.315, 317, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2114, 4dh1A, 0.7845, 2.52, 0.285, 333, 246, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
2115, 5ng3D, 0.7844, 2.59, 0.228, 278, 246, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2116, 5n7uA, 0.7844, 2.59, 0.287, 350, 247, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
2117, 5kkrC, 0.7844, 2.33, 0.278, 309, 245, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
2118, 4z83E, 0.7844, 2.58, 0.283, 335, 247, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
2119, 4dg3E, 0.7844, 2.53, 0.285, 335, 246, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
2120, 3we4A, 0.7844, 2.54, 0.315, 286, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
2121, 5n7pA, 0.7843, 2.59, 0.287, 350, 247, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
2122, 4iaiA, 0.7843, 2.52, 0.285, 333, 246, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2123, 2uw0A, 0.7842, 2.52, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
2124, 2r5tA, 0.7842, 2.23, 0.281, 284, 242, CRYSTAL STRUCTURE OF INACTIVE SERUM AND GLUCOCORTICOID- REGULATED KINASE 1 IN COMPLEX WITH AMP-PNP
2125, 2qurA, 0.7842, 2.55, 0.283, 338, 247, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2126, 3zo1A, 0.7841, 2.51, 0.289, 339, 246, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2127, 3tnpF, 0.7841, 2.52, 0.285, 334, 246, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2128, 3tnpC, 0.7841, 2.52, 0.285, 334, 246, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2129, 1bx6A, 0.7841, 2.52, 0.279, 337, 247, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2130, 5j5xA, 0.7840, 2.58, 0.287, 340, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
2131, 4obqA, 0.7840, 2.30, 0.272, 275, 243, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
2132, 5xvgA, 0.7839, 2.81, 0.274, 292, 248, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH226
2133, 4x6qC, 0.7839, 2.52, 0.285, 334, 246, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2134, 4hpuE, 0.7839, 2.53, 0.285, 336, 246, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2135, 3pvbA, 0.7839, 2.54, 0.285, 341, 246, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2136, 2uw9A, 0.7839, 2.54, 0.296, 316, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
2137, 5n1eA, 0.7838, 2.60, 0.287, 347, 247, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YL)-2-PIPERIDIN-1- YLACETAMIDE
2138, 4wnkA, 0.7838, 2.71, 0.281, 499, 249, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
2139, 4y5qA, 0.7837, 2.30, 0.313, 449, 243, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH AMP
2140, 2uw6A, 0.7837, 2.53, 0.280, 334, 246, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2141, 2jedA, 0.7837, 2.54, 0.296, 324, 247, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2142, 5n1lA, 0.7835, 2.55, 0.289, 347, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 25-DIMETHYL-N-PYRIDIN-4-YLFURAN-3- CARBOXAMIDE
2143, 5jr7A, 0.7835, 2.51, 0.285, 335, 246, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2144, 4xw5A, 0.7835, 2.53, 0.285, 334, 246, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
2145, 4wb6A, 0.7835, 2.56, 0.293, 336, 246, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2146, 2vd5A, 0.7835, 2.70, 0.281, 390, 249, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2147, 2gcdA, 0.7835, 2.63, 0.288, 308, 250, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
2148, 5vhbA, 0.7834, 2.55, 0.285, 325, 246, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
2149, 1q8uA, 0.7834, 2.55, 0.283, 341, 247, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
2150, 3ambA, 0.7833, 2.56, 0.291, 340, 247, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
2151, 2weiA, 0.7832, 2.37, 0.317, 278, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
2152, 5n23A, 0.7831, 2.53, 0.293, 333, 246, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
2153, 1xh7A, 0.7830, 2.54, 0.285, 337, 246, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2154, 5n33A, 0.7829, 2.54, 0.289, 347, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(TRIFLUOROMETHYL)-1H-PYRIDIN-2- ONE
2155, 5n32A, 0.7829, 2.55, 0.285, 345, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
2156, 4l42A, 0.7829, 2.38, 0.314, 299, 245, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
2157, 4dg0E, 0.7829, 2.54, 0.285, 338, 246, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2158, 1xh4A, 0.7829, 2.55, 0.285, 334, 246, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2159, 5mhiA, 0.7828, 2.62, 0.287, 348, 247, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2160, 3tv7D, 0.7827, 2.81, 0.279, 397, 251, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2161, 4dinA, 0.7826, 2.57, 0.283, 340, 247, NOVEL LOCALIZATION AND QUATERNARY STRUCTURE OF THE PKA RI BETA HOLOENZYME
2162, 3mv5A, 0.7826, 2.57, 0.296, 315, 247, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2163, 3tv7B, 0.7825, 2.80, 0.279, 397, 251, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2164, 5n39A, 0.7824, 2.57, 0.289, 347, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(23-DIHYDROBENZO[B][14]DIOXIN-6-YL) PYRROLIDINE
2165, 4iayA, 0.7822, 2.54, 0.285, 333, 246, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2166, 3v8sB, 0.7822, 2.82, 0.279, 397, 251, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2167, 3mwuA, 0.7822, 2.32, 0.313, 447, 243, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
2168, 3bwjA, 0.7821, 2.57, 0.285, 338, 246, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2169, 5n1nA, 0.7820, 2.58, 0.289, 348, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-9-PROPAN-2-YLPURINE
2170, 3v8sD, 0.7820, 2.83, 0.279, 397, 251, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2171, 3mvhA, 0.7820, 2.60, 0.296, 311, 247, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2172, 3l9lA, 0.7820, 2.55, 0.287, 338, 247, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2173, 2jdoA, 0.7818, 2.57, 0.296, 314, 247, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
2174, 3w2sA, 0.7817, 2.65, 0.210, 307, 248, EGFR KINASE DOMAIN WITH COMPOUND4
2175, 5n1mA, 0.7816, 2.58, 0.289, 347, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2176, 3nynB, 0.7816, 2.76, 0.285, 553, 249, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
2177, 3ocbB, 0.7815, 2.59, 0.296, 319, 247, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2178, 3ncgA, 0.7815, 2.33, 0.313, 426, 243, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
2179, 2hy81, 0.7815, 2.60, 0.306, 293, 248, PAK1 COMPLEX WITH ST2001
2180, 6c0tA, 0.7814, 2.66, 0.237, 334, 249, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
2181, 5hzeA, 0.7813, 2.39, 0.269, 305, 245, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
2182, 5upkB, 0.7812, 2.73, 0.274, 288, 248, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
2183, 5izfA, 0.7812, 2.61, 0.287, 336, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
2184, 4jdiA, 0.7812, 2.75, 0.274, 289, 248, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2185, 1u5qA, 0.7812, 2.66, 0.288, 308, 250, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2186, 5n37A, 0.7811, 2.60, 0.289, 347, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
2187, 5n3eA, 0.7810, 2.60, 0.289, 348, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
2188, 4iazA, 0.7810, 2.56, 0.285, 334, 246, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2189, 5n3aA, 0.7809, 2.61, 0.289, 349, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
2190, 5n36A, 0.7809, 2.59, 0.289, 347, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3H-ISOINDOL-2-IUM-1-AMINE
2191, 5lihA, 0.7809, 2.63, 0.305, 324, 246, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
2192, 5m75A, 0.7808, 2.58, 0.283, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
2193, 5jr7C, 0.7808, 2.53, 0.285, 335, 246, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2194, 3hdmA, 0.7808, 2.29, 0.269, 285, 242, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
2195, 5vedA, 0.7807, 2.75, 0.274, 289, 248, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2196, 4m69A, 0.7807, 2.75, 0.266, 284, 248, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
2197, 3nynA, 0.7807, 2.78, 0.285, 553, 249, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
2198, 3wigA, 0.7806, 2.45, 0.276, 278, 246, HUMAN MEK1 KINASE IN COMPLEX WITH CH5126766 AND MGAMP-PNP
2199, 3fmeA, 0.7806, 2.74, 0.245, 268, 249, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
2200, 4l67A, 0.7805, 2.71, 0.275, 289, 247, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
2201, 3l9lB, 0.7805, 2.58, 0.287, 337, 247, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2202, 5n1kA, 0.7804, 2.62, 0.289, 341, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
2203, 4a4oA, 0.7804, 2.57, 0.276, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
2204, 3is5C, 0.7804, 2.02, 0.304, 259, 237, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2205, 5uplA, 0.7803, 2.74, 0.270, 290, 248, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
2206, 4u44B, 0.7803, 2.54, 0.250, 296, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2207, 4fijA, 0.7803, 2.81, 0.270, 291, 248, CATALYTIC DOMAIN OF HUMAN PAK4
2208, 3wf6A, 0.7803, 2.39, 0.321, 277, 243, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2209, 3wf5A, 0.7803, 2.35, 0.321, 277, 243, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2210, 3kb7A, 0.7803, 2.57, 0.276, 289, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2211, 6gt1B, 0.7802, 2.53, 0.340, 269, 244, NEK7 BOUND TO PURINE INHIBITOR 
2212, 1u5rB, 0.7802, 2.70, 0.288, 308, 250, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2213, 5n3bA, 0.7801, 2.60, 0.289, 342, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(PYRIDIN-3-YL)ETHANAMINE
2214, 3ocbA, 0.7801, 2.61, 0.296, 315, 247, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2215, 5vibA, 0.7800, 2.56, 0.287, 308, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
2216, 4fiiA, 0.7800, 2.81, 0.270, 291, 248, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2217, 3v8sA, 0.7799, 2.78, 0.276, 395, 250, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2218, 3w2rA, 0.7798, 2.46, 0.222, 297, 243, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
2219, 3v8sC, 0.7798, 2.79, 0.276, 395, 250, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2220, 5n3cA, 0.7797, 2.60, 0.289, 348, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
2221, 3pfqA, 0.7797, 2.56, 0.259, 520, 247, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
2222, 5n3dA, 0.7796, 2.62, 0.289, 346, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE
2223, 5n1oA, 0.7796, 2.61, 0.285, 335, 246, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-4-(CHLOROMETHYL)-5- HYDROXYPHENYL)ETHAN-1-ONE
2224, 4fieB, 0.7796, 2.71, 0.274, 300, 248, FULL-LENGTH HUMAN PAK4
2225, 4fieA, 0.7796, 2.71, 0.274, 300, 248, FULL-LENGTH HUMAN PAK4
2226, 5d9kA, 0.7795, 2.64, 0.294, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2227, 4fihA, 0.7795, 2.83, 0.270, 291, 248, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
2228, 3a62A, 0.7795, 2.25, 0.332, 263, 241, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
2229, 4zy5B, 0.7794, 2.67, 0.316, 287, 250, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2230, 4xbrA, 0.7793, 2.73, 0.274, 315, 248, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
2231, 4wboC, 0.7793, 2.69, 0.277, 481, 249, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2232, 4a4lA, 0.7793, 2.57, 0.276, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
2233, 4zy6B, 0.7792, 2.62, 0.313, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2234, 3l9mB, 0.7792, 2.59, 0.287, 336, 247, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2235, 2yacA, 0.7792, 2.66, 0.271, 290, 247, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
2236, 5lihB, 0.7791, 2.42, 0.306, 318, 242, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
2237, 5ho8A, 0.7791, 2.51, 0.298, 278, 245, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2238, 4cffC, 0.7791, 2.28, 0.307, 422, 241, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2239, 3l9mA, 0.7791, 2.59, 0.287, 338, 247, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2240, 5vefA, 0.7789, 2.83, 0.270, 289, 248, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
2241, 4cfeC, 0.7789, 2.28, 0.307, 403, 241, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2242, 3orxA, 0.7789, 2.58, 0.297, 283, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2243, 5lcpA, 0.7788, 2.58, 0.287, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
2244, 4w7pD, 0.7788, 2.73, 0.269, 387, 249, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2245, 4w7pC, 0.7788, 2.72, 0.270, 383, 248, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2246, 3orxC, 0.7788, 2.58, 0.297, 283, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2247, 3orxB, 0.7788, 2.58, 0.297, 280, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2248, 3h9oA, 0.7787, 2.62, 0.297, 275, 246, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2249, 3cqwA, 0.7787, 2.62, 0.296, 318, 247, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2250, 5lcuA, 0.7786, 2.58, 0.287, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
2251, 4jdjA, 0.7786, 2.78, 0.271, 288, 247, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2252, 3orxD, 0.7786, 2.58, 0.297, 282, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2253, 3hdnA, 0.7786, 2.29, 0.270, 280, 241, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 2
2254, 2j0iA, 0.7786, 2.78, 0.275, 289, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2255, 5ng3B, 0.7784, 2.58, 0.230, 275, 244, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2256, 5isoA, 0.7784, 2.39, 0.306, 453, 242, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2257, 4eqmD, 0.7784, 2.37, 0.249, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2258, 3ionA, 0.7784, 2.63, 0.297, 274, 246, PDK1 IN COMPLEX WITH COMPOUND 8H
2259, 4usdA, 0.7783, 2.46, 0.321, 268, 246, HUMAN STK10 (LOK) WITH SB-633825
2260, 4cffA, 0.7783, 2.29, 0.307, 424, 241, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2261, 5kktB, 0.7782, 2.90, 0.275, 394, 251, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2262, 4eqmF, 0.7782, 2.36, 0.249, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2263, 4cfeA, 0.7782, 2.29, 0.307, 425, 241, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2264, 5kksB, 0.7781, 2.89, 0.279, 395, 251, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2265, 3w33A, 0.7781, 2.69, 0.206, 297, 247, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
2266, 3iopA, 0.7781, 2.64, 0.297, 275, 246, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2267, 2fumB, 0.7781, 2.34, 0.277, 262, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2268, 4w7pB, 0.7780, 2.78, 0.269, 387, 249, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2269, 4eqmE, 0.7780, 2.36, 0.249, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2270, 5w5qB, 0.7779, 2.52, 0.231, 297, 247, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
2271, 5n3fA, 0.7779, 2.56, 0.287, 318, 244, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-[3-(AMINOMETHYL)PHENYL]ACETAMIDE
2272, 4w7pA, 0.7779, 2.74, 0.269, 388, 249, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2273, 5hkmA, 0.7778, 2.53, 0.298, 272, 245, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2274, 4jdkA, 0.7778, 2.78, 0.271, 288, 247, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2275, 5bmsA, 0.7776, 2.79, 0.274, 290, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2276, 4gv1A, 0.7776, 2.64, 0.300, 329, 247, PKB ALPHA IN COMPLEX WITH AZD5363
2277, 6fu5B, 0.7775, 2.72, 0.220, 286, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
2278, 5n1dA, 0.7775, 2.60, 0.287, 348, 247, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
2279, 4jdhA, 0.7775, 2.83, 0.270, 289, 248, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2280, 2etkB, 0.7775, 2.89, 0.275, 398, 251, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2281, 4pniA, 0.7774, 2.66, 0.277, 492, 249, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
2282, 3nyoB, 0.7774, 2.80, 0.285, 553, 249, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
2283, 5ar4B, 0.7773, 2.81, 0.227, 279, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2284, 4yuqA, 0.7773, 2.48, 0.315, 462, 241, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2285, 4b9dB, 0.7773, 2.35, 0.272, 295, 239, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2286, 3pp0B, 0.7773, 2.76, 0.215, 296, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2287, 2pe0A, 0.7773, 2.64, 0.293, 275, 246, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2288, 4zseA, 0.7772, 2.73, 0.203, 297, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2289, 3wf8A, 0.7772, 2.65, 0.319, 287, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
2290, 2vd5B, 0.7772, 2.67, 0.287, 380, 247, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2291, 2rfeA, 0.7772, 2.57, 0.220, 286, 246, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2292, 5xzvB, 0.7771, 2.40, 0.332, 371, 238, CRYSTAL STRUCTURE OF RAD53 1-466 IN COMPLEX WITH AMP-PNP
2293, 3igoA, 0.7771, 2.46, 0.313, 446, 243, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CDPK1 CGD3_920
2294, 4apcB, 0.7770, 2.40, 0.271, 296, 240, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2295, 4aotA, 0.7770, 2.61, 0.329, 278, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2296, 3tnqB, 0.7770, 2.64, 0.285, 331, 246, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2297, 5j7bB, 0.7769, 2.83, 0.227, 281, 251, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2298, 4rewA, 0.7769, 2.32, 0.320, 411, 241, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
2299, 4o0tB, 0.7769, 2.59, 0.316, 280, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2300, 4ks7A, 0.7769, 2.80, 0.275, 286, 247, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
2301, 4fifA, 0.7769, 2.76, 0.274, 293, 248, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2302, 3wf9A, 0.7769, 2.66, 0.319, 287, 248, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
2303, 3nuuA, 0.7769, 2.54, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2304, 2fumA, 0.7769, 2.29, 0.274, 263, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2305, 1z5mA, 0.7769, 2.65, 0.293, 275, 246, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2306, 5m6vA, 0.7768, 2.62, 0.283, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
2307, 3sc1A, 0.7768, 2.64, 0.297, 278, 246, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2308, 2xchA, 0.7768, 2.65, 0.293, 278, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2309, 5deyB, 0.7767, 2.67, 0.313, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2310, 4u8zA, 0.7767, 2.62, 0.280, 289, 246, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
2311, 4fifB, 0.7767, 2.76, 0.274, 292, 248, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2312, 6c9dA, 0.7766, 2.69, 0.325, 425, 246, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
2313, 4wotD, 0.7766, 2.90, 0.279, 389, 251, ROCK2 IN COMPLEX WITH 1426382-07-1
2314, 4figB, 0.7766, 2.74, 0.274, 292, 248, CATALYTIC DOMAIN OF HUMAN PAK4
2315, 4figA, 0.7766, 2.74, 0.274, 292, 248, CATALYTIC DOMAIN OF HUMAN PAK4
2316, 3rwqA, 0.7766, 2.67, 0.293, 283, 246, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2317, 2esmB, 0.7766, 2.90, 0.275, 398, 251, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2318, 1okzA, 0.7766, 2.54, 0.298, 276, 245, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2319, 5ho7A, 0.7765, 2.66, 0.293, 280, 246, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2320, 5lcrA, 0.7764, 2.62, 0.287, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
2321, 4yuqB, 0.7764, 2.43, 0.317, 462, 240, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2322, 4b6lA, 0.7764, 2.69, 0.291, 281, 247, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
2323, 3tv7A, 0.7764, 2.84, 0.276, 394, 250, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2324, 1okyA, 0.7764, 2.64, 0.293, 281, 246, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2325, 5isoC, 0.7763, 2.32, 0.307, 429, 241, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2326, 4l53A, 0.7763, 2.78, 0.293, 296, 246, CRYSTAL STRUCTURE OF (1R4R)-4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7- YL)-3-CHLOROFURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}CYCLOHEXAN-1-OL BOUND TO TAK1-TAB1
2327, 2r7bA, 0.7763, 2.65, 0.293, 274, 246, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2328, 5u7qB, 0.7762, 2.91, 0.279, 385, 251, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2329, 5m71A, 0.7762, 2.60, 0.283, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
2330, 1xkkA, 0.7762, 2.72, 0.211, 289, 246, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
2331, 6b1uC, 0.7761, 2.33, 0.307, 459, 241, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2332, 6b1uA, 0.7761, 2.33, 0.307, 441, 241, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2333, 6b16B, 0.7761, 2.61, 0.319, 281, 248, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2334, 5o0eA, 0.7761, 2.57, 0.289, 349, 246, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
2335, 4zhxC, 0.7761, 2.31, 0.307, 452, 241, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2336, 5d9kB, 0.7760, 2.65, 0.296, 280, 247, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2337, 4zy4B, 0.7760, 2.72, 0.316, 292, 250, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2338, 4wboA, 0.7760, 2.71, 0.277, 497, 249, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2339, 4o27B, 0.7760, 2.59, 0.280, 281, 246, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
2340, 6es0B, 0.7759, 2.82, 0.231, 287, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
2341, 2pe2A, 0.7759, 2.66, 0.293, 275, 246, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2342, 5x2aD, 0.7758, 2.66, 0.208, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
2343, 5ta6A, 0.7758, 2.69, 0.271, 294, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
2344, 3twjD, 0.7758, 2.90, 0.273, 395, 249, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2345, 3nyoA, 0.7758, 2.82, 0.285, 553, 249, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
2346, 4wboD, 0.7757, 2.73, 0.277, 491, 249, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2347, 4c35A, 0.7757, 2.61, 0.289, 337, 246, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
2348, 3nusA, 0.7757, 2.56, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2349, 5cnnB, 0.7756, 2.55, 0.209, 304, 244, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
2350, 4yvcB, 0.7756, 2.93, 0.279, 392, 251, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2351, 3tv7C, 0.7756, 2.85, 0.276, 394, 250, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2352, 3rwpA, 0.7756, 2.68, 0.293, 277, 246, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2353, 5xzwB, 0.7755, 2.29, 0.333, 379, 237, CRYSTAL STRUCTURE OF RAD53 1-466
2354, 3dxnA, 0.7755, 2.37, 0.325, 258, 240, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
2355, 3a8xA, 0.7755, 2.57, 0.296, 334, 247, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2356, 5izjA, 0.7754, 2.61, 0.287, 328, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
2357, 4usdB, 0.7754, 2.47, 0.327, 267, 245, HUMAN STK10 (LOK) WITH SB-633825
2358, 3qcqA, 0.7754, 2.58, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2359, 2owbA, 0.7754, 2.69, 0.271, 294, 247, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2360, 2etrB, 0.7754, 2.92, 0.279, 398, 251, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2361, 5m53A, 0.7753, 2.17, 0.298, 255, 238, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
2362, 5j7bA, 0.7753, 2.79, 0.228, 277, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2363, 5d41B, 0.7753, 2.65, 0.208, 302, 245, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
2364, 4zhxA, 0.7753, 2.35, 0.307, 408, 241, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2365, 4wbbB, 0.7753, 2.66, 0.285, 334, 246, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
2366, 3a7fA, 0.7753, 2.66, 0.280, 283, 246, HUMAN MST3 KINASE
2367, 5m6yA, 0.7752, 2.63, 0.283, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
2368, 3nunA, 0.7752, 2.59, 0.298, 278, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2369, 2rfdA, 0.7752, 2.63, 0.212, 288, 245, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2370, 2g1tC, 0.7752, 2.67, 0.238, 276, 244, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2371, 5dh3B, 0.7751, 2.82, 0.296, 283, 250, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2372, 4zk5B, 0.7751, 2.48, 0.245, 294, 245, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2373, 3ggfA, 0.7751, 2.55, 0.283, 275, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2374, 4wotA, 0.7750, 2.95, 0.279, 389, 251, ROCK2 IN COMPLEX WITH 1426382-07-1
2375, 6c9dB, 0.7749, 2.69, 0.325, 422, 246, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
2376, 5lctA, 0.7749, 2.63, 0.287, 350, 247, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
2377, 5hngA, 0.7749, 2.67, 0.297, 280, 246, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2378, 4nzwB, 0.7749, 2.44, 0.280, 266, 243, CRYSTAL STRUCTURE OF STK25-MO25 COMPLEX
2379, 4m97A, 0.7749, 2.61, 0.310, 465, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM NEOSPORA CANINUM
2380, 3l9nA, 0.7749, 2.68, 0.283, 332, 247, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
2381, 2jedB, 0.7749, 2.67, 0.296, 320, 247, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2382, 4u3yA, 0.7748, 2.84, 0.227, 295, 251, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
2383, 4mx9A, 0.7748, 2.62, 0.310, 459, 245, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR UW1294
2384, 3lm0A, 0.7748, 2.87, 0.242, 278, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2385, 3fc2A, 0.7748, 2.62, 0.276, 293, 246, PLK1 IN COMPLEX WITH BI6727
2386, 5ezvC, 0.7747, 2.34, 0.307, 440, 241, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2387, 5dewB, 0.7747, 2.63, 0.319, 281, 248, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2388, 5ar7B, 0.7747, 2.81, 0.224, 278, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
2389, 4c34A, 0.7747, 2.63, 0.289, 336, 246, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
2390, 3twjB, 0.7747, 2.69, 0.275, 395, 247, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2391, 6bfaA, 0.7746, 2.63, 0.310, 464, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1553
2392, 5nw8A, 0.7746, 2.61, 0.285, 337, 246, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
2393, 5x2cA, 0.7745, 2.67, 0.212, 304, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
2394, 5ok3A, 0.7745, 2.59, 0.285, 349, 246, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
2395, 5fd2A, 0.7745, 2.38, 0.217, 264, 240, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
2396, 5bmlB, 0.7745, 2.95, 0.275, 395, 251, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2397, 4zseD, 0.7745, 2.75, 0.212, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2398, 4qmoA, 0.7745, 2.66, 0.280, 288, 246, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
2399, 3nuyA, 0.7745, 2.58, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2400, 2g1tB, 0.7745, 2.63, 0.243, 273, 243, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2401, 5wneA, 0.7744, 2.85, 0.276, 384, 250, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2402, 4j52A, 0.7744, 2.64, 0.276, 293, 246, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
2403, 5kktA, 0.7743, 2.79, 0.269, 389, 249, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2404, 5ezvA, 0.7743, 2.36, 0.303, 441, 241, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2405, 4eklA, 0.7743, 2.68, 0.296, 329, 247, AKT1 WITH GDC0068
2406, 3qcsA, 0.7743, 2.60, 0.298, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2407, 5veeA, 0.7742, 2.86, 0.277, 289, 249, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
2408, 4crsA, 0.7742, 2.52, 0.302, 331, 245, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
2409, 3qklA, 0.7742, 2.69, 0.296, 317, 247, SPIROCHROMANE AKT INHIBITORS
2410, 4mxaA, 0.7741, 2.63, 0.310, 459, 245, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR RM-1-132
2411, 4ks8A, 0.7741, 2.81, 0.287, 286, 247, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2412, 4rvtB, 0.7740, 2.83, 0.233, 297, 249, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
2413, 4qmpA, 0.7740, 2.68, 0.280, 289, 246, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
2414, 4appA, 0.7740, 2.83, 0.259, 291, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
2415, 3ku2A, 0.7740, 2.61, 0.310, 457, 245, CRYSTAL STRUCTURE OF INACTIVATED FORM OF CDPK1 FROM TOXOPLASMA GONDII TGME49.101440
2416, 2g1tD, 0.7740, 2.65, 0.235, 277, 243, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2417, 5m0uA, 0.7739, 2.51, 0.284, 346, 243, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
2418, 4nusA, 0.7738, 2.75, 0.291, 301, 247, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2419, 5u7rC, 0.7737, 2.95, 0.279, 387, 251, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2420, 4yveB, 0.7737, 2.97, 0.279, 393, 251, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2421, 3dy7A, 0.7737, 2.34, 0.287, 260, 240, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
2422, 2pe1A, 0.7737, 2.69, 0.293, 275, 246, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2423, 5kksA, 0.7735, 2.88, 0.276, 395, 250, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2424, 3qcxA, 0.7735, 2.62, 0.294, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2425, 3ow4A, 0.7735, 2.70, 0.296, 317, 247, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2426, 2xh5A, 0.7735, 2.72, 0.296, 316, 247, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
2427, 1uu7A, 0.7735, 2.60, 0.298, 280, 245, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
2428, 5x2fD, 0.7733, 2.81, 0.207, 309, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
2429, 4u3yB, 0.7733, 2.83, 0.229, 300, 249, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
2430, 4aw1A, 0.7733, 2.63, 0.294, 283, 245, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2431, 6e4tA, 0.7732, 2.39, 0.320, 361, 241, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2432, 4w8eA, 0.7732, 2.69, 0.280, 290, 246, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
2433, 4m84A, 0.7732, 2.64, 0.310, 464, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1455
2434, 3w32A, 0.7732, 2.81, 0.202, 317, 248, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
2435, 3sxfA, 0.7732, 2.62, 0.310, 452, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-89
2436, 3o7lB, 0.7732, 2.56, 0.275, 326, 244, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2437, 2g1tA, 0.7732, 2.63, 0.243, 271, 243, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2438, 4apcA, 0.7731, 2.36, 0.269, 293, 238, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2439, 2xckA, 0.7731, 2.73, 0.289, 275, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2440, 2evaA, 0.7731, 2.85, 0.294, 295, 245, STRUCTURAL BASIS FOR THE INTERACTION OF TAK1 KINASE WITH ITS ACTIVATING PROTEIN TAB1
2441, 1uu8A, 0.7731, 2.54, 0.295, 277, 244, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2442, 5u8lA, 0.7730, 2.76, 0.211, 289, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
2443, 4rerA, 0.7730, 2.39, 0.328, 458, 241, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
2444, 4l52A, 0.7730, 2.71, 0.299, 295, 244, CRYSTAL STRUCTURE OF 1-(4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7-YL) FURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}PIPERIDIN-1-YL)ETHAN-1-ONE BOUND TO TAK1-TAB1
2445, 4i24B, 0.7730, 2.81, 0.203, 304, 246, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
2446, 5x2fA, 0.7729, 2.83, 0.207, 301, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
2447, 5x2aA, 0.7729, 2.66, 0.205, 297, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
2448, 5hg5A, 0.7729, 2.84, 0.206, 302, 247, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
2449, 4j53A, 0.7729, 2.72, 0.271, 293, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
2450, 4b9dA, 0.7729, 2.37, 0.269, 290, 238, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2451, 3qkkA, 0.7729, 2.70, 0.300, 326, 247, SPIROCHROMANE AKT INHIBITORS
2452, 6gttA, 0.7728, 2.59, 0.316, 282, 247, HUMAN STK10 BOUND TO BIRB-796 
2453, 4o0tA, 0.7728, 2.77, 0.287, 292, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2454, 3ow4B, 0.7728, 2.73, 0.296, 317, 247, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2455, 3mftA, 0.7728, 2.78, 0.306, 302, 245, CASK-4M CAM KINASE DOMAIN MN2+
2456, 4ehgA, 0.7727, 2.58, 0.216, 262, 241, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
2457, 3qd3A, 0.7727, 2.64, 0.294, 278, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2458, 1uu3A, 0.7727, 2.71, 0.293, 276, 246, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2459, 6e4wA, 0.7726, 2.42, 0.328, 361, 241, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2460, 6aywB, 0.7726, 2.68, 0.320, 293, 244, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2461, 3qcyA, 0.7726, 2.63, 0.298, 275, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2462, 3q53A, 0.7726, 2.78, 0.309, 291, 249, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
2463, 2rkuA, 0.7726, 2.66, 0.276, 294, 246, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
2464, 1u5rA, 0.7726, 2.78, 0.284, 308, 250, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2465, 5vloB, 0.7725, 2.68, 0.320, 293, 244, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2466, 5vjaB, 0.7725, 2.45, 0.281, 266, 242, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2467, 5x2aB, 0.7724, 2.77, 0.203, 322, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
2468, 4u3zA, 0.7724, 2.63, 0.241, 282, 245, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
2469, 4tzrA, 0.7724, 2.58, 0.320, 461, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1561
2470, 4l6qA, 0.7724, 2.90, 0.272, 388, 250, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2471, 3gt8B, 0.7724, 2.75, 0.197, 292, 244, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2472, 4wg3A, 0.7723, 2.53, 0.309, 460, 243, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1610
2473, 4onaA, 0.7723, 2.67, 0.310, 465, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1517
2474, 4l6qB, 0.7723, 2.90, 0.276, 388, 250, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2475, 3dfaA, 0.7723, 2.28, 0.301, 265, 239, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
2476, 5f9eB, 0.7722, 2.70, 0.289, 293, 246, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2477, 5cnoA, 0.7722, 2.66, 0.213, 300, 244, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
2478, 4w8dA, 0.7722, 2.69, 0.280, 289, 246, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
2479, 4qfsA, 0.7722, 2.41, 0.320, 361, 241, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
2480, 6gt1A, 0.7721, 2.60, 0.329, 267, 243, NEK7 BOUND TO PURINE INHIBITOR 
2481, 5hg8A, 0.7721, 2.86, 0.211, 300, 247, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
2482, 4wg5A, 0.7721, 2.66, 0.310, 464, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1647
2483, 3t3uA, 0.7721, 2.63, 0.310, 452, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-130
2484, 2v55C, 0.7721, 2.85, 0.272, 396, 250, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
2485, 5x2cB, 0.7720, 2.69, 0.204, 303, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
2486, 5maiA, 0.7720, 2.03, 0.326, 312, 236, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
2487, 5gtyH, 0.7720, 2.80, 0.211, 300, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2488, 4otdA, 0.7720, 2.61, 0.297, 334, 246, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
2489, 1uvrA, 0.7720, 2.72, 0.297, 284, 246, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
2490, 5vjaC, 0.7719, 2.32, 0.293, 265, 239, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2491, 5ta8A, 0.7719, 2.77, 0.271, 294, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
2492, 5j95B, 0.7719, 2.76, 0.239, 300, 247, MAP4K4 IN COMPLEX WITH INHIBITOR
2493, 5ajqB, 0.7719, 2.59, 0.327, 267, 245, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
2494, 4fr4F, 0.7719, 2.90, 0.247, 346, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2495, 3v5tA, 0.7719, 2.59, 0.320, 460, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1299
2496, 3qkmA, 0.7719, 2.71, 0.300, 329, 247, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
2497, 3qd4A, 0.7719, 2.65, 0.294, 276, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2498, 1vzoA, 0.7719, 2.44, 0.261, 319, 241, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
2499, 5wngA, 0.7718, 2.94, 0.271, 395, 251, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2500, 4jbvA, 0.7718, 2.54, 0.309, 458, 243, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1268
2501, 3ndmB, 0.7718, 2.92, 0.276, 396, 250, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2502, 3ag9B, 0.7718, 2.74, 0.287, 317, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2503, 1uu9A, 0.7718, 2.56, 0.295, 276, 244, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2504, 5yu9C, 0.7717, 2.80, 0.211, 306, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
2505, 4yjnA, 0.7717, 2.59, 0.311, 460, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1639
2506, 4wotC, 0.7717, 2.91, 0.276, 392, 250, ROCK2 IN COMPLEX WITH 1426382-07-1
2507, 4wotB, 0.7717, 2.97, 0.271, 394, 251, ROCK2 IN COMPLEX WITH 1426382-07-1
2508, 4qmmA, 0.7717, 2.70, 0.280, 288, 246, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
2509, 5w91A, 0.7716, 2.61, 0.320, 451, 244, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LZH118
2510, 5u7qD, 0.7716, 3.03, 0.266, 383, 252, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2511, 5t5tA, 0.7716, 2.42, 0.324, 368, 241, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2512, 5ebzL, 0.7716, 3.33, 0.263, 655, 255, CRYSTAL STRUCTURE OF HUMAN IKK1
2513, 4at5A, 0.7716, 2.71, 0.239, 294, 247, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
2514, 3upxA, 0.7716, 2.61, 0.320, 445, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1300
2515, 4c8bB, 0.7715, 2.87, 0.232, 281, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2516, 3t3vA, 0.7715, 2.59, 0.320, 453, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-87
2517, 3gubA, 0.7715, 2.51, 0.286, 278, 241, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2518, 1phkA, 0.7715, 2.52, 0.302, 277, 242, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
2519, 1h1wA, 0.7715, 2.74, 0.293, 284, 246, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
2520, 5di1B, 0.7714, 2.76, 0.239, 300, 247, MAP4K4 IN COMPLEX WITH AN INHIBITOR
2521, 4wg4A, 0.7714, 2.60, 0.320, 454, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1613
2522, 4o0rB, 0.7714, 2.68, 0.316, 282, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2523, 4idtB, 0.7714, 2.77, 0.257, 335, 245, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
2524, 4gs6A, 0.7714, 2.80, 0.287, 294, 244, IRREVERSIBLE INHIBITION OF TAK1 KINASE BY 5Z-7-OXOZEAENOL
2525, 1q8wA, 0.7714, 2.65, 0.280, 334, 246, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
2526, 5x2fC, 0.7713, 2.55, 0.206, 302, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
2527, 5wngD, 0.7713, 2.94, 0.280, 396, 250, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2528, 4obqB, 0.7713, 2.50, 0.246, 293, 244, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
2529, 3n51A, 0.7713, 2.65, 0.310, 448, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
2530, 3c0gA, 0.7713, 2.81, 0.298, 309, 245, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2531, 2xikA, 0.7713, 2.72, 0.289, 288, 246, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
2532, 2v55A, 0.7713, 2.85, 0.276, 393, 250, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
2533, 6e4uA, 0.7712, 2.42, 0.324, 365, 241, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2534, 5izjB, 0.7712, 2.67, 0.287, 325, 247, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
2535, 4qfrA, 0.7712, 2.43, 0.324, 361, 241, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
2536, 4ihpA, 0.7712, 2.72, 0.310, 454, 245, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
2537, 4ih8A, 0.7712, 2.55, 0.317, 433, 243, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
2538, 5w80A, 0.7711, 2.61, 0.320, 453, 244, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-237
2539, 5gtyG, 0.7711, 2.76, 0.212, 299, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2540, 5ebzE, 0.7711, 3.24, 0.268, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
2541, 5ar2B, 0.7711, 2.90, 0.223, 285, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2542, 4zp5B, 0.7711, 2.76, 0.239, 300, 247, MAP4K4 IN COMPLEX WITH INHIBITOR
2543, 4wboB, 0.7711, 2.80, 0.277, 495, 249, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
2544, 4q9zB, 0.7711, 2.72, 0.285, 308, 246, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2545, 4ifgA, 0.7711, 2.62, 0.320, 452, 244, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
2546, 5u7rD, 0.7710, 2.72, 0.279, 382, 247, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2547, 5kq5A, 0.7710, 2.43, 0.320, 362, 241, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2548, 5ar5A, 0.7710, 2.85, 0.232, 284, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2549, 4qmqA, 0.7710, 2.74, 0.276, 289, 246, MST3 IN COMPLEX WITH CP-673451
2550, 4zloA, 0.7709, 2.51, 0.313, 277, 243, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
2551, 4zjjC, 0.7709, 2.49, 0.306, 276, 242, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2552, 4idtA, 0.7709, 2.80, 0.261, 334, 245, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
2553, 3v5pA, 0.7709, 2.59, 0.320, 450, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1288
2554, 3ndmD, 0.7709, 2.92, 0.276, 396, 250, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2555, 5f9eA, 0.7708, 2.75, 0.296, 334, 247, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2556, 5ebzJ, 0.7708, 3.26, 0.260, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
2557, 5cnnA, 0.7708, 2.73, 0.212, 300, 245, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
2558, 4fr4D, 0.7708, 2.91, 0.247, 346, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2559, 3orxG, 0.7708, 2.69, 0.293, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2560, 2esmA, 0.7708, 2.90, 0.276, 400, 250, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2561, 5jmsA, 0.7707, 2.63, 0.320, 447, 244, CRYSTAL STRUCTURE OF TGCDPK1 BOUND TO CGP060476
2562, 5d7vB, 0.7707, 2.48, 0.260, 264, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2563, 3sx9A, 0.7707, 2.61, 0.320, 457, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-132
2564, 3orxE, 0.7707, 2.69, 0.293, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2565, 3a61A, 0.7707, 2.08, 0.326, 254, 236, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM II)
2566, 2rgpA, 0.7707, 2.57, 0.210, 284, 243, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
2567, 5jn2A, 0.7706, 2.63, 0.320, 450, 244, CRYSTAL STRUCTURE OF TGCDPK1 BOUND TO NVPACU106
2568, 4zseB, 0.7706, 2.77, 0.207, 313, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2569, 4u45B, 0.7706, 2.65, 0.233, 295, 245, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2570, 4j7bA, 0.7706, 2.76, 0.287, 284, 247, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2571, 4fr4A, 0.7706, 2.90, 0.247, 350, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2572, 4euuB, 0.7706, 2.90, 0.241, 307, 249, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2573, 3d9vB, 0.7706, 2.96, 0.275, 398, 251, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2574, 5d7vC, 0.7705, 2.43, 0.253, 264, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2575, 5cnoB, 0.7705, 2.72, 0.216, 302, 245, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
2576, 3c0iA, 0.7705, 2.83, 0.298, 298, 245, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
2577, 5ebzI, 0.7704, 3.27, 0.268, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
2578, 3bhyA, 0.7704, 2.55, 0.289, 268, 242, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2579, 4euuA, 0.7703, 2.90, 0.245, 307, 249, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2580, 3upzA, 0.7703, 2.56, 0.309, 458, 243, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
2581, 3qd0A, 0.7703, 2.67, 0.294, 274, 245, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2582, 3i79A, 0.7703, 2.69, 0.299, 455, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1)
2583, 3c0gB, 0.7703, 2.82, 0.298, 320, 245, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2584, 2jiuB, 0.7703, 2.82, 0.185, 309, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2585, 5w8rA, 0.7702, 2.63, 0.311, 456, 244, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR 3CIB-PPI
2586, 5d7vD, 0.7702, 2.43, 0.253, 264, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2587, 4ypdA, 0.7701, 2.54, 0.286, 281, 241, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2588, 4q9zA, 0.7701, 2.76, 0.296, 331, 247, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2589, 3orxH, 0.7701, 2.70, 0.293, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2590, 3lm5A, 0.7701, 2.79, 0.248, 274, 246, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2591, 3lijA, 0.7701, 2.54, 0.336, 465, 241, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
2592, 2fumD, 0.7701, 2.38, 0.270, 258, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2593, 2biyA, 0.7701, 2.76, 0.297, 287, 246, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
2594, 1yrpA, 0.7701, 2.46, 0.283, 275, 240, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2595, 4ra5B, 0.7700, 2.75, 0.289, 310, 246, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2596, 1yrpB, 0.7700, 2.46, 0.283, 275, 240, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2597, 5d9lA, 0.7699, 2.56, 0.273, 299, 245, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2598, 3gu6A, 0.7699, 2.54, 0.286, 280, 241, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2599, 1xjdA, 0.7699, 2.51, 0.289, 280, 242, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2600, 5w9rA, 0.7698, 2.63, 0.320, 445, 244, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LJQ138
2601, 3gu4A, 0.7698, 2.53, 0.286, 280, 241, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2602, 2x4zA, 0.7698, 2.84, 0.244, 290, 246, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2603, 5wnfA, 0.7697, 2.93, 0.276, 395, 250, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2604, 5w9eA, 0.7697, 2.63, 0.320, 451, 244, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-186
2605, 5dzcA, 0.7697, 2.71, 0.274, 816, 248, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
2606, 4ty1A, 0.7697, 2.47, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2607, 3rcjA, 0.7697, 2.69, 0.294, 281, 245, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
2608, 1gzkA, 0.7697, 2.57, 0.303, 271, 241, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
2609, 5ebzH, 0.7696, 3.32, 0.264, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
2610, 5bmlA, 0.7696, 2.84, 0.274, 393, 248, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2611, 4u41B, 0.7696, 2.70, 0.232, 297, 246, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2612, 3q4zB, 0.7696, 2.66, 0.305, 279, 246, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2613, 3mfrA, 0.7696, 2.83, 0.306, 302, 245, CASK-4M CAM KINASE DOMAIN NATIVE
2614, 5ufuA, 0.7695, 2.47, 0.324, 368, 241, STRUCTURE OF AMPK BOUND TO ACTIVATOR
2615, 5t6aA, 0.7695, 2.63, 0.320, 431, 244, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GA
2616, 4yo4A, 0.7695, 2.54, 0.286, 280, 241, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2617, 4qfgA, 0.7695, 2.47, 0.324, 365, 241, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
2618, 4oboB, 0.7695, 2.72, 0.232, 297, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
2619, 4ixpA, 0.7695, 2.38, 0.320, 334, 241, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
2620, 3orxF, 0.7695, 2.70, 0.293, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2621, 3i7bA, 0.7695, 2.66, 0.310, 459, 245, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
2622, 3gu8A, 0.7695, 2.52, 0.286, 278, 241, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2623, 3dfcB, 0.7695, 2.52, 0.286, 280, 241, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2624, 5wneD, 0.7694, 2.93, 0.276, 396, 250, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2625, 5ntjA, 0.7694, 2.69, 0.285, 346, 246, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
2626, 5imeB, 0.7694, 2.69, 0.313, 280, 246, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2627, 5hvuA, 0.7694, 2.92, 0.272, 394, 250, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
2628, 5ezrA, 0.7694, 2.69, 0.274, 803, 248, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
2629, 5ebzF, 0.7694, 3.40, 0.263, 655, 255, CRYSTAL STRUCTURE OF HUMAN IKK1
2630, 4iw0A, 0.7694, 2.97, 0.244, 647, 250, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
2631, 4ehgB, 0.7694, 2.64, 0.207, 260, 241, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
2632, 3nczA, 0.7694, 2.97, 0.267, 399, 251, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2633, 3g51A, 0.7694, 2.38, 0.312, 280, 240, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
2634, 5ebzK, 0.7693, 3.30, 0.264, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
2635, 4zseC, 0.7693, 2.69, 0.205, 301, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
2636, 3gt8D, 0.7693, 2.69, 0.202, 295, 243, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2637, 1szmA, 0.7693, 2.61, 0.286, 317, 245, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2638, 5yu9D, 0.7692, 2.79, 0.204, 300, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
2639, 5vjaA, 0.7692, 2.45, 0.282, 266, 241, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2640, 5ng3C, 0.7692, 2.58, 0.232, 272, 241, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2641, 4ynzB, 0.7692, 2.45, 0.289, 323, 242, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
2642, 1gzoA, 0.7692, 2.58, 0.303, 271, 241, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
2643, 6aywA, 0.7691, 2.58, 0.309, 293, 243, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2644, 3uohB, 0.7691, 2.46, 0.315, 264, 241, AURORA A IN COMPLEX WITH RPM1722
2645, 3uohA, 0.7691, 2.46, 0.315, 264, 241, AURORA A IN COMPLEX WITH RPM1722
2646, 3gt8C, 0.7691, 2.80, 0.201, 296, 244, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2647, 5ebzC, 0.7690, 3.32, 0.260, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
2648, 4ysjA, 0.7690, 2.56, 0.322, 459, 239, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2649, 4j7bD, 0.7690, 2.74, 0.293, 281, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2650, 4mbjA, 0.7689, 2.75, 0.218, 269, 243, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
2651, 4ejnA, 0.7689, 2.50, 0.303, 376, 241, CRYSTAL STRUCTURE OF AUTOINHIBITED FORM OF AKT1 IN COMPLEX WITH N-(4- (5-(3-ACETAMIDOPHENYL)-2-(2-AMINOPYRIDIN-3-YL)-3H-IMIDAZO[45- B]PYRIDIN-3-YL)BENZYL)-3-FLUOROBENZAMIDE
2652, 3pwyA, 0.7689, 2.67, 0.302, 281, 245, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
2653, 3c4wB, 0.7689, 2.89, 0.277, 518, 249, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
2654, 1jklA, 0.7689, 2.55, 0.286, 280, 241, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2655, 5w5oM, 0.7688, 2.72, 0.228, 276, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2656, 5hvuB, 0.7688, 2.91, 0.277, 394, 249, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
2657, 5ebzA, 0.7688, 3.27, 0.268, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
2658, 3tv6A, 0.7688, 2.63, 0.219, 268, 242, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
2659, 3gu7A, 0.7688, 2.54, 0.286, 280, 241, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2660, 2oi4X, 0.7688, 2.42, 0.270, 275, 241, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2661, 2h9vA, 0.7688, 2.93, 0.268, 383, 250, STRUCTURAL BASIS FOR INDUCED-FIT BINDING OF RHO-KINASE TO THE INHIBITOR Y27632
2662, 4ysjB, 0.7687, 2.52, 0.322, 462, 239, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2663, 4ra5A, 0.7687, 2.80, 0.296, 332, 247, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2664, 3gu5A, 0.7687, 2.54, 0.286, 280, 241, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2665, 1ql6A, 0.7687, 2.65, 0.300, 281, 243, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
2666, 5wnhA, 0.7686, 2.93, 0.276, 394, 250, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2667, 5u7rA, 0.7686, 2.97, 0.280, 387, 250, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2668, 5dh3A, 0.7686, 2.92, 0.296, 287, 250, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2669, 4l3pA, 0.7686, 2.83, 0.291, 295, 244, CRYSTAL STRUCTURE OF 2-(1-BENZOTHIOPHEN-7-YL)-4-[1-(PIPERIDIN-4-YL)- 1H-PYRAZOL-4-YL]FURO[23-C]PYRIDIN-7-AMINE BOUND TO TAK1-TAB1
2670, 4k0yA, 0.7686, 2.46, 0.274, 274, 241, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2671, 3gt8A, 0.7686, 2.50, 0.195, 300, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
2672, 3a8xB, 0.7686, 2.62, 0.285, 329, 246, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2673, 4yveA, 0.7685, 2.90, 0.277, 390, 249, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2674, 4wo5B, 0.7685, 2.52, 0.221, 257, 240, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
2675, 3orzA, 0.7685, 2.73, 0.294, 276, 245, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2676, 3dgkA, 0.7685, 2.54, 0.286, 278, 241, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2677, 3ckxA, 0.7685, 2.81, 0.280, 276, 246, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2678, 5uwdA, 0.7684, 2.57, 0.211, 271, 242, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH THE COVALENT INHIBITOR CO-1686
2679, 4pp7A, 0.7684, 2.56, 0.220, 267, 241, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
2680, 3v51A, 0.7684, 2.64, 0.320, 459, 244, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR RM-1-176
2681, 3c4xB, 0.7684, 2.91, 0.277, 475, 249, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
2682, 6b2eA, 0.7683, 2.43, 0.311, 442, 241, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
2683, 5n4vA, 0.7683, 2.47, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 2-CYCLOPROPYL-45- DIMETHYLTHIENO[54-D]PYRIMIDINE-6-CARBOXYLIC ACID
2684, 4ra4A, 0.7683, 2.70, 0.264, 317, 246, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2685, 3tv6B, 0.7683, 2.48, 0.217, 276, 240, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
2686, 3c0hA, 0.7683, 2.83, 0.298, 300, 245, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2687, 2etkA, 0.7683, 2.93, 0.272, 400, 250, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2688, 2acxA, 0.7683, 2.77, 0.283, 495, 247, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
2689, 5wnfD, 0.7682, 2.97, 0.280, 396, 250, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2690, 5v82A, 0.7682, 2.46, 0.274, 273, 241, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2691, 4otgA, 0.7682, 2.64, 0.305, 322, 246, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2692, 4eheA, 0.7682, 2.76, 0.222, 266, 243, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
2693, 4cfhA, 0.7682, 2.46, 0.324, 401, 241, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
2694, 3tv4B, 0.7682, 2.69, 0.215, 276, 242, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
2695, 6fu5A, 0.7681, 2.81, 0.234, 282, 248, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
2696, 5w5oO, 0.7681, 2.74, 0.228, 276, 246, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2697, 4zjjD, 0.7681, 2.61, 0.307, 274, 244, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2698, 3uokA, 0.7681, 2.57, 0.298, 265, 242, AURORA A IN COMPLEX WITH YL5-81-1
2699, 3orzC, 0.7681, 2.80, 0.297, 276, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2700, 2f2uA, 0.7681, 2.96, 0.271, 386, 251, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2701, 5kziA, 0.7680, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2702, 3uokB, 0.7680, 2.57, 0.298, 265, 242, AURORA A IN COMPLEX WITH YL5-81-1
2703, 3skcB, 0.7680, 2.69, 0.219, 276, 242, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
2704, 3q5iA, 0.7680, 2.45, 0.321, 470, 240, CRYSTAL STRUCTURE OF PBANKA_031420
2705, 1ig1A, 0.7680, 2.55, 0.286, 280, 241, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2706, 1gznA, 0.7680, 2.48, 0.304, 271, 240, STRUCTURE OF PKB KINASE DOMAIN
2707, 5o5mA, 0.7679, 2.73, 0.285, 336, 246, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
2708, 5ebzB, 0.7679, 3.33, 0.260, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
2709, 4qmvA, 0.7679, 2.76, 0.280, 288, 246, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2710, 4fr4C, 0.7679, 2.94, 0.247, 344, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2711, 4e4xB, 0.7679, 2.56, 0.216, 274, 241, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
2712, 3orzB, 0.7679, 2.81, 0.297, 278, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2713, 1jksA, 0.7679, 2.55, 0.286, 280, 241, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2714, 5gtyA, 0.7678, 2.87, 0.211, 300, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2715, 3orzD, 0.7678, 2.81, 0.297, 278, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2716, 3c0hB, 0.7678, 2.83, 0.298, 300, 245, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2717, 5gtyB, 0.7677, 2.76, 0.208, 299, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2718, 4qmyA, 0.7676, 2.79, 0.280, 287, 246, MST3 IN COMPLEX WITH STAUROSPORINE
2719, 4im2A, 0.7676, 2.82, 0.244, 618, 246, STRUCTURE OF TANK-BINDING KINASE 1
2720, 4e4xA, 0.7676, 2.59, 0.216, 267, 241, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
2721, 5ebzG, 0.7675, 3.36, 0.267, 655, 255, CRYSTAL STRUCTURE OF HUMAN IKK1
2722, 5ebzD, 0.7675, 3.41, 0.259, 655, 255, CRYSTAL STRUCTURE OF HUMAN IKK1
2723, 4pp7B, 0.7675, 2.49, 0.217, 274, 240, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
2724, 4jx7A, 0.7675, 2.48, 0.274, 274, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2725, 4fr4E, 0.7675, 2.96, 0.247, 342, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2726, 4eheB, 0.7675, 2.69, 0.219, 276, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
2727, 3pozA, 0.7675, 2.74, 0.208, 293, 245, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
2728, 2z7sA, 0.7675, 2.02, 0.321, 256, 234, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
2729, 4u42B, 0.7674, 2.39, 0.264, 265, 239, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2730, 4rzvA, 0.7674, 2.41, 0.213, 261, 239, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
2731, 4mtaA, 0.7674, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2732, 3uo6B, 0.7674, 2.48, 0.307, 264, 241, AURORA A IN COMPLEX WITH YL5-083
2733, 3uo6A, 0.7674, 2.48, 0.307, 264, 241, AURORA A IN COMPLEX WITH YL5-083
2734, 5u7rB, 0.7673, 2.98, 0.280, 387, 250, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2735, 5lvpD, 0.7673, 2.71, 0.297, 276, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2736, 1jkkA, 0.7673, 2.56, 0.286, 277, 241, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2737, 5lvlA, 0.7672, 2.81, 0.293, 285, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2738, 4yvcA, 0.7672, 2.89, 0.273, 388, 249, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2739, 4mbjB, 0.7672, 2.64, 0.215, 276, 242, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
2740, 4btjB, 0.7672, 3.04, 0.193, 293, 249, TTBK1 IN COMPLEX WITH ATP
2741, 2w4jA, 0.7672, 2.57, 0.286, 276, 241, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2742, 6bskA, 0.7671, 2.49, 0.282, 273, 241, HUMAN PIM1 KINASE IN COMPLEX WITH COMPOUND 12B
2743, 5h2uC, 0.7671, 2.44, 0.254, 264, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2744, 5h2uB, 0.7671, 2.49, 0.261, 263, 241, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2745, 5h9bA, 0.7670, 2.55, 0.344, 269, 241, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2746, 5dvrA, 0.7670, 2.50, 0.303, 386, 241, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH GW780159X
2747, 4im0A, 0.7670, 2.82, 0.244, 619, 246, STRUCTURE OF TANK-BINDING KINASE 1
2748, 4dawA, 0.7670, 2.82, 0.294, 293, 248, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2749, 3nayB, 0.7670, 2.72, 0.290, 278, 245, PDK1 IN COMPLEX WITH INHIBITOR MP6
2750, 2ou7A, 0.7670, 2.76, 0.268, 292, 246, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2751, 5x2aC, 0.7669, 2.60, 0.206, 303, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
2752, 5u7qC, 0.7669, 2.98, 0.276, 390, 250, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2753, 5h2uD, 0.7669, 2.44, 0.254, 263, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2754, 3belA, 0.7669, 2.50, 0.212, 280, 241, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
2755, 5x2fB, 0.7668, 2.89, 0.199, 312, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
2756, 4pf4A, 0.7668, 2.57, 0.286, 278, 241, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2757, 4btmB, 0.7668, 2.97, 0.197, 293, 249, TTBK1 IN COMPLEX WITH INHIBITOR
2758, 3mfuA, 0.7668, 2.86, 0.306, 302, 245, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
2759, 6ccyA, 0.7667, 2.79, 0.296, 325, 247, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
2760, 3vbqA, 0.7667, 2.53, 0.278, 271, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2761, 3uolB, 0.7667, 2.46, 0.315, 263, 241, AURORA A IN COMPLEX WITH SO2-162
2762, 3uolA, 0.7667, 2.46, 0.315, 263, 241, AURORA A IN COMPLEX WITH SO2-162
2763, 3jpvA, 0.7667, 2.48, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2764, 2xj0A, 0.7667, 2.54, 0.278, 274, 241, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2765, 2etrA, 0.7667, 3.00, 0.267, 400, 251, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2766, 2bzhB, 0.7667, 2.46, 0.270, 275, 241, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2767, 4aotB, 0.7666, 2.73, 0.321, 279, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
2768, 4alvA, 0.7666, 2.53, 0.274, 274, 241, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2769, 3cxwA, 0.7666, 2.49, 0.274, 272, 241, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND I
2770, 5jgbA, 0.7665, 2.95, 0.290, 295, 245, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 10
2771, 5es1A, 0.7665, 2.46, 0.333, 304, 240, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2772, 5diaA, 0.7665, 2.44, 0.275, 273, 240, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2773, 4yzbA, 0.7665, 2.57, 0.318, 466, 242, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
2774, 4wrsA, 0.7665, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2775, 2o64A, 0.7665, 2.53, 0.270, 274, 241, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2776, 2jitB, 0.7665, 2.86, 0.186, 312, 247, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
2777, 5w5oJ, 0.7664, 2.78, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2778, 5t6iA, 0.7664, 2.64, 0.317, 427, 243, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GB
2779, 4qmsA, 0.7664, 2.75, 0.253, 283, 245, MST3 IN COMPLEX WITH DASATINIB
2780, 3f5uA, 0.7664, 2.52, 0.283, 279, 240, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2781, 5n4uA, 0.7663, 2.49, 0.282, 272, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 5-(2-AMINO-13-THIAZOL-4- YL)-13-DIHYDROBENZIMIDAZOL-2-ONE
2782, 5d7vA, 0.7663, 2.55, 0.260, 268, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
2783, 3f2aA, 0.7663, 2.50, 0.274, 276, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
2784, 3ehaA, 0.7663, 2.52, 0.287, 279, 240, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2785, 5ipjA, 0.7662, 2.44, 0.275, 273, 240, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2786, 2z7qA, 0.7662, 2.00, 0.326, 255, 233, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
2787, 2xj2A, 0.7662, 2.49, 0.275, 273, 240, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2788, 5wnhD, 0.7661, 2.98, 0.280, 397, 250, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2789, 5ar4A, 0.7661, 2.78, 0.231, 274, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2790, 4mblA, 0.7661, 2.49, 0.270, 274, 241, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2791, 4gw8A, 0.7661, 2.49, 0.282, 273, 241, HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND LEUCETTINE L41
2792, 3f5gA, 0.7661, 2.53, 0.287, 279, 240, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2793, 6babD, 0.7660, 2.76, 0.320, 291, 244, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2794, 5dgzA, 0.7660, 2.49, 0.282, 273, 241, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2795, 5ar3B, 0.7660, 2.80, 0.227, 276, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
2796, 5ar3A, 0.7660, 2.89, 0.233, 279, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
2797, 3r00A, 0.7660, 2.54, 0.274, 274, 241, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2798, 3eh9A, 0.7660, 2.54, 0.287, 278, 240, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2799, 3c51A, 0.7660, 2.90, 0.277, 487, 249, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
2800, 2rfdB, 0.7660, 2.88, 0.203, 286, 246, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2801, 5t6kA, 0.7659, 2.57, 0.314, 432, 242, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH GW780159X
2802, 5dhjA, 0.7659, 2.42, 0.275, 273, 240, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2803, 4n6zA, 0.7659, 2.51, 0.283, 272, 240, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2804, 3vc4A, 0.7659, 2.54, 0.270, 274, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2805, 1yxtA, 0.7659, 2.57, 0.270, 274, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2806, 5n4rA, 0.7658, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(AZEPAN-1-YL)-1-(1H-INDOL-3-YL) PROPAN-1-ONE
2807, 4u3zB, 0.7658, 2.65, 0.245, 294, 245, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
2808, 5v80A, 0.7657, 2.51, 0.282, 273, 241, PIM1 KINASE IN COMPLEX WITH CPD1 (1-METHYL-4-(3-(6-(PIPERAZIN-1-YL) PYRIDIN-2-YL)-1H-PYRAZOLO[3;4-C]PYRIDIN-5-YL)PIPERAZIN-2-ONE) 
2809, 5lxmA, 0.7657, 2.60, 0.307, 266, 241, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
2810, 5jsmA, 0.7657, 2.64, 0.207, 265, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2811, 5fg8A, 0.7657, 2.58, 0.344, 269, 241, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2812, 4rqvA, 0.7657, 2.82, 0.293, 288, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
2813, 4g5pB, 0.7657, 2.90, 0.190, 303, 248, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
2814, 4at3A, 0.7657, 2.82, 0.229, 289, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
2815, 3unzB, 0.7657, 2.51, 0.307, 263, 241, AURORA A IN COMPLEX WITH RPM1679
2816, 3unzA, 0.7657, 2.51, 0.307, 263, 241, AURORA A IN COMPLEX WITH RPM1679
2817, 3nayA, 0.7657, 2.73, 0.294, 278, 245, PDK1 IN COMPLEX WITH INHIBITOR MP6
2818, 1zrzA, 0.7657, 2.72, 0.298, 310, 245, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
2819, 5jgaA, 0.7656, 3.07, 0.297, 296, 246, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 11C
2820, 5av0A, 0.7656, 2.53, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2821, 4yhjB, 0.7656, 2.84, 0.279, 490, 247, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
2822, 4fr4B, 0.7656, 2.97, 0.247, 350, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2823, 4a06A, 0.7656, 2.76, 0.294, 282, 245, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2824, 3q52A, 0.7656, 2.85, 0.279, 292, 247, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2825, 5w5oK, 0.7655, 2.79, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2826, 5u7qA, 0.7655, 3.01, 0.276, 388, 250, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2827, 5lvpC, 0.7655, 2.74, 0.297, 275, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2828, 5lvnA, 0.7655, 2.83, 0.293, 283, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
2829, 5kgdA, 0.7655, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2830, 4wt6A, 0.7655, 2.52, 0.286, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2831, 3qf9A, 0.7655, 2.51, 0.282, 274, 241, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN- THIAZOLIDINEDIONE LIGAND
2832, 3mfsA, 0.7655, 2.88, 0.306, 303, 245, CASK-4M CAM KINASE DOMAIN AMPPNP
2833, 2bilB, 0.7655, 2.50, 0.274, 274, 241, THE HUMAN PROTEIN KINASE PIM1 IN COMPLEX WITH ITS CONSENSUS PEPTIDE PIMTIDE
2834, 5f0aA, 0.7654, 2.77, 0.274, 811, 248, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
2835, 3c4wA, 0.7654, 2.92, 0.277, 494, 249, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
2836, 2rfeB, 0.7654, 2.52, 0.216, 273, 241, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
2837, 1xqzA, 0.7654, 2.60, 0.281, 277, 242, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2838, 4xx9A, 0.7653, 2.83, 0.293, 288, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2839, 4wsyA, 0.7653, 2.52, 0.286, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2840, 4u43B, 0.7653, 2.91, 0.235, 302, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2841, 4n70A, 0.7653, 2.50, 0.275, 274, 240, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2842, 4i22A, 0.7653, 2.60, 0.211, 297, 242, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
2843, 4alwA, 0.7653, 2.58, 0.270, 273, 241, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2844, 2xj1A, 0.7653, 2.51, 0.275, 273, 240, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
2845, 5uzjB, 0.7652, 2.94, 0.278, 386, 248, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2846, 4qmxA, 0.7652, 2.82, 0.280, 287, 246, MST3 IN COMPLEX WITH SARACATINIB
2847, 3d5wA, 0.7652, 2.78, 0.289, 284, 246, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
2848, 6babA, 0.7651, 2.66, 0.317, 290, 243, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2849, 5w5oD, 0.7651, 2.78, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2850, 5ndtA, 0.7651, 2.50, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(2-(THIOPHEN-2-YL)VINYL)-3; 4-DIHYDROQUINOXALIN-2(1H)-ONE 
2851, 4rqkA, 0.7651, 2.82, 0.293, 285, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2852, 4k18A, 0.7651, 2.59, 0.277, 277, 242, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2853, 3uojB, 0.7651, 2.50, 0.315, 263, 241, AURORA A IN COMPLEX WITH RPM1715
2854, 3uojA, 0.7651, 2.50, 0.315, 263, 241, AURORA A IN COMPLEX WITH RPM1715
2855, 5vjaD, 0.7650, 2.38, 0.286, 261, 238, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2856, 5n4xA, 0.7650, 2.51, 0.282, 272, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 45-DIBROMOTHIOPHENE-2- CARBOHYDRAZIDE
2857, 5eakA, 0.7650, 2.63, 0.322, 305, 242, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2858, 4yhfB, 0.7650, 2.52, 0.204, 269, 240, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
2859, 4obpB, 0.7650, 2.50, 0.244, 290, 242, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2860, 3a8wA, 0.7650, 2.62, 0.302, 326, 245, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2861, 5yu9A, 0.7649, 2.67, 0.205, 302, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
2862, 5gtyE, 0.7649, 2.83, 0.212, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2863, 5eolA, 0.7649, 2.54, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
2864, 5ackA, 0.7649, 2.84, 0.293, 286, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2865, 3r04A, 0.7649, 2.53, 0.278, 271, 241, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2866, 3d9vA, 0.7649, 3.02, 0.271, 400, 251, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2867, 3c50A, 0.7649, 2.93, 0.277, 499, 249, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
2868, 3c4eD, 0.7649, 2.53, 0.278, 273, 241, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2869, 3bbtB, 0.7649, 2.43, 0.226, 274, 239, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
2870, 2xuuA, 0.7649, 2.58, 0.285, 301, 242, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2871, 2j2iB, 0.7649, 2.49, 0.278, 273, 241, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2872, 5av1A, 0.7648, 2.55, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2873, 4tnbA, 0.7648, 2.93, 0.275, 529, 247, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
2874, 4n6yA, 0.7648, 2.46, 0.283, 273, 240, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
2875, 4dtkA, 0.7648, 2.53, 0.282, 273, 241, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2876, 3o96A, 0.7648, 2.74, 0.300, 367, 243, CRYSTAL STRUCTURE OF HUMAN AKT1 WITH AN ALLOSTERIC INHIBITOR
2877, 2phkA, 0.7648, 2.58, 0.303, 277, 241, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2878, 1wvxA, 0.7648, 2.49, 0.287, 275, 240, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2879, 5gtyD, 0.7647, 2.82, 0.208, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2880, 5dwrA, 0.7647, 2.51, 0.275, 273, 240, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
2881, 4utdA, 0.7647, 2.67, 0.314, 266, 242, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2882, 3vbtA, 0.7647, 2.53, 0.278, 267, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2883, 3dbeA, 0.7647, 2.73, 0.290, 284, 245, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
2884, 2v5qA, 0.7647, 2.88, 0.271, 285, 247, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2885, 2r4bA, 0.7647, 2.61, 0.225, 292, 240, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
2886, 1yxxA, 0.7647, 2.65, 0.281, 274, 242, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2887, 5op2A, 0.7646, 2.61, 0.288, 263, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2888, 4ygaC, 0.7646, 2.72, 0.311, 449, 244, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
2889, 4jx3A, 0.7646, 2.50, 0.274, 274, 241, CRYSTAL STRUCTURE OF PIM1 KINASE
2890, 4hzsA, 0.7646, 2.53, 0.257, 319, 241, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2891, 4ct2A, 0.7646, 2.87, 0.297, 277, 246, HUMAN PDK1-PKCZETA KINASE CHIMERA
2892, 3r02A, 0.7646, 2.54, 0.278, 271, 241, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2893, 2v5qB, 0.7646, 2.81, 0.268, 285, 246, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2894, 1yvjA, 0.7646, 2.92, 0.261, 288, 245, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
2895, 6gl9A, 0.7645, 3.08, 0.251, 292, 247, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
2896, 4hzsB, 0.7645, 2.54, 0.257, 319, 241, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2897, 4eqcA, 0.7645, 2.90, 0.313, 296, 249, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2898, 3vbvA, 0.7645, 2.54, 0.278, 268, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2899, 3tv4A, 0.7645, 2.66, 0.212, 264, 240, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
2900, 5n4zA, 0.7644, 2.51, 0.282, 272, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-4-(4-HYDROXYPHENYL)BUT-3-EN-2- ONE
2901, 5d41A, 0.7644, 2.71, 0.210, 300, 243, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
2902, 4hzsD, 0.7644, 2.54, 0.257, 319, 241, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2903, 4hzsC, 0.7644, 2.54, 0.257, 319, 241, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2904, 3f69B, 0.7644, 2.55, 0.262, 282, 240, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2905, 5w5oE, 0.7643, 2.79, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2906, 5vuaB, 0.7643, 2.43, 0.272, 270, 239, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2907, 5h2uA, 0.7643, 2.48, 0.254, 265, 240, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
2908, 5av3A, 0.7643, 2.55, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2909, 4qnaA, 0.7643, 2.85, 0.280, 284, 246, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2910, 4eqmA, 0.7643, 2.62, 0.253, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2911, 4aluA, 0.7643, 2.56, 0.274, 274, 241, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2912, 4ae6A, 0.7643, 2.74, 0.272, 319, 246, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2913, 2ozoA, 0.7643, 2.98, 0.215, 545, 246, AUTOINHIBITED INTACT HUMAN ZAP-70
2914, 5yu9B, 0.7642, 2.81, 0.209, 295, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
2915, 5w5oA, 0.7642, 2.80, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2916, 4ythA, 0.7642, 2.70, 0.258, 287, 244, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2917, 3bhhB, 0.7642, 2.65, 0.332, 289, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2918, 3bbwA, 0.7642, 2.45, 0.230, 268, 239, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
2919, 5w5oG, 0.7641, 2.80, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2920, 5ugaA, 0.7641, 2.66, 0.211, 283, 242, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2921, 4ygaA, 0.7641, 2.66, 0.309, 448, 243, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
2922, 4xhkB, 0.7641, 2.49, 0.283, 269, 240, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
2923, 4eqmC, 0.7641, 2.63, 0.253, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2924, 4eqmB, 0.7641, 2.63, 0.253, 269, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
2925, 3cy2A, 0.7641, 2.55, 0.282, 271, 241, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND II
2926, 2acxB, 0.7641, 2.73, 0.290, 492, 245, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
2927, 5iisA, 0.7640, 2.51, 0.283, 273, 240, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
2928, 3vbxA, 0.7640, 2.54, 0.278, 268, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2929, 4ll5A, 0.7639, 2.52, 0.282, 268, 241, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2930, 4as0A, 0.7639, 2.43, 0.275, 273, 240, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2931, 3d5uA, 0.7639, 2.80, 0.289, 288, 246, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2932, 3c50B, 0.7639, 2.96, 0.277, 496, 249, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
2933, 1yxuD, 0.7639, 2.54, 0.278, 273, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2934, 6gt1C, 0.7638, 2.57, 0.329, 257, 240, NEK7 BOUND TO PURINE INHIBITOR 
2935, 5v5nA, 0.7638, 3.01, 0.294, 294, 245, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
2936, 4xh6A, 0.7638, 2.53, 0.282, 273, 241, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2937, 4l9iB, 0.7638, 2.95, 0.259, 493, 247, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
2938, 3vbyA, 0.7638, 2.54, 0.282, 267, 241, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2939, 3cy3A, 0.7638, 2.48, 0.283, 270, 240, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND THE JNK INHIBITOR V
2940, 3bbwB, 0.7638, 2.45, 0.230, 275, 239, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
2941, 2xizA, 0.7638, 2.51, 0.275, 273, 240, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2942, 2ckeD, 0.7638, 2.70, 0.280, 300, 243, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2943, 5uzjA, 0.7637, 2.86, 0.274, 387, 248, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2944, 5n5lA, 0.7637, 2.48, 0.283, 271, 240, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND [2-OXO-2-(1H-PYRROL-2-YL)ETHYL] 5-BROMO-1H- INDOLE-3-CARBOXYLATE
2945, 5jrqA, 0.7637, 2.46, 0.214, 258, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
2946, 5auvA, 0.7637, 2.56, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2947, 3r01A, 0.7637, 2.57, 0.274, 274, 241, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2948, 3bgzA, 0.7637, 2.42, 0.276, 267, 239, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
2949, 5w5oB, 0.7636, 2.80, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2950, 5j79B, 0.7636, 2.84, 0.227, 277, 247, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2951, 5auxA, 0.7636, 2.56, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2952, 4uy9A, 0.7636, 2.48, 0.277, 313, 238, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
2953, 4bznA, 0.7636, 2.52, 0.283, 272, 240, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
2954, 3bbtD, 0.7636, 2.45, 0.226, 259, 239, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
2955, 2vz6A, 0.7636, 2.72, 0.314, 291, 242, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2956, 2clqA, 0.7636, 2.66, 0.303, 263, 241, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2957, 2a2aD, 0.7636, 2.70, 0.280, 303, 243, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2958, 5kgiA, 0.7635, 2.53, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2959, 5gjgA, 0.7635, 2.69, 0.293, 289, 242, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 4
2960, 5dfpA, 0.7635, 2.90, 0.313, 292, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2961, 4mbiA, 0.7635, 2.53, 0.270, 274, 241, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2962, 4k2rA, 0.7635, 2.90, 0.220, 551, 246, STRUCTURAL BASIS FOR ACTIVATION OF ZAP-70 BY PHOSPHORYLATION OF THE SH2-KINASE LINKER
2963, 4d28C, 0.7635, 2.63, 0.339, 279, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2964, 3krwA, 0.7635, 2.88, 0.262, 618, 248, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
2965, 3dkcA, 0.7635, 2.77, 0.218, 312, 243, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
2966, 5n50A, 0.7634, 2.52, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(4-CHLOROPHENYL) SULFANYLACETOHYDRAZIDE
2967, 5av2A, 0.7634, 2.57, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2968, 2pmnX, 0.7634, 3.11, 0.231, 340, 251, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
2969, 5kgeA, 0.7633, 2.54, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2970, 5gtyF, 0.7633, 2.78, 0.209, 297, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
2971, 5auyA, 0.7633, 2.55, 0.287, 275, 240, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2972, 4wo5A, 0.7633, 2.37, 0.211, 266, 237, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
2973, 3nczD, 0.7633, 3.03, 0.267, 397, 251, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2974, 3h0zA, 0.7633, 2.42, 0.310, 248, 239, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
2975, 3c4xA, 0.7633, 3.01, 0.277, 496, 249, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
2976, 6glbA, 0.7632, 3.00, 0.252, 288, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
2977, 6glaB, 0.7632, 3.00, 0.252, 286, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
2978, 6cpfA, 0.7632, 2.63, 0.315, 259, 241, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
2979, 5w5oF, 0.7632, 2.81, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2980, 5opbA, 0.7632, 2.62, 0.288, 262, 243, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2981, 2bujA, 0.7632, 2.73, 0.256, 291, 242, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2982, 1j3hB, 0.7632, 2.77, 0.268, 327, 246, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2983, 5n4yA, 0.7631, 2.53, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 25-DIHYDRO-1H-ISOTHIOCHROMENO[3 4-D]PYRAZOL-3-ONE
2984, 5lvpB, 0.7631, 2.77, 0.297, 276, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2985, 5kcxA, 0.7631, 2.57, 0.282, 272, 241, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2986, 4k1bA, 0.7631, 2.47, 0.275, 273, 240, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2987, 5vloA, 0.7630, 2.47, 0.314, 290, 239, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2988, 5telA, 0.7630, 2.56, 0.274, 273, 241, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2989, 5dbxB, 0.7630, 2.49, 0.285, 282, 239, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
2990, 4i24A, 0.7630, 2.65, 0.207, 295, 241, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
2991, 3hrfA, 0.7630, 2.79, 0.294, 284, 245, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2992, 5xgnB, 0.7629, 2.91, 0.174, 308, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2993, 5lwmA, 0.7629, 3.03, 0.252, 290, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
2994, 4b4lA, 0.7629, 2.70, 0.284, 299, 243, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2995, 3c4cA, 0.7629, 2.69, 0.207, 258, 241, B-RAF KINASE IN COMPLEX WITH PLX4720
2996, 1yxvA, 0.7629, 2.67, 0.281, 274, 242, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2997, 5w5oH, 0.7628, 2.81, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2998, 2objA, 0.7628, 2.51, 0.283, 272, 240, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
2999, 5m5aA, 0.7627, 2.30, 0.329, 315, 237, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3000, 4yzbB, 0.7627, 2.77, 0.318, 464, 242, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
3001, 4qmuA, 0.7627, 2.83, 0.253, 286, 245, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
3002, 4nfnA, 0.7627, 3.04, 0.189, 293, 249, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
3003, 3bgpA, 0.7627, 2.52, 0.287, 272, 240, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
3004, 3a8wB, 0.7627, 2.63, 0.294, 327, 245, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3005, 2o3pA, 0.7627, 2.57, 0.270, 274, 241, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
3006, 5turA, 0.7626, 2.56, 0.274, 270, 241, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3007, 5o2cA, 0.7626, 2.98, 0.254, 368, 244, CRYSTAL STRUCTURE OF WNK3 KINASE AND CCT1 DIDOMAIN IN A UNPHOSPHORYLATED STATE
3008, 5lwnA, 0.7626, 3.03, 0.252, 290, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
3009, 4nttB, 0.7626, 2.79, 0.279, 339, 247, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
3010, 4btjA, 0.7626, 3.16, 0.193, 292, 249, TTBK1 IN COMPLEX WITH ATP
3011, 3krxA, 0.7626, 2.89, 0.266, 618, 248, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
3012, 3jxwA, 0.7626, 2.59, 0.274, 274, 241, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3013, 2ckeC, 0.7626, 2.72, 0.280, 300, 243, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3014, 2bzjA, 0.7626, 2.53, 0.278, 273, 241, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
3015, 6glbB, 0.7625, 3.01, 0.252, 288, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
3016, 6glaA, 0.7625, 3.01, 0.252, 288, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
3017, 5lvoA, 0.7625, 2.85, 0.293, 285, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
3018, 5ar5B, 0.7625, 2.82, 0.243, 279, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3019, 4qmzA, 0.7625, 2.91, 0.291, 286, 247, MST3 IN COMPLEX WITH SUNITINIB
3020, 4ow8A, 0.7625, 2.50, 0.275, 276, 240, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PKNA FROM MTB
3021, 3ma6A, 0.7625, 2.63, 0.313, 267, 243, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
3022, 2ckeA, 0.7625, 2.72, 0.280, 301, 243, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3023, 1yxuC, 0.7625, 2.56, 0.282, 272, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3024, 1yhwA, 0.7625, 2.89, 0.294, 293, 248, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
3025, 6gl9B, 0.7624, 3.02, 0.252, 291, 246, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3026, 5w5oP, 0.7624, 2.80, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3027, 5vucB, 0.7624, 2.43, 0.273, 269, 238, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3028, 5os2A, 0.7624, 2.66, 0.314, 261, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3029, 5n4nA, 0.7624, 2.53, 0.282, 273, 241, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIMETHYL-5-(1H-124-TRIAZOL- 3-YL)THIOPHENE-2-CARBONITRILE
3030, 3qc4A, 0.7624, 2.72, 0.279, 276, 244, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3031, 2xiyA, 0.7624, 2.55, 0.275, 273, 240, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3032, 5dt3A, 0.7623, 2.75, 0.313, 263, 243, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3033, 4ygaG, 0.7623, 2.73, 0.316, 447, 244, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
3034, 4enxA, 0.7623, 2.48, 0.280, 266, 239, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
3035, 3hrcA, 0.7623, 2.86, 0.293, 279, 246, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
3036, 1yxuA, 0.7623, 2.56, 0.278, 273, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3037, 5os4A, 0.7622, 2.67, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3038, 5nxcL, 0.7622, 2.47, 0.236, 274, 237, LIM DOMAIN KINASE 1 (LIMK1) IN COMPLEX WITH PF-00477736
3039, 5de2A, 0.7622, 2.59, 0.337, 267, 240, STRUCTURAL MECHANISM OF NEK7 ACTIVATION BY NEK9-INDUCED DIMERISATION
3040, 4ygaE, 0.7622, 2.70, 0.309, 442, 243, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
3041, 4rrvA, 0.7622, 2.87, 0.293, 283, 246, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
3042, 3a7iA, 0.7622, 2.93, 0.291, 286, 247, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
3043, 2a2aA, 0.7622, 2.74, 0.280, 304, 243, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3044, 5ih5A, 0.7621, 2.94, 0.198, 286, 248, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
3045, 4qoxA, 0.7621, 2.77, 0.303, 462, 244, CRYSTAL STRUCTURE OF CDPK4 FROM PLASMODIUM FALCIPARUM PF3D7_0717500
3046, 4qmnA, 0.7621, 2.83, 0.253, 283, 245, MST3 IN COMPLEX WITH BOSUTINIB
3047, 4bicA, 0.7621, 2.59, 0.305, 260, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3048, 2f57B, 0.7621, 2.97, 0.249, 299, 245, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3049, 1yhsA, 0.7621, 2.48, 0.285, 267, 239, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
3050, 5orzA, 0.7620, 2.66, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3051, 5gjfA, 0.7620, 2.95, 0.296, 298, 243, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 3
3052, 5dylA, 0.7620, 2.68, 0.269, 802, 245, CRYSTAL STRUCTURE OF PVX_084705
3053, 3e63A, 0.7620, 2.74, 0.262, 290, 244, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3054, 3bgqA, 0.7620, 2.55, 0.283, 272, 240, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
3055, 5he0A, 0.7619, 2.90, 0.255, 621, 247, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
3056, 5drdA, 0.7618, 2.81, 0.313, 259, 243, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3057, 4ct1A, 0.7618, 2.87, 0.297, 283, 246, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
3058, 3vs3B, 0.7618, 2.57, 0.246, 431, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
3059, 2pmoX, 0.7618, 3.11, 0.227, 340, 251, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
3060, 1yhvA, 0.7618, 2.89, 0.294, 293, 248, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
3061, 6b2pA, 0.7617, 2.44, 0.276, 255, 239, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3062, 5hg7A, 0.7617, 2.72, 0.219, 280, 242, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-{(3R4R)-3-[5-CHLORO-2- (1-METHYL-1H-PYRAZOL-4-YLAMINO)-7H-PYRROLO[23-D]PYRIMIDIN-4- YLOXYMETHYL]-4-METHOXY-PYRROLIDIN-1-YL}PROPENONE (PF-06459988)
3063, 5dykA, 0.7617, 2.70, 0.264, 809, 246, CRYSTAL STRUCTURE OF PF3D7_1436600
3064, 3qc4B, 0.7617, 2.67, 0.288, 278, 243, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3065, 3e62A, 0.7617, 2.75, 0.262, 291, 244, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3066, 1yi3A, 0.7617, 2.49, 0.285, 267, 239, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
3067, 5orvA, 0.7616, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3068, 5orpA, 0.7616, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3069, 5n5mA, 0.7616, 2.50, 0.283, 272, 240, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND (R)-3-(2-((ISOQUINOLIN-5-YLMETHYL)(METHYL) CARBAMOYL)PHENYL)PYRROLIDIN-1-IUM
3070, 5jgdA, 0.7616, 3.11, 0.301, 295, 246, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 12
3071, 5av4A, 0.7616, 2.55, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
3072, 4bzoA, 0.7616, 2.54, 0.283, 272, 240, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
3073, 1yxuB, 0.7616, 2.57, 0.278, 273, 241, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3074, 5w5oL, 0.7615, 2.82, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3075, 5osdA, 0.7615, 2.68, 0.314, 266, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3076, 4gfmA, 0.7615, 2.76, 0.262, 289, 244, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
3077, 3bwfA, 0.7615, 2.55, 0.278, 273, 241, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
3078, 5fetA, 0.7614, 2.64, 0.270, 802, 244, CRYSTAL STRUCTURE OF PVX_084705 IN PRESENCE OF COMPOUND 2
3079, 3nczC, 0.7614, 3.01, 0.269, 389, 249, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
3080, 3jyaA, 0.7614, 2.58, 0.282, 274, 241, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3081, 2jiuA, 0.7614, 2.80, 0.221, 303, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3082, 5vubB, 0.7613, 2.51, 0.280, 269, 239, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3083, 5toeA, 0.7613, 2.60, 0.274, 272, 241, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3084, 5lvmA, 0.7613, 2.89, 0.293, 283, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
3085, 2yabA, 0.7613, 2.74, 0.288, 299, 243, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3086, 2gs7A, 0.7613, 2.61, 0.216, 281, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3087, 1cmkE, 0.7613, 2.82, 0.276, 348, 246, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
3088, 5oseA, 0.7612, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3089, 5os5A, 0.7612, 2.68, 0.314, 267, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3090, 3t8oA, 0.7612, 2.91, 0.277, 493, 249, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
3091, 5li9A, 0.7611, 2.73, 0.299, 329, 244, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
3092, 5gtyC, 0.7611, 2.87, 0.213, 295, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
3093, 5auwA, 0.7611, 2.55, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
3094, 3skcA, 0.7611, 2.70, 0.208, 260, 240, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
3095, 3bhhA, 0.7611, 2.64, 0.325, 289, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3096, 1mruB, 0.7611, 2.58, 0.274, 271, 241, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3097, 5os0A, 0.7610, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3098, 5orrA, 0.7610, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3099, 5kggA, 0.7610, 2.58, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
3100, 2hckA, 0.7610, 2.51, 0.243, 437, 239, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
3101, 1ol7A, 0.7610, 2.71, 0.314, 261, 242, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
3102, 5osfA, 0.7609, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3103, 5os1A, 0.7609, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3104, 4hnfB, 0.7609, 2.96, 0.190, 290, 248, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3105, 3umwA, 0.7609, 2.44, 0.282, 264, 238, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
3106, 2r4bB, 0.7609, 2.50, 0.227, 291, 238, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
3107, 5u94A, 0.7608, 2.63, 0.273, 263, 242, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
3108, 5os6A, 0.7608, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3109, 5oryA, 0.7608, 2.68, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3110, 5kbqB, 0.7608, 2.64, 0.310, 273, 242, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3111, 5auzA, 0.7608, 2.56, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
3112, 4jboA, 0.7608, 2.66, 0.306, 266, 242, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3113, 2ckeB, 0.7608, 2.76, 0.280, 300, 243, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3114, 2a2aC, 0.7608, 2.76, 0.280, 303, 243, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3115, 1zwsD, 0.7608, 2.65, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3116, 5dt4A, 0.7607, 2.80, 0.313, 259, 243, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3117, 4lmuA, 0.7607, 2.47, 0.280, 265, 239, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
3118, 1mryA, 0.7607, 2.47, 0.303, 270, 238, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
3119, 5orxA, 0.7606, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3120, 4rc4A, 0.7606, 2.53, 0.283, 272, 240, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3121, 4jbpA, 0.7606, 2.62, 0.307, 255, 241, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3122, 4yhjA, 0.7605, 2.91, 0.279, 501, 247, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
3123, 4a7cA, 0.7605, 2.53, 0.283, 273, 240, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
3124, 3c4zA, 0.7605, 2.98, 0.263, 493, 247, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
3125, 1zwsC, 0.7605, 2.67, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3126, 5os3A, 0.7604, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3127, 5ih6A, 0.7604, 2.98, 0.202, 286, 248, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
3128, 4ytiA, 0.7604, 2.71, 0.259, 284, 243, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3129, 4twcA, 0.7604, 3.00, 0.194, 293, 248, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3130, 4g3fA, 0.7604, 2.95, 0.257, 312, 245, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 2-(AMINOTHIAZOLY)PHENOL (CMP2)
3131, 3fxzA, 0.7604, 2.94, 0.294, 292, 248, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
3132, 2xixA, 0.7604, 2.53, 0.276, 272, 239, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3133, 1wvyA, 0.7604, 2.53, 0.287, 273, 240, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3134, 1ctpE, 0.7604, 2.82, 0.280, 332, 246, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
3135, 6gt1D, 0.7603, 2.54, 0.328, 260, 238, NEK7 BOUND TO PURINE INHIBITOR 
3136, 6cpeA, 0.7603, 2.61, 0.312, 256, 240, STRUCTURE OF APO; DEPHOSPHORYLATED AURORA A (122-403) IN AN ACTIVE CONFORMATION 
3137, 5xgnA, 0.7603, 2.89, 0.234, 302, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
3138, 5orwA, 0.7603, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3139, 5oroA, 0.7603, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3140, 5ornA, 0.7603, 2.69, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3141, 5cf5B, 0.7603, 2.78, 0.262, 294, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3142, 3c4eC, 0.7603, 2.57, 0.278, 272, 241, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3143, 1z9xB, 0.7603, 2.66, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3144, 1z9xA, 0.7603, 2.66, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3145, 6aydA, 0.7602, 2.56, 0.282, 272, 241, PIM1 COMPLEXED WITH N-(6-(4-HYDROXYPHENYL)-1H-INDAZOL-3-YL) CYCLOPROPANECARBOXAMIDE
3146, 5kgkA, 0.7602, 2.56, 0.282, 273, 241, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
3147, 5dr2A, 0.7602, 2.84, 0.309, 264, 243, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
3148, 5dbxA, 0.7602, 2.67, 0.282, 284, 241, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
3149, 4txcA, 0.7602, 2.60, 0.286, 276, 241, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3150, 4tw9A, 0.7602, 2.98, 0.198, 290, 248, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3151, 4hjoA, 0.7602, 2.63, 0.212, 278, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
3152, 4dn5A, 0.7602, 2.93, 0.265, 331, 245, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
3153, 4ae9A, 0.7602, 2.75, 0.273, 321, 245, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
3154, 3fy0A, 0.7602, 2.83, 0.265, 292, 245, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
3155, 6g4zA, 0.7601, 3.04, 0.249, 322, 245, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
3156, 5w5oI, 0.7601, 2.83, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3157, 5tvtA, 0.7601, 2.51, 0.329, 321, 240, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3158, 5c1qB, 0.7601, 2.56, 0.290, 273, 241, SERINE/THREONINE-PROTEIN KINASE PIM-1
3159, 4uy9B, 0.7601, 2.49, 0.277, 315, 238, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3160, 4btmA, 0.7601, 3.10, 0.194, 292, 248, TTBK1 IN COMPLEX WITH INHIBITOR
3161, 3kexA, 0.7601, 2.56, 0.208, 292, 240, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
3162, 2rfeD, 0.7601, 2.73, 0.219, 278, 242, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
3163, 2pmlX, 0.7601, 3.05, 0.232, 340, 250, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
3164, 6ccfB, 0.7600, 2.57, 0.293, 262, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3165, 5dnrA, 0.7600, 2.71, 0.314, 264, 242, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
3166, 3vrzB, 0.7600, 2.57, 0.247, 430, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
3167, 3lmgA, 0.7600, 2.60, 0.208, 268, 240, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3168, 3ggfB, 0.7600, 2.75, 0.283, 270, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
3169, 1zwsF, 0.7600, 2.65, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3170, 1eh4A, 0.7600, 3.15, 0.190, 293, 252, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3171, 1ad5A, 0.7600, 2.54, 0.243, 437, 239, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
3172, 5wneC, 0.7599, 2.76, 0.283, 384, 244, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3173, 5w5oC, 0.7599, 2.86, 0.229, 275, 245, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3174, 4g3gA, 0.7599, 2.95, 0.257, 312, 245, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) V408L BOUND TO A 2-(AMINOTHIAZOLYL)PHENOL (CMP3)
3175, 4cegA, 0.7599, 2.71, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
3176, 4c8bA, 0.7599, 2.74, 0.230, 279, 244, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3177, 3q32B, 0.7599, 2.80, 0.262, 294, 244, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3178, 3dcvA, 0.7599, 2.57, 0.287, 273, 240, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
3179, 2hckB, 0.7599, 2.54, 0.243, 437, 239, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
3180, 5uvcA, 0.7598, 2.87, 0.252, 457, 246, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
3181, 3vs3A, 0.7598, 2.58, 0.251, 434, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
3182, 5o21B, 0.7597, 2.64, 0.247, 273, 239, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3183, 5hg9A, 0.7597, 2.75, 0.215, 280, 242, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-[(3R4R)-3-[({2-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY) METHYL]-4-(TRIFLUOROMETHYL)PYRROLIDIN-1-YL]PROP-2-EN-1-ONE
3184, 3vryA, 0.7597, 2.56, 0.247, 428, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
3185, 1ad5B, 0.7597, 2.62, 0.250, 437, 240, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
3186, 5v24B, 0.7596, 2.75, 0.300, 263, 240, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3187, 5lvpA, 0.7596, 2.81, 0.297, 275, 246, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
3188, 5ih4A, 0.7596, 2.98, 0.198, 286, 248, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
3189, 5dn3A, 0.7596, 2.71, 0.314, 264, 242, AURORA A IN COMPLEX WITH ATP AND AA35.
3190, 4rzvB, 0.7596, 2.59, 0.209, 271, 239, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
3191, 4kikB, 0.7596, 3.41, 0.292, 648, 253, HUMAN IKB KINASE BETA
3192, 2gs7B, 0.7596, 2.64, 0.220, 288, 241, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3193, 4rpvA, 0.7595, 2.56, 0.286, 273, 241, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
3194, 3p86A, 0.7595, 2.29, 0.229, 250, 236, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
3195, 3c4eA, 0.7595, 2.58, 0.278, 273, 241, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3196, 5vioB, 0.7594, 2.79, 0.299, 271, 241, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3197, 5ar7A, 0.7594, 2.94, 0.226, 278, 248, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3198, 4lm5A, 0.7594, 2.57, 0.279, 264, 240, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
3199, 4enyA, 0.7594, 2.40, 0.274, 261, 237, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
3200, 2w4kA, 0.7594, 2.78, 0.284, 301, 243, X-RAY STRUCTURE OF A DAP-KINASE 2-302
3201, 2bziB, 0.7594, 2.53, 0.279, 272, 240, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
3202, 5orsA, 0.7593, 2.70, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3203, 5ng2B, 0.7593, 2.97, 0.238, 278, 248, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3204, 5jsmD, 0.7593, 2.52, 0.224, 259, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3205, 5he2A, 0.7593, 2.88, 0.256, 628, 246, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
3206, 5he1A, 0.7593, 2.80, 0.257, 618, 245, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
3207, 4o91A, 0.7593, 2.78, 0.292, 293, 243, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
3208, 4o0rA, 0.7593, 2.88, 0.264, 293, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3209, 4m7iA, 0.7593, 2.35, 0.288, 247, 233, CRYSTAL STRUCTURE OF GSK6157 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.34A RESOLUTION
3210, 4i41A, 0.7593, 2.55, 0.287, 272, 240, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
3211, 1ywvA, 0.7593, 2.61, 0.270, 274, 241, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
3212, 1xwsA, 0.7593, 2.49, 0.275, 273, 240, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
3213, 4iwoA, 0.7592, 3.16, 0.254, 629, 248, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3214, 3pvwA, 0.7592, 2.84, 0.248, 613, 246, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
3215, 3kexB, 0.7592, 2.58, 0.208, 283, 240, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
3216, 3e64A, 0.7592, 2.78, 0.262, 291, 244, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3217, 2a2aB, 0.7592, 2.79, 0.280, 303, 243, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3218, 1yxsA, 0.7592, 2.61, 0.274, 274, 241, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
3219, 1eh4B, 0.7592, 3.16, 0.187, 293, 252, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3220, 6g4yA, 0.7591, 3.05, 0.253, 322, 245, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
3221, 5wngC, 0.7591, 2.87, 0.278, 387, 245, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3222, 5o21A, 0.7591, 2.58, 0.252, 272, 238, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3223, 5auuA, 0.7591, 2.58, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
3224, 4qmtA, 0.7591, 2.97, 0.291, 284, 247, MST3 IN COMPLEX WITH HESPERADIN
3225, 3vs6B, 0.7591, 2.57, 0.247, 434, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
3226, 3d14A, 0.7591, 2.60, 0.307, 262, 241, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3227, 2yaaA, 0.7591, 2.65, 0.289, 300, 242, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3228, 1zwsH, 0.7591, 2.68, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3229, 5v19B, 0.7590, 2.68, 0.305, 260, 239, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3230, 5o13A, 0.7590, 2.52, 0.285, 270, 239, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3231, 5gnkA, 0.7590, 2.60, 0.217, 277, 240, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
3232, 4tndA, 0.7590, 3.00, 0.275, 529, 247, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
3233, 3db6A, 0.7590, 2.83, 0.286, 287, 245, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
3234, 1ckjB, 0.7590, 3.01, 0.198, 293, 248, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3235, 5zwjA, 0.7589, 2.60, 0.217, 267, 240, CRYSTAL STRUCTURE OF EGFR 675-1022 T790M/C797S/V948R IN COMPLEX WITH EAI045 
3236, 5oq8A, 0.7589, 2.61, 0.282, 261, 241, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3237, 5n4oA, 0.7589, 2.50, 0.285, 271, 239, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE (E)-3-(P-TOLYL)ACRYLIC ACID
3238, 5mrdA, 0.7589, 2.92, 0.293, 283, 246, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
3239, 3ppzA, 0.7589, 2.63, 0.250, 264, 240, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3240, 2x4fB, 0.7589, 2.65, 0.290, 288, 241, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3241, 4y95C, 0.7588, 2.57, 0.192, 266, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3242, 4wd5B, 0.7588, 2.88, 0.167, 304, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
3243, 4rc2A, 0.7588, 2.56, 0.283, 272, 240, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3244, 4qmwA, 0.7588, 2.99, 0.291, 286, 247, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
3245, 4i92A, 0.7588, 2.79, 0.172, 289, 244, STRUCTURE OF THE BSK8 KINASE DOMAIN
3246, 3ikaB, 0.7588, 2.90, 0.167, 310, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
3247, 2yabB, 0.7588, 2.77, 0.288, 299, 243, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3248, 2g2fA, 0.7588, 2.86, 0.226, 275, 243, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3249, 2fumC, 0.7588, 2.44, 0.266, 254, 237, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3250, 2clqB, 0.7588, 2.67, 0.296, 259, 240, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3251, 5itaA, 0.7587, 2.35, 0.221, 250, 235, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
3252, 5aadA, 0.7587, 2.55, 0.318, 252, 239, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3253, 4yomB, 0.7587, 2.65, 0.286, 322, 241, STRUCTURE OF SAD KINASE
3254, 4y95B, 0.7587, 2.57, 0.192, 266, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3255, 4pnkA, 0.7587, 2.95, 0.244, 625, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
3256, 4bn1A, 0.7587, 2.68, 0.307, 261, 241, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
3257, 4aw0A, 0.7587, 2.86, 0.294, 283, 245, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
3258, 3qc9C, 0.7587, 3.03, 0.281, 482, 249, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
3259, 3pp0A, 0.7587, 2.78, 0.223, 286, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
3260, 1zwsB, 0.7587, 2.70, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3261, 5vilA, 0.7586, 2.84, 0.298, 271, 242, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3262, 5t8oA, 0.7586, 2.98, 0.258, 324, 244, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
3263, 5hu3A, 0.7586, 2.54, 0.345, 266, 238, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
3264, 5aepA, 0.7586, 2.75, 0.263, 287, 243, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
3265, 4d28B, 0.7586, 2.71, 0.339, 277, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
3266, 4d0xA, 0.7586, 2.79, 0.262, 291, 244, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3267, 3vs4B, 0.7586, 2.58, 0.247, 434, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
3268, 3krrA, 0.7586, 2.81, 0.262, 291, 244, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
3269, 3c4eB, 0.7586, 2.59, 0.278, 273, 241, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
3270, 2c0tB, 0.7586, 2.66, 0.247, 429, 239, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
3271, 4lg4B, 0.7585, 2.92, 0.296, 284, 247, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3272, 3vs2B, 0.7585, 2.53, 0.252, 433, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
3273, 3nrmA, 0.7585, 2.67, 0.315, 263, 241, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
3274, 5dosA, 0.7584, 2.85, 0.309, 259, 243, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3275, 4rx5A, 0.7584, 2.56, 0.200, 265, 240, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
3276, 4nttA, 0.7584, 2.79, 0.257, 339, 245, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
3277, 4a07A, 0.7584, 2.84, 0.294, 282, 245, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
3278, 3qc9D, 0.7584, 2.99, 0.259, 486, 247, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
3279, 3i7cA, 0.7584, 2.69, 0.311, 449, 241, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NA-PP2
3280, 4g3eA, 0.7583, 3.20, 0.248, 314, 246, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
3281, 3we8A, 0.7583, 2.60, 0.282, 273, 241, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
3282, 3qc9B, 0.7583, 2.99, 0.259, 481, 247, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
3283, 3qc9A, 0.7583, 2.99, 0.259, 486, 247, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
3284, 2c0iB, 0.7583, 2.67, 0.247, 433, 239, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
3285, 5zj6B, 0.7582, 2.73, 0.253, 270, 241, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
3286, 5autA, 0.7582, 2.58, 0.289, 274, 239, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
3287, 4nfmA, 0.7582, 3.16, 0.192, 293, 250, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
3288, 4i94B, 0.7582, 2.82, 0.173, 297, 243, STRUCTURE OF BSK8 IN COMPLEX WITH AMP-PNP
3289, 4fl2A, 0.7582, 2.59, 0.212, 555, 241, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
3290, 3vs6A, 0.7582, 2.59, 0.247, 434, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
3291, 3vryB, 0.7582, 2.58, 0.251, 434, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
3292, 3brbB, 0.7582, 2.54, 0.230, 271, 239, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
3293, 2o63A, 0.7582, 2.62, 0.270, 274, 241, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
3294, 1xr1A, 0.7582, 2.70, 0.278, 277, 241, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
3295, 5zj6A, 0.7581, 2.73, 0.253, 271, 241, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
3296, 5wnhC, 0.7581, 2.86, 0.278, 388, 245, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3297, 5wnfC, 0.7581, 2.78, 0.283, 386, 244, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3298, 5vilB, 0.7581, 2.87, 0.298, 271, 242, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3299, 5nttA, 0.7581, 2.64, 0.310, 276, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
3300, 5lohA, 0.7581, 2.50, 0.309, 248, 236, KINASE DOMAIN OF HUMAN GREATWALL
3301, 4ivaA, 0.7581, 2.79, 0.258, 290, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
3302, 1ckiB, 0.7581, 3.04, 0.202, 286, 248, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3303, 5w5oN, 0.7580, 2.71, 0.231, 272, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3304, 5u6bC, 0.7580, 2.79, 0.226, 270, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3305, 4wnpA, 0.7580, 2.67, 0.312, 273, 240, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3306, 4d0wA, 0.7580, 2.86, 0.262, 289, 244, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3307, 2c0oA, 0.7580, 2.56, 0.248, 433, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
3308, 5uoxA, 0.7579, 2.76, 0.300, 263, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3309, 5cf4B, 0.7579, 2.81, 0.262, 291, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3310, 4dn5B, 0.7579, 2.92, 0.269, 330, 245, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
3311, 3vs4A, 0.7579, 2.58, 0.247, 429, 239, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
3312, 3ppjB, 0.7579, 2.81, 0.212, 264, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
3313, 3o7lD, 0.7579, 2.87, 0.283, 333, 247, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
3314, 3f69A, 0.7579, 2.53, 0.269, 270, 238, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3315, 6g4yB, 0.7578, 3.07, 0.249, 328, 245, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
3316, 5oktB, 0.7578, 3.10, 0.189, 281, 249, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3317, 5n93A, 0.7578, 2.44, 0.305, 259, 239, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
3318, 4rioA, 0.7578, 2.86, 0.255, 285, 243, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
3319, 4jajA, 0.7578, 2.79, 0.306, 265, 242, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
3320, 3q32A, 0.7578, 2.79, 0.262, 291, 244, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3321, 3pvuA, 0.7578, 2.88, 0.248, 609, 246, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
3322, 3plsA, 0.7578, 2.76, 0.219, 298, 242, RON IN COMPLEX WITH LIGAND AMP-PNP
3323, 3lmgB, 0.7578, 2.63, 0.208, 268, 240, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
3324, 3a4pA, 0.7578, 2.95, 0.220, 285, 245, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
3325, 2c0oB, 0.7578, 2.54, 0.248, 433, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
3326, 5vioA, 0.7577, 2.85, 0.298, 271, 242, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3327, 5ttvA, 0.7577, 2.97, 0.254, 280, 244, JAK3 WITH COVALENT INHIBITOR 6
3328, 5objA, 0.7577, 2.68, 0.314, 260, 242, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
3329, 5da3A, 0.7577, 2.73, 0.264, 263, 242, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
3330, 4otwA, 0.7577, 2.60, 0.208, 272, 240, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
3331, 2c0iA, 0.7577, 2.55, 0.248, 433, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
3332, 5ortA, 0.7576, 2.72, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3333, 4prjA, 0.7576, 2.56, 0.315, 251, 238, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3334, 3vs0B, 0.7576, 2.55, 0.248, 433, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
3335, 3ocsA, 0.7576, 2.57, 0.200, 264, 240, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
3336, 1ckiA, 0.7576, 3.03, 0.198, 292, 248, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3337, 6g4zB, 0.7575, 3.05, 0.250, 325, 244, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
3338, 4i21B, 0.7575, 3.11, 0.206, 302, 248, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
3339, 2yaaB, 0.7575, 2.68, 0.289, 299, 242, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3340, 5vioD, 0.7574, 2.75, 0.299, 271, 241, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3341, 5jsmC, 0.7574, 2.74, 0.218, 262, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3342, 5deyA, 0.7574, 2.95, 0.294, 295, 248, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3343, 4ynzA, 0.7574, 2.38, 0.295, 313, 237, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
3344, 4y95D, 0.7574, 2.49, 0.192, 265, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3345, 4g31A, 0.7574, 2.38, 0.292, 248, 233, CRYSTAL STRUCTURE OF GSK6414 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.28 A RESOLUTION
3346, 3ikaA, 0.7574, 2.98, 0.224, 310, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
3347, 5t8qA, 0.7573, 3.07, 0.249, 323, 245, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
3348, 4y95A, 0.7573, 2.49, 0.192, 266, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3349, 3vs2A, 0.7573, 2.56, 0.252, 430, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
3350, 3m11A, 0.7573, 2.64, 0.315, 256, 241, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3351, 2c0tA, 0.7573, 2.56, 0.248, 427, 238, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
3352, 1zwsG, 0.7573, 2.69, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3353, 1ckjA, 0.7573, 3.04, 0.194, 296, 248, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3354, 5eakB, 0.7572, 2.62, 0.325, 300, 240, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3355, 4wsqB, 0.7572, 2.66, 0.255, 310, 239, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3356, 3rcdC, 0.7572, 2.80, 0.193, 281, 243, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
3357, 3rcdA, 0.7572, 2.80, 0.193, 281, 243, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
3358, 3dj7A, 0.7572, 2.63, 0.307, 257, 241, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3359, 2o65A, 0.7572, 2.62, 0.270, 274, 241, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
3360, 6ccfA, 0.7571, 2.66, 0.289, 260, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3361, 5uuuA, 0.7571, 2.94, 0.270, 414, 248, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
3362, 5ug9A, 0.7571, 2.77, 0.215, 280, 242, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
3363, 5t8pA, 0.7571, 3.15, 0.248, 327, 246, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
3364, 5t8oB, 0.7571, 3.02, 0.254, 328, 244, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
3365, 5oneA, 0.7571, 2.72, 0.314, 257, 242, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
3366, 4fk3A, 0.7571, 2.40, 0.212, 251, 236, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
3367, 3vs5B, 0.7571, 2.56, 0.248, 427, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
3368, 3uixA, 0.7571, 2.54, 0.280, 266, 239, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3369, 3rvgA, 0.7571, 2.74, 0.263, 285, 243, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
3370, 3r22A, 0.7571, 2.67, 0.315, 255, 241, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3371, 6es0A, 0.7570, 2.99, 0.238, 288, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
3372, 6bqpA, 0.7570, 2.62, 0.297, 263, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
3373, 4yhfA, 0.7570, 2.64, 0.200, 268, 240, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
3374, 4o0sA, 0.7570, 2.74, 0.314, 265, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3375, 4e6qA, 0.7570, 2.79, 0.266, 296, 244, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3376, 3jy0A, 0.7570, 2.66, 0.275, 275, 240, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3377, 3cikA, 0.7570, 2.99, 0.240, 619, 246, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3378, 2x6dA, 0.7570, 2.74, 0.307, 255, 241, AURORA-A BOUND TO AN INHIBITOR
3379, 2c3iB, 0.7570, 2.54, 0.280, 266, 239, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I
3380, 2bikB, 0.7570, 2.55, 0.279, 272, 240, HUMAN PIM1 PHOSPHORYLATED ON SER261
3381, 5vgoA, 0.7569, 2.57, 0.200, 265, 240, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
3382, 5u6bA, 0.7569, 2.80, 0.226, 270, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3383, 5orlA, 0.7569, 2.72, 0.314, 264, 242, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3384, 5jsmB, 0.7569, 2.63, 0.214, 263, 238, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3385, 5cf5A, 0.7569, 2.76, 0.263, 287, 243, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3386, 4qmlA, 0.7569, 3.02, 0.287, 280, 247, MST3 IN COMPLEX WITH AMP-PNP
3387, 4i6hA, 0.7569, 2.80, 0.262, 285, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3388, 4g34A, 0.7569, 2.39, 0.292, 248, 233, CRYSTAL STRUCTURE OF GSK6924 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.70 A RESOLUTION
3389, 3hztA, 0.7569, 2.67, 0.331, 421, 242, CRYSTAL STRUCTURE OF TOXOPLASMA GONDII CDPK3 TGME49_105860
3390, 1mq4A, 0.7569, 2.76, 0.307, 261, 241, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
3391, 5oktA, 0.7568, 3.01, 0.190, 285, 248, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3392, 5k00A, 0.7568, 2.41, 0.342, 311, 237, MELK IN COMPLEX WITH NVS-MELK5
3393, 4otqA, 0.7568, 2.62, 0.196, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
3394, 4otfA, 0.7568, 2.58, 0.200, 262, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
3395, 4i6bA, 0.7568, 2.80, 0.258, 285, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3396, 3vrzA, 0.7568, 2.57, 0.248, 429, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
3397, 3brbA, 0.7568, 2.38, 0.229, 260, 236, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
3398, 1jktA, 0.7568, 2.78, 0.285, 276, 242, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3399, 5t8pB, 0.7567, 3.16, 0.248, 328, 246, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
3400, 4h58A, 0.7567, 2.72, 0.217, 263, 240, BRAF IN COMPLEX WITH COMPOUND 3
3401, 3ppjA, 0.7567, 2.75, 0.212, 262, 240, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
3402, 3d4qB, 0.7567, 2.80, 0.212, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3403, 2xruA, 0.7567, 2.69, 0.307, 253, 241, AURORA-A T288E COMPLEXED WITH PHA-828300
3404, 5vilC, 0.7566, 2.83, 0.303, 271, 241, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3405, 5texA, 0.7566, 2.65, 0.274, 274, 241, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
3406, 5obrA, 0.7566, 2.64, 0.315, 255, 241, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3407, 5mahA, 0.7566, 2.47, 0.329, 316, 237, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3408, 5cf6A, 0.7566, 2.76, 0.263, 285, 243, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3409, 4zimB, 0.7566, 2.83, 0.262, 294, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3410, 4x7nA, 0.7566, 2.90, 0.270, 259, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
3411, 3naxA, 0.7566, 2.82, 0.287, 278, 244, PDK1 IN COMPLEX WITH INHIBITOR MP7
3412, 1jktB, 0.7566, 2.76, 0.285, 276, 242, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3413, 5w7tB, 0.7565, 2.69, 0.259, 276, 239, STRUCTURE OF PHOSPHORYLATED WNK1 
3414, 5kupA, 0.7565, 2.58, 0.200, 265, 240, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
3415, 5bpyA, 0.7565, 2.64, 0.200, 263, 240, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
3416, 4wsqA, 0.7565, 2.67, 0.264, 317, 239, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3417, 4otrA, 0.7565, 2.62, 0.196, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
3418, 3vs5A, 0.7565, 2.57, 0.248, 429, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
3419, 3d4qA, 0.7565, 2.81, 0.216, 264, 241, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3420, 2jivA, 0.7565, 2.66, 0.220, 270, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
3421, 5j5tA, 0.7564, 2.71, 0.298, 297, 242, GLK CO-CRYSTAL STRUCTURE WITH AMINOPYRROLOPYRIMIDINE INHIBITOR
3422, 4i94A, 0.7564, 2.87, 0.173, 297, 243, STRUCTURE OF BSK8 IN COMPLEX WITH AMP-PNP
3423, 4deeA, 0.7564, 2.78, 0.314, 271, 242, AURORA A IN COMPLEX WITH ADP
3424, 4aqcA, 0.7564, 2.81, 0.262, 289, 244, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3425, 3uo5A, 0.7564, 2.75, 0.314, 267, 242, AURORA A IN COMPLEX WITH YL1-038-31
3426, 3ppkB, 0.7564, 2.84, 0.216, 264, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3427, 3is5E, 0.7564, 1.82, 0.308, 252, 227, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3428, 5ng0A, 0.7563, 2.77, 0.238, 274, 244, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3429, 4wnpD, 0.7563, 2.74, 0.312, 272, 240, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3430, 4wnpC, 0.7563, 2.68, 0.314, 271, 239, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3431, 4twcB, 0.7563, 3.01, 0.194, 292, 248, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3432, 4i5pA, 0.7563, 2.81, 0.258, 284, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3433, 2wtkB, 0.7563, 2.72, 0.250, 311, 244, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3434, 1zwsA, 0.7563, 2.73, 0.285, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3435, 5mrbA, 0.7562, 2.39, 0.319, 264, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
3436, 5j87B, 0.7562, 2.63, 0.200, 274, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3437, 4qpsC, 0.7562, 2.74, 0.261, 276, 241, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3438, 4f08B, 0.7562, 2.82, 0.262, 288, 244, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3439, 4bkjB, 0.7562, 2.97, 0.223, 297, 247, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3440, 2jivB, 0.7562, 2.69, 0.216, 272, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
3441, 1o6yA, 0.7562, 2.59, 0.271, 260, 240, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3442, 5vilD, 0.7561, 2.77, 0.299, 271, 241, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3443, 5u6cA, 0.7561, 2.54, 0.230, 272, 239, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
3444, 5twlA, 0.7561, 2.71, 0.328, 319, 241, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3445, 4zegA, 0.7561, 2.67, 0.311, 260, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3446, 4medA, 0.7561, 2.58, 0.287, 272, 240, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
3447, 5p9fA, 0.7560, 2.63, 0.200, 266, 240, BTK IN COMPLEX WITH GDC-0834
3448, 5he3A, 0.7560, 2.86, 0.245, 623, 245, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
3449, 4iwpA, 0.7560, 3.02, 0.257, 628, 245, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3450, 4f08A, 0.7560, 2.82, 0.262, 288, 244, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3451, 4bicB, 0.7560, 2.75, 0.303, 259, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3452, 4bhnA, 0.7560, 2.65, 0.304, 256, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3453, 3vs0A, 0.7560, 2.59, 0.248, 428, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
3454, 3nyvA, 0.7560, 2.59, 0.310, 445, 239, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH NON-SPECIFIC INHIBITOR WHI-P180
3455, 2yakA, 0.7560, 2.73, 0.285, 277, 242, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
3456, 2bcjA, 0.7560, 2.85, 0.249, 624, 245, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
3457, 5gjdA, 0.7559, 3.18, 0.296, 292, 247, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
3458, 5ar2A, 0.7559, 2.86, 0.237, 277, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3459, 5ap7A, 0.7559, 2.33, 0.316, 263, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3460, 4rc3A, 0.7559, 2.56, 0.289, 271, 239, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3461, 3r21A, 0.7559, 2.69, 0.311, 254, 241, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3462, 3otuA, 0.7559, 2.89, 0.295, 276, 244, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
3463, 2wzjB, 0.7559, 2.43, 0.316, 310, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3464, 2gdoA, 0.7559, 2.90, 0.294, 269, 245, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
3465, 5vioC, 0.7558, 2.82, 0.299, 271, 241, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3466, 5ug8A, 0.7558, 2.79, 0.215, 280, 242, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
3467, 5lohB, 0.7558, 2.74, 0.317, 250, 240, KINASE DOMAIN OF HUMAN GREATWALL
3468, 5j87D, 0.7558, 2.65, 0.200, 263, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3469, 4dhfA, 0.7558, 2.79, 0.314, 258, 242, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3470, 4aqcB, 0.7558, 2.86, 0.262, 295, 244, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3471, 3uytC, 0.7558, 3.04, 0.198, 286, 248, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3472, 3psdB, 0.7558, 2.86, 0.212, 264, 241, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
3473, 3d15A, 0.7558, 2.61, 0.308, 256, 240, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3474, 2h8hA, 0.7558, 2.71, 0.242, 444, 240, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
3475, 6cd6C, 0.7557, 2.64, 0.289, 265, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3476, 6b2qC, 0.7557, 2.51, 0.277, 264, 238, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3477, 4i6fA, 0.7557, 2.82, 0.262, 285, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3478, 4dhfB, 0.7557, 2.80, 0.314, 258, 242, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3479, 6bleA, 0.7556, 2.64, 0.297, 265, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
3480, 5hesA, 0.7556, 2.64, 0.254, 287, 236, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
3481, 4rfyA, 0.7556, 2.64, 0.196, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
3482, 3t9iA, 0.7556, 2.58, 0.276, 273, 239, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3483, 1yi4A, 0.7556, 2.55, 0.285, 267, 239, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3484, 5ng0B, 0.7555, 3.04, 0.238, 282, 248, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3485, 5j79A, 0.7555, 2.89, 0.229, 283, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3486, 4ntsB, 0.7555, 2.88, 0.268, 341, 246, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3487, 4neuA, 0.7555, 3.04, 0.220, 286, 250, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
3488, 4g3cA, 0.7555, 3.18, 0.244, 315, 246, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
3489, 3vs1B, 0.7555, 2.51, 0.241, 433, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
3490, 3mygA, 0.7555, 2.63, 0.318, 252, 239, AURORA A KINASE COMPLEXED WITH SCH 1473759
3491, 2qu5A, 0.7555, 2.85, 0.222, 292, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
3492, 2f57A, 0.7555, 2.96, 0.253, 297, 245, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3493, 4x7kA, 0.7554, 2.92, 0.270, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
3494, 4hvgA, 0.7554, 2.75, 0.261, 281, 241, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
3495, 4g3eB, 0.7554, 2.99, 0.251, 325, 243, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
3496, 4g3cB, 0.7554, 3.18, 0.248, 327, 246, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
3497, 4f09A, 0.7554, 2.82, 0.258, 288, 244, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3498, 3a7jA, 0.7554, 3.03, 0.264, 286, 246, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
3499, 5ugcA, 0.7553, 2.79, 0.215, 280, 242, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-METHYL-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
3500, 5t8qB, 0.7553, 3.19, 0.248, 328, 246, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
3501, 5dr9A, 0.7553, 2.74, 0.314, 257, 242, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3502, 5cswA, 0.7553, 2.67, 0.206, 254, 238, B-RAF IN COMPLEX WITH DABRAFENIB
3503, 5ap1A, 0.7553, 2.57, 0.315, 268, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3504, 4iaaA, 0.7553, 2.58, 0.287, 272, 240, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
3505, 4c57A, 0.7553, 3.08, 0.265, 310, 249, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
3506, 2ya9A, 0.7553, 2.70, 0.289, 299, 242, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3507, 2wzjD, 0.7553, 2.44, 0.316, 313, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3508, 4xv9A, 0.7552, 2.75, 0.200, 261, 240, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
3509, 3omvA, 0.7552, 2.79, 0.199, 264, 241, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
3510, 3lxlA, 0.7552, 2.88, 0.256, 281, 242, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3511, 3a99A, 0.7552, 2.76, 0.282, 273, 241, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
3512, 2xngA, 0.7552, 2.65, 0.308, 253, 240, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3513, 2wtkE, 0.7552, 2.78, 0.258, 308, 244, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3514, 1ym7C, 0.7552, 3.01, 0.232, 607, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3515, 5oq7A, 0.7551, 2.64, 0.299, 259, 241, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3516, 4x7lA, 0.7551, 2.93, 0.270, 260, 241, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
3517, 4wnpB, 0.7551, 2.72, 0.317, 272, 240, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3518, 4l9iA, 0.7551, 3.03, 0.271, 504, 247, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
3519, 5h0hA, 0.7550, 2.69, 0.250, 446, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
3520, 5h0eA, 0.7550, 2.70, 0.250, 446, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
3521, 4ytfA, 0.7550, 2.76, 0.260, 283, 242, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3522, 4tl0A, 0.7550, 2.81, 0.284, 300, 243, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
3523, 4ot6A, 0.7550, 2.65, 0.196, 265, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
3524, 3vs7A, 0.7550, 2.58, 0.256, 432, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
3525, 3vs1A, 0.7550, 2.59, 0.252, 424, 238, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
3526, 3mj2A, 0.7550, 2.48, 0.231, 259, 238, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
3527, 3eyhA, 0.7550, 2.89, 0.259, 285, 243, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3528, 1ym7A, 0.7550, 3.01, 0.232, 608, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3529, 5up3A, 0.7549, 2.76, 0.310, 258, 239, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3530, 5h09A, 0.7549, 2.70, 0.250, 446, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
3531, 5dt0A, 0.7549, 2.91, 0.313, 259, 243, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3532, 3d2iA, 0.7549, 2.65, 0.307, 255, 241, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3533, 5hznG, 0.7548, 2.87, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3534, 4kbkB, 0.7548, 3.05, 0.198, 289, 248, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3535, 4iwqA, 0.7548, 2.92, 0.258, 626, 244, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3536, 4idvB, 0.7548, 2.94, 0.263, 335, 243, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3537, 4e6qB, 0.7548, 2.82, 0.266, 296, 244, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3538, 3psbB, 0.7548, 2.87, 0.212, 264, 241, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
3539, 3pjcA, 0.7548, 2.84, 0.260, 286, 242, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
3540, 1ym7D, 0.7548, 3.01, 0.232, 599, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3541, 1ym7B, 0.7548, 3.01, 0.232, 608, 246, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3542, 1wvwA, 0.7548, 2.60, 0.292, 275, 240, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3543, 5tozA, 0.7547, 2.87, 0.260, 278, 242, JAK3 WITH COVALENT INHIBITOR PF-06651600
3544, 5hznC, 0.7547, 2.87, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3545, 5cf6B, 0.7547, 2.77, 0.264, 290, 242, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3546, 4rblA, 0.7547, 2.57, 0.285, 271, 239, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3547, 3ppkA, 0.7547, 2.59, 0.214, 262, 238, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3548, 3j4rE, 0.7547, 2.90, 0.249, 325, 245, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3549, 3j4rD, 0.7547, 2.90, 0.249, 325, 245, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3550, 3j4qE, 0.7547, 2.90, 0.249, 325, 245, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3551, 3j4qD, 0.7547, 2.90, 0.249, 325, 245, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3552, 2v7oA, 0.7547, 2.68, 0.320, 305, 241, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
3553, 2qvsE, 0.7547, 2.90, 0.249, 323, 245, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
3554, 5x5oA, 0.7546, 2.84, 0.248, 291, 238, CRYSTAL STRUCTURE OF ZAK IN COMPLEX WITH COMPOUND D2829
3555, 5p9gA, 0.7546, 2.63, 0.200, 265, 240, STRUCTURE OF BTK WITH RN486
3556, 5hznE, 0.7546, 2.88, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3557, 5dewA, 0.7546, 3.02, 0.294, 295, 248, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3558, 4idvC, 0.7546, 3.00, 0.254, 335, 244, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3559, 4idvA, 0.7546, 3.09, 0.253, 335, 245, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3560, 3uzpA, 0.7546, 3.16, 0.183, 292, 251, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3561, 2y7jA, 0.7546, 2.72, 0.295, 284, 241, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3562, 5jt2B, 0.7545, 2.54, 0.219, 251, 237, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3563, 5hznA, 0.7545, 2.88, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3564, 4jbqA, 0.7545, 2.76, 0.314, 257, 242, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3565, 4at4A, 0.7545, 2.93, 0.239, 292, 247, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3566, 3uodA, 0.7545, 2.83, 0.314, 266, 242, AURORA A IN COMPLEX WITH RPM1693
3567, 3lzbC, 0.7545, 2.66, 0.217, 259, 240, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
3568, 3kckA, 0.7545, 2.76, 0.260, 285, 242, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
3569, 3cblA, 0.7545, 2.79, 0.249, 356, 241, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
3570, 5o91A, 0.7544, 2.52, 0.312, 266, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604W MUTANT IN COMPLEX WITH CPD-5
3571, 4yhtB, 0.7544, 2.67, 0.209, 258, 239, BRAF COMPLEXED WITH AN INHIBITOR
3572, 4yhtA, 0.7544, 2.61, 0.206, 256, 238, BRAF COMPLEXED WITH AN INHIBITOR
3573, 2srcA, 0.7544, 2.69, 0.246, 449, 240, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
3574, 5j87A, 0.7543, 2.65, 0.200, 263, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3575, 4jjrA, 0.7543, 2.92, 0.200, 284, 245, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3576, 4h58B, 0.7543, 2.79, 0.216, 262, 241, BRAF IN COMPLEX WITH COMPOUND 3
3577, 4g3dA, 0.7543, 2.92, 0.264, 324, 242, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
3578, 4e4mA, 0.7543, 2.88, 0.266, 296, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3579, 3psdA, 0.7543, 2.85, 0.216, 262, 241, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
3580, 5eymB, 0.7542, 2.47, 0.270, 292, 237, MEK1 IN COMPLEX WITH BI 847325
3581, 5eymA, 0.7542, 2.49, 0.270, 292, 237, MEK1 IN COMPLEX WITH BI 847325
3582, 5aaeA, 0.7542, 2.65, 0.317, 252, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3583, 4wnoA, 0.7542, 2.79, 0.317, 272, 240, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
3584, 4rz7A, 0.7542, 2.80, 0.261, 801, 245, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND PCI32765
3585, 3uytA, 0.7542, 3.03, 0.189, 287, 249, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3586, 3bkbA, 0.7542, 2.90, 0.240, 373, 242, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
3587, 1zycB, 0.7542, 2.88, 0.286, 254, 241, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3588, 1zy5A, 0.7542, 2.92, 0.277, 271, 242, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
3589, 5ihcA, 0.7541, 2.27, 0.325, 305, 234, MELK IN COMPLEX WITH NVS-MELK12B
3590, 5h0bA, 0.7541, 2.71, 0.250, 446, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
3591, 4ytcA, 0.7541, 2.77, 0.260, 284, 242, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3592, 3pscA, 0.7541, 2.99, 0.248, 614, 246, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3593, 3hmiA, 0.7541, 2.78, 0.224, 268, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3594, 2rfeC, 0.7541, 2.61, 0.218, 262, 239, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
3595, 2fb8A, 0.7541, 2.76, 0.208, 259, 240, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3596, 2dwbA, 0.7541, 2.69, 0.318, 259, 239, AURORA-A KINASE COMPLEXED WITH AMPPNP
3597, 2cgxA, 0.7541, 2.97, 0.293, 265, 246, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3598, 5uorB, 0.7540, 2.79, 0.301, 262, 239, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3599, 5mzlA, 0.7540, 2.41, 0.275, 269, 236, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE N-QUINOLIN-5-YLPYRIDINE- 3-CARBOXAMIDE
3600, 4k11A, 0.7540, 2.72, 0.242, 447, 240, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
3601, 4e4mE, 0.7540, 2.88, 0.262, 296, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3602, 3uysC, 0.7540, 3.02, 0.194, 286, 247, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3603, 3omvB, 0.7540, 2.84, 0.195, 264, 241, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
3604, 3h0yA, 0.7540, 2.62, 0.310, 250, 239, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3605, 3f66B, 0.7540, 2.72, 0.228, 269, 241, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3606, 2qnjB, 0.7540, 2.67, 0.331, 322, 242, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3607, 1snuB, 0.7540, 2.41, 0.230, 241, 235, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3608, 5x17B, 0.7539, 3.04, 0.194, 289, 247, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3609, 5dr6A, 0.7539, 2.78, 0.314, 257, 242, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3610, 4zy4A, 0.7539, 2.85, 0.266, 288, 244, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3611, 4tw9B, 0.7539, 3.04, 0.194, 289, 248, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3612, 3vs7B, 0.7539, 2.51, 0.245, 426, 237, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
3613, 3priB, 0.7539, 2.86, 0.212, 264, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3614, 3fdnA, 0.7539, 2.79, 0.310, 261, 242, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3615, 4ztrA, 0.7538, 2.49, 0.314, 249, 239, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3616, 4mnfB, 0.7538, 2.57, 0.215, 257, 237, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3617, 3zosB, 0.7538, 3.13, 0.221, 303, 249, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3618, 3uytD, 0.7538, 3.02, 0.194, 268, 248, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3619, 3priA, 0.7538, 2.86, 0.212, 264, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3620, 2w1cA, 0.7538, 2.76, 0.314, 261, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3621, 6cmjA, 0.7537, 2.80, 0.303, 285, 241, HUMAN CAMKK2 WITH GSK650393
3622, 6b2qB, 0.7537, 2.50, 0.278, 266, 237, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3623, 5h0gA, 0.7537, 2.71, 0.250, 446, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
3624, 3dlsD, 0.7537, 2.68, 0.262, 284, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3625, 3bprA, 0.7537, 2.55, 0.223, 261, 238, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
3626, 2w1iB, 0.7537, 2.80, 0.264, 284, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3627, 2vz6B, 0.7537, 2.84, 0.317, 294, 243, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3628, 5ng2A, 0.7536, 2.86, 0.234, 274, 244, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3629, 4zs0A, 0.7536, 2.61, 0.318, 257, 239, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3630, 4ji9A, 0.7536, 2.77, 0.264, 284, 242, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3631, 2wtkC, 0.7536, 3.01, 0.290, 285, 248, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3632, 3c4yB, 0.7535, 2.67, 0.266, 466, 241, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3633, 2wzjF, 0.7535, 2.46, 0.321, 310, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3634, 5mqvC, 0.7534, 2.98, 0.195, 288, 246, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3635, 5hznF, 0.7534, 2.89, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3636, 4d28D, 0.7534, 2.48, 0.331, 271, 236, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
3637, 4btkA, 0.7534, 3.03, 0.191, 287, 246, TTBK1 IN COMPLEX WITH INHIBITOR
3638, 4b0gA, 0.7534, 2.52, 0.308, 247, 237, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3639, 3v5wA, 0.7534, 3.05, 0.232, 623, 246, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
3640, 3d5xA, 0.7534, 2.70, 0.286, 279, 241, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
3641, 2w1iA, 0.7534, 2.79, 0.264, 284, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3642, 2cgvA, 0.7534, 2.90, 0.294, 264, 245, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3643, 6cd6A, 0.7533, 2.67, 0.293, 264, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3644, 5hznB, 0.7533, 2.89, 0.217, 296, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3645, 5e8wA, 0.7533, 2.78, 0.221, 303, 240, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
3646, 4bkjA, 0.7533, 3.01, 0.223, 295, 247, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3647, 3utoB, 0.7533, 3.03, 0.245, 566, 245, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
3648, 3psbA, 0.7533, 2.61, 0.210, 262, 238, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
3649, 1zycC, 0.7533, 2.94, 0.276, 271, 243, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3650, 6cmjB, 0.7532, 2.81, 0.303, 284, 241, HUMAN CAMKK2 WITH GSK650393
3651, 6bkuA, 0.7532, 2.68, 0.293, 267, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
3652, 5o11A, 0.7532, 2.51, 0.283, 268, 237, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3653, 5jebA, 0.7532, 3.12, 0.214, 299, 248, CRYSTAL STRUCTURE OF EGFR TYROSINE KINASE DOMAIN WITH NOVEL INHIBITOR OF ACTIVE STATE OF HER2
3654, 4ysmB, 0.7532, 2.79, 0.310, 475, 242, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
3655, 4riyA, 0.7532, 2.59, 0.206, 269, 238, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3656, 4rgjA, 0.7532, 2.79, 0.306, 463, 242, APO CRYSTAL STRUCTURE OF CDPK4 FROM PLASMODIUM FALCIPARUM PF3D7_0717500
3657, 4hctA, 0.7532, 2.61, 0.233, 265, 240, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
3658, 4e26A, 0.7532, 2.78, 0.212, 270, 240, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3659, 3prfA, 0.7532, 2.82, 0.217, 262, 240, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3660, 1zltA, 0.7532, 3.06, 0.293, 272, 246, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
3661, 6cd6D, 0.7531, 2.68, 0.297, 267, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3662, 6c2yA, 0.7531, 2.94, 0.268, 617, 246, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
3663, 5vfiA, 0.7531, 2.66, 0.200, 271, 240, BRUTON S TYROSINE KINASE (BTK) WITH GDC-0853
3664, 5uyjA, 0.7531, 2.74, 0.292, 281, 240, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3665, 4rfzA, 0.7531, 2.68, 0.192, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
3666, 4i5mA, 0.7531, 2.86, 0.254, 273, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3667, 4g5pA, 0.7531, 2.81, 0.227, 299, 242, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3668, 4deaA, 0.7531, 2.77, 0.314, 266, 242, AURORA A IN COMPLEX WITH YL1-038-18
3669, 4bibA, 0.7531, 2.54, 0.306, 254, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3670, 3k5uA, 0.7531, 2.79, 0.314, 260, 242, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3671, 1zy4A, 0.7531, 3.04, 0.276, 271, 243, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
3672, 1sm2B, 0.7531, 2.45, 0.230, 241, 235, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3673, 5e8uA, 0.7530, 2.78, 0.220, 306, 241, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
3674, 4e26B, 0.7530, 2.80, 0.216, 264, 241, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3675, 4c57B, 0.7530, 3.11, 0.265, 308, 249, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
3676, 3iokA, 0.7530, 2.79, 0.264, 285, 242, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3677, 3dlsC, 0.7530, 2.66, 0.258, 281, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3678, 1kswA, 0.7530, 2.81, 0.249, 449, 241, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
3679, 6bl8A, 0.7529, 3.03, 0.242, 270, 244, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3680, 4ludB, 0.7529, 2.61, 0.252, 409, 238, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3681, 4kikA, 0.7529, 3.34, 0.261, 618, 249, HUMAN IKB KINASE BETA
3682, 4c0tA, 0.7529, 2.96, 0.268, 290, 246, CANDIDA ALBICANS PKH KINASE DOMAIN
3683, 5dpvA, 0.7528, 2.80, 0.314, 257, 242, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3684, 4x7hA, 0.7528, 2.81, 0.268, 256, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
3685, 4rg0A, 0.7528, 2.69, 0.192, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
3686, 4deiA, 0.7528, 2.84, 0.227, 287, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
3687, 3nyxA, 0.7528, 2.85, 0.227, 287, 242, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
3688, 3lzbB, 0.7528, 2.64, 0.217, 265, 240, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
3689, 3h0zC, 0.7528, 2.39, 0.315, 246, 235, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3690, 3eygA, 0.7528, 2.80, 0.270, 280, 241, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3691, 2yiyA, 0.7528, 2.95, 0.291, 293, 244, CRYSTAL STRUCTURE OF COMPOUND 8 BOUND TO TAK1-TAB
3692, 5x17A, 0.7527, 3.08, 0.194, 290, 247, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3693, 5uklA, 0.7527, 3.07, 0.232, 630, 246, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
3694, 5opuA, 0.7527, 2.67, 0.296, 261, 240, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3695, 4bbfD, 0.7527, 2.89, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3696, 1zwsE, 0.7527, 2.76, 0.289, 278, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3697, 1iasB, 0.7527, 2.88, 0.220, 324, 241, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3698, 4nwmA, 0.7526, 2.63, 0.201, 261, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
3699, 4bbfA, 0.7526, 2.90, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3700, 3q4cA, 0.7526, 2.83, 0.216, 264, 241, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
3701, 2vn9B, 0.7526, 2.76, 0.310, 301, 242, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
3702, 2cguA, 0.7526, 2.87, 0.295, 263, 244, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3703, 5jrsA, 0.7525, 2.48, 0.203, 258, 236, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
3704, 5ci7A, 0.7525, 2.78, 0.318, 276, 239, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
3705, 4y93A, 0.7525, 2.67, 0.196, 429, 240, CRYSTAL STRUCTURE OF THE PH-TH-KINASE CONSTRUCT OF BRUTON S TYROSINE KINASE (BTK)
3706, 4mk0A, 0.7525, 3.03, 0.248, 631, 246, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
3707, 4j8mA, 0.7525, 2.65, 0.303, 265, 241, AURORA A IN COMPLEX WITH CD532
3708, 4aszA, 0.7525, 2.87, 0.237, 289, 245, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
3709, 4hvhA, 0.7524, 2.91, 0.261, 278, 241, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
3710, 3zzeA, 0.7524, 2.79, 0.223, 286, 242, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
3711, 3lxnA, 0.7524, 3.13, 0.245, 287, 245, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3712, 5tq5A, 0.7523, 2.98, 0.262, 291, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3713, 4rixA, 0.7523, 2.59, 0.206, 269, 238, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3714, 5ig1A, 0.7522, 2.87, 0.296, 300, 243, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
3715, 4ckrA, 0.7522, 3.00, 0.223, 295, 247, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
3716, 4bieA, 0.7522, 2.61, 0.309, 257, 236, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3717, 3rcdB, 0.7522, 2.88, 0.198, 271, 243, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
3718, 3ndmA, 0.7522, 2.82, 0.277, 383, 242, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
3719, 3dlsA, 0.7522, 2.66, 0.262, 285, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3720, 2j0jA, 0.7522, 2.65, 0.254, 611, 240, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
3721, 6f3fA, 0.7521, 2.70, 0.250, 448, 240, AUTOINHIBITED SRC KINASE BOUND TO ADP
3722, 5w7tA, 0.7521, 2.73, 0.264, 276, 239, STRUCTURE OF PHOSPHORYLATED WNK1 
3723, 5mafA, 0.7521, 2.56, 0.329, 315, 237, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3724, 5e8xA, 0.7521, 2.80, 0.216, 304, 241, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
3725, 4x7jA, 0.7521, 2.86, 0.268, 257, 239, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
3726, 4uv0A, 0.7521, 2.83, 0.284, 300, 243, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
3727, 4umtA, 0.7521, 2.72, 0.314, 316, 239, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3728, 4riyC, 0.7521, 2.57, 0.214, 275, 238, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3729, 4rixC, 0.7521, 2.62, 0.213, 275, 239, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3730, 4ji9B, 0.7521, 2.82, 0.264, 288, 242, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3731, 4fg8B, 0.7521, 2.74, 0.287, 268, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3732, 3zosA, 0.7521, 3.18, 0.221, 301, 249, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3733, 1sm2A, 0.7521, 2.47, 0.225, 245, 236, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3734, 5k0kA, 0.7520, 2.59, 0.236, 260, 237, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2434
3735, 4ot5A, 0.7520, 2.69, 0.196, 263, 240, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
3736, 3up2A, 0.7520, 2.80, 0.314, 266, 242, AURORA A IN COMPLEX WITH RPM1686
3737, 3rcdD, 0.7520, 2.88, 0.198, 271, 243, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
3738, 3lxkA, 0.7520, 2.90, 0.256, 279, 242, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3739, 2qohB, 0.7520, 3.07, 0.242, 281, 244, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3740, 4zimA, 0.7519, 2.83, 0.263, 285, 243, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3741, 4e5wB, 0.7519, 2.79, 0.270, 278, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3742, 4e4mD, 0.7519, 2.89, 0.262, 296, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3743, 3qgyB, 0.7519, 2.52, 0.228, 245, 237, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
3744, 3prfB, 0.7519, 2.64, 0.214, 262, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3745, 2np8A, 0.7519, 2.63, 0.310, 256, 239, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3746, 2hz0A, 0.7519, 2.86, 0.241, 265, 241, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3747, 1zysA, 0.7519, 2.97, 0.290, 271, 245, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
3748, 1vjyA, 0.7519, 2.81, 0.220, 299, 241, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
3749, 5mqvF, 0.7518, 3.03, 0.195, 286, 246, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3750, 5l2qA, 0.7518, 2.70, 0.205, 293, 239, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3751, 5kcvA, 0.7518, 2.38, 0.295, 353, 234, CRYSTAL STRUCTURE OF ALLOSTERIC INHIBITOR ARQ 092 IN COMPLEX WITH AUTOINHIBITED FORM OF AKT1
3752, 5cf4A, 0.7518, 2.79, 0.264, 283, 242, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3753, 4usfB, 0.7518, 3.12, 0.285, 285, 249, HUMAN SLK WITH SB-440719
3754, 3vbwA, 0.7518, 2.54, 0.274, 264, 237, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3755, 3io7A, 0.7518, 2.76, 0.261, 282, 241, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3756, 2vn9A, 0.7518, 2.77, 0.314, 301, 242, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
3757, 1zycD, 0.7518, 2.77, 0.283, 256, 240, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
3758, 1k2pA, 0.7518, 2.58, 0.202, 258, 238, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3759, 5ih9A, 0.7517, 2.66, 0.331, 308, 239, MELK IN COMPLEX WITH NVS-MELK8A
3760, 4ztsA, 0.7517, 2.56, 0.318, 249, 239, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3761, 3ppzB, 0.7517, 2.55, 0.246, 264, 236, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3762, 3cd3A, 0.7517, 2.84, 0.245, 352, 241, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
3763, 2wqnA, 0.7517, 2.59, 0.304, 259, 237, STRUCTURE OF ADP-BOUND HUMAN NEK7
3764, 2fb8B, 0.7517, 2.72, 0.222, 259, 239, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3765, 1zydA, 0.7517, 2.94, 0.279, 270, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
3766, 6b2qA, 0.7516, 2.48, 0.280, 261, 236, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3767, 5aagA, 0.7516, 2.68, 0.317, 253, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3768, 4l7sA, 0.7516, 2.55, 0.235, 250, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
3769, 4hvdA, 0.7516, 2.82, 0.258, 276, 240, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
3770, 3nlbA, 0.7516, 2.78, 0.295, 261, 241, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
3771, 3i6uA, 0.7516, 2.82, 0.303, 390, 238, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
3772, 3dlsF, 0.7516, 2.73, 0.262, 281, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3773, 3dlsE, 0.7516, 2.72, 0.262, 282, 240, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3774, 5uy6A, 0.7515, 2.72, 0.293, 282, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3775, 5ukmA, 0.7515, 3.07, 0.232, 621, 246, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
3776, 4zjvA, 0.7515, 2.78, 0.224, 282, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
3777, 4e4mB, 0.7515, 2.89, 0.262, 296, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3778, 3dbqA, 0.7515, 2.71, 0.307, 259, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
3779, 6cd6B, 0.7514, 2.71, 0.301, 266, 239, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3780, 5vcyA, 0.7514, 2.51, 0.308, 296, 237, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3781, 5p9hA, 0.7514, 2.62, 0.201, 264, 239, BTK1 COCRYSTALLIZED WITH RN983
3782, 4ll0A, 0.7514, 2.94, 0.217, 291, 244, EGFR L858R/T790M IN COMPLEX WITH PD168393
3783, 4byiA, 0.7514, 2.66, 0.317, 254, 240, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3784, 3jy9A, 0.7514, 2.77, 0.257, 282, 241, JANUS KINASE 2 INHIBITORS
3785, 2hakF, 0.7514, 2.58, 0.328, 318, 241, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3786, 1qcfA, 0.7514, 2.73, 0.246, 449, 240, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
3787, 1mrvA, 0.7514, 2.31, 0.305, 261, 233, CRYSTAL STRUCTURE OF AN INACTIVE AKT2 KINASE DOMAIN
3788, 6bbvA, 0.7513, 2.73, 0.266, 289, 241, CRYSTAL STRUCTURE OF JAK2 IN COMPLEX WITH COMPOUND 25
3789, 5walA, 0.7513, 3.06, 0.234, 286, 244, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3790, 4hcuA, 0.7513, 2.65, 0.229, 263, 240, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
3791, 4fl3A, 0.7513, 2.69, 0.217, 538, 240, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
3792, 4bibB, 0.7513, 2.77, 0.300, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3793, 3dlsB, 0.7513, 2.63, 0.259, 280, 239, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3794, 5op7A, 0.7512, 2.71, 0.286, 261, 241, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3795, 5eydA, 0.7512, 2.85, 0.219, 289, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
3796, 4o0wA, 0.7512, 2.80, 0.310, 259, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3797, 4lqpA, 0.7512, 2.98, 0.276, 383, 246, CRYSTAL STRUCTURE OF THE CBK1(T743E)-MOB2 KINASE-COACTIVATOR COMPLEX IN CRYSTAL FORM A
3798, 2ydiA, 0.7512, 2.99, 0.302, 279, 245, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3799, 5nadA, 0.7511, 2.69, 0.314, 256, 239, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
3800, 4nwmB, 0.7511, 2.67, 0.201, 261, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
3801, 4hyhA, 0.7511, 2.80, 0.298, 263, 242, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
3802, 4fg9B, 0.7511, 2.83, 0.283, 279, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
3803, 2wzjC, 0.7511, 2.50, 0.321, 310, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3804, 1snxB, 0.7511, 2.46, 0.229, 245, 236, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3805, 5hznH, 0.7510, 2.93, 0.217, 303, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3806, 4mnfA, 0.7510, 2.69, 0.214, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3807, 4kbaC, 0.7510, 3.17, 0.192, 277, 250, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3808, 4e5wA, 0.7510, 2.85, 0.269, 292, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3809, 1iasD, 0.7510, 3.00, 0.224, 330, 241, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3810, 5ttsA, 0.7509, 2.81, 0.258, 274, 240, JAK3 WITH COVALENT INHIBITOR 4
3811, 5tq8A, 0.7509, 2.99, 0.262, 291, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3812, 5tq3A, 0.7509, 3.00, 0.258, 282, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3813, 5kbqA, 0.7509, 3.05, 0.275, 289, 247, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3814, 4qt1A, 0.7509, 2.63, 0.265, 277, 238, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
3815, 4idvD, 0.7509, 3.15, 0.253, 335, 245, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3816, 3lzbD, 0.7509, 2.76, 0.220, 261, 241, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
3817, 2y7jC, 0.7509, 2.76, 0.295, 284, 241, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3818, 5tq3B, 0.7508, 3.02, 0.258, 285, 244, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3819, 5o23B, 0.7508, 2.74, 0.238, 278, 239, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3820, 5hznD, 0.7508, 2.93, 0.217, 304, 244, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3821, 3vw6A, 0.7508, 2.68, 0.308, 255, 237, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3822, 2ya9B, 0.7508, 2.76, 0.289, 299, 242, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3823, 2fo0A, 0.7508, 3.03, 0.226, 465, 243, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
3824, 1snxA, 0.7508, 2.47, 0.229, 245, 236, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3825, 1lufA, 0.7508, 2.67, 0.242, 275, 240, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
3826, 6bbuA, 0.7507, 2.86, 0.269, 279, 242, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH COMPOUND 25
3827, 5oorA, 0.7507, 2.85, 0.298, 273, 242, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
3828, 5ig1B, 0.7507, 2.89, 0.296, 304, 243, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
3829, 5e1eB, 0.7507, 2.87, 0.269, 280, 242, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3830, 4riwA, 0.7507, 2.63, 0.210, 269, 238, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3831, 4kb8A, 0.7507, 3.08, 0.202, 265, 247, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3832, 3q4cB, 0.7507, 2.76, 0.217, 264, 240, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
3833, 3aloA, 0.7507, 2.99, 0.261, 289, 241, CRYSTAL STRUCTURE OF HUMAN NON-PHOSPHORYLATED MKK4 KINASE DOMAIN TERNARY COMPLEX WITH AMP-PNP AND P38 PEPTIDE
3834, 5w4wC, 0.7506, 3.21, 0.191, 284, 251, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3835, 5nclA, 0.7506, 2.88, 0.281, 418, 242, CRYSTAL STRUCTURE OF THE CBK1-MOB2 KINASE-COACTIVATOR COMPLEX WITH AN SSD1 PEPTIDE 
3836, 4ysmA, 0.7506, 2.83, 0.310, 475, 242, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
3837, 4umqA, 0.7506, 2.79, 0.324, 314, 241, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3838, 4i6qA, 0.7506, 2.86, 0.258, 277, 240, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
3839, 3utoA, 0.7506, 3.01, 0.246, 559, 244, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
3840, 2jitA, 0.7506, 2.75, 0.232, 299, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3841, 5j87C, 0.7505, 2.70, 0.200, 261, 240, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3842, 4riwC, 0.7505, 2.65, 0.213, 275, 239, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3843, 4jiaA, 0.7505, 2.91, 0.258, 298, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
3844, 4g3dB, 0.7505, 2.86, 0.271, 318, 240, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
3845, 3l8pA, 0.7505, 2.44, 0.261, 292, 234, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
3846, 2x8dA, 0.7505, 3.00, 0.294, 279, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3847, 1mruA, 0.7505, 2.71, 0.270, 269, 241, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3848, 5hieC, 0.7504, 2.87, 0.204, 253, 240, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3849, 5aafA, 0.7504, 2.73, 0.317, 254, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3850, 3c4yA, 0.7504, 3.04, 0.277, 478, 249, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3851, 2ptkA, 0.7504, 2.43, 0.251, 425, 235, CHICKEN SRC TYROSINE KINASE
3852, 1j3hA, 0.7504, 2.90, 0.261, 329, 245, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3853, 5n52A, 0.7503, 2.50, 0.280, 268, 236, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(23-DIMETHOXYPHENYL)ACRYLIC ACID
3854, 5mqvA, 0.7503, 3.05, 0.200, 286, 245, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3855, 4dfyE, 0.7503, 3.07, 0.282, 312, 248, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3856, 3qgwA, 0.7503, 2.50, 0.220, 244, 236, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
3857, 3qd2B, 0.7503, 2.61, 0.272, 271, 235, CRSYTAL STRUCTURE OF MOUSE PERK KINASE DOMAIN
3858, 3fupB, 0.7503, 2.84, 0.264, 287, 242, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3859, 2a27C, 0.7503, 2.78, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3860, 5wg4A, 0.7502, 2.97, 0.254, 621, 244, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
3861, 5n87A, 0.7502, 2.52, 0.305, 255, 239, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3862, 5cf8B, 0.7502, 2.80, 0.266, 288, 241, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3863, 4bbeC, 0.7502, 2.92, 0.262, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3864, 3zclA, 0.7502, 2.76, 0.224, 289, 241, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
3865, 3umxA, 0.7502, 2.49, 0.284, 261, 236, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3866, 1ia8A, 0.7502, 2.99, 0.294, 272, 245, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
3867, 6groA, 0.7501, 3.23, 0.204, 293, 250, HUMAN CSNK1G3 BOUND TO SB-223133 
3868, 5w5jB, 0.7501, 2.52, 0.212, 257, 236, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
3869, 4zogA, 0.7501, 3.00, 0.230, 269, 243, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3870, 4hyiA, 0.7501, 3.02, 0.293, 269, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
3871, 2b7aB, 0.7501, 2.84, 0.264, 287, 242, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3872, 2a27A, 0.7501, 2.78, 0.281, 304, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3873, 1iasA, 0.7501, 2.99, 0.224, 330, 241, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3874, 5oq7B, 0.7500, 2.59, 0.294, 256, 238, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3875, 5e1eA, 0.7500, 2.85, 0.261, 279, 241, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3876, 4gmyA, 0.7500, 2.91, 0.258, 298, 244, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3877, 4fk6B, 0.7500, 2.94, 0.258, 284, 244, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3878, 2hxlA, 0.7500, 3.11, 0.293, 272, 246, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
3879, 5vcwA, 0.7499, 2.48, 0.309, 285, 236, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
3880, 5u6yK, 0.7499, 2.93, 0.317, 459, 243, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3881, 5d9hB, 0.7499, 3.30, 0.273, 293, 245, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
3882, 5d9hA, 0.7499, 3.19, 0.275, 290, 244, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
3883, 4kbcB, 0.7499, 2.88, 0.197, 277, 244, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3884, 4bkyA, 0.7499, 2.54, 0.331, 311, 236, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH PYRROLOPYRAZOLE INHIBITOR
3885, 3zc6B, 0.7499, 2.78, 0.268, 276, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
3886, 2a27E, 0.7499, 2.78, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3887, 5vi9A, 0.7498, 2.93, 0.276, 306, 243, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
3888, 5u6yC, 0.7498, 2.92, 0.317, 459, 243, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3889, 4py1A, 0.7498, 3.07, 0.242, 289, 244, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
3890, 4kb8C, 0.7498, 3.19, 0.192, 277, 250, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3891, 3mdyA, 0.7498, 2.84, 0.228, 320, 241, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3892, 2g2hA, 0.7498, 2.95, 0.223, 272, 242, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3893, 2chlA, 0.7498, 3.23, 0.208, 298, 250, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
3894, 5eycA, 0.7497, 2.76, 0.221, 288, 240, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
3895, 4ewhA, 0.7497, 2.90, 0.252, 274, 242, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
3896, 3vquA, 0.7497, 2.67, 0.312, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
3897, 5wg3A, 0.7496, 3.00, 0.234, 618, 244, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG258748
3898, 5friA, 0.7496, 2.62, 0.224, 301, 237, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
3899, 4z3vA, 0.7496, 2.71, 0.200, 271, 240, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
3900, 4hcvA, 0.7496, 2.69, 0.229, 263, 240, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
3901, 4bidB, 0.7496, 2.82, 0.300, 258, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3902, 2wotA, 0.7496, 2.91, 0.221, 303, 240, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
3903, 2w1fA, 0.7496, 2.75, 0.315, 253, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3904, 5op5A, 0.7495, 2.66, 0.289, 259, 239, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3905, 5hx8A, 0.7495, 2.89, 0.269, 291, 242, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3906, 5hesB, 0.7495, 2.58, 0.261, 278, 234, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
3907, 4aoiA, 0.7495, 2.77, 0.224, 289, 241, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
3908, 3dk7B, 0.7495, 3.08, 0.235, 268, 243, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3909, 2y7jB, 0.7495, 2.77, 0.295, 281, 241, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3910, 5n84A, 0.7494, 2.56, 0.314, 256, 239, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
3911, 5n51A, 0.7494, 2.51, 0.280, 268, 236, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIBROMOTHIOPHENE-2-CARBOXYLIC ACID
3912, 4x2fA, 0.7494, 2.83, 0.221, 303, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3913, 4umrA, 0.7494, 2.77, 0.320, 313, 241, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3914, 4fg9A, 0.7494, 2.85, 0.278, 278, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
3915, 4bl1A, 0.7494, 2.56, 0.331, 312, 236, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH AMP-PNP
3916, 3tjcB, 0.7494, 2.85, 0.264, 287, 242, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3917, 3iecD, 0.7494, 2.62, 0.325, 311, 237, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3918, 1snuA, 0.7494, 2.50, 0.225, 245, 236, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
3919, 4xv2A, 0.7493, 2.45, 0.214, 247, 234, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
3920, 4lg4F, 0.7493, 2.95, 0.296, 276, 247, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3921, 4debA, 0.7493, 2.79, 0.315, 264, 241, AURORA A IN COMPLEX WITH RK2-17-01
3922, 2bzkB, 0.7493, 2.45, 0.272, 268, 235, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE
3923, 2a27F, 0.7493, 2.78, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3924, 6babB, 0.7492, 2.74, 0.324, 285, 238, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3925, 5vd1A, 0.7492, 2.49, 0.309, 295, 236, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3926, 5tq7A, 0.7492, 2.97, 0.263, 275, 243, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3927, 5cf8A, 0.7492, 2.79, 0.266, 285, 241, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3928, 4bbeB, 0.7492, 2.94, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3929, 3u6iA, 0.7492, 2.95, 0.206, 281, 243, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
3930, 3lpbB, 0.7492, 2.82, 0.266, 284, 241, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3931, 3bprD, 0.7492, 2.54, 0.225, 259, 236, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
3932, 3bprB, 0.7492, 2.59, 0.229, 256, 236, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
3933, 2y0aA, 0.7492, 2.89, 0.284, 300, 243, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
3934, 2a27H, 0.7492, 2.79, 0.281, 304, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3935, 1iasC, 0.7492, 2.92, 0.225, 330, 240, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3936, 4e3cD, 0.7491, 3.19, 0.278, 624, 248, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3937, 3wzkA, 0.7491, 2.61, 0.310, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
3938, 3kulA, 0.7491, 2.64, 0.205, 267, 239, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3939, 3iecB, 0.7491, 2.69, 0.326, 313, 239, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3940, 2j0kB, 0.7491, 2.68, 0.250, 612, 240, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
3941, 1k9aB, 0.7491, 2.73, 0.238, 441, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3942, 5u6yI, 0.7490, 2.98, 0.317, 459, 243, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3943, 5ap0A, 0.7490, 2.49, 0.311, 254, 238, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3944, 4zlzA, 0.7490, 2.73, 0.200, 270, 240, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
3945, 4p7eB, 0.7490, 2.90, 0.264, 285, 242, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3946, 3wzjA, 0.7490, 2.53, 0.303, 257, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
3947, 3u6hA, 0.7490, 2.91, 0.207, 280, 242, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
3948, 3rzfA, 0.7490, 3.12, 0.291, 541, 247, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPAB KINASE BETA (I4122)
3949, 3lpbA, 0.7490, 2.84, 0.266, 278, 241, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3950, 3hmpA, 0.7490, 2.57, 0.310, 258, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
3951, 3dk3B, 0.7490, 3.09, 0.235, 269, 243, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3952, 1wmkD, 0.7490, 2.88, 0.280, 314, 243, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3953, 1wmkB, 0.7490, 2.87, 0.280, 314, 243, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3954, 1rw8A, 0.7490, 2.79, 0.222, 301, 239, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
3955, 1omwA, 0.7490, 3.08, 0.232, 614, 246, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
3956, 5hieB, 0.7489, 2.70, 0.218, 259, 238, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3957, 5g1xA, 0.7489, 2.86, 0.315, 262, 241, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
3958, 5ap4A, 0.7489, 2.47, 0.312, 257, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3959, 4gl9B, 0.7489, 2.85, 0.260, 280, 242, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
3960, 3iecC, 0.7489, 2.61, 0.325, 311, 237, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3961, 2c3kA, 0.7489, 2.86, 0.293, 262, 242, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3962, 5wo4A, 0.7488, 2.91, 0.269, 292, 242, JAK1 COMPLEXED WITH COMPOUND 28
3963, 4xhgA, 0.7488, 3.32, 0.167, 357, 251, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
3964, 4gj2A, 0.7488, 3.08, 0.238, 288, 244, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3965, 4bidA, 0.7488, 2.67, 0.302, 254, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3966, 2w1gA, 0.7488, 2.78, 0.315, 254, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3967, 2hziA, 0.7488, 2.96, 0.240, 268, 242, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3968, 2a27G, 0.7488, 2.80, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3969, 1kobA, 0.7488, 2.89, 0.251, 352, 243, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3970, 4itjB, 0.7487, 2.97, 0.222, 276, 243, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3971, 4d28A, 0.7487, 2.56, 0.329, 274, 237, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
3972, 3zc6A, 0.7487, 3.00, 0.260, 277, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
3973, 3tjcA, 0.7487, 2.85, 0.264, 284, 242, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3974, 3bprC, 0.7487, 2.56, 0.225, 259, 236, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
3975, 2a27D, 0.7487, 2.80, 0.281, 304, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3976, 4usfA, 0.7486, 3.25, 0.285, 277, 249, HUMAN SLK WITH SB-440719
3977, 4gihA, 0.7486, 3.08, 0.238, 288, 244, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
3978, 3t9tA, 0.7486, 2.60, 0.202, 263, 238, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
3979, 2hxqA, 0.7486, 3.02, 0.294, 272, 245, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
3980, 2b7aA, 0.7486, 2.86, 0.264, 284, 242, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3981, 1wmkG, 0.7486, 2.88, 0.280, 313, 243, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3982, 1wmkE, 0.7486, 2.88, 0.280, 313, 243, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3983, 1wmkC, 0.7486, 2.88, 0.280, 303, 243, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3984, 1wmkA, 0.7486, 2.88, 0.280, 303, 243, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3985, 1iasE, 0.7486, 2.92, 0.225, 330, 240, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3986, 4x3fB, 0.7485, 2.44, 0.262, 278, 237, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
3987, 4umuA, 0.7485, 2.79, 0.314, 316, 239, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3988, 4qygB, 0.7485, 2.89, 0.293, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3989, 3fupA, 0.7485, 2.85, 0.264, 284, 242, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3990, 1wmkH, 0.7485, 2.88, 0.280, 304, 243, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3991, 1wmkF, 0.7485, 2.88, 0.280, 303, 243, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3992, 1tkiB, 0.7485, 3.27, 0.223, 321, 247, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3993, 6d1zA, 0.7484, 2.92, 0.235, 290, 243, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
3994, 5l2qB, 0.7484, 2.83, 0.203, 282, 241, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3995, 4qyhB, 0.7484, 2.90, 0.293, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3996, 4hgeA, 0.7484, 2.83, 0.264, 284, 242, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3997, 4bbfC, 0.7484, 2.97, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3998, 4bbfB, 0.7484, 2.96, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3999, 2x4fA, 0.7484, 2.68, 0.286, 289, 238, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
4000, 2j0mB, 0.7484, 2.67, 0.243, 257, 239, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
4001, 5k0xA, 0.7483, 2.34, 0.232, 258, 233, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2541
4002, 5e90A, 0.7483, 2.83, 0.222, 303, 239, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
4003, 4lqsA, 0.7483, 2.88, 0.281, 372, 242, CRYSTAL STRUCTURE OF THE CBK1-MOB2 KINASE-COACTIVATOR COMPLEX
4004, 4hviA, 0.7483, 2.79, 0.259, 274, 239, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
4005, 4gl9D, 0.7483, 2.87, 0.260, 282, 242, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4006, 4ewhB, 0.7483, 2.83, 0.253, 273, 241, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
4007, 2yexA, 0.7483, 2.92, 0.288, 269, 243, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
4008, 2wd1A, 0.7483, 2.86, 0.224, 289, 241, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
4009, 6d20A, 0.7482, 2.93, 0.235, 296, 243, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
4010, 5vczA, 0.7482, 2.51, 0.309, 294, 236, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
4011, 5e8tA, 0.7482, 2.88, 0.221, 302, 240, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
4012, 4x2nA, 0.7482, 2.84, 0.221, 303, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4013, 4x0mA, 0.7482, 2.84, 0.221, 303, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4014, 3sxsA, 0.7482, 2.73, 0.221, 264, 240, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
4015, 3lzbA, 0.7482, 2.69, 0.217, 265, 240, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
4016, 2x9eA, 0.7482, 2.50, 0.312, 253, 237, HUMAN MPS1 IN COMPLEX WITH NMS-P715
4017, 2j7tA, 0.7482, 2.67, 0.324, 285, 238, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4018, 6dkiA, 0.7481, 2.83, 0.236, 279, 242, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
4019, 4x2gA, 0.7481, 2.84, 0.221, 303, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4020, 4ll0B, 0.7481, 2.80, 0.216, 281, 241, EGFR L858R/T790M IN COMPLEX WITH PD168393
4021, 3kcfC, 0.7481, 2.94, 0.225, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4022, 3eqrB, 0.7481, 2.79, 0.254, 271, 240, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
4023, 6b8yA, 0.7480, 2.85, 0.221, 304, 240, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
4024, 5te0A, 0.7480, 2.80, 0.255, 316, 239, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
4025, 4xyfA, 0.7480, 2.87, 0.220, 290, 241, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
4026, 4fsnA, 0.7480, 2.85, 0.290, 270, 241, CRYSTAL STRUCTURE OF THE CHK1
4027, 2z8cA, 0.7480, 3.08, 0.209, 297, 244, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
4028, 1ol5A, 0.7480, 2.76, 0.318, 263, 239, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
4029, 5fbnD, 0.7479, 2.67, 0.201, 255, 239, BTK KINASE DOMAIN WITH INHIBITOR 1
4030, 4ivbB, 0.7479, 2.87, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
4031, 4fg8A, 0.7479, 2.45, 0.289, 263, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4032, 3eqrA, 0.7479, 2.98, 0.251, 270, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
4033, 2a27B, 0.7479, 2.81, 0.281, 303, 242, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
4034, 4zjvB, 0.7478, 2.85, 0.212, 273, 241, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
4035, 4e6dB, 0.7478, 2.83, 0.270, 286, 241, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4036, 4asxA, 0.7478, 2.78, 0.235, 310, 238, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
4037, 3zxzA, 0.7478, 2.78, 0.224, 289, 241, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
4038, 3wyxA, 0.7478, 2.71, 0.312, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4039, 2wzjE, 0.7478, 2.52, 0.316, 310, 237, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4040, 5fbnC, 0.7477, 2.71, 0.200, 256, 240, BTK KINASE DOMAIN WITH INHIBITOR 1
4041, 5eh0A, 0.7477, 2.58, 0.318, 258, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4042, 5cswB, 0.7477, 2.57, 0.217, 252, 235, B-RAF IN COMPLEX WITH DABRAFENIB
4043, 4p7eA, 0.7477, 2.86, 0.264, 281, 242, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
4044, 4mhaA, 0.7477, 2.34, 0.227, 256, 233, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1817
4045, 4hgeB, 0.7477, 2.88, 0.264, 288, 242, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4046, 3zbxA, 0.7477, 2.78, 0.224, 282, 241, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
4047, 2rfsA, 0.7477, 2.76, 0.228, 264, 237, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
4048, 2cgwA, 0.7477, 2.87, 0.292, 262, 243, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4049, 1tkiA, 0.7477, 3.19, 0.224, 321, 246, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
4050, 5hieA, 0.7476, 2.68, 0.219, 258, 237, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4051, 5f1zA, 0.7476, 2.74, 0.231, 281, 238, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4052, 3q6wA, 0.7476, 3.23, 0.219, 297, 247, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
4053, 1csnA, 0.7476, 3.22, 0.189, 293, 249, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
4054, 1bygA, 0.7476, 2.59, 0.230, 246, 235, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
4055, 5usqA, 0.7475, 2.75, 0.223, 299, 238, ALK-5 KINASE INHIBITOR COMPLEX
4056, 5o12A, 0.7475, 2.43, 0.278, 264, 234, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4057, 4zy5A, 0.7475, 2.84, 0.270, 283, 241, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
4058, 4l7sB, 0.7475, 2.53, 0.232, 250, 237, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4059, 4bf2A, 0.7475, 2.54, 0.313, 253, 233, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4060, 2yerA, 0.7475, 2.87, 0.289, 268, 242, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
4061, 2w1eA, 0.7475, 2.78, 0.315, 252, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4062, 2hziB, 0.7475, 2.95, 0.241, 264, 241, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
4063, 1koaA, 0.7475, 3.14, 0.245, 447, 245, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
4064, 1fmkA, 0.7475, 2.76, 0.262, 437, 240, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
4065, 5ukkA, 0.7474, 3.16, 0.232, 613, 246, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
4066, 4ymjA, 0.7474, 2.88, 0.240, 270, 242, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4067, 4hgtA, 0.7474, 2.91, 0.198, 283, 243, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4068, 4gj3A, 0.7474, 3.10, 0.234, 288, 244, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
4069, 4bbeD, 0.7474, 2.95, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
4070, 3f66A, 0.7474, 2.93, 0.210, 288, 243, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4071, 3dk7A, 0.7474, 2.93, 0.237, 265, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4072, 3d7uC, 0.7474, 2.75, 0.243, 257, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4073, 3d7uA, 0.7474, 2.75, 0.243, 257, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4074, 2e9oA, 0.7474, 2.93, 0.293, 269, 242, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
4075, 1k9aA, 0.7474, 2.75, 0.238, 439, 239, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4076, 4pmmA, 0.7473, 2.94, 0.230, 285, 243, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
4077, 4g9rA, 0.7473, 2.79, 0.208, 262, 240, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
4078, 4g16A, 0.7473, 3.30, 0.188, 302, 250, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
4079, 4bbeA, 0.7473, 2.96, 0.258, 288, 244, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
4080, 3gqiA, 0.7473, 3.06, 0.238, 304, 244, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4081, 3fe3B, 0.7473, 2.77, 0.331, 317, 242, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4082, 2wgjA, 0.7473, 2.79, 0.224, 289, 241, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
4083, 2j0kA, 0.7473, 2.91, 0.244, 598, 242, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4084, 4qo9B, 0.7472, 2.99, 0.235, 285, 243, MST3 IN COMPLEX WITH DANUSERTIB
4085, 4ivcB, 0.7472, 2.87, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4086, 4e6dA, 0.7472, 2.82, 0.270, 286, 241, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4087, 4ap7A, 0.7472, 2.79, 0.224, 289, 241, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
4088, 3zhpD, 0.7472, 2.94, 0.254, 264, 244, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4089, 3nz0A, 0.7472, 2.95, 0.237, 285, 241, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
4090, 3gniB, 0.7472, 2.69, 0.254, 304, 240, STRUCTURE OF STRAD AND MO25
4091, 2g2hB, 0.7472, 3.05, 0.235, 272, 243, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
4092, 5jfsA, 0.7471, 2.76, 0.229, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
4093, 4x2kA, 0.7471, 2.86, 0.221, 303, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4094, 4x2jA, 0.7471, 2.86, 0.221, 303, 240, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4095, 4w9wA, 0.7471, 2.80, 0.268, 306, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
4096, 4rfmA, 0.7471, 2.58, 0.214, 249, 238, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
4097, 3w1fA, 0.7471, 2.69, 0.308, 259, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4098, 2aypA, 0.7471, 2.87, 0.293, 268, 242, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
4099, 5u6yL, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4100, 5u6yJ, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4101, 5u6yH, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4102, 5u6yG, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4103, 5u6yF, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4104, 5u6yE, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4105, 5u6yD, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4106, 5u6yB, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4107, 5u6yA, 0.7470, 2.85, 0.320, 459, 241, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4108, 5mqvB, 0.7470, 3.05, 0.196, 287, 245, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4109, 5imeA, 0.7470, 2.77, 0.293, 280, 239, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4110, 5grnA, 0.7470, 3.08, 0.216, 285, 245, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
4111, 5e8sA, 0.7470, 2.65, 0.224, 301, 237, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
4112, 4zogB, 0.7470, 3.06, 0.230, 268, 243, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
4113, 4ft3A, 0.7470, 2.75, 0.296, 269, 240, CRYSTAL STRUCTURE OF THE CHK1
4114, 4e4lD, 0.7470, 2.91, 0.264, 281, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4115, 3kcfB, 0.7470, 2.85, 0.226, 324, 239, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4116, 1kobB, 0.7470, 2.93, 0.251, 352, 243, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
4117, 4w9xA, 0.7469, 2.76, 0.269, 300, 238, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
4118, 4rvkA, 0.7469, 2.90, 0.293, 264, 242, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
4119, 4r1vA, 0.7469, 2.82, 0.220, 289, 241, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
4120, 4qygA, 0.7469, 2.95, 0.293, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4121, 4qyeA, 0.7469, 2.90, 0.293, 271, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
4122, 4js8A, 0.7469, 2.62, 0.310, 259, 239, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4123, 4asxB, 0.7469, 3.01, 0.237, 307, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
4124, 3hmmA, 0.7469, 2.67, 0.224, 293, 237, STRUCTURE OF ALK5 + GW855857
4125, 2c6dA, 0.7469, 2.88, 0.303, 254, 241, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
4126, 6b16A, 0.7468, 2.85, 0.269, 285, 242, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
4127, 5w4wD, 0.7468, 3.11, 0.194, 287, 248, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4128, 5usyA, 0.7468, 2.93, 0.267, 287, 243, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
4129, 5jh6A, 0.7468, 2.79, 0.294, 288, 238, CRYSTAL STRUCTURE OF TL10-92 BOUND TO TAK1-TAB1
4130, 5ehlA, 0.7468, 2.68, 0.324, 258, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4131, 4k6zA, 0.7468, 2.91, 0.261, 279, 241, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
4132, 4cqeA, 0.7468, 2.58, 0.216, 250, 236, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4133, 3vapA, 0.7468, 2.73, 0.305, 249, 239, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
4134, 6eimB, 0.7467, 2.74, 0.322, 295, 239, HUMAN STK10 BOUND TO GW683134A
4135, 4i21A, 0.7467, 2.83, 0.216, 290, 241, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
4136, 3socB, 0.7467, 3.04, 0.237, 309, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4137, 3qgyA, 0.7467, 2.49, 0.221, 246, 235, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4138, 3q4tB, 0.7467, 2.81, 0.235, 308, 238, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4139, 2z60A, 0.7467, 3.12, 0.239, 281, 243, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
4140, 1zycA, 0.7467, 3.09, 0.266, 261, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4141, 5wnlA, 0.7466, 2.62, 0.223, 262, 238, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO STAUROSPORINE 
4142, 5ih8A, 0.7466, 2.59, 0.331, 306, 236, MELK IN COMPLEX WITH NVS-MELK1
4143, 4lrmA, 0.7466, 3.21, 0.210, 307, 248, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4144, 4hgsA, 0.7466, 3.30, 0.188, 302, 250, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
4145, 3kcfD, 0.7466, 3.06, 0.224, 330, 241, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4146, 3dk3A, 0.7466, 2.95, 0.237, 266, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4147, 2xzsA, 0.7466, 2.82, 0.285, 301, 242, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
4148, 2w5aA, 0.7466, 2.74, 0.281, 267, 242, HUMAN NEK2 KINASE ADP-BOUND
4149, 1m52A, 0.7466, 3.06, 0.235, 271, 243, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
4150, 4j8nB, 0.7465, 2.89, 0.314, 266, 242, AURORA A KINASE APO
4151, 3kulB, 0.7465, 2.84, 0.203, 271, 241, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
4152, 2qohA, 0.7465, 3.04, 0.236, 271, 242, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
4153, 5wg5A, 0.7464, 2.84, 0.252, 617, 242, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224061
4154, 4kbaA, 0.7464, 3.03, 0.200, 263, 245, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4155, 4j8nC, 0.7464, 2.89, 0.314, 266, 242, AURORA A KINASE APO
4156, 4ehzA, 0.7464, 2.97, 0.259, 290, 243, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4157, 3og7A, 0.7464, 2.48, 0.215, 247, 233, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4158, 2wqmA, 0.7464, 2.58, 0.306, 258, 235, STRUCTURE OF APO HUMAN NEK7
4159, 2brnA, 0.7464, 3.08, 0.273, 268, 245, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4160, 5mqvE, 0.7463, 3.06, 0.196, 287, 245, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4161, 4qrcA, 0.7463, 2.86, 0.256, 297, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
4162, 4k77B, 0.7463, 2.89, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4163, 4j8nD, 0.7463, 2.90, 0.314, 265, 242, AURORA A KINASE APO
4164, 4j8nA, 0.7463, 2.89, 0.314, 266, 242, AURORA A KINASE APO
4165, 4g17A, 0.7463, 3.30, 0.188, 302, 250, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
4166, 1zydB, 0.7463, 2.89, 0.283, 253, 240, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
4167, 5l3aA, 0.7462, 2.98, 0.258, 290, 244, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
4168, 4ivbA, 0.7462, 2.90, 0.266, 291, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
4169, 4e20A, 0.7462, 3.13, 0.239, 282, 243, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
4170, 1u4dB, 0.7462, 2.52, 0.264, 262, 235, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
4171, 1f3mC, 0.7462, 3.22, 0.266, 287, 248, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4172, 6cqhB, 0.7461, 3.19, 0.136, 316, 250, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4173, 5bmmB, 0.7461, 2.72, 0.251, 275, 239, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
4174, 4hglA, 0.7461, 3.31, 0.188, 302, 250, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
4175, 4giiA, 0.7461, 3.11, 0.234, 289, 244, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
4176, 3zhpC, 0.7461, 2.93, 0.251, 272, 243, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4177, 1u59A, 0.7461, 2.97, 0.225, 282, 244, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
4178, 6babC, 0.7460, 2.66, 0.321, 284, 237, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
4179, 5p9jA, 0.7460, 2.75, 0.200, 263, 240, BTK1 COCRYSTALLIZED WITH IBRUTINIB
4180, 5mqvD, 0.7460, 3.07, 0.196, 287, 245, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4181, 4lrmC, 0.7460, 2.92, 0.223, 293, 242, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4182, 4ivdB, 0.7460, 2.89, 0.261, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4183, 3zc5A, 0.7460, 2.81, 0.224, 289, 241, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
4184, 5wo4B, 0.7459, 2.91, 0.266, 280, 241, JAK1 COMPLEXED WITH COMPOUND 28
4185, 5jrqB, 0.7459, 2.33, 0.222, 246, 230, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4186, 5e8zA, 0.7459, 2.86, 0.222, 303, 239, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
4187, 3zepD, 0.7459, 2.88, 0.264, 272, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4188, 1x8bA, 0.7459, 2.49, 0.239, 259, 234, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
4189, 5csxA, 0.7458, 2.88, 0.203, 261, 241, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
4190, 4c3rA, 0.7458, 2.77, 0.317, 252, 240, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
4191, 6fckA, 0.7457, 2.94, 0.288, 269, 243, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
4192, 5bmmA, 0.7457, 2.73, 0.251, 275, 239, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
4193, 4z16B, 0.7457, 2.90, 0.267, 276, 240, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4194, 4pmpA, 0.7457, 3.02, 0.230, 280, 243, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
4195, 3q4uB, 0.7457, 2.90, 0.247, 300, 239, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4196, 3q4tA, 0.7457, 3.05, 0.237, 305, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4197, 3ma3A, 0.7457, 2.56, 0.280, 266, 236, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
4198, 3gopA, 0.7457, 2.74, 0.180, 300, 239, CRYSTAL STRUCTURE OF THE EGF RECEPTOR JUXTAMEMBRANE AND KINASE DOMAINS
4199, 2ywpA, 0.7457, 2.96, 0.293, 269, 242, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
4200, 2p2iA, 0.7457, 3.01, 0.230, 289, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4201, 4wd5A, 0.7456, 2.99, 0.222, 307, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
4202, 3wyyA, 0.7456, 2.75, 0.317, 258, 240, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4203, 1m52B, 0.7456, 3.17, 0.230, 272, 244, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
4204, 6cz3A, 0.7455, 2.65, 0.269, 262, 238, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE I INHIBITOR (3- FLUORO-4-{[6-METHYL-3-(1H-PYRAZOL-4-YL)IMIDAZO[1;2-A]PYRAZIN-8- YL]AMINO}PHENYL)(MORPHOLIN-4-YL)METHANONE 
4205, 5p9kA, 0.7455, 2.76, 0.200, 271, 240, CRYSTAL STRUCTURE OF BTK WITH CNX 774
4206, 5ootA, 0.7455, 2.80, 0.296, 260, 240, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4207, 5ehoA, 0.7455, 2.55, 0.319, 258, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4208, 5oq5A, 0.7454, 2.93, 0.305, 265, 243, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4209, 5ei6A, 0.7454, 2.62, 0.321, 264, 240, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4210, 4rwiA, 0.7454, 3.08, 0.241, 305, 245, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
4211, 4i5cA, 0.7454, 2.91, 0.261, 279, 241, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4212, 3a7gB, 0.7454, 3.09, 0.287, 290, 247, HUMAN MST3 KINASE
4213, 2csnA, 0.7454, 3.18, 0.194, 293, 248, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
4214, 1u4dA, 0.7454, 2.69, 0.257, 258, 237, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
4215, 5jznA, 0.7453, 2.61, 0.297, 268, 236, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
4216, 3uo4A, 0.7453, 2.87, 0.314, 266, 242, AURORA A IN COMPLEX WITH RPM1680
4217, 3r7oA, 0.7453, 3.18, 0.220, 299, 246, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
4218, 4ftuA, 0.7452, 2.91, 0.303, 270, 241, CRYSTAL STRUCTURE OF THE CHK1
4219, 4dfyA, 0.7452, 3.04, 0.285, 310, 246, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4220, 4dehA, 0.7452, 2.83, 0.222, 286, 239, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
4221, 3tkiA, 0.7452, 2.94, 0.293, 272, 242, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
4222, 3sv0A, 0.7452, 3.25, 0.190, 294, 247, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
4223, 2wzjA, 0.7452, 2.47, 0.322, 310, 236, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4224, 1oplB, 0.7452, 2.95, 0.237, 365, 241, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4225, 5opsA, 0.7451, 2.63, 0.287, 258, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4226, 5hieD, 0.7451, 2.80, 0.211, 253, 237, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4227, 4rwkA, 0.7451, 3.10, 0.241, 308, 245, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
4228, 4ludA, 0.7451, 2.47, 0.249, 421, 233, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4229, 4d1sA, 0.7451, 2.89, 0.260, 280, 242, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
4230, 4cqgA, 0.7451, 2.63, 0.326, 313, 236, THE CRYSTAL STRUCTURE OF MPK38 IN COMPLEX WITH OTSSP167 AN ORALLY-ADMINISTRATIVE MELK SELECTIVE INHIBITOR
4231, 4bfmA, 0.7451, 2.66, 0.326, 313, 236, THE CRYSTAL STRUCTURE OF MOUSE PK38
4232, 3up7A, 0.7451, 2.80, 0.317, 264, 240, AURORA A IN COMPLEX WITH YL1-038-09
4233, 3ha6A, 0.7451, 2.84, 0.308, 263, 240, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
4234, 2iztA, 0.7451, 3.26, 0.205, 296, 249, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4235, 1t46A, 0.7451, 3.00, 0.239, 297, 243, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
4236, 1p4fA, 0.7451, 2.53, 0.295, 269, 234, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
4237, 1opkA, 0.7451, 3.10, 0.231, 449, 242, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4238, 6cz2A, 0.7450, 2.65, 0.273, 261, 238, STRUCTURE OF THE PTK6 KINASE DOMAIN 
4239, 5w4wA, 0.7450, 3.32, 0.191, 291, 251, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4240, 5tq6A, 0.7450, 2.91, 0.266, 274, 241, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4241, 5hibA, 0.7450, 3.22, 0.210, 314, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4242, 4rvmA, 0.7450, 2.93, 0.293, 264, 242, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
4243, 4qyhA, 0.7450, 2.98, 0.293, 264, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4244, 4e3cA, 0.7450, 3.30, 0.274, 624, 248, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4245, 3qa8C, 0.7450, 3.13, 0.289, 622, 246, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4246, 2z2wA, 0.7450, 2.56, 0.238, 260, 235, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
4247, 5w4wB, 0.7449, 3.33, 0.191, 291, 251, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4248, 5kz8A, 0.7449, 2.70, 0.322, 302, 239, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4249, 5fqdF, 0.7449, 3.18, 0.201, 294, 249, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
4250, 5f20A, 0.7449, 2.69, 0.237, 274, 236, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4251, 4zsaA, 0.7449, 3.07, 0.237, 289, 245, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
4252, 4ymjB, 0.7449, 2.87, 0.241, 275, 241, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4253, 4jnwA, 0.7449, 3.25, 0.224, 320, 246, BACTERIALLY EXPRESSED TITIN KINASE
4254, 4ftiA, 0.7449, 2.94, 0.293, 270, 242, CRYSTAL STRUCTURE OF THE CHK1
4255, 4cv9A, 0.7449, 2.59, 0.311, 254, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4256, 3qa8E, 0.7449, 3.13, 0.289, 622, 246, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4257, 3mdyC, 0.7449, 2.76, 0.227, 320, 238, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4258, 3kcfA, 0.7449, 2.92, 0.226, 328, 239, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4259, 3cqeA, 0.7449, 2.56, 0.238, 258, 235, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
4260, 2x0gA, 0.7449, 2.83, 0.285, 318, 242, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
4261, 2e9vA, 0.7449, 2.88, 0.295, 268, 241, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4262, 5usyB, 0.7448, 2.94, 0.263, 287, 243, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
4263, 5oopA, 0.7448, 2.87, 0.298, 261, 242, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
4264, 4bi0A, 0.7448, 2.51, 0.316, 254, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4265, 5vcxA, 0.7447, 2.60, 0.309, 287, 236, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
4266, 4x3fC, 0.7447, 2.53, 0.286, 273, 238, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
4267, 4gu6A, 0.7447, 2.79, 0.249, 271, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4268, 4e3cC, 0.7447, 3.35, 0.277, 624, 249, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4269, 5opvA, 0.7446, 2.76, 0.289, 261, 239, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4270, 5jfvA, 0.7446, 2.78, 0.229, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
4271, 5j8iA, 0.7446, 2.86, 0.289, 288, 239, CRYSTAL STRUCTURE OF TL11-113 BOUND TO TAK1-TAB1
4272, 4u0iA, 0.7446, 3.02, 0.239, 297, 243, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
4273, 4tn6B, 0.7446, 3.22, 0.188, 285, 250, CK1D IN COMPLEX WITH INHIBITOR
4274, 4bieB, 0.7446, 2.80, 0.307, 257, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4275, 3qa8D, 0.7446, 3.18, 0.283, 622, 247, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4276, 3og7B, 0.7446, 2.70, 0.223, 254, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4277, 2c30A, 0.7446, 3.05, 0.248, 289, 242, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
4278, 4uwcB, 0.7445, 3.07, 0.237, 301, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
4279, 4knbA, 0.7445, 2.73, 0.223, 273, 238, C-MET IN COMPLEX WITH OSI LIGAND
4280, 4ei4B, 0.7445, 2.92, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4281, 4e3cB, 0.7445, 3.28, 0.274, 632, 248, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4282, 2brbA, 0.7445, 3.17, 0.293, 272, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4283, 4o6lB, 0.7444, 2.58, 0.304, 256, 237, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4284, 4hniA, 0.7444, 2.86, 0.203, 284, 241, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4285, 3uytB, 0.7444, 3.17, 0.197, 286, 249, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4286, 3kfaB, 0.7444, 3.16, 0.230, 284, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4287, 3i6uB, 0.7444, 2.56, 0.297, 376, 232, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
4288, 2e9uA, 0.7444, 2.96, 0.293, 269, 242, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
4289, 6gipA, 0.7443, 2.82, 0.241, 296, 237, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 2; 5-DIMETHYL CORE. 
4290, 6fdzU, 0.7443, 2.91, 0.353, 265, 241, UNC-51-LIKE KINASE 3 (ULK3) IN COMPLEX WITH MOMELOTINIB 
4291, 6b2qD, 0.7443, 2.55, 0.281, 259, 235, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4292, 5p9mA, 0.7443, 2.73, 0.201, 271, 239, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
4293, 5ar8A, 0.7443, 2.42, 0.241, 255, 232, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4294, 4k77A, 0.7443, 2.93, 0.266, 282, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4295, 4fk6A, 0.7443, 2.93, 0.256, 285, 242, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
4296, 3tzmA, 0.7443, 2.64, 0.225, 295, 236, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
4297, 3cr0A, 0.7443, 2.52, 0.239, 257, 234, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
4298, 2welA, 0.7443, 2.83, 0.321, 304, 240, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
4299, 2dq7X, 0.7443, 2.76, 0.249, 262, 237, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4300, 2br1A, 0.7443, 3.10, 0.294, 272, 245, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4301, 5n7vA, 0.7442, 2.59, 0.318, 260, 239, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4302, 5k9iA, 0.7442, 2.62, 0.249, 258, 237, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4303, 5fqdC, 0.7442, 3.19, 0.201, 294, 249, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
4304, 4lqqA, 0.7442, 2.87, 0.278, 388, 241, CRYSTAL STRUCTURE OF THE CBK1(T743E)-MOB2 KINASE-COACTIVATOR COMPLEX IN CRYSTAL FORM B
4305, 4fgbA, 0.7442, 2.87, 0.287, 282, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
4306, 4bggB, 0.7442, 2.74, 0.242, 293, 236, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4307, 3iecA, 0.7442, 2.69, 0.329, 311, 237, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
4308, 2w1dA, 0.7442, 2.80, 0.317, 251, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4309, 5vndB, 0.7441, 3.08, 0.237, 295, 245, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
4310, 5u9dA, 0.7441, 2.80, 0.200, 271, 240, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
4311, 5na0A, 0.7441, 2.58, 0.308, 253, 237, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4312, 5jznB, 0.7441, 2.58, 0.309, 266, 236, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
4313, 4e4nB, 0.7441, 2.93, 0.266, 280, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4314, 4czuD, 0.7441, 2.87, 0.307, 302, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4315, 4bggA, 0.7441, 2.73, 0.242, 296, 236, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4316, 3tacA, 0.7441, 3.04, 0.276, 324, 243, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
4317, 3nczB, 0.7441, 2.86, 0.270, 379, 241, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
4318, 3faaD, 0.7441, 3.08, 0.224, 330, 241, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4319, 3dk6A, 0.7441, 2.90, 0.243, 262, 239, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4320, 2ivsA, 0.7441, 3.10, 0.252, 284, 242, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4321, 1uwjA, 0.7441, 2.97, 0.203, 264, 241, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4322, 1fotA, 0.7441, 3.05, 0.233, 299, 245, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
4323, 5jfxA, 0.7440, 2.78, 0.229, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
4324, 5ew8A, 0.7440, 3.09, 0.237, 291, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
4325, 5am6B, 0.7440, 2.97, 0.239, 280, 243, NATIVE FGFR1 WITH AN INHIBITOR
4326, 4ntsA, 0.7440, 3.02, 0.266, 341, 244, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
4327, 4m15A, 0.7440, 2.73, 0.209, 263, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
4328, 4jnwB, 0.7440, 3.24, 0.224, 321, 246, BACTERIALLY EXPRESSED TITIN KINASE
4329, 4e3cF, 0.7440, 3.38, 0.273, 624, 249, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4330, 3tjdB, 0.7440, 3.09, 0.262, 287, 244, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4331, 3tjdA, 0.7440, 2.91, 0.264, 284, 242, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4332, 3kfaA, 0.7440, 3.16, 0.234, 284, 244, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4333, 3gqlA, 0.7440, 3.07, 0.237, 287, 245, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4334, 3e5aA, 0.7440, 2.87, 0.308, 264, 240, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
4335, 5p9iA, 0.7439, 2.75, 0.197, 271, 239, BTK1 SOAKED WITH IBRUTINIB-REV
4336, 5jt2A, 0.7439, 2.46, 0.224, 257, 232, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4337, 5ihaA, 0.7439, 2.58, 0.333, 303, 234, MELK IN COMPLEX WITH NVS-MELK8F
4338, 5ct7B, 0.7439, 2.66, 0.203, 254, 236, BRAF IN COMPLEX WITH RAF265
4339, 4kbaB, 0.7439, 3.06, 0.195, 285, 246, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4340, 4g9cB, 0.7439, 3.10, 0.215, 264, 242, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
4341, 4bf2B, 0.7439, 2.66, 0.315, 252, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4342, 3txoA, 0.7439, 2.65, 0.292, 317, 236, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4343, 3qa8G, 0.7439, 3.20, 0.283, 541, 247, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4344, 3mvjB, 0.7439, 3.03, 0.258, 320, 244, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
4345, 2w5bA, 0.7439, 2.80, 0.269, 271, 242, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
4346, 2r0iB, 0.7439, 2.63, 0.325, 300, 237, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4347, 2brmA, 0.7439, 3.14, 0.273, 263, 245, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4348, 5tq7B, 0.7438, 2.91, 0.267, 269, 240, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4349, 5hx8B, 0.7438, 2.94, 0.261, 279, 241, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
4350, 5ehyA, 0.7438, 2.57, 0.315, 255, 238, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4351, 4uwbB, 0.7438, 3.09, 0.237, 299, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
4352, 4q2aA, 0.7438, 2.83, 0.265, 271, 238, WNK1: A CHLORIDE SENSOR VIA AUTOPHOSPHORYLATION
4353, 4fszA, 0.7438, 2.89, 0.283, 268, 240, CRYSTAL STRUCTURE OF THE CHK1
4354, 4c4jA, 0.7438, 2.70, 0.312, 261, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4355, 3ugcA, 0.7438, 3.04, 0.262, 274, 244, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
4356, 3tt0A, 0.7438, 3.07, 0.237, 305, 245, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4357, 3q4uD, 0.7438, 3.03, 0.242, 299, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4358, 5tq6B, 0.7437, 2.89, 0.267, 271, 240, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4359, 5j9lA, 0.7437, 2.83, 0.300, 286, 237, CRYSTAL STRUCTURE OF CPT1691 BOUND TO TAK1-TAB1
4360, 4o0uA, 0.7437, 2.86, 0.310, 259, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4361, 4m13A, 0.7437, 2.73, 0.209, 264, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4362, 4kbkC, 0.7437, 3.08, 0.196, 280, 245, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4363, 4cv8A, 0.7437, 2.61, 0.315, 255, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4364, 3lxpA, 0.7437, 3.11, 0.235, 285, 243, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4365, 3kcfE, 0.7437, 3.00, 0.221, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
4366, 3dajA, 0.7437, 2.52, 0.311, 245, 235, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4367, 2izsA, 0.7437, 3.38, 0.188, 298, 250, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4368, 2e9nA, 0.7437, 2.98, 0.293, 269, 242, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
4369, 6fc8A, 0.7436, 2.96, 0.292, 269, 243, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
4370, 5ikwA, 0.7436, 2.83, 0.268, 297, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4371, 5ew8B, 0.7436, 3.09, 0.237, 290, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
4372, 4kioC, 0.7436, 2.63, 0.223, 251, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4373, 3qa8F, 0.7436, 3.15, 0.289, 622, 246, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4374, 3qa8A, 0.7436, 3.20, 0.283, 622, 247, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4375, 3q4zA, 0.7436, 2.86, 0.267, 282, 240, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4376, 3oriB, 0.7436, 2.87, 0.271, 267, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4377, 6dkgA, 0.7435, 2.89, 0.231, 276, 242, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
4378, 5tehB, 0.7435, 2.67, 0.245, 262, 237, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4379, 5ljjA, 0.7435, 2.70, 0.318, 264, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4380, 4useA, 0.7435, 2.96, 0.320, 286, 241, HUMAN STK10 (LOK) WITH SB-633825
4381, 2xa4A, 0.7435, 2.85, 0.271, 276, 240, INHIBITORS OF JAK2 KINASE DOMAIN
4382, 2bdwB, 0.7435, 2.95, 0.322, 309, 242, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
4383, 1oplA, 0.7435, 2.99, 0.232, 451, 241, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4384, 5vd3A, 0.7434, 2.55, 0.311, 293, 235, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
4385, 4iebA, 0.7434, 2.95, 0.320, 472, 241, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
4386, 4dedA, 0.7434, 2.92, 0.315, 265, 241, AURORA A IN COMPLEX WITH YL1-038-21
4387, 3u4wA, 0.7434, 2.83, 0.262, 275, 240, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
4388, 3dkfA, 0.7434, 2.97, 0.223, 294, 242, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4389, 2hogA, 0.7434, 3.00, 0.302, 272, 242, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
4390, 2c3lA, 0.7434, 2.99, 0.293, 265, 242, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4391, 5wngB, 0.7433, 2.82, 0.289, 365, 239, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4392, 5itaB, 0.7433, 2.74, 0.208, 252, 236, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4393, 5b2lA, 0.7433, 3.30, 0.222, 288, 252, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4394, 4zy6A, 0.7433, 2.86, 0.270, 284, 241, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
4395, 4ivcA, 0.7433, 2.94, 0.266, 291, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4396, 3qa8B, 0.7433, 3.20, 0.283, 622, 247, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4397, 3q4uC, 0.7433, 3.00, 0.242, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4398, 3lcdA, 0.7433, 2.84, 0.221, 290, 240, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
4399, 3hx4A, 0.7433, 2.88, 0.317, 467, 240, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
4400, 5l8lA, 0.7432, 2.83, 0.283, 263, 240, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
4401, 4xv2B, 0.7432, 2.55, 0.209, 249, 234, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
4402, 4riyD, 0.7432, 2.99, 0.223, 297, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4403, 4c4fA, 0.7432, 2.53, 0.308, 254, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4404, 3qa8H, 0.7432, 3.20, 0.283, 541, 247, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4405, 2x7oA, 0.7432, 2.95, 0.225, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4406, 1py5A, 0.7432, 3.08, 0.220, 301, 241, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
4407, 6fekA, 0.7431, 3.07, 0.252, 294, 242, ONCOGENIC POINT MUTATION OF RET RECEPTOR TYROSINE KINASE
4408, 6b4wA, 0.7431, 2.57, 0.315, 259, 238, TTK IN COMPLEX WITH INHIBITOR
4409, 4xmoA, 0.7431, 2.81, 0.209, 289, 239, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
4410, 4fk3B, 0.7431, 2.79, 0.218, 257, 239, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4411, 2x7oD, 0.7431, 2.95, 0.225, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4412, 2rf9A, 0.7431, 2.87, 0.220, 280, 241, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4413, 2bujB, 0.7431, 2.95, 0.258, 286, 240, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
4414, 4z16A, 0.7430, 2.83, 0.265, 271, 238, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4415, 4rwlB, 0.7430, 3.04, 0.234, 285, 244, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4416, 4qyfA, 0.7430, 2.99, 0.302, 269, 242, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
4417, 4gl9C, 0.7430, 2.95, 0.260, 282, 242, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4418, 4ft9A, 0.7430, 2.89, 0.292, 270, 240, CRYSTAL STRUCTURE OF THE CHK1
4419, 4ehzB, 0.7430, 2.97, 0.269, 280, 242, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4420, 3zc6C, 0.7430, 2.73, 0.271, 275, 236, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4421, 2x2kA, 0.7430, 3.09, 0.252, 289, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4422, 5jfwA, 0.7429, 2.80, 0.229, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
4423, 4m12A, 0.7429, 2.76, 0.205, 264, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4424, 4m0zA, 0.7429, 2.75, 0.209, 264, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
4425, 4m0yA, 0.7429, 2.75, 0.209, 263, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
4426, 4g9cA, 0.7429, 2.98, 0.217, 265, 240, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
4427, 3repA, 0.7429, 2.74, 0.168, 268, 238, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
4428, 3js2A, 0.7429, 3.09, 0.237, 295, 245, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
4429, 6drwA, 0.7428, 2.92, 0.261, 289, 241, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
4430, 6ao5A, 0.7428, 2.49, 0.269, 321, 234, CRYSTAL STRUCTURE OF HUMAN MST2 IN COMPLEX WITH SAV1 SARAH DOMAIN
4431, 5vd0A, 0.7428, 2.58, 0.309, 293, 236, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
4432, 5kz8B, 0.7428, 2.77, 0.324, 300, 238, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4433, 5ap3A, 0.7428, 2.54, 0.312, 253, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4434, 4riwD, 0.7428, 2.99, 0.219, 297, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
4435, 4lrmE, 0.7428, 2.88, 0.220, 290, 241, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4436, 4j98B, 0.7428, 3.20, 0.239, 304, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
4437, 4bi1A, 0.7428, 2.48, 0.314, 252, 236, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4438, 4bhnB, 0.7428, 2.83, 0.303, 257, 238, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4439, 3js2B, 0.7428, 3.00, 0.238, 291, 244, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
4440, 2x7oB, 0.7428, 2.96, 0.225, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4441, 2jiiB, 0.7428, 3.22, 0.133, 326, 248, STRUCTURE OF VACCINIA RELATED KINASE 3
4442, 1nvqA, 0.7428, 2.97, 0.293, 264, 242, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
4443, 5xd6A, 0.7427, 2.87, 0.212, 282, 236, CARK1 PHOSPHORYLATES ABA RECEPTORS
4444, 4lg4C, 0.7427, 3.16, 0.301, 288, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4445, 4hniB, 0.7427, 2.81, 0.205, 284, 239, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4446, 4gg7A, 0.7427, 2.82, 0.216, 278, 241, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4447, 4degA, 0.7427, 2.82, 0.223, 286, 238, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
4448, 3uzpB, 0.7427, 2.84, 0.196, 284, 240, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4449, 3u51A, 0.7427, 2.59, 0.242, 256, 236, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4450, 3oriA, 0.7427, 2.81, 0.272, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4451, 3f3zA, 0.7427, 2.86, 0.262, 271, 240, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
4452, 3c4fA, 0.7427, 3.06, 0.230, 290, 244, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
4453, 2bvaB, 0.7427, 2.78, 0.256, 274, 238, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4454, 1uwhA, 0.7427, 3.13, 0.218, 264, 243, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4455, 5xd6B, 0.7426, 2.93, 0.211, 282, 237, CARK1 PHOSPHORYLATES ABA RECEPTORS
4456, 5eobA, 0.7426, 2.96, 0.219, 288, 242, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4457, 5bq0A, 0.7426, 2.79, 0.197, 265, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4458, 4cvaA, 0.7426, 2.60, 0.311, 254, 238, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4459, 4ckiA, 0.7426, 3.11, 0.252, 293, 242, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
4460, 3a7hB, 0.7426, 3.13, 0.264, 290, 246, HUMAN MST3 KINASE IN COMPLEX WITH ATP
4461, 2hy0A, 0.7426, 2.99, 0.293, 272, 242, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
4462, 5a46B, 0.7425, 3.11, 0.237, 297, 245, FGFR1 IN COMPLEX WITH DOVITINIB
4463, 4rixD, 0.7425, 3.02, 0.223, 297, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
4464, 4rixB, 0.7425, 2.92, 0.220, 293, 241, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
4465, 4i5cB, 0.7425, 2.96, 0.261, 291, 241, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4466, 4byjA, 0.7425, 2.53, 0.315, 246, 235, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4467, 3socA, 0.7425, 3.10, 0.237, 307, 241, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4468, 3hkoA, 0.7425, 3.00, 0.266, 319, 244, CRYSTAL STRUCTURE OF A CDPK KINASE DOMAIN FROM CRYPTOSPORIDIUM PARVUM CGD7_40
4469, 5kmjA, 0.7424, 2.91, 0.236, 300, 242, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
4470, 4iwdA, 0.7424, 3.23, 0.220, 299, 246, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
4471, 4fsrA, 0.7424, 2.90, 0.292, 269, 240, CRYSTAL STRUCTURE OF THE CHK1
4472, 4pmsA, 0.7423, 3.01, 0.230, 283, 243, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
4473, 4lueA, 0.7423, 2.65, 0.256, 422, 234, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
4474, 4equB, 0.7423, 2.96, 0.315, 282, 241, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4475, 3fe3A, 0.7423, 2.84, 0.331, 317, 242, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4476, 2xzsB, 0.7423, 3.00, 0.284, 293, 243, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
4477, 2x7oE, 0.7423, 2.96, 0.225, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4478, 2izuA, 0.7423, 3.21, 0.206, 297, 248, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4479, 5khwB, 0.7422, 2.90, 0.271, 276, 240, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4480, 5flfD, 0.7422, 3.24, 0.238, 290, 244, DISEASE LINKED MUTATION IN FGFR
4481, 3kmwA, 0.7422, 2.73, 0.168, 268, 238, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
4482, 3aqvA, 0.7422, 2.80, 0.283, 267, 240, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
4483, 2in6A, 0.7422, 2.59, 0.239, 256, 234, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
4484, 1uwhB, 0.7422, 3.14, 0.214, 264, 243, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4485, 1nvsA, 0.7422, 2.98, 0.293, 264, 242, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
4486, 5w86D, 0.7421, 2.88, 0.264, 272, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4487, 5a4cB, 0.7421, 3.12, 0.237, 286, 245, FGFR1 LIGAND COMPLEX
4488, 4xhlA, 0.7421, 3.12, 0.177, 330, 243, STRUCTURE OF S. CEREVISIAE HRR25 1-394 (K38R MUTANT)
4489, 4jjrB, 0.7421, 3.13, 0.192, 283, 245, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4490, 3c4fB, 0.7421, 3.10, 0.237, 290, 245, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
4491, 2x7oC, 0.7421, 2.96, 0.225, 330, 240, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4492, 2wouA, 0.7421, 2.68, 0.225, 299, 236, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
4493, 2broA, 0.7421, 3.23, 0.272, 272, 246, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4494, 5wnjA, 0.7420, 2.68, 0.224, 264, 237, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH LESTAURTINIB 
4495, 5twzA, 0.7420, 2.64, 0.322, 313, 236, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4496, 5op4A, 0.7420, 2.72, 0.290, 259, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
4497, 4c4eA, 0.7420, 2.57, 0.312, 256, 237, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4498, 3faaE, 0.7420, 3.10, 0.220, 330, 241, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4499, 2j4zA, 0.7420, 2.73, 0.317, 263, 240, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4500, 5oxgB, 0.7419, 2.77, 0.242, 296, 236, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4501, 5am7A, 0.7419, 2.95, 0.232, 294, 241, FGFR1 MUTANT WITH AN INHIBITOR
4502, 4zlyA, 0.7419, 2.81, 0.200, 270, 240, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
4503, 4czuA, 0.7419, 2.94, 0.311, 297, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4504, 4bi2A, 0.7419, 2.54, 0.316, 253, 237, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4505, 4bc6A, 0.7419, 2.97, 0.320, 285, 241, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4506, 3uztA, 0.7419, 2.81, 0.264, 586, 239, STRUCTURE OF THE C13.18 RNA APTAMER IN COMPLEX WITH G PROTEIN-COUPLED RECEPTOR KINASE 2
4507, 3faaB, 0.7419, 2.89, 0.222, 324, 239, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4508, 2ivtA, 0.7419, 3.09, 0.252, 288, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4509, 4ksqA, 0.7418, 3.08, 0.212, 258, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
4510, 3ue4A, 0.7418, 3.14, 0.239, 270, 243, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
4511, 6brcA, 0.7417, 2.78, 0.303, 265, 238, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
4512, 5e8yA, 0.7417, 2.91, 0.238, 298, 239, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
4513, 4zsaB, 0.7417, 2.87, 0.236, 282, 242, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
4514, 4mneB, 0.7417, 2.88, 0.215, 270, 237, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4515, 4li5A, 0.7417, 2.98, 0.224, 306, 241, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
4516, 3ky2A, 0.7417, 3.07, 0.243, 307, 243, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4517, 3dtcA, 0.7417, 2.03, 0.283, 245, 226, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
4518, 3a7gA, 0.7417, 3.21, 0.272, 289, 246, HUMAN MST3 KINASE
4519, 2jiiA, 0.7417, 3.43, 0.132, 321, 250, STRUCTURE OF VACCINIA RELATED KINASE 3
4520, 4m66A, 0.7416, 2.63, 0.277, 268, 235, CRYSTAL STRUCTURE OF THE MOUSE RIP3 KINASE DOMAIN
4521, 4kb8B, 0.7416, 3.10, 0.199, 285, 246, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4522, 4i93A, 0.7416, 2.87, 0.183, 281, 240, STRUCTURE OF THE BSK8 KINASE DOMAIN (SEMET LABELED)
4523, 2j4zB, 0.7416, 2.79, 0.315, 269, 241, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4524, 2c6eA, 0.7416, 2.77, 0.315, 251, 241, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4525, 5vamB, 0.7415, 2.90, 0.217, 260, 240, BRAF IN COMPLEX WITH RAF709
4526, 4m14A, 0.7415, 2.77, 0.209, 263, 239, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
4527, 4j96B, 0.7415, 3.22, 0.239, 305, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
4528, 3vw6B, 0.7415, 2.80, 0.312, 253, 237, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4529, 2hz4B, 0.7415, 2.74, 0.229, 261, 236, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4530, 1uwjB, 0.7415, 3.01, 0.207, 263, 241, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4531, 5wevA, 0.7414, 2.91, 0.257, 293, 241, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
4532, 5oktC, 0.7414, 3.10, 0.191, 285, 246, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
4533, 5o49B, 0.7414, 3.08, 0.234, 286, 244, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4534, 4ft7A, 0.7414, 2.95, 0.295, 270, 241, CRYSTAL STRUCTURE OF THE CHK1
4535, 3v8tB, 0.7414, 2.55, 0.230, 244, 235, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4536, 3hmoA, 0.7414, 2.60, 0.319, 257, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4537, 2e9vB, 0.7414, 2.94, 0.295, 268, 241, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4538, 5wr7A, 0.7413, 3.00, 0.235, 301, 243, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
4539, 5vcvA, 0.7413, 2.61, 0.309, 287, 236, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH DASATINIB
4540, 5flfA, 0.7413, 3.19, 0.239, 296, 243, DISEASE LINKED MUTATION IN FGFR
4541, 4z16C, 0.7413, 2.88, 0.252, 271, 238, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4542, 4pp9B, 0.7413, 2.56, 0.225, 247, 236, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4543, 4ksqB, 0.7413, 2.82, 0.210, 255, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
4544, 4gvjA, 0.7413, 3.19, 0.242, 290, 244, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
4545, 3q4uA, 0.7413, 2.87, 0.241, 298, 237, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4546, 4cnhB, 0.7412, 2.91, 0.187, 293, 241, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
4547, 5drbA, 0.7411, 2.90, 0.256, 273, 238, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
4548, 4umpD, 0.7411, 2.98, 0.317, 321, 240, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4549, 4e93A, 0.7411, 2.93, 0.249, 361, 241, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
4550, 4e3cE, 0.7411, 3.18, 0.280, 624, 246, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4551, 3s95B, 0.7411, 3.06, 0.249, 290, 241, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
4552, 3rhkA, 0.7411, 2.94, 0.207, 298, 241, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4553, 3et7A, 0.7411, 2.86, 0.212, 261, 241, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
4554, 5w86C, 0.7410, 2.89, 0.265, 273, 238, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4555, 4ybkA, 0.7410, 2.85, 0.254, 266, 240, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4556, 4o2pA, 0.7410, 2.79, 0.248, 265, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4557, 4cztA, 0.7410, 2.94, 0.311, 294, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4558, 3w8qA, 0.7410, 2.66, 0.275, 318, 236, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
4559, 1sykA, 0.7410, 3.14, 0.250, 348, 244, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4560, 6c3eA, 0.7409, 2.76, 0.221, 258, 235, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
4561, 5hcxA, 0.7409, 3.24, 0.202, 298, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
4562, 5ew3A, 0.7409, 2.92, 0.217, 274, 240, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4563, 4riyB, 0.7409, 2.94, 0.220, 293, 241, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4564, 2y7jD, 0.7409, 2.90, 0.295, 281, 241, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
4565, 5vndA, 0.7408, 3.12, 0.237, 302, 245, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
4566, 5ct7A, 0.7408, 2.92, 0.213, 257, 239, BRAF IN COMPLEX WITH RAF265
4567, 4y85A, 0.7408, 2.76, 0.242, 307, 236, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
4568, 4uwcA, 0.7408, 3.13, 0.237, 300, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
4569, 3qgwB, 0.7408, 2.58, 0.226, 240, 234, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4570, 2x6eA, 0.7408, 2.67, 0.318, 249, 236, AURORA-A BOUND TO AN INHIBITOR
4571, 5jt2C, 0.7407, 2.48, 0.221, 251, 231, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4572, 4rwjA, 0.7407, 3.13, 0.241, 307, 245, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4573, 1t45A, 0.7407, 2.99, 0.240, 331, 242, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
4574, 1sykB, 0.7407, 3.14, 0.254, 323, 244, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4575, 1nvrA, 0.7407, 3.01, 0.302, 264, 242, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
4576, 5u6bB, 0.7406, 3.06, 0.226, 291, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4577, 5am6A, 0.7406, 3.03, 0.236, 295, 242, NATIVE FGFR1 WITH AN INHIBITOR
4578, 4yneA, 0.7406, 2.82, 0.237, 281, 241, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4579, 4qqtA, 0.7406, 2.88, 0.250, 283, 240, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
4580, 4e4lE, 0.7406, 2.92, 0.262, 280, 240, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4581, 2rf9B, 0.7406, 2.84, 0.218, 269, 239, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4582, 1pkgB, 0.7406, 3.04, 0.237, 277, 241, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4583, 5uv4A, 0.7405, 3.06, 0.174, 290, 242, CRYSTAL STRUCTURE OF MAIZE SIRK1 (SUCROSE-INDUCED RECEPTOR KINASE 1) KINASE DOMAIN BOUND TO AMP-PNP
4584, 5ui0B, 0.7405, 3.24, 0.235, 304, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
4585, 5u6cB, 0.7405, 2.32, 0.222, 257, 230, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4586, 4tn6A, 0.7405, 3.31, 0.198, 292, 248, CK1D IN COMPLEX WITH INHIBITOR
4587, 4ft0A, 0.7405, 2.85, 0.297, 266, 239, CRYSTAL STRUCTURE OF THE CHK1
4588, 4cztD, 0.7405, 2.91, 0.311, 302, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
4589, 3zepA, 0.7405, 2.94, 0.265, 274, 238, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4590, 3rhxB, 0.7405, 2.95, 0.240, 275, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4591, 3qtiA, 0.7405, 2.99, 0.224, 292, 241, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4592, 3ik3A, 0.7405, 3.21, 0.230, 280, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4593, 3fzrA, 0.7405, 2.91, 0.212, 261, 241, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
4594, 3d94A, 0.7405, 2.93, 0.221, 288, 240, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
4595, 3bi6A, 0.7405, 2.63, 0.238, 258, 235, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
4596, 2xneA, 0.7405, 2.64, 0.308, 246, 237, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4597, 2x8eA, 0.7405, 2.89, 0.292, 259, 240, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4598, 5oxgD, 0.7404, 2.85, 0.241, 293, 237, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4599, 4ivdA, 0.7404, 2.94, 0.262, 290, 240, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4600, 4ithB, 0.7404, 2.89, 0.218, 270, 238, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4601, 2izrA, 0.7404, 3.36, 0.185, 298, 249, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4602, 1fgiA, 0.7404, 3.03, 0.238, 283, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4603, 5e91A, 0.7403, 3.05, 0.233, 297, 240, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
4604, 4uwbA, 0.7403, 3.14, 0.237, 299, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
4605, 3wzeA, 0.7403, 3.11, 0.226, 298, 243, KDR IN COMPLEX WITH LIGAND SORAFENIB
4606, 3ot3A, 0.7403, 2.85, 0.293, 259, 239, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
4607, 3geqB, 0.7403, 2.73, 0.257, 273, 237, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4608, 5x28A, 0.7402, 3.27, 0.219, 310, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
4609, 5oprA, 0.7402, 2.76, 0.290, 258, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
4610, 5o49A, 0.7402, 3.13, 0.237, 289, 245, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4611, 4qo9A, 0.7402, 3.20, 0.290, 280, 245, MST3 IN COMPLEX WITH DANUSERTIB
4612, 4gl9A, 0.7402, 2.99, 0.260, 282, 242, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4613, 3u51B, 0.7402, 2.58, 0.243, 255, 235, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4614, 3eqpB, 0.7402, 3.09, 0.251, 270, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
4615, 2v7aA, 0.7402, 3.23, 0.234, 269, 244, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
4616, 2qluA, 0.7402, 2.96, 0.226, 297, 239, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
4617, 4xv3A, 0.7401, 2.45, 0.216, 244, 231, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7922
4618, 3p86B, 0.7401, 2.29, 0.236, 239, 229, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4619, 3faaA, 0.7401, 3.07, 0.224, 328, 241, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4620, 5hu9A, 0.7400, 3.13, 0.227, 266, 242, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
4621, 5cenA, 0.7400, 2.83, 0.270, 281, 237, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
4622, 4nk9B, 0.7400, 3.05, 0.230, 282, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4623, 4e4nA, 0.7400, 2.99, 0.261, 291, 241, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4624, 4e1zA, 0.7400, 3.04, 0.236, 288, 242, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
4625, 4ag8A, 0.7400, 3.11, 0.218, 296, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
4626, 3geqA, 0.7400, 2.74, 0.257, 272, 237, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4627, 5jzjA, 0.7399, 2.61, 0.311, 271, 235, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
4628, 4z16D, 0.7399, 2.91, 0.256, 271, 238, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4629, 4fsuA, 0.7399, 2.88, 0.293, 260, 239, CRYSTAL STRUCTURE OF THE CHK1
4630, 4ehzD, 0.7399, 2.98, 0.266, 280, 241, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4631, 3ik3B, 0.7399, 3.22, 0.234, 286, 244, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4632, 2zmcA, 0.7399, 2.72, 0.296, 260, 240, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
4633, 1muoA, 0.7399, 2.85, 0.310, 251, 239, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
4634, 1k2pB, 0.7399, 2.78, 0.206, 258, 238, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
4635, 5vo6A, 0.7398, 2.81, 0.262, 271, 237, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
4636, 4u5jB, 0.7398, 2.77, 0.252, 267, 238, C-SRC IN COMPLEX WITH RUXOLITINIB
4637, 4ix6A, 0.7398, 3.45, 0.204, 346, 245, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4638, 3tcpA, 0.7398, 2.52, 0.220, 256, 232, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC569
4639, 3rhxA, 0.7398, 3.13, 0.237, 289, 245, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4640, 3oy3B, 0.7398, 3.22, 0.230, 284, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4641, 2i1mA, 0.7398, 3.09, 0.222, 311, 243, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4642, 6bl8B, 0.7397, 3.17, 0.230, 268, 243, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
4643, 5xp7B, 0.7397, 2.81, 0.252, 267, 238, C-SRC IN COMPLEX WITH ATP-CHCL
4644, 5t3qA, 0.7397, 2.91, 0.201, 278, 239, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4645, 4p90A, 0.7397, 2.56, 0.274, 272, 234, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4646, 4kspA, 0.7397, 2.87, 0.210, 257, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4647, 4hnfA, 0.7397, 3.22, 0.189, 289, 249, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4648, 4aojC, 0.7397, 3.01, 0.230, 261, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4649, 2zv2A, 0.7397, 2.67, 0.294, 256, 235, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
4650, 2wkmA, 0.7397, 2.96, 0.219, 286, 242, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
4651, 2r0iA, 0.7397, 2.80, 0.324, 300, 238, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4652, 5oq6A, 0.7396, 2.80, 0.294, 257, 238, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4653, 3p1aA, 0.7396, 2.67, 0.308, 281, 237, STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE- SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1)
4654, 5khwA, 0.7395, 2.95, 0.271, 276, 240, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4655, 4ix5A, 0.7395, 3.46, 0.204, 346, 245, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4656, 4aojA, 0.7395, 2.97, 0.231, 260, 242, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4657, 5oxgA, 0.7394, 2.84, 0.242, 293, 236, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4658, 5o26A, 0.7394, 3.06, 0.242, 271, 240, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
4659, 5am7B, 0.7394, 2.86, 0.237, 287, 240, FGFR1 MUTANT WITH AN INHIBITOR
4660, 4xliA, 0.7394, 3.05, 0.241, 264, 241, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
4661, 4x7oA, 0.7394, 2.39, 0.281, 246, 228, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 1-[5-(4-AMINO-27-DIMETHYL-7H- PYRROLO[23-D]PYRIMIDIN-5-YL)-23-DIHYDRO-1H-INDOL-1-YL]-2-[3-FLUORO- 5-(TRIFLUOROMETHYL)PHENYL]ETHANONE INHIBITOR
4662, 4qpsA, 0.7394, 2.63, 0.264, 270, 235, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4663, 4o6lA, 0.7394, 2.81, 0.311, 257, 238, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4664, 4mh7B, 0.7394, 2.43, 0.221, 255, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1896
4665, 4g9rB, 0.7394, 2.92, 0.204, 261, 240, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
4666, 3zc6D, 0.7394, 2.80, 0.271, 267, 236, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4667, 3vntA, 0.7394, 3.11, 0.222, 301, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4668, 3tkhA, 0.7394, 2.88, 0.297, 269, 239, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
4669, 5gtzA, 0.7393, 3.34, 0.214, 317, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
4670, 4fsyA, 0.7393, 2.85, 0.286, 267, 238, CRYSTAL STRUCTURE OF THE CHK1
4671, 3uysD, 0.7393, 3.10, 0.184, 284, 245, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4672, 3oriD, 0.7393, 2.99, 0.271, 267, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4673, 3cekA, 0.7393, 2.70, 0.305, 256, 239, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4674, 6c3eB, 0.7392, 2.88, 0.219, 259, 237, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
4675, 5odtA, 0.7392, 2.97, 0.282, 258, 241, AURORA-A IN COMPLEX WITH TACC3
4676, 5eg3A, 0.7392, 3.17, 0.234, 301, 244, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
4677, 5ap6A, 0.7392, 2.69, 0.318, 262, 239, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4678, 4x3fA, 0.7392, 2.59, 0.252, 274, 238, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
4679, 4wa9B, 0.7392, 3.10, 0.218, 276, 243, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
4680, 3g0fB, 0.7392, 3.08, 0.244, 293, 242, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4681, 3alnA, 0.7392, 2.62, 0.262, 270, 233, CRYSTAL STRUCTURE OF HUMAN NON-PHOSPHORYLATED MKK4 KINASE DOMAIN COMPLEXED WITH AMP-PNP
4682, 2xa4B, 0.7392, 2.81, 0.277, 275, 238, INHIBITORS OF JAK2 KINASE DOMAIN
4683, 1zxeC, 0.7392, 2.91, 0.272, 267, 239, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: D835N INACTIVATING MUTANT IN APO FORM
4684, 5vcwB, 0.7391, 2.65, 0.305, 285, 236, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
4685, 5t18A, 0.7391, 2.66, 0.208, 261, 236, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
4686, 4f0iA, 0.7391, 3.02, 0.236, 284, 242, CRYSTAL STRUCTURE OF APO TRKA
4687, 4asdA, 0.7391, 3.10, 0.218, 305, 243, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
4688, 2x2lA, 0.7391, 3.14, 0.252, 287, 242, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
4689, 2c3jA, 0.7391, 2.80, 0.290, 257, 238, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4690, 1f3mD, 0.7391, 3.32, 0.271, 285, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4691, 5hicA, 0.7390, 3.20, 0.203, 302, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
4692, 4f0iB, 0.7390, 3.05, 0.235, 294, 243, CRYSTAL STRUCTURE OF APO TRKA
4693, 3bu6A, 0.7390, 3.16, 0.213, 294, 244, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
4694, 6bqqA, 0.7389, 2.83, 0.294, 271, 238, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
4695, 6b8uA, 0.7389, 2.94, 0.214, 253, 238, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4696, 5u6bD, 0.7389, 3.09, 0.226, 291, 243, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4697, 4twpB, 0.7389, 3.10, 0.231, 271, 242, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
4698, 4knbC, 0.7389, 2.78, 0.226, 271, 235, C-MET IN COMPLEX WITH OSI LIGAND
4699, 4ix3A, 0.7389, 3.50, 0.203, 346, 246, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4700, 4dbnB, 0.7389, 2.83, 0.210, 263, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4701, 3beaA, 0.7389, 3.09, 0.222, 310, 243, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
4702, 3b2wA, 0.7389, 2.85, 0.243, 261, 239, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
4703, 2qnjA, 0.7389, 2.86, 0.331, 318, 242, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4704, 2ghgA, 0.7389, 3.09, 0.292, 269, 243, H-CHK1 COMPLEXED WITH A431994
4705, 5hcyA, 0.7388, 3.20, 0.203, 302, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
4706, 4twpA, 0.7388, 3.04, 0.233, 266, 240, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
4707, 4riwB, 0.7388, 2.97, 0.220, 293, 241, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
4708, 3zmmA, 0.7388, 2.83, 0.273, 273, 238, INHIBITORS OF JAK2 KINASE DOMAIN
4709, 3v5lC, 0.7388, 2.51, 0.231, 244, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4710, 3i5nA, 0.7388, 2.88, 0.223, 280, 238, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
4711, 3genA, 0.7388, 2.73, 0.198, 264, 237, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
4712, 3g0eA, 0.7388, 3.00, 0.236, 332, 242, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
4713, 2ivuA, 0.7388, 3.11, 0.253, 288, 241, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
4714, 2f4jA, 0.7388, 3.12, 0.231, 287, 242, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
4715, 5k9iB, 0.7387, 2.75, 0.256, 262, 238, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4716, 5ei8A, 0.7387, 2.81, 0.320, 261, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4717, 5bpyB, 0.7387, 2.66, 0.204, 247, 235, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4718, 4tyiA, 0.7387, 3.07, 0.251, 277, 243, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
4719, 4lgdB, 0.7387, 3.22, 0.257, 350, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4720, 3vo3A, 0.7387, 3.11, 0.218, 303, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
4721, 3ag9A, 0.7387, 3.17, 0.258, 323, 244, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
4722, 6bu6D, 0.7386, 3.31, 0.153, 318, 249, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4723, 5x3fB, 0.7386, 3.02, 0.267, 348, 243, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
4724, 5ttuA, 0.7386, 2.82, 0.263, 271, 236, JAK3 WITH COVALENT INHIBITOR 7
4725, 5l6wL, 0.7386, 3.17, 0.248, 290, 242, STRUCTURE OF THE LIMK1-ATPGAMMAS-CFL1 COMPLEX
4726, 5l2qD, 0.7386, 3.06, 0.203, 294, 241, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4727, 5kkrB, 0.7386, 2.64, 0.197, 272, 233, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
4728, 4kbcA, 0.7386, 3.18, 0.193, 288, 244, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4729, 3zepC, 0.7386, 3.03, 0.259, 276, 239, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4730, 2c47D, 0.7386, 3.17, 0.203, 290, 246, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4731, 5uu1A, 0.7385, 3.47, 0.151, 315, 251, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
4732, 5n9sA, 0.7385, 2.69, 0.303, 259, 238, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
4733, 4y85B, 0.7385, 2.78, 0.242, 306, 236, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
4734, 4v05B, 0.7385, 3.18, 0.233, 286, 245, FGFR1 IN COMPLEX WITH AZD4547.
4735, 4ix5B, 0.7385, 3.50, 0.203, 350, 246, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4736, 4hvsA, 0.7385, 3.10, 0.231, 326, 242, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
4737, 3eqpA, 0.7385, 2.99, 0.253, 268, 241, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
4738, 5capA, 0.7384, 3.18, 0.211, 303, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
4739, 5a46A, 0.7384, 3.11, 0.238, 289, 244, FGFR1 IN COMPLEX WITH DOVITINIB
4740, 4gt4B, 0.7384, 2.85, 0.226, 273, 239, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4741, 4c62A, 0.7384, 2.84, 0.273, 273, 238, INHIBITORS OF JAK2 KINASE DOMAIN
4742, 4c4gA, 0.7384, 2.55, 0.322, 251, 236, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4743, 4bggC, 0.7384, 3.00, 0.244, 279, 238, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4744, 3vhkA, 0.7384, 3.12, 0.222, 297, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BACK POCKET BINDER
4745, 3v5lD, 0.7384, 2.61, 0.233, 246, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4746, 3oriC, 0.7384, 2.87, 0.269, 267, 238, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4747, 3d2kA, 0.7384, 2.60, 0.308, 245, 234, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4748, 3a60A, 0.7384, 2.49, 0.320, 263, 231, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
4749, 1pkgA, 0.7384, 3.03, 0.242, 290, 240, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4750, 5tkxA, 0.7383, 3.48, 0.151, 315, 251, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
4751, 5kmkA, 0.7383, 2.97, 0.236, 304, 242, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
4752, 5i4nA, 0.7383, 2.83, 0.209, 275, 239, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
4753, 4ix6B, 0.7383, 3.51, 0.203, 350, 246, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4754, 4ftjA, 0.7383, 2.85, 0.298, 266, 238, CRYSTAL STRUCTURE OF THE CHK1
4755, 3oy3A, 0.7383, 3.23, 0.234, 284, 244, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4756, 3ormA, 0.7383, 2.93, 0.268, 266, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4757, 3a7hA, 0.7383, 3.27, 0.272, 289, 246, HUMAN MST3 KINASE IN COMPLEX WITH ATP
4758, 5oy6B, 0.7382, 3.03, 0.243, 292, 239, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4759, 5o23A, 0.7382, 2.76, 0.242, 269, 236, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4760, 5jzjB, 0.7382, 2.52, 0.309, 261, 233, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
4761, 4u5jA, 0.7382, 2.93, 0.255, 267, 239, C-SRC IN COMPLEX WITH RUXOLITINIB
4762, 2xirA, 0.7382, 3.12, 0.218, 296, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
4763, 2vwiD, 0.7382, 3.09, 0.272, 284, 239, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4764, 2pvfA, 0.7382, 3.17, 0.239, 285, 243, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
4765, 6bu6B, 0.7381, 3.28, 0.141, 307, 248, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4766, 5wnkA, 0.7381, 2.67, 0.220, 263, 236, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TG100-115 
4767, 5hczA, 0.7381, 3.27, 0.202, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
4768, 5cy3A, 0.7381, 2.90, 0.208, 276, 240, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
4769, 3gvuA, 0.7381, 3.08, 0.232, 271, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
4770, 3c4cB, 0.7381, 2.82, 0.210, 257, 238, B-RAF KINASE IN COMPLEX WITH PLX4720
4771, 1fvrB, 0.7381, 2.94, 0.245, 300, 241, TIE2 KINASE DOMAIN
4772, 6dkbA, 0.7380, 2.95, 0.231, 272, 242, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 10B. 
4773, 5y5uA, 0.7380, 2.95, 0.204, 266, 240, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
4774, 5wnmA, 0.7380, 2.74, 0.224, 263, 237, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TOZASERTIB (VX-680) 
4775, 5oxgC, 0.7380, 3.08, 0.242, 301, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4776, 4ix4B, 0.7380, 3.51, 0.203, 350, 246, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4777, 6fnfA, 0.7379, 2.90, 0.200, 267, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
4778, 6brcB, 0.7379, 2.89, 0.303, 260, 238, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
4779, 5x26A, 0.7379, 3.19, 0.216, 302, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
4780, 5kmoA, 0.7379, 2.88, 0.232, 291, 241, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
4781, 5de2B, 0.7379, 2.59, 0.335, 262, 236, STRUCTURAL MECHANISM OF NEK7 ACTIVATION BY NEK9-INDUCED DIMERISATION
4782, 4lqmA, 0.7379, 3.36, 0.210, 305, 248, EGFR L858R IN COMPLEX WITH PD168393
4783, 3ii5A, 0.7379, 3.02, 0.207, 262, 241, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4784, 3hmnA, 0.7379, 2.68, 0.311, 255, 238, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4785, 3eflA, 0.7379, 2.74, 0.224, 286, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4786, 1zmwB, 0.7379, 2.78, 0.316, 302, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4787, 5calA, 0.7378, 3.26, 0.202, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
4788, 5c9cA, 0.7378, 3.00, 0.209, 254, 239, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4789, 4f64B, 0.7378, 3.01, 0.240, 272, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
4790, 2gs6A, 0.7378, 3.24, 0.211, 311, 246, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
4791, 5canA, 0.7377, 3.26, 0.202, 301, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
4792, 4rj7A, 0.7377, 3.27, 0.203, 295, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
4793, 4hgtB, 0.7377, 2.77, 0.190, 280, 237, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4794, 2jfmA, 0.7377, 2.63, 0.288, 287, 236, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4795, 6eimA, 0.7376, 2.59, 0.322, 286, 233, HUMAN STK10 BOUND TO GW683134A
4796, 6cswB, 0.7376, 3.17, 0.138, 308, 246, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4797, 5f4nA, 0.7376, 2.85, 0.298, 258, 238, MULTI-PARAMETER LEAD OPTIMIZATION TO GIVE AN ORAL CHK1 INHIBITOR CLINICAL CANDIDATE: (R)-5-((4-((MORPHOLIN-2-YLMETHYL)AMINO)-5- (TRIFLUOROMETHYL)PYRIDIN-2-YL)AMINO)PYRAZINE-2-CARBONITRILE (CCT245737)
4798, 4ix4A, 0.7376, 3.52, 0.203, 346, 246, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4799, 2gqgB, 0.7376, 3.11, 0.244, 276, 242, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
4800, 1qpjA, 0.7376, 3.05, 0.246, 265, 240, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
4801, 4yzmB, 0.7375, 2.93, 0.239, 262, 238, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
4802, 4qqjA, 0.7375, 2.85, 0.251, 282, 239, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
4803, 4dbnA, 0.7375, 2.98, 0.209, 257, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4804, 4pdpB, 0.7374, 2.68, 0.323, 265, 235, CRYSTAL STRUCTURE OF RAD53 KINASE DOMAIN AND SCD2
4805, 4ix3B, 0.7374, 3.52, 0.207, 350, 246, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4806, 4fg7A, 0.7374, 2.49, 0.293, 250, 232, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4807, 4ei4A, 0.7374, 2.90, 0.259, 289, 239, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4808, 3dakB, 0.7374, 3.28, 0.272, 278, 239, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4809, 6d1yA, 0.7373, 3.11, 0.225, 300, 244, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
4810, 5bvkA, 0.7373, 3.28, 0.223, 278, 247, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4811, 4xh0A, 0.7373, 3.20, 0.167, 350, 245, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (SO4 CONDITION)
4812, 3wzuA, 0.7373, 2.99, 0.239, 270, 243, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4813, 3faaC, 0.7373, 3.24, 0.222, 330, 243, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4814, 6gi6A, 0.7372, 2.83, 0.242, 298, 236, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 5-METHYL CORE. 
4815, 5khxA, 0.7372, 2.89, 0.252, 276, 238, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
4816, 4v05A, 0.7372, 3.16, 0.237, 287, 245, FGFR1 IN COMPLEX WITH AZD4547.
4817, 4umpB, 0.7372, 2.86, 0.328, 324, 238, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4818, 4e4lB, 0.7372, 2.97, 0.262, 279, 240, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4819, 4ckjA, 0.7372, 3.20, 0.252, 292, 242, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
4820, 3gxlA, 0.7372, 2.67, 0.218, 285, 234, ALK-5 KINASE COMPLEX WITH GW857175
4821, 3en5B, 0.7372, 2.69, 0.254, 261, 236, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4822, 2ydkA, 0.7372, 3.06, 0.286, 263, 241, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4823, 2wtwA, 0.7372, 2.96, 0.318, 256, 242, AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)
4824, 2j50B, 0.7372, 2.69, 0.301, 249, 236, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4825, 2j50A, 0.7372, 2.69, 0.301, 249, 236, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4826, 2ivsB, 0.7372, 3.21, 0.256, 277, 242, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4827, 6dd4B, 0.7371, 3.23, 0.142, 309, 247, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4828, 5x2kA, 0.7371, 3.33, 0.206, 314, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
4829, 5em7A, 0.7371, 3.32, 0.206, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4830, 5ei2A, 0.7371, 2.75, 0.314, 256, 239, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4831, 3h9rA, 0.7371, 3.06, 0.247, 312, 239, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
4832, 3gfwA, 0.7371, 2.74, 0.311, 253, 238, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4833, 3g0fA, 0.7371, 3.17, 0.243, 291, 243, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4834, 3fbvM, 0.7371, 3.10, 0.300, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4835, 3fbvD, 0.7371, 3.10, 0.300, 422, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4836, 1opjA, 0.7371, 3.18, 0.227, 287, 242, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4837, 5x27A, 0.7370, 3.19, 0.220, 302, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
4838, 5valB, 0.7370, 2.89, 0.203, 254, 237, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4839, 5ugbA, 0.7370, 3.20, 0.212, 307, 245, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
4840, 4nkaB, 0.7370, 3.16, 0.226, 287, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4841, 4lg4A, 0.7370, 3.15, 0.260, 289, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4842, 4gh2A, 0.7370, 2.78, 0.300, 266, 237, CRYSTAL STRUCTURE OF THE CHK1
4843, 3zewA, 0.7370, 2.91, 0.221, 269, 240, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
4844, 3sdmG, 0.7370, 3.10, 0.300, 415, 240, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4845, 3sdmF, 0.7370, 3.10, 0.300, 415, 240, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4846, 3sdmE, 0.7370, 3.10, 0.300, 415, 240, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4847, 3sdmD, 0.7370, 3.10, 0.300, 415, 240, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4848, 3sdmC, 0.7370, 3.10, 0.300, 415, 240, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4849, 3sdmB, 0.7370, 3.10, 0.300, 415, 240, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4850, 3sdmA, 0.7370, 3.10, 0.300, 415, 240, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4851, 3fbvN, 0.7370, 3.10, 0.300, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4852, 3fbvK, 0.7370, 3.10, 0.300, 422, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4853, 3fbvH, 0.7370, 3.11, 0.304, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4854, 3fbvB, 0.7370, 3.10, 0.300, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4855, 3fbvA, 0.7370, 3.10, 0.300, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4856, 2x9fA, 0.7370, 2.94, 0.220, 265, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4857, 4mneG, 0.7369, 2.79, 0.209, 259, 235, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4858, 3fbvL, 0.7369, 3.10, 0.300, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4859, 3fbvG, 0.7369, 3.10, 0.300, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4860, 3fbvE, 0.7369, 3.11, 0.304, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4861, 3b8qA, 0.7369, 2.99, 0.237, 292, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4862, 2p0cA, 0.7369, 2.27, 0.232, 249, 228, CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER
4863, 5x02A, 0.7368, 2.90, 0.225, 305, 240, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
4864, 5nkgA, 0.7368, 2.99, 0.207, 292, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
4865, 4uxlA, 0.7368, 3.06, 0.239, 288, 243, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
4866, 4i20A, 0.7368, 2.94, 0.212, 287, 241, CRYSTAL STRUCTURE OF MONOMERIC (V948R) PRIMARY ONCOGENIC MUTANT L858R EGFR KINASE DOMAIN
4867, 4ehzC, 0.7368, 2.98, 0.267, 278, 240, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4868, 4bhzA, 0.7368, 2.47, 0.316, 251, 234, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4869, 3fbvF, 0.7368, 3.11, 0.300, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4870, 3fbvC, 0.7368, 3.11, 0.300, 415, 240, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4871, 2g15A, 0.7368, 2.92, 0.205, 301, 239, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
4872, 1zmwA, 0.7368, 2.79, 0.316, 302, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4873, 1z9xC, 0.7368, 3.06, 0.270, 303, 244, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
4874, 6cz4A, 0.7367, 2.73, 0.228, 257, 237, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE II INHIBITOR 2- {[(3R;4S)-3-FLUORO-1-{[4-(TRIFLUOROMETHOXY)PHENYL]ACETYL}PIPERIDIN-4- YL]OXY}-5-(1-METHYL-1H-IMIDAZOL-4-YL)PYRIDINE-3-CARBOXAMIDE 
4875, 5ukfA, 0.7367, 3.20, 0.137, 322, 248, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4876, 4fvrA, 0.7367, 2.87, 0.209, 274, 239, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
4877, 4e4lA, 0.7367, 2.93, 0.264, 277, 239, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4878, 4ae6B, 0.7367, 3.09, 0.260, 321, 242, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
4879, 3zfxI, 0.7367, 2.85, 0.229, 263, 240, CRYSTAL STRUCTURE OF EPHB1
4880, 3v8wB, 0.7367, 2.51, 0.227, 242, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4881, 3efkA, 0.7367, 3.00, 0.195, 276, 241, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4882, 2x8iA, 0.7367, 2.84, 0.290, 261, 238, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4883, 1agwB, 0.7367, 2.94, 0.241, 272, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4884, 5zv2B, 0.7366, 3.05, 0.235, 282, 243, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4885, 2pwlA, 0.7366, 3.19, 0.236, 284, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
4886, 5y25A, 0.7365, 3.23, 0.215, 292, 246, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
4887, 5o4aA, 0.7365, 3.18, 0.237, 290, 245, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4888, 3cohB, 0.7365, 2.70, 0.308, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4889, 2c47B, 0.7365, 3.20, 0.196, 289, 245, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4890, 1b6cD, 0.7365, 3.06, 0.222, 326, 239, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4891, 6bu6A, 0.7364, 3.21, 0.137, 322, 248, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4892, 5magA, 0.7364, 2.71, 0.319, 314, 235, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4893, 5gmpA, 0.7364, 3.39, 0.219, 305, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
4894, 4pqnA, 0.7364, 2.46, 0.237, 240, 232, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
4895, 4kspB, 0.7364, 2.91, 0.210, 256, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4896, 3hngA, 0.7364, 2.97, 0.238, 288, 239, CRYSTAL STRUCTURE OF VEGFR1 IN COMPLEX WITH N-(4-CHLOROPHENYL)-2- ((PYRIDIN-4-YLMETHYL)AMINO)BENZAMIDE
4897, 2y4iB, 0.7364, 2.67, 0.209, 265, 234, KSR2-MEK1 HETERODIMER
4898, 2hznA, 0.7364, 3.17, 0.232, 272, 241, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
4899, 2e2bA, 0.7364, 3.25, 0.236, 270, 242, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4900, 5i3oA, 0.7363, 2.93, 0.276, 302, 239, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4901, 4ztqA, 0.7363, 2.67, 0.318, 247, 236, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4902, 4p90B, 0.7363, 2.70, 0.314, 262, 236, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4903, 3a4oX, 0.7363, 2.97, 0.237, 259, 240, LYN KINASE DOMAIN
4904, 2hyyD, 0.7363, 3.02, 0.242, 264, 240, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4905, 1iepB, 0.7363, 3.05, 0.237, 274, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
4906, 1fpuB, 0.7363, 3.11, 0.232, 270, 241, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4907, 1fgkB, 0.7363, 2.95, 0.241, 272, 241, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4908, 5p9lA, 0.7362, 2.72, 0.195, 252, 236, BTK1 IN COMPLEX WITH CC 292
4909, 5kmnA, 0.7362, 2.99, 0.236, 296, 242, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4910, 4xi2A, 0.7362, 2.90, 0.201, 421, 239, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
4911, 4czuC, 0.7362, 3.04, 0.308, 281, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
4912, 3cd8A, 0.7362, 2.82, 0.229, 278, 236, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4913, 2hyyA, 0.7362, 3.06, 0.237, 263, 241, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4914, 5o4aB, 0.7361, 3.05, 0.235, 291, 243, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4915, 5flfB, 0.7361, 3.28, 0.239, 292, 243, DISEASE LINKED MUTATION IN FGFR
4916, 3v5lA, 0.7361, 2.50, 0.232, 240, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4917, 2zmdA, 0.7361, 2.72, 0.310, 259, 239, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4918, 2g2iB, 0.7361, 2.81, 0.233, 265, 236, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
4919, 5y90A, 0.7360, 3.37, 0.218, 304, 252, MAP2K7 MUTANT -C218S
4920, 5t0pA, 0.7360, 2.78, 0.253, 264, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4921, 5l8kA, 0.7360, 2.91, 0.264, 266, 239, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
4922, 5iu2A, 0.7360, 2.75, 0.234, 312, 235, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
4923, 5ia2A, 0.7360, 3.10, 0.206, 287, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
4924, 5cauA, 0.7360, 3.27, 0.203, 297, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
4925, 4aojB, 0.7360, 2.82, 0.230, 258, 239, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4926, 3pxkB, 0.7360, 2.87, 0.243, 258, 239, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4927, 3kf4A, 0.7360, 3.22, 0.236, 281, 242, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4928, 3ii5B, 0.7360, 3.03, 0.217, 257, 240, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4929, 6ginA, 0.7359, 3.13, 0.242, 296, 240, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
4930, 5ap5A, 0.7359, 2.65, 0.316, 252, 237, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4931, 4tksA, 0.7359, 3.21, 0.212, 307, 245, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
4932, 4nksB, 0.7359, 2.99, 0.241, 271, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
4933, 4lg4D, 0.7359, 2.37, 0.252, 250, 230, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4934, 4c61B, 0.7359, 2.79, 0.280, 274, 236, INHIBITORS OF JAK2 KINASE DOMAIN
4935, 3oxzA, 0.7359, 3.16, 0.233, 268, 240, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
4936, 3efjA, 0.7359, 3.03, 0.199, 276, 241, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4937, 3ckwA, 0.7359, 2.90, 0.273, 255, 238, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4938, 1opjB, 0.7359, 3.18, 0.236, 288, 242, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4939, 5v19A, 0.7358, 2.76, 0.312, 250, 234, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4940, 5iu2B, 0.7358, 2.76, 0.234, 313, 235, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
4941, 5hlwA, 0.7358, 3.00, 0.218, 284, 239, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
4942, 5em6A, 0.7358, 3.30, 0.202, 301, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4943, 4mf1A, 0.7358, 2.58, 0.231, 243, 234, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4944, 4g3dD, 0.7358, 2.78, 0.261, 290, 234, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
4945, 4f63B, 0.7358, 3.01, 0.241, 271, 241, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
4946, 4dggA, 0.7358, 2.70, 0.246, 261, 236, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4947, 4c4iA, 0.7358, 2.57, 0.314, 253, 236, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4948, 3idpA, 0.7358, 3.13, 0.212, 255, 240, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4949, 2jkmA, 0.7358, 2.89, 0.246, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4950, 6cmmD, 0.7357, 3.27, 0.138, 315, 247, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
4951, 5y8uA, 0.7357, 2.94, 0.233, 267, 240, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4952, 5wfjA, 0.7357, 2.94, 0.257, 265, 237, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
4953, 4nk9A, 0.7357, 3.12, 0.230, 281, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4954, 3uqfB, 0.7357, 2.48, 0.251, 253, 231, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4955, 3sdjN, 0.7357, 3.13, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4956, 3sdjM, 0.7357, 3.13, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4957, 3sdjH, 0.7357, 3.13, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4958, 3sdjG, 0.7357, 3.13, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4959, 3sdjF, 0.7357, 3.13, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4960, 3sdjA, 0.7357, 3.12, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4961, 2wmrA, 0.7357, 2.75, 0.297, 254, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4962, 2j5fA, 0.7357, 3.38, 0.222, 308, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
4963, 2hyyB, 0.7357, 3.06, 0.237, 265, 241, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4964, 5casA, 0.7356, 3.27, 0.203, 299, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
4965, 5b7vA, 0.7356, 3.04, 0.232, 282, 241, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
4966, 4v04B, 0.7356, 3.07, 0.227, 287, 242, FGFR1 IN COMPLEX WITH PONATINIB.
4967, 4nt4A, 0.7356, 3.26, 0.198, 300, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
4968, 4neuB, 0.7356, 3.17, 0.224, 268, 246, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
4969, 3sdjK, 0.7356, 3.13, 0.300, 422, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4970, 3sdjE, 0.7356, 3.13, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4971, 3sdjD, 0.7356, 3.13, 0.300, 422, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4972, 3sdjC, 0.7356, 3.12, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4973, 3sdjB, 0.7356, 3.13, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4974, 3cohA, 0.7356, 2.71, 0.308, 247, 237, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4975, 2c6eB, 0.7356, 2.68, 0.314, 246, 236, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4976, 5xp5A, 0.7355, 2.94, 0.259, 267, 239, C-SRC IN COMPLEX WITH ATP-CHF
4977, 5cxzA, 0.7355, 2.97, 0.212, 269, 240, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
4978, 4jaiA, 0.7355, 2.78, 0.315, 249, 238, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH N-{4-[(6-OXO-56- DIHYDROBENZO[C][18]NAPHTHYRIDIN-1-YL)AMINO]PHENYL}BENZAMIDE
4979, 4c61A, 0.7355, 2.85, 0.274, 272, 237, INHIBITORS OF JAK2 KINASE DOMAIN
4980, 3sdjL, 0.7355, 3.13, 0.300, 415, 240, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4981, 3ms9B, 0.7355, 3.04, 0.242, 272, 240, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4982, 3k5vB, 0.7355, 3.24, 0.231, 283, 242, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4983, 3efjB, 0.7355, 2.99, 0.196, 275, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4984, 3cp9B, 0.7355, 2.95, 0.222, 269, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4985, 2bdjA, 0.7355, 2.85, 0.256, 254, 238, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
4986, 5vo1A, 0.7354, 2.60, 0.284, 269, 232, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
4987, 5ui0A, 0.7354, 3.29, 0.235, 301, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
4988, 5nk1A, 0.7354, 3.08, 0.202, 284, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
4989, 5i9yA, 0.7354, 3.11, 0.206, 287, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
4990, 5hidB, 0.7354, 3.33, 0.217, 269, 244, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
4991, 4uzhA, 0.7354, 2.70, 0.314, 251, 236, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4992, 3i6wB, 0.7354, 2.66, 0.299, 382, 231, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
4993, 2xynA, 0.7354, 3.02, 0.233, 264, 240, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
4994, 2v7aB, 0.7354, 3.32, 0.237, 268, 245, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
4995, 2j51A, 0.7354, 2.69, 0.288, 288, 236, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4996, 1fvrA, 0.7354, 2.93, 0.246, 299, 240, TIE2 KINASE DOMAIN
4997, 5cepA, 0.7353, 2.58, 0.284, 269, 232, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
4998, 5caoA, 0.7353, 3.24, 0.207, 300, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
4999, 3zfxH, 0.7353, 2.88, 0.229, 266, 240, CRYSTAL STRUCTURE OF EPHB1
5000, 3h9fA, 0.7353, 2.83, 0.312, 260, 240, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
